https://clinresonc-new.lhten.com/2026-10-25always1 https://clinresonc-new.lhten.com/contact2026-10-25daily0.9 https://clinresonc-new.lhten.com/disclaimer2026-10-25daily0.9 https://clinresonc-new.lhten.com/legal-notice2026-10-25daily0.9 https://clinresonc-new.lhten.com/privacy2026-10-25daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-first-line-bevacizumab-plus-trebananib-for-mcrc2021-01-31daily0.9 https://clinresonc-new.lhten.com/analysis-of-durable-mrd-negativity-with-daratumumab-combination2021-01-31daily0.9 https://clinresonc-new.lhten.com/dose-reduced-radiation-therapy-for-hpv-associated-opscc2021-01-30daily0.9 https://clinresonc-new.lhten.com/long-term-mental-health-service-utilization-among-survivors-of2021-01-30daily0.9 https://clinresonc-new.lhten.com/t-cell-therapy-for-lymphoma-using-nonengineered-multiantigen-targeted2021-01-29daily0.9 https://clinresonc-new.lhten.com/outomes-of-various-treatments-for-chronic-myelomonocytic-leukemia2021-02-01daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-with-or-without-ipilimumab-for-mnsclc-with-pd-l1-tps-502021-01-30daily0.9 https://clinresonc-new.lhten.com/continuing-bevacizumab-beyond-progression-of-platinum-sensitive2021-02-02daily0.9 https://clinresonc-new.lhten.com/pet-guided-omission-of-consolidation-radiotherapy-for-early-stage2021-02-02daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-4-gy-versus-24-gy-radiotherapy-for-follicular-and2021-02-02daily0.9 https://clinresonc-new.lhten.com/first-line-pembrolizumab-for-advanced-non-clear-cell-renal-cell2021-02-03daily0.9 https://clinresonc-new.lhten.com/first-line-pembrolizumab-for-advanced-clear-cell-renal-cell-carcinoma2021-02-03daily0.9 https://clinresonc-new.lhten.com/comparison-of-two-radiotherapy-schedules-for-locally-advanced-bladder2021-02-02daily0.9 https://clinresonc-new.lhten.com/association-of-use-of-high-dose-cyproterone-acetate-and-risk-of2021-02-04daily0.9 https://clinresonc-new.lhten.com/association-of-transanal-total-mesorectal-excision-with-local2021-02-04daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-endocrine-therapies-for-breast-cancer-in2021-02-05daily0.9 https://clinresonc-new.lhten.com/six-year-follow-up-of-adjuvant-pertuzumab-plus-trarstuzumab-for-early2021-02-05daily0.9 https://clinresonc-new.lhten.com/added-value-of-baseline-ctdna-profiling-in-patients-with-left-sided2021-02-06daily0.9 https://clinresonc-new.lhten.com/preoperative-high-dose-rate-brachytherapy-for-early-stage-cervical2021-02-06daily0.9 https://clinresonc-new.lhten.com/race-ethnicity-and-risk-of-second-primary-contralateral-breast-cancer2021-02-07daily0.9 https://clinresonc-new.lhten.com/addition-of-lenalidomide-to-first-line-r-chop-for-dlbcl2021-02-09daily0.9 https://clinresonc-new.lhten.com/breast-cancer-mortality-rates-in-u-s-women-younger-than-40-years2021-02-10daily0.9 https://clinresonc-new.lhten.com/value-of-primary-tumor-resection-before-chemotherapy-in-crc-with2021-02-10daily0.9 https://clinresonc-new.lhten.com/phase-3-trials-of-tirbanibulin-ointment-for-actinic-keratosis2021-02-11daily0.9 https://clinresonc-new.lhten.com/pyrotinib-plus-capecitabine-versus-lapatinib-plus-capecitabine-for2021-02-12daily0.9 https://clinresonc-new.lhten.com/lutetium-177-psma-617-versus-cabazitaxel-for-mcrpc2021-02-12daily0.9 https://clinresonc-new.lhten.com/enfortumab-vedotin-in-previously-treated-advanced-urothelial-carcinoma2021-02-13daily0.9 https://clinresonc-new.lhten.com/ctdna-levels-predict-clinical-outcomes-of-targeted-therapy-for2021-02-13daily0.9 https://clinresonc-new.lhten.com/lenvatinib-plus-pembrolizumab-in-renal-cell-cancer2021-02-14daily0.9 https://clinresonc-new.lhten.com/sunitinib-versus-cabozantinib-crizotinib-or-savolitinib-for-advanced2021-02-14daily0.9 https://clinresonc-new.lhten.com/pan-cancer-germline-testing-in-patients-with-pediatric-solid-tumors2021-02-16daily0.9 https://clinresonc-new.lhten.com/endoscopic-surgery-versus-imrt-for-resectable-locally-recurrent-npc2021-02-16daily0.9 https://clinresonc-new.lhten.com/diagnosis-and-treatment-of-metastatic-colorectal-cancer2021-02-16daily0.9 https://clinresonc-new.lhten.com/enzalutamide-plus-trastuzumab-for-her2-positive-ar-positive-advanced2021-02-17daily0.9 https://clinresonc-new.lhten.com/atovaquone-increases-tumor-oxygenation-and-inhibits-hypoxic-gene2021-02-17daily0.9 https://clinresonc-new.lhten.com/bone-metastatic-burden-and-survival-benefit-from-prostate-rt-in-newly2021-02-18daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-eprenetapopt-plus-azacitidine-for-tp53-mutated-mds2021-02-19daily0.9 https://clinresonc-new.lhten.com/ibrutinib-with-or-without-ublituximab-for-r-r-high-risk-cll2021-02-23daily0.9 https://clinresonc-new.lhten.com/idecabtagene-vicleucel-for-relapsed-or-refractory-multiple-myeloma2021-02-25daily0.9 https://clinresonc-new.lhten.com/impact-of-risk-adapted-therapy-for-pediatric-hodgkin-lymphoma-on-long2021-02-26daily0.9 https://clinresonc-new.lhten.com/adjuvant-tlpldc-vaccine-after-surgical-resection-of-stage-iii-iv2021-02-28daily0.9 https://clinresonc-new.lhten.com/high-dose-versus-standard-dose-twice-daily-thoracic-rt-for-ls-sclc2021-03-02daily0.9 https://clinresonc-new.lhten.com/entrectinib-for-advanced-ros1-fusion-positive-non-small-cell-lung2021-03-02daily0.9 https://clinresonc-new.lhten.com/consecutive-mammography-screenings-and-breast-cancer-death2021-03-03daily0.9 https://clinresonc-new.lhten.com/global-effect-of-the-covid-19-pandemic-on-pediatric-cancer-care2021-03-04daily0.9 https://clinresonc-new.lhten.com/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell2021-03-04daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-versus-chemotherapy-as-second-line-or-third-line2021-03-05daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-first-line-tpex-versus-extreme-for-r-m2021-03-06daily0.9 https://clinresonc-new.lhten.com/pirtobrutinib-for-relapsed-or-refractory-b-cell-malignancies2021-03-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2b-study-of-umbralisib-for-relapsed-or-refractory2021-03-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-secondary-cytoreduction-in-platinum2021-03-09daily0.9 https://clinresonc-new.lhten.com/whole-genome-sequencing-as-an-alternative-to-cytogenetic-analysis-in2021-03-11daily0.9 https://clinresonc-new.lhten.com/treatment-free-remission-following-frontline-nilotinib-for-cml-cp2021-03-11daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-versus-brentuximab-vedotin-for-relapsed-or-refractory2021-03-13daily0.9 https://clinresonc-new.lhten.com/70-gene-signature-as-an-aid-for-treatment-decisions-in-early-breast2021-03-13daily0.9 https://clinresonc-new.lhten.com/tumor-mutation-burden-as-predictive-biomarker-for-response-to-immune2021-03-15daily0.9 https://clinresonc-new.lhten.com/survival-of-breast-cancer-patients-with-distant-versus-ipsilateral2021-03-16daily0.9 https://clinresonc-new.lhten.com/cardiovascular-risk-factors-are-associated-with-future-cancer2021-03-17daily0.9 https://clinresonc-new.lhten.com/socioeconomic-deprivation-and-cancer-outcomes-in-patients-treated-in2021-03-18daily0.9 https://clinresonc-new.lhten.com/olaparib-tablets-maintenance-therapy-for-platinum-sensitive-relapsed2021-03-19daily0.9 https://clinresonc-new.lhten.com/glofitamab-for-relapsed-or-refractory-b-cell-lymphoma2021-03-20daily0.9 https://clinresonc-new.lhten.com/tipifarnib-for-recurrent-and-or-metastatic-head-and-neck-squamous2021-03-23daily0.9 https://clinresonc-new.lhten.com/deep-learning-models-for-classification-of-breast-cancer-receptor2021-03-24daily0.9 https://clinresonc-new.lhten.com/t-cells-persist-for-years-in-melanoma-patients-after-durable2021-03-25daily0.9 https://clinresonc-new.lhten.com/enfortumab-vedotin-for-previously-treated-advanced-urothelial2021-03-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-oral-azacitidine-for-lower-risk-mds2021-03-26daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-cd19-car-t-cell-therapy-in-children-and-young2021-03-26daily0.9 https://clinresonc-new.lhten.com/impact-of-deviations-in-her2-expression-test-results-on-survival-in2021-03-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-study-of-furmonertinib-for-advanced-egfr-t790m2021-03-27daily0.9 https://clinresonc-new.lhten.com/correlative-biomarker-analysis-of-intrinsic-subtypes-and-efficacy2021-03-27daily0.9 https://clinresonc-new.lhten.com/tumor-subtypes-and-survival-in-male-breast-cancer2021-03-27daily0.9 https://clinresonc-new.lhten.com/exercise-and-health-related-fitness-predictors-of-chemotherapy2021-03-29daily0.9 https://clinresonc-new.lhten.com/cancer-diagnoses-and-survival-rise-as-65-year-olds-become-medicare2021-03-29daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-association-of-obesity-with-survival-outcomes-in2021-03-29daily0.9 https://clinresonc-new.lhten.com/alpelisib-plus-fulvestrant-for-pik3ca-mutated-hr-positive-her22021-03-30daily0.9 https://clinresonc-new.lhten.com/cost-effectiveness-of-novel-treatment-sequences-for-transplant2021-03-30daily0.9 https://clinresonc-new.lhten.com/mri-guided-adaptive-brachytherapy-for-locally-advanced-cervical-cancer2021-03-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-second-line-folfox-for-advanced-biliary2021-03-31daily0.9 https://clinresonc-new.lhten.com/pediatric-style-chemotherapy-versus-ma-allohct-for-ph-negative-all-in2021-03-31daily0.9 https://clinresonc-new.lhten.com/delayed-immune-related-adverse-events-with-anti-pd1-based2021-03-31daily0.9 https://clinresonc-new.lhten.com/adjuvant-nivolumab-in-resected-esophageal-or-gastroesophageal2021-04-01daily0.9 https://clinresonc-new.lhten.com/mri-guided-adaptive-brachytherapy-for-locally-advanced-cervical-cancer-22021-04-01daily0.9 https://clinresonc-new.lhten.com/celtil-score-as-surrogate-for-survival-in-early-stage-her2-positive2021-04-01daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-addition-of-tislelizumab-to-first-line-chemotherapy2021-04-02daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-pembrolizumab-for-advanced-msi-h-gastric-or2021-04-02daily0.9 https://clinresonc-new.lhten.com/hrqol-with-first-line-pembrolizumab-versus-chemotherapy-for-msi-h-or2021-04-02daily0.9 https://clinresonc-new.lhten.com/cyclophosphamide-free-adjuvant-chemotherapy-for-ovarian-protection-in2021-04-03daily0.9 https://clinresonc-new.lhten.com/perioperative-durvalumab-and-tremelimumab-for-colorectal-cancer-liver2021-04-03daily0.9 https://clinresonc-new.lhten.com/association-of-recalled-age-at-menarche-with-risk-of-site-specific2021-04-06daily0.9 https://clinresonc-new.lhten.com/camrelizumab-with-or-without-decitabine-for-relapsed-or-refractory2021-04-06daily0.9 https://clinresonc-new.lhten.com/addition-of-celecoxib-to-adjuvant-folfox-for-stage-iii-colon-cancer2021-04-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-pembrolizumab-for-advanced-mesothelioma2021-04-07daily0.9 https://clinresonc-new.lhten.com/predicting-outcomes-of-metastatic-nonseminomatous-germ-cell-tumors2021-04-07daily0.9 https://clinresonc-new.lhten.com/estimated-projection-of-us-cancer-incidence-and-death-to-20402021-04-07daily0.9 https://clinresonc-new.lhten.com/egfr-amplification-in-mcrc-clinical-consequences-and-genomic2021-04-07daily0.9 https://clinresonc-new.lhten.com/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell2021-04-08daily0.9 https://clinresonc-new.lhten.com/brentuximab-vedotin-and-risk-adapted-residual-node-radiation-for2021-04-08daily0.9 https://clinresonc-new.lhten.com/management-and-outcomes-of-men-diagnosed-with-primary-breast-cancer2021-04-08daily0.9 https://clinresonc-new.lhten.com/palbociclib-for-progressive-brain-metastases-harboring-cdk-pathway2021-04-09daily0.9 https://clinresonc-new.lhten.com/pd-l1-protein-expression-in-primary-versus-metastatic-lesions-in-nsclc2021-04-09daily0.9 https://clinresonc-new.lhten.com/network-meta-analytic-comparison-of-four-treatments-for-nonmetastatic2021-04-09daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-javelin-lung-2002021-04-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-tisotumab-vedotin-for-previously2021-04-10daily0.9 https://clinresonc-new.lhten.com/copanlisib-plus-rituximab-versus-placebo-plus-rituximab-for-relapsed2021-04-10daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-nivolumab-plus-platinum-doublet-chemotherapy-for2021-04-10daily0.9 https://clinresonc-new.lhten.com/tebentafusp-versus-investigator-s-choice-for-previously-untreated2021-04-11daily0.9 https://clinresonc-new.lhten.com/oncolytic-hsv-1-g207-immunotherapy-for-pediatric-high-grade-gliomas2021-04-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-avapritinib-for-advanced-systemic2021-04-11daily0.9 https://clinresonc-new.lhten.com/characteristics-and-outcomes-of-rare-histology-tnbcs2021-04-12daily0.9 https://clinresonc-new.lhten.com/distant-metastasis-free-survival-with-adjuvant-pembrolizumab-versus2021-04-13daily0.9 https://clinresonc-new.lhten.com/hrqol-with-adjuvant-pembrolizumab-versus-placebo-for-resected-stage2021-04-13daily0.9 https://clinresonc-new.lhten.com/non-inferiority-study-of-lobaplatin-based-versus-cisplatin-based2021-04-13daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-for-metastatisc-breast-cancer-with-high-tumor2021-04-13daily0.9 https://clinresonc-new.lhten.com/addition-of-neoadjuvant-folfirinox-to-standard-treatment-for-locally2021-04-14daily0.9 https://clinresonc-new.lhten.com/patient-centred-outcomes-in-solo1-study2021-04-14daily0.9 https://clinresonc-new.lhten.com/prognostic-impact-of-ets-and-dor-in-msi-h-dmmr-mcrc-patients2021-04-14daily0.9 https://clinresonc-new.lhten.com/outcomes-after-slnb-and-rt-for-early-stage-er-positive-breast-cancer2021-04-15daily0.9 https://clinresonc-new.lhten.com/weekly-carfilzomib-lenalidomide-dexamethasone-and-daratumumab-for2021-04-15daily0.9 https://clinresonc-new.lhten.com/novel-nomogram-for-individualized-prediction-of-survival-in-cancer-of2021-04-16daily0.9 https://clinresonc-new.lhten.com/efficacy-of-the-bnt162b2-mrna-covid-19-vaccine-in-cll-patients2021-04-16daily0.9 https://clinresonc-new.lhten.com/cumulative-covid-19-incidence-and-prognosis-in-cancer-survivors2021-04-17daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-keynote-0242021-04-20daily0.9 https://clinresonc-new.lhten.com/real-world-effectiveness-of-hpv-vaccination-against-cervical-cancer2021-04-20daily0.9 https://clinresonc-new.lhten.com/phase-2a-study-of-belumosudil-for-the-treatment-of-chronic-graft2021-04-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-first-line-pembrolizumab-for-advanced2021-04-21daily0.9 https://clinresonc-new.lhten.com/sacituzumab-govitecan-for-metastatic-triple-negative-breast-cancer2021-04-22daily0.9 https://clinresonc-new.lhten.com/first-line-single-agent-carboplatin-vs-carboplatin-plus-paclitaxel2021-04-22daily0.9 https://clinresonc-new.lhten.com/safety-of-stereotactic-body-radiotherapy-for-patients-with-multiple2021-04-23daily0.9 https://clinresonc-new.lhten.com/serum-levels-of-sbtla-predict-overall-survival-in-patients-undergoing2021-04-23daily0.9 https://clinresonc-new.lhten.com/ten-year-outcome-of-neoadjuvant-chemoradiotherapy-followed-by-surgery2021-04-24daily0.9 https://clinresonc-new.lhten.com/ipd-meta-analysis-of-assocation-of-germline-brca-pathogenic-variant2021-04-24daily0.9 https://clinresonc-new.lhten.com/factors-associated-with-late-risks-of-breast-cancer-specific2021-04-25daily0.9 https://clinresonc-new.lhten.com/laparoscopic-versus-open-pancreatoduodenectomy-for-pancreatic-or2021-04-27daily0.9 https://clinresonc-new.lhten.com/two-lower-intensity-regimes-for-newly-diagnosed-aml-in-elderly2021-04-27daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-safety-data-from-clinical-trials-evaluating2021-04-27daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-hla-mismatched-unrelated-donor-bone-marrow2021-04-28daily0.9 https://clinresonc-new.lhten.com/one-versus-two-doses-of-the-covid-19-vaccine-bnt162b2-for-patients2021-04-28daily0.9 https://clinresonc-new.lhten.com/hrqol-with-neratinib-plus-capecitabine-for-mbc-after-two-prior-her22021-04-28daily0.9 https://clinresonc-new.lhten.com/role-of-induction-chemotherapy-for-oral-cavity-squamous-cell-carcinoma2021-04-29daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-trabectedin-versus-best-supportive-care-for-pre2021-04-29daily0.9 https://clinresonc-new.lhten.com/addition-of-apalutamide-or-placebo-to-adt-for-mcspc-final-survival2021-04-30daily0.9 https://clinresonc-new.lhten.com/outcomes-of-patients-treated-with-car-t-cell-therapy-who-were2021-05-01daily0.9 https://clinresonc-new.lhten.com/third-party-bk-virus-specific-cytotoxic-t-lymphocyte-therapy-for2021-05-01daily0.9 https://clinresonc-new.lhten.com/sacituzumab-govitecan-for-metastatic-urothelial-carcinoma-progressing2021-05-01daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-nelfinavir-added-to-chemoradiotherapy-for-locally2021-05-02daily0.9 https://clinresonc-new.lhten.com/burden-of-pancreatic-cancer-in-europe-between-1990-and-2019-and2021-05-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-trastuzumab-deruxtecan-for-her22021-05-05daily0.9 https://clinresonc-new.lhten.com/survival-benefit-for-individuals-with-constitutional-mismatch-repair2021-05-05daily0.9 https://clinresonc-new.lhten.com/lenvatinib-for-advanced-grade-1-2-pancreatic-and-gastrointestinal2021-05-05daily0.9 https://clinresonc-new.lhten.com/estimating-cvd-risk-by-automatic-quantification-of-cacs-on-rt2021-05-06daily0.9 https://clinresonc-new.lhten.com/comparison-of-three-conditioning-regimes-for-pcnsl-patients2021-05-06daily0.9 https://clinresonc-new.lhten.com/sugar-sweetened-beverage-intake-and-risk-of-early-onset-colorectal2021-05-07daily0.9 https://clinresonc-new.lhten.com/18f-fluciclovine-pet-ct-imaging-for-guiding-postprostatectomy-salvage2021-05-08daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-apatinib-as-second-line-or-later-therapy-for2021-05-08daily0.9 https://clinresonc-new.lhten.com/outcomes-of-various-treatments-for-intrahepatic-cholangiocarcinoma2021-05-08daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-association-of-metformin-use-and-survival2021-05-10daily0.9 https://clinresonc-new.lhten.com/tepotinib-versus-sorafenib-for-met-overexpressing-advanced2021-05-10daily0.9 https://clinresonc-new.lhten.com/rucaparib-maintenance-for-platinum-sensitive-advanced-pac-and2021-05-11daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-pembrolizumab-plus-cetuximab-for-recurrent-or2021-05-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-loncastuximab-tesirine-for-relapsed-or2021-05-12daily0.9 https://clinresonc-new.lhten.com/ipilimumab-with-or-without-anti-pd-1-therapy-for-metastatic-melanoma2021-05-12daily0.9 https://clinresonc-new.lhten.com/lifileucel-for-metastatic-melanoma-after-immune-checkpoint-inhibition2021-05-13daily0.9 https://clinresonc-new.lhten.com/enfortumab-vedotin-after-pd-l-1-inhibitors-for-advanced-urothelial2021-05-13daily0.9 https://clinresonc-new.lhten.com/vemurafenib-plus-rituximab-for-relapsed-or-refractory-hairy-cell2021-05-13daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-stereotactic2021-05-14daily0.9 https://clinresonc-new.lhten.com/pretreatment-metastatic-growth-rate-predicts-os-with-anti-pd-1-for2021-05-14daily0.9 https://clinresonc-new.lhten.com/adjuvant-and-concurrent-temozolomide-for-1p-19q-non-co-deleted2021-05-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-cemiplimab-for-locally-advanced-basal2021-05-15daily0.9 https://clinresonc-new.lhten.com/active-surveillance-for-low-risk-prostate-cancer-association-of-psa2021-05-17daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-durvalumab-with-or-without-sbrt-for-early-stage-nsclc2021-05-18daily0.9 https://clinresonc-new.lhten.com/correlation-of-early-change-in-sulmax-with-pcr-of-breast-cancer-to2021-05-18daily0.9 https://clinresonc-new.lhten.com/pet-guided-de-escalation-of-neoadjuvant-treatment-for-her2-positive2021-05-19daily0.9 https://clinresonc-new.lhten.com/timing-of-adjuvant-chemotherapy-for-early-stage-breast-cancer2021-05-20daily0.9 https://clinresonc-new.lhten.com/bloodstreaminfections-after-curative-intent-radiotherapy-for-hnscc2021-05-20daily0.9 https://clinresonc-new.lhten.com/anthracycline-free-neoadjuvant-chemotherapy-with-dual-her2-blockade2021-05-20daily0.9 https://clinresonc-new.lhten.com/association-of-screening-lower-endoscopy-with-crc-incidence-and2021-05-21daily0.9 https://clinresonc-new.lhten.com/a-novel-dosing-strategy-for-ruxolitinib-in-the-treatment-of-patients2021-05-21daily0.9 https://clinresonc-new.lhten.com/capecitabine-maintenance-therapy-after-induction-chemotherapy-for2021-05-22daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-addition-of-tislelizumab-to-first-line-induction2021-05-22daily0.9 https://clinresonc-new.lhten.com/apatinib-plus-gefitinib-as-first-line-treatment-for-advanced-egfr2021-05-22daily0.9 https://clinresonc-new.lhten.com/impact-of-ruxolitinib-pretreatment-on-outcomes-of-allogeneic2021-05-23daily0.9 https://clinresonc-new.lhten.com/real-world-treatment-outcomes-with-brigatinib-for-pretreated-alk2021-05-23daily0.9 https://clinresonc-new.lhten.com/survival-in-male-breast-cancer-over-the-past-three-decades2021-05-24daily0.9 https://clinresonc-new.lhten.com/all-oral-regimen-of-tesetaxel-plus-reduced-dose-capecitabine-for2021-05-24daily0.9 https://clinresonc-new.lhten.com/oral-capecitabine-maintenance-versus-active-monitoring-for-mcrc-with2021-05-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-second-line-tislelizumab-versus-ic2021-05-25daily0.9 https://clinresonc-new.lhten.com/crc-incidence-and-mortality-in-european-countries-in-the-crc2021-05-26daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-first-line-sintilimab-plus-platinum-and-gemcitabine2021-05-26daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-monotherapy-for-non-muscle-invasive-bladder-cancer2021-05-27daily0.9 https://clinresonc-new.lhten.com/seer-based-analysis-of-risk-of-contralateral-breast-cancer2021-05-27daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-with-atezolizumab-bevacizumab-versus2021-05-28daily0.9 https://clinresonc-new.lhten.com/venetoclax-plus-flag-ida-induction-and-consolidation-for-nd-aml-and-r2021-05-28daily0.9 https://clinresonc-new.lhten.com/seropositivity-after-bnt162b2-vaccination-in-patients-undergoing2021-05-29daily0.9 https://clinresonc-new.lhten.com/model-for-estimating-personalized-breast-cancer-risk-after-chest2021-05-29daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-anlotinib-versus-dacarbazine-for-advanced-or2021-05-30daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-cabozantinib-plus-nivolumab-for-non-clear-cell-renal2021-05-30daily0.9 https://clinresonc-new.lhten.com/molecular-determinants-of-outcomes-with-pembrolizumab-versus2021-05-31daily0.9 https://clinresonc-new.lhten.com/first-line-masitinib-plus-gemcitabine-for-locally-advanced-or2021-05-31daily0.9 https://clinresonc-new.lhten.com/overall-survival-after-crs-hipec-for-gastric-cancer-with-synchronous2021-06-01daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-addition-of-daratumumab-to-pomalidomide2021-06-02daily0.9 https://clinresonc-new.lhten.com/prognostic-and-predictive-impact-of-primary-tumor-sidedness-for2021-06-02daily0.9 https://clinresonc-new.lhten.com/primary-definitive-chemoradiotherapy-versus-upfront-surgery-for2021-06-02daily0.9 https://clinresonc-new.lhten.com/adjuvant-nivolumab-versus-placebo-in-muscle-invasive-urothelial2021-06-03daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-adjuvant-olaparib-for-brca1-or-brca2-mutated-breast2021-06-04daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-continuous-or-limited-duration-venetoclax-plus2021-06-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-acalabrutinib-versus-ibrutinib-for2021-06-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-atezolizumab-after-adjuvant2021-06-05daily0.9 https://clinresonc-new.lhten.com/crossover-and-rechallenge-with-pembrolizumab-after-recurrence-in2021-06-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-pembrolizumab-plus-ccrt-for2021-06-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-sotorasib-for-previously-treated-kras2021-06-06daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-ipilimumab-or-nivolumab-plus-chemotherapy2021-06-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-lutetium-177-psma-617-for-previously2021-06-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-pembrolizumab-versus-placebo-after2021-06-07daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-adjuvant-metronomic-capecitabine-for-locoregionally2021-06-08daily0.9 https://clinresonc-new.lhten.com/covid-19-outcomes-in-hospitalized-patients-with-active-cancer2021-06-08daily0.9 https://clinresonc-new.lhten.com/durvalumab-for-advanced-mismatch-repair-deficient-and-repair2021-06-09daily0.9 https://clinresonc-new.lhten.com/breast-cancer-risk-among-cariers-of-pathogenic-variants-in2021-06-09daily0.9 https://clinresonc-new.lhten.com/reduced-intenstity-hematopoietic-cell-transplantation-for-higher-risk2021-06-10daily0.9 https://clinresonc-new.lhten.com/association-of-chemotherapy-timing-in-pregnancy-with-congenital2021-06-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-pralsetinib-for-ret-fusion-positive2021-06-10daily0.9 https://clinresonc-new.lhten.com/reduced-dose-and-reduced-volume-radiotherapy-with-chemotherapy-for2021-06-11daily0.9 https://clinresonc-new.lhten.com/pathogenic-germline-variants-in-patients-with-hepatocellular-carcinoma2021-06-11daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-ibrutinib-plus-venetoclax-for-previously-untreated2021-06-11daily0.9 https://clinresonc-new.lhten.com/binational-phase-2-3-study-of-sbrt-versus-conventional-ebrt-for2021-06-12daily0.9 https://clinresonc-new.lhten.com/fixed-duration-ibrutinib-plus-venetoclax-versus-chlorambucil2021-06-12daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-indoximod-plus-pembrolizumab-for-advanced-melanoma2021-06-12daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-lenalidomide-dexamethasone-with-or-without2021-06-13daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-prognostic-significance-of-neutrophil-to2021-06-14daily0.9 https://clinresonc-new.lhten.com/population-diversity-in-phase-iii-trials-of-cancer-drugs-supporting2021-06-14daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-first-line-nivolumab-or-placebo-with-carboplatin2021-06-15daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-maternal-and-fetal-outcomes-of-pregnancy2021-06-15daily0.9 https://clinresonc-new.lhten.com/association-of-body-mass-index-dosing-strategy-and-efficacy-of-immune2021-06-15daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-3-study-of-sintilimab-plus-ibi305-versus-sorafenib2021-06-16daily0.9 https://clinresonc-new.lhten.com/lenvatinib-plus-pembrolizumab-for-either-treatment-naive-or2021-06-16daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-monitoring-of-ctdna-for-early-relapse-detection2021-06-17daily0.9 https://clinresonc-new.lhten.com/donor-clonal-hematopoiesis-increases-risk-of-acute-graft-versus-host2021-06-17daily0.9 https://clinresonc-new.lhten.com/therapeutic-implications-of-germline-testing-in-patients-with2021-06-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-imetelstat-for-relapsed-or-refractory2021-06-18daily0.9 https://clinresonc-new.lhten.com/convalescent-plasma-therapy-for-patients-with-hematologic-cancers-and2021-06-18daily0.9 https://clinresonc-new.lhten.com/frontline-hyper-cvad-plus-ofatumumab-versus-hyper-cvad-plus-rituximab2021-06-18daily0.9 https://clinresonc-new.lhten.com/impt-versus-imrt-for-newly-diagnosed-nonmetastatic-nasopharyngeal2021-06-19daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-two-induction-therapy-regimens-for-high-risk2021-06-22daily0.9 https://clinresonc-new.lhten.com/savolitinib-for-pulmonary-sarcomatoid-carcinomas-and-other-nsclcs2021-06-22daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-pet-adapted-regimen-for-advanced-hl-impact-on2021-06-23daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-romyelocel-l-to-reduce-infections-during-induction2021-06-23daily0.9 https://clinresonc-new.lhten.com/humanized-cd19-targeted-car-t-cells-for-r-r-all-in-car-naive-and-car2021-06-23daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-camrelizumab-versus-placebo-added-to-first-line2021-06-24daily0.9 https://clinresonc-new.lhten.com/incidence-risk-factors-and-management-of-venous-thromboembolism-in2021-06-24daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-neoadjuvant-chemoradiotherapy-for2021-06-24daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-trastuzumab-pertuzumab-and-docetaxel-versus-trastuzumab2021-06-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-5-versus-2-years-of-adjuvant-zoledronate2021-06-25daily0.9 https://clinresonc-new.lhten.com/phase-1b-2-study-of-ciltacabtagene-autoleucel-for-relapsed-or2021-06-25daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-second-line-pembro-gvd-for-relapsed-or-refractory2021-06-26daily0.9 https://clinresonc-new.lhten.com/parenthood-rates-and-use-of-assisted-reproductive-techniques-in2021-06-26daily0.9 https://clinresonc-new.lhten.com/dna-thioguanine-concentration-and-relapse-risk-in-children-and-young2021-06-27daily0.9 https://clinresonc-new.lhten.com/increased-incidence-of-cancer-diagnoses-in-patients-with-heart2021-06-28daily0.9 https://clinresonc-new.lhten.com/association-of-copy-number-variation-signature-and-survival-in2021-06-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-carfilzomib-bendamustine-and2021-06-29daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-neoadjuvant-immunotherapy-for-locoregionally2021-06-29daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-cpx-351-versus-7-3-cytarabine-and-daunorubicin2021-06-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-study-of-donafenib-versus-sorafenib-for2021-07-01daily0.9 https://clinresonc-new.lhten.com/daratumumab-based-treatment-for-immunoglobulin-light-chain-amyloidosis2021-07-01daily0.9 https://clinresonc-new.lhten.com/prospective-trial-of-addition-of-docetaxel-to-adt-and-rt-for2021-07-02daily0.9 https://clinresonc-new.lhten.com/association-between-neuronal-autoantibodies-and-cognitive-impairment2021-07-02daily0.9 https://clinresonc-new.lhten.com/cabozantinib-for-radioiodine-refractory-differentiated-thyroid-cancer2021-07-06daily0.9 https://clinresonc-new.lhten.com/association-of-timing-of-corticosteroid-initiation-with-efficacy-of2021-07-06daily0.9 https://clinresonc-new.lhten.com/sbrt-plus-pembrolizumab-and-trametinib-for-locally-recurrent2021-07-06daily0.9 https://clinresonc-new.lhten.com/global-breast-cancer-incidence-and-mortality-rates-1990-20172021-07-07daily0.9 https://clinresonc-new.lhten.com/post-treatment-circulating-biomarkers-of-inflammation-and-survival2021-07-07daily0.9 https://clinresonc-new.lhten.com/infliximab-for-corticosteroid-refractory-immune-checkpoint-inhibitor2021-07-08daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-novel-targeted-agents-for-her2-positive2021-07-08daily0.9 https://clinresonc-new.lhten.com/mri-guided-versus-standard-biopsy-in-prostate-cancer-screening2021-07-09daily0.9 https://clinresonc-new.lhten.com/nomograms-to-predict-outcomes-after-lu-177-psma-for-metastatic2021-07-09daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-apatinib-plus-sox-chemotherapy-for-locally-advanced2021-07-10daily0.9 https://clinresonc-new.lhten.com/clinical-and-molecular-characteristics-of-her2-low-positive-breast2021-07-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-ipatasertib-plus-abiraterone-and2021-07-10daily0.9 https://clinresonc-new.lhten.com/clinical-course-of-breast-cancer-patients-with-local-regional2021-07-11daily0.9 https://clinresonc-new.lhten.com/risk-of-primary-lung-cancer-after-treatment-for-breast-cancer-two2021-07-12daily0.9 https://clinresonc-new.lhten.com/association-between-use-of-proton-pump-inhibitors-and-survival-of2021-07-12daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-perioperative-durvalumab-plus-neoadjuvant2021-07-13daily0.9 https://clinresonc-new.lhten.com/simulation-model-based-clinical-decision-tool-to-identify-patients2021-07-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-first-line-bempegaldesleukin-plus2021-07-14daily0.9 https://clinresonc-new.lhten.com/global-burden-of-cancer-in-2020-attributable-to-alcohol-consumption2021-07-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-ruxolitinib-for-glucocorticoid2021-07-15daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-study-of-addition-of-cmb305-to2021-07-15daily0.9 https://clinresonc-new.lhten.com/phase-1-2-study-of-tandem-cd19-cd20-car-therapy-for-relapsed-or2021-07-16daily0.9 https://clinresonc-new.lhten.com/combination-of-atezolizumab-bevacizumab-pemetrexed-and-carboplatin2021-07-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-adjuvant-icotinib-versus-chemotherapy2021-07-17daily0.9 https://clinresonc-new.lhten.com/comparison-of-three-mibg-regimens-for-relapsed-or-refractory2021-07-17daily0.9 https://clinresonc-new.lhten.com/explanation-of-male-excess-risk-of-advanced-colorectal-neoplasms-by2021-07-19daily0.9 https://clinresonc-new.lhten.com/skeletal-adverse-events-in-childhood-cancer-survivors2021-07-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-pembrolizumab-monotherapy-for-locally2021-07-20daily0.9 https://clinresonc-new.lhten.com/combining-tumor-deposits-with-number-of-lymph-node-metastases-to2021-07-20daily0.9 https://clinresonc-new.lhten.com/comparison-between-5-azacytidine-treatment-and-allogeneic-hsct-for2021-07-21daily0.9 https://clinresonc-new.lhten.com/physiologic-frailty-and-neurocognitive-decline-among-young-adult2021-07-21daily0.9 https://clinresonc-new.lhten.com/deep-learning-based-system-for-detecting-gastric-neoplasms-during2021-07-21daily0.9 https://clinresonc-new.lhten.com/real-time-remote-symptom-monitoring-during-chemotherapy-for-cancer2021-07-22daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-first-line-treatments-for2021-07-22daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-mrd-status-after-metastatic-resection-in2021-07-22daily0.9 https://clinresonc-new.lhten.com/tremelimumab-and-durvalumab-as-monotherapies-or-in-combination-for2021-07-23daily0.9 https://clinresonc-new.lhten.com/os-impact-of-addition-of-bone-resorption-inhibitors-to-first-line2021-07-23daily0.9 https://clinresonc-new.lhten.com/risk-of-late-onset-breast-cancer-in-genetically-predisposed-women2021-07-23daily0.9 https://clinresonc-new.lhten.com/survival-outcomes-with-second-generation-androgen-receptor-inhibitors2021-07-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-first-line-avelumab-for-metastatic2021-07-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-the-probody-pd-l1-inhibitor-pacmilimab2021-07-24daily0.9 https://clinresonc-new.lhten.com/risk-of-venous-thromboembolism-in-ovarian-cancer-patients-receiving2021-07-25daily0.9 https://clinresonc-new.lhten.com/final-os-analysis-of-impower1502021-07-25daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-between-kidney-function-and-cancer-risk2021-07-26daily0.9 https://clinresonc-new.lhten.com/correlation-between-surrogate-end-points-and-overall-survival-in-a2021-07-26daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-postdiagnosis-smoking-cessation-and-risk-of-lung2021-07-27daily0.9 https://clinresonc-new.lhten.com/use-of-donor-derived-expanded-nk-cells-to-decrease-post-transplant2021-07-27daily0.9 https://clinresonc-new.lhten.com/pulse-therapy-with-vincristine-and-dexamethasone-for-childhood-all2021-07-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-acalabrutinib-versus-ibrutinib-for-22021-07-28daily0.9 https://clinresonc-new.lhten.com/genetic-risk-for-overall-cancer-and-the-benefit-of-adherence-to-a2021-07-28daily0.9 https://clinresonc-new.lhten.com/duration-of-adjuvant-aromatase-inhibitor-therapy-in-postmenopausal2021-07-29daily0.9 https://clinresonc-new.lhten.com/next-generation-sequencing-derived-machine-learning-risk-predicition2021-07-29daily0.9 https://clinresonc-new.lhten.com/chemotherapy-versus-chemotherapy-plus-total-hysterectomy-for-uterine2021-07-29daily0.9 https://clinresonc-new.lhten.com/phase-1b-study-of-neoadjuvant-cabozantinib-and-nivolumab-for-locally2021-07-30daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-addition-of-metformin-to2021-07-30daily0.9 https://clinresonc-new.lhten.com/donor-derived-anti-cd7-car-t-cells-for-relapsed-or-refractory-t-all2021-07-30daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-pertuzumab-plus-trastuzumab-for-her2-positive2021-07-31daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-seven-randomized-trials-of-trastuzumab-for-early2021-07-31daily0.9 https://clinresonc-new.lhten.com/association-of-circulating-ar-gene-amplification-with-resistance-of2021-08-01daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-anamorelin-combined-with-physical-activity-and2021-08-01daily0.9 https://clinresonc-new.lhten.com/dose-dense-brentuximab-vedotin-plus-ice-chemotherapy-for-second-line2021-08-02daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-venetoclax-plus-intensive-chemotherapy-for-newly2021-08-02daily0.9 https://clinresonc-new.lhten.com/influence-2-0-model-for-improved-risk-estimation-in-early-breast2021-08-03daily0.9 https://clinresonc-new.lhten.com/amivantamab-for-egfr-exon-20-insertion-mutated-nsclc-progressing-on2021-08-03daily0.9 https://clinresonc-new.lhten.com/association-of-statin-use-with-clinical-outcomes-in-patients-with2021-08-04daily0.9 https://clinresonc-new.lhten.com/vincristine-irinotecan-with-or-without-temozolomide-for-relapsed-or2021-08-04daily0.9 https://clinresonc-new.lhten.com/generalizability-of-polygenic-risk-scores-for-breast-cancer-among2021-08-05daily0.9 https://clinresonc-new.lhten.com/causes-of-death-among-patients-with-metastatic-prostate-cancer-in-the2021-08-05daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-adding-s-1-chemotherapy-to-radiotherapy-for2021-08-05daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-topical-remetinostat-gel-for-basal-cell-carcinoma2021-08-06daily0.9 https://clinresonc-new.lhten.com/impact-of-performance-status-on-response-and-survival-among-patients2021-08-06daily0.9 https://clinresonc-new.lhten.com/elective-neck-dissection-versus-observation-in-patients-with-head-and2021-08-07daily0.9 https://clinresonc-new.lhten.com/determinants-of-patient-reported-xerostomia-among-long-term2021-08-07daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-first-line-sintilimab-plus-chemotherapy-for2021-08-08daily0.9 https://clinresonc-new.lhten.com/detection-of-leptomeningeal-disease-using-cell-free-dna-from2021-08-09daily0.9 https://clinresonc-new.lhten.com/impact-of-liver-metastasis-on-efficacy-of-anti-pd-l-1-therapy-for2021-08-09daily0.9 https://clinresonc-new.lhten.com/association-of-genetic-testing-results-with-mortality-among-women2021-08-10daily0.9 https://clinresonc-new.lhten.com/model-for-predicting-individualized-outcomes-in-patients-with-newly2021-08-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-talazoparib-monotherapy-for-mcrpc-with2021-08-11daily0.9 https://clinresonc-new.lhten.com/recurrence-of-colorectal-neoplastich-polyps-after-incomplete-resection2021-08-11daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-the-eclipse-study-of-cryoablation-for2021-08-11daily0.9 https://clinresonc-new.lhten.com/first-line-gemcitabine-cisplatin-versus-fluorouracil-cisplatin-for2021-08-12daily0.9 https://clinresonc-new.lhten.com/durability-of-response-to-sars-cov-2-bnt162b2-vaccination-in-patients2021-08-12daily0.9 https://clinresonc-new.lhten.com/prophylactic-cranial-irradiation-with-or-without-hippocampal2021-08-12daily0.9 https://clinresonc-new.lhten.com/incidence-of-cancer-among-adults-with-thrombocytosis2021-08-13daily0.9 https://clinresonc-new.lhten.com/cetuximab-rechallenge-plus-avelumab-for-pretreated-ras-wild-type2021-08-13daily0.9 https://clinresonc-new.lhten.com/mipogg-cancer-predisposition-screening-tool-predicts-subsequent2021-08-13daily0.9 https://clinresonc-new.lhten.com/causes-of-death-and-mortality-rates-in-a-population-based-cohort-of2021-08-14daily0.9 https://clinresonc-new.lhten.com/ixazomib-rituximab-dexamethasone-for-relapsed-or-refractory2021-08-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-i-study-of-vendd-and-vendvd-for-rrmm-with-or2021-08-14daily0.9 https://clinresonc-new.lhten.com/predicted-cardiovascular-disease-risk-following-chemotherapy-and2021-08-15daily0.9 https://clinresonc-new.lhten.com/interim-analysis-of-ice3-trial-of-cryoablation-without-excision-for2021-08-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-camrelizumab-plus-famitinib-for-advanced2021-08-16daily0.9 https://clinresonc-new.lhten.com/multinational-cohort-study-of-adjuvant-platinum-based-chemotherapy2021-08-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-lenvatinib-with-etoposide-plus2021-08-18daily0.9 https://clinresonc-new.lhten.com/comparison-of-early-onset-and-average-onset-colorectal-cancers2021-08-18daily0.9 https://clinresonc-new.lhten.com/evaluation-of-addition-of-ultrasonography-to-mammography-in-breast2021-08-19daily0.9 https://clinresonc-new.lhten.com/long-term-results-of-radiation-versus-observation-after-lumpectomy2021-08-19daily0.9 https://clinresonc-new.lhten.com/association-of-physical-activity-before-during-and-after-chemotherapy2021-08-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-asciminib-versus-bosutinib-for-cml-cp2021-08-20daily0.9 https://clinresonc-new.lhten.com/impact-of-prior-treatment-on-the-efficacy-of-adoptive-transfer-of2021-08-20daily0.9 https://clinresonc-new.lhten.com/outcomes-of-breast-cancer-patients-with-low-hormone-receptor2021-08-20daily0.9 https://clinresonc-new.lhten.com/factors-predicting-poor-recovery-of-hrqol-in-pediatric-cancer2021-08-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-ii-study-of-neoadjuvant-gemcitabine-cisplatin2021-08-25daily0.9 https://clinresonc-new.lhten.com/targeted-introperative-molecular-imaging-for-localizing-nonpalpable2021-08-25daily0.9 https://clinresonc-new.lhten.com/radiotherapy-versus-inguinofemoral-lymphadenectomy-in-vulvar-cancer2021-08-26daily0.9 https://clinresonc-new.lhten.com/cardioprotection-for-patients-receiving-anthracycline-based-therapy2021-08-27daily0.9 https://clinresonc-new.lhten.com/adding-everolimus-to-first-line-treatment-of-premenopausal-advanced2021-08-27daily0.9 https://clinresonc-new.lhten.com/outcomes-of-sars-cov-2-infection-in-children-and-adolescents-with2021-08-28daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-the-association-of-bilateral-oophorectomy2021-08-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-first-line-pembrolizumab-plus2021-08-29daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-single-fraction-versus-multifraction2021-08-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-oncolytic-coxsackievirus-a21-v937-for2021-09-01daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-cardiovascular-risk-associated-with2021-09-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-fast-off-rate-cd19-car-t-therapy-for2021-09-01daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-antibiotics-use-and-subsequent-risk-of2021-09-02daily0.9 https://clinresonc-new.lhten.com/six-month-efficacy-and-toxicity-profile-of-bnt162b2-vaccine-in2021-09-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-ensartinib-versus-crizotinib-for-alk2021-09-03daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-risks-and-benefits-of-anticancer-drugs-in-advanced2021-09-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-second-line-gemcitabine-with-or-without2021-09-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-study-of-cabozantinib-plus-atezolizumab-for2021-09-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-epcoritamab-for-relapsed-or2021-09-09daily0.9 https://clinresonc-new.lhten.com/regulatory-and-clinical-consequences-of-negative-confirmatory-trials2021-09-09daily0.9 https://clinresonc-new.lhten.com/40-year-trends-in-late-mortality-and-life-expectancy-after-allogeneic2021-09-10daily0.9 https://clinresonc-new.lhten.com/cancer-incidence-in-world-trade-center-rescue-and-recovery-workers-142021-09-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-tisagenlecleucel-for-r-r-aggressive-b2021-09-11daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-adjuvant-3d-crt-versus-image-guided-imrt-after2021-09-11daily0.9 https://clinresonc-new.lhten.com/covid-19-vaccine-efficaccy-in-patients-with-hematologic-malignancies2021-09-13daily0.9 https://clinresonc-new.lhten.com/cassiopeia-part-2-daratumumab-maintenance-versus-observation-after-d2021-09-14daily0.9 https://clinresonc-new.lhten.com/stereotactic-ablative-radiotherapy-compared-with-vats-l-mlnd-for2021-09-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-addition-of-camrelizumab-to-first-line2021-09-15daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-frontline-acalabrutinib-venetoclax-and-obinutuzumab2021-09-15daily0.9 https://clinresonc-new.lhten.com/extended-therapy-with-letrozole-as-adjuvant-treatment-for2021-09-17daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-addition-of-panitumumab-to-maintenance-therapy2021-09-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-trastuzumab-deruxtecan-for-her2-mutant2021-09-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-pembrolizumab-for-persistent-recurrent2021-09-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-adjuvant-atezolizumab-after-adjuvant2021-09-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-radioembolization-with-chemotherapy2021-09-20daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-metronomic-chemotherapy-for2021-09-22daily0.9 https://clinresonc-new.lhten.com/retrospective-single-center-study-of-prognostic-significance-of-tils2021-09-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-tebentafusp-for-metastatic-uveal2021-09-23daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-poziotinib-for-her2-exon-20-mutant-non-small-cell2021-09-23daily0.9 https://clinresonc-new.lhten.com/trend-and-survival-benefit-of-contralateral-prophylactic-mastectomy2021-09-24daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-ivosidenib-for-advanced-cholangiocarcinoma-with2021-09-24daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-addition-of-tace-to-rfa-as-initial-treatment-for2021-09-27daily0.9 https://clinresonc-new.lhten.com/hearing-loss-after-radiation-and-chemotherapy-for-cns-and-head-and2021-09-28daily0.9 https://clinresonc-new.lhten.com/excess-risk-of-subsequent-malignant-neoplasms-in-adolescent-and-young2021-09-29daily0.9 https://clinresonc-new.lhten.com/outcomes-after-delayed-surgery-for-locally-advanced-rectal-cancer-not2021-09-29daily0.9 https://clinresonc-new.lhten.com/incidence-and-predictors-of-second-primary-cancers-in-patients-with2021-09-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-abiraterone-prednisone-plus2021-10-01daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-abiraterone-acetate-for-castration-resistant2021-10-02daily0.9 https://clinresonc-new.lhten.com/cancer-in-children-with-fanconi-anemia-and-ataxia-telangiectasia-in2021-10-02daily0.9 https://clinresonc-new.lhten.com/final-analysis-of-innovate-study-of-ibrutinib-plus-rituximab-for2021-10-05daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-camrelizumab-plus-apatinib-for-high-risk2021-10-06daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-systemic-treatmens-versus-primary-tumor-resection2021-10-06daily0.9 https://clinresonc-new.lhten.com/validation-of-pod24-as-a-robust-early-predictor-of-poor-survival-in2021-10-07daily0.9 https://clinresonc-new.lhten.com/efficacy-and-safety-of-cabozantinib-for-patients-with-advanced2021-10-07daily0.9 https://clinresonc-new.lhten.com/mrd-guided-discontinuation-of-first-line-ibrutinib-plus-venetoclax2021-10-08daily0.9 https://clinresonc-new.lhten.com/four-year-outcomes-of-checkmate-227-first-line-nivolumab-plus2021-10-12daily0.9 https://clinresonc-new.lhten.com/survival-in-young-onset-versus-older-onset-metastatic-colorectal2021-10-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-nab-sirolimus-for-malignant-perivascular2021-10-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-first-line-nivolumab-plus-low-dose2021-10-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-zilovertamab-vedotin-for-lymphoid-cancers2021-10-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-mobocertinib-for-platinum-pretreated2021-10-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-nivolumab-versus-placebo-for-relapsed2021-10-15daily0.9 https://clinresonc-new.lhten.com/addition-of-liposomal-irinotecan-to-second-line-fluorouracil2021-10-15daily0.9 https://clinresonc-new.lhten.com/adjuvant-trastuzumab-with-or-without-chemotherapy-for-pt1n0-her22021-10-16daily0.9 https://clinresonc-new.lhten.com/cancer-and-risk-of-covid-19-diagnosis-hospitalization-and-death2021-10-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-study-of-first-line-enasidenib-plus2021-10-19daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-prostate-cancer-screening-program-among2021-10-20daily0.9 https://clinresonc-new.lhten.com/menopausal-hormone-therapy-and-risk-of-esophageal-adenocarcinoma2021-10-21daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-cohort-study-of-cabozantinib-for-brain2021-10-21daily0.9 https://clinresonc-new.lhten.com/germline-pathogenic-variants-in-cancer-predisposition-genes-among2021-10-22daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-y90-radioembolization-followed-by-nivolumab-for2021-10-23daily0.9 https://clinresonc-new.lhten.com/effect-of-elective-internal-mammary-node-irradiation-on-disease-free2021-10-25daily0.9 https://clinresonc-new.lhten.com/mortality-trends-in-multiple-myeloma-after-the-introduction-of-novel2021-10-26daily0.9 https://clinresonc-new.lhten.com/maintenance-olaparib-for-newly-diagnosed-advanced-ovarian-cancer-in2021-10-27daily0.9 https://clinresonc-new.lhten.com/adjuvant-anthracycline-plus-taxane-versus-taxane-based-chemotherapy2021-10-28daily0.9 https://clinresonc-new.lhten.com/definitive-radiotherapy-in-lieu-of-systemic-therapy-for2021-10-28daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-cll14-first-line-obinutuzumab-with-veneticlax2021-10-29daily0.9 https://clinresonc-new.lhten.com/covid-19-mortality-and-adverse-outcomes-in-us-patients-with-or2021-10-29daily0.9 https://clinresonc-new.lhten.com/monosialotetrahexosylganglioside-for-chronic-oxaliplatin-induced2021-10-30daily0.9 https://clinresonc-new.lhten.com/impact-of-postoperative-chemotherapy-on-outcomes-of-adjuvant2021-11-02daily0.9 https://clinresonc-new.lhten.com/associations-of-kras-variant-subtypes-with-recurrence-and-survival2021-11-03daily0.9 https://clinresonc-new.lhten.com/association-between-mode-of-detection-of-melanoma-and-mortality2021-11-03daily0.9 https://clinresonc-new.lhten.com/prevalence-and-impact-of-covid-19-sequelae-on-treatment-and-survival2021-11-04daily0.9 https://clinresonc-new.lhten.com/association-of-her2-low-expression-with-efficacy-of-cdk4-6-inhibitor2021-11-05daily0.9 https://clinresonc-new.lhten.com/poor-outcomes-of-covid-19-after-car-t-cell-therapy-for-b-cell2021-11-08daily0.9 https://clinresonc-new.lhten.com/incidence-of-breast-cancer-recurrence-10-32-years-after-the-primary2021-11-08daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-the-italian-flexible-sigmoidoscopy-screening2021-11-09daily0.9 https://clinresonc-new.lhten.com/mrna-1273-covid-19-vaccination-in-patients-receiving-systemic-therapy2021-11-10daily0.9 https://clinresonc-new.lhten.com/treatment-free-survival-after-immune-checkpoint-inhibitor-therapy2021-11-10daily0.9 https://clinresonc-new.lhten.com/quality-of-life-with-docetaxel-plus-soc-versus-abiraterone-plus-soc2021-11-11daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-of-nivolumab-plus-ipilimumab-in-patients-with2021-11-11daily0.9 https://clinresonc-new.lhten.com/assessment-of-arsenic-trioxide-and-all-trans-retinoic-acid-for-the2021-11-12daily0.9 https://clinresonc-new.lhten.com/family-history-of-plasma-cell-disorders-and-overall-survival-in-mgus2021-11-12daily0.9 https://clinresonc-new.lhten.com/comparative-effectiveness-of-atezolizumab-nivolumab-and-docetaxel-for2021-11-12daily0.9 https://clinresonc-new.lhten.com/cancer-incidence-and-patterns-in-individuals-with-pathogenic-or2021-11-13daily0.9 https://clinresonc-new.lhten.com/effect-of-immunotherapy-time-of-day-infusion-on-overall-survival2021-11-13daily0.9 https://clinresonc-new.lhten.com/intensive-chemotherapy-versus-hypomethylating-agents-for-newly2021-11-14daily0.9 https://clinresonc-new.lhten.com/final-overall-survival-analysis-of-addition-of-177-lu-dotatate-to2021-11-16daily0.9 https://clinresonc-new.lhten.com/nivolumab-plus-ipilimumab-for-advanced-renal-cell-carcinoma-with2021-11-16daily0.9 https://clinresonc-new.lhten.com/tumor-site-and-the-prognosis-and-immunogenomics-of-hpv-related-cancers2021-11-18daily0.9 https://clinresonc-new.lhten.com/venetoclax-monotherapy-in-previously-treated-waldenstrom2021-11-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-fosnetupitant-versus-fosaprepitant-for2021-11-19daily0.9 https://clinresonc-new.lhten.com/preferred-sequence-of-crt-and-ct-in-neoadjuvant-therapy-for-locally2021-11-19daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-first-line-ibrutinib-plus-rituximab-for-mantle-cell2021-11-20daily0.9 https://clinresonc-new.lhten.com/radiation-therapy-enhances-immunotherapy-response-in-mss-colorectal2021-11-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-first-line-cabozantinib-plus2021-11-21daily0.9 https://clinresonc-new.lhten.com/virtual-reality-videos-for-educating-outpatients-for-bowel2021-11-22daily0.9 https://clinresonc-new.lhten.com/impact-of-fit-based-screening-on-crc-incidence-and-stage-at-crc2021-11-23daily0.9 https://clinresonc-new.lhten.com/response-to-a-third-dose-of-bnt162b2-mrna-vaccine-in-patients2021-11-23daily0.9 https://clinresonc-new.lhten.com/association-of-mammographic-density-with-risk-of-ipsilateral-breast2021-11-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-dabrafenib-plus-trametinib-for-braf2021-11-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-belzutifan-for-renal-cell-carcinoma-in2021-11-25daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-nivolumab-plus-ipilimumab-or-nivolumab-alone2021-11-25daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-triptrelin-during-chemotherapy-for-early2021-11-26daily0.9 https://clinresonc-new.lhten.com/association-of-dlnr-with-tumor-t-cell-infiltration-and-outcome-of2021-11-26daily0.9 https://clinresonc-new.lhten.com/imaging-biomarker-of-tumor-infiltrating-lymphocytes-to-risk-stratify2021-11-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-poziotinib-for-previously-treated2021-11-30daily0.9 https://clinresonc-new.lhten.com/association-of-tp53-gain-of-function-versus-non-gof-mutations-with2021-11-30daily0.9 https://clinresonc-new.lhten.com/phase-1b-2-study-of-polatuzumab-vedotin-obinutuzumab-lenalidomide-for2021-12-01daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-the-association-of-healthy-lifestyle-with-risk2021-12-01daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-21-gene-assay-to-inform-chemotherapy-benefit2021-12-02daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-cytoreductive-surgery-for-relapsed2021-12-02daily0.9 https://clinresonc-new.lhten.com/association-of-cd123-expression-with-high-risk-disease2021-12-03daily0.9 https://clinresonc-new.lhten.com/carfilzomib-en-dexamethason-met-of-zonder-daratumumab-voor2021-12-04daily0.9 https://clinresonc-new.lhten.com/impact-of-tp53-genomic-alterations-in-lbcl-treated-with-cd19-car-t2021-12-04daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-addition-of-hu14-18k322a-to-chemotherapy-for-newly2021-12-07daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-neoadjuvant-chemotherapy-to-allow-mandibular2021-12-07daily0.9 https://clinresonc-new.lhten.com/adjuvant-palbociclib-for-early-breast-cancer2021-12-08daily0.9 https://clinresonc-new.lhten.com/trastuzumab-deruxtecan-versus-trastuzumab-emtansine-for-her2-positive2021-12-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-axicabtagene-ciloleucel-for-relapsed-or2021-12-09daily0.9 https://clinresonc-new.lhten.com/association-of-hla-a-03-with-response-of-advanced-cancers-to-icis2021-12-10daily0.9 https://clinresonc-new.lhten.com/disease-burden-affects-outcomes-of-commercial-tisagenlecleucel-for-b2021-12-10daily0.9 https://clinresonc-new.lhten.com/response-adapted-omission-of-radiotherapy-for-intermediate-and2021-12-10daily0.9 https://clinresonc-new.lhten.com/association-between-residual-cancer-burden-after-neoadjuvant2021-12-11daily0.9 https://clinresonc-new.lhten.com/associations-of-response-rate-and-event-free-survival-with-overall2021-12-11daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-2nd-line-axicabtagene-ciloleucel-versus-standard-of2021-12-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-ponatinib-flag-ida-for-blast-phase-cml2021-12-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-addition-of-ivosidenib-to-azacitidine2021-12-13daily0.9 https://clinresonc-new.lhten.com/minimal-residual-disease-response-adapted-dara-krd-therapy-for-newly2021-12-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-pola-r-chp-versus-r-chop-for-newly2021-12-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-nivolumab-versus-sorafenib-for2021-12-14daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-hepatic-arterial-chemotherapy-infusion-versus2021-12-15daily0.9 https://clinresonc-new.lhten.com/triple-therapy-for-unresectable-or-metastatic-her2-positive-gastric2021-12-15daily0.9 https://clinresonc-new.lhten.com/mrd-response-and-prognosis-in-treatment-naive-aml-with-venetoclax-and2021-12-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-apatinib-versus-placebo-for-locally2021-12-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-mosunetuzumab-for-relapsed-or2021-12-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-camrelizumab-plus-carboplatin2021-12-17daily0.9 https://clinresonc-new.lhten.com/dietary-supplement-use-by-individuals-living-with-and-beyond-breast2021-12-20daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-nedaplatin-versus-cisplatin-based-concurrent2021-12-20daily0.9 https://clinresonc-new.lhten.com/adaptive-dosing-of-nivolumab-ipilimumab-based-upon-interim-ct-scan-in2021-12-21daily0.9 https://clinresonc-new.lhten.com/hrqol-with-enzalutamide-for-metastatic-hormone-sensitive-prostate2021-12-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-second-line-balstilimab-plus2021-12-22daily0.9 https://clinresonc-new.lhten.com/evaluation-of-pcr-in-neoadjuvant-clinical-trials-of-early-stage2021-12-22daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-tucatinib-added-to-trastuzumab-capecitabine-for2021-12-23daily0.9 https://clinresonc-new.lhten.com/cancer-risk-in-patients-with-bipolar-disorder-and-their-unaffected2021-12-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-combination-of-first-line-afatinib-plus2021-12-23daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-first-line-atezolizumab-plus-bevacizumab-versus2021-12-24daily0.9 https://clinresonc-new.lhten.com/abiraterone-acetate-and-prednisolone-with-or-without-enzalutamide-for2021-12-24daily0.9 https://clinresonc-new.lhten.com/short-term-changes-in-body-mass-index-and-waist-circumference-and-hcc2021-12-27daily0.9 https://clinresonc-new.lhten.com/survival-by-age-in-pediatric-and-adolescent-patients-with-hodgkin2021-12-29daily0.9 https://clinresonc-new.lhten.com/comparison-of-response-to-definitive-radiotherapy-for-localized2021-12-29daily0.9 https://clinresonc-new.lhten.com/updated-os-results-with-ribociclib-or-placebo-added-to-endocrine2021-12-30daily0.9 https://clinresonc-new.lhten.com/global-incidence-mortality-years-of-life-lost-years-lived-with2021-12-30daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-gnrha-to-protect-ovarian-function-in-women2021-12-31daily0.9 https://clinresonc-new.lhten.com/quantitative-scoring-system-for-the-diagnosis-of-inflammatory-breast2022-01-01daily0.9 https://clinresonc-new.lhten.com/d-rd-versus-rd-for-newly-diagnosed-mm-in-transplant-ineligible2022-01-02daily0.9 https://clinresonc-new.lhten.com/pten-promoter-methylation-predicts-10-year-prognosis-after-adjuvant2022-01-03daily0.9 https://clinresonc-new.lhten.com/hilotherapy-versus-frozen-gloves-for-prevention-of-taxane-related2022-01-04daily0.9 https://clinresonc-new.lhten.com/nmr-analysis-of-metabolomics-in-blood-samples-identify-cancers-in-a2022-01-05daily0.9 https://clinresonc-new.lhten.com/first-line-abiraterone-or-enzalutamide-for-mcrpc-in-african-american2022-01-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-3-study-of-addition-of-relatlimab-to-nivolumab2022-01-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-pembrolizumab-for-previously-treated2022-01-07daily0.9 https://clinresonc-new.lhten.com/oral-azacitidine-prolongs-survival-of-patients-with-aml-in-remission2022-01-08daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-value-of-telomerase-based-ctc-detection-for2022-01-10daily0.9 https://clinresonc-new.lhten.com/naive-t-cell-depletion-to-prevent-chronic-graft-versus-host-disease2022-01-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-ii-trial-of-inotuzumab-ozogamicin-for-r-r-b-all-in2022-01-11daily0.9 https://clinresonc-new.lhten.com/analysis-of-platelet-count-and-new-cancer-diagnosis-over-a-10-year2022-01-12daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-a-phase-2-study-of-erdafitinib-for-previously2022-01-12daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-chemotherapy-for-her2-negative-unresectable2022-01-12daily0.9 https://clinresonc-new.lhten.com/adjuvant-capecitabine-for-early-breast-cancer-15-year-overall2022-01-13daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-with-first-line-nivolumab-cabozantinib2022-01-13daily0.9 https://clinresonc-new.lhten.com/pilot-study-of-neoadjuvant-camrelizumab-plus-chemotherapy-for2022-01-13daily0.9 https://clinresonc-new.lhten.com/incidence-of-diabetes-and-hypertension-in-women-with-and-without-a2022-01-14daily0.9 https://clinresonc-new.lhten.com/myelodysplastic-syndrome-allohct-from-older-matched-sibling-donors2022-01-14daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-risk-stratification-for-early-onset-colorectal2022-01-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-ibrutinib-plus-rituximab-for-indolent2022-01-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-sugemalimab-versus-placebo-for-locally2022-01-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-chemotherapy-with-sugemalimab2022-01-15daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-adt-use-and-duration-with-definitive-rt-for2022-01-18daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-video-assisted-thoracoscopic-versus-open2022-01-19daily0.9 https://clinresonc-new.lhten.com/phase-ii-trial-of-imatinib-plus-binimetinib-for-treatment-naive2022-01-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-lenvatinib-plus-pembrolizumab-for2022-01-20daily0.9 https://clinresonc-new.lhten.com/risk-of-second-primary-malignancies-after-radioactive-iodine2022-01-20daily0.9 https://clinresonc-new.lhten.com/association-of-use-of-h1-antihistamines-with-hcc-risk-in-patients2022-01-20daily0.9 https://clinresonc-new.lhten.com/risk-of-breast-cancer-in-men-in-relation-to-weight-change2022-01-21daily0.9 https://clinresonc-new.lhten.com/association-of-familial-burden-of-cancer-with-outcomes-of2022-01-21daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-frontline-ibrutinib-rituximab-followed-by-r-hcvad2022-01-22daily0.9 https://clinresonc-new.lhten.com/prediction-of-severe-fatigue-after-breast-cancer-diagnosis2022-01-22daily0.9 https://clinresonc-new.lhten.com/outcomes-of-breast-cancer-patients-with-an-ultralow-risk-70-gene2022-01-22daily0.9 https://clinresonc-new.lhten.com/a-novel-nomogram-model-to-predict-postoperative-outcome-of-colorectal2022-01-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pyrotinib-plus-capecitabine-for-her22022-01-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-trastuzumab-pertuzumab-and-docetaxel-for2022-01-25daily0.9 https://clinresonc-new.lhten.com/cancer-risks-associated-with-brca1-and-brca2-pathogenic-variants2022-01-26daily0.9 https://clinresonc-new.lhten.com/excess-long-term-morbidity-with-abvd-and-limited-field-radiotherapy2022-01-26daily0.9 https://clinresonc-new.lhten.com/association-of-beta-blocker-use-at-time-of-radical-prostatectomy-with2022-01-26daily0.9 https://clinresonc-new.lhten.com/predictive-score-for-vertebral-compression-fracture-after2022-01-27daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-chemoradiotherapy-versus-upfront-surgery-for-resectable2022-01-28daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-efficacy-and-safety-of-larotrectinib-for-trk2022-01-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-neoadjuvant-atezolizumab-with2022-01-29daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-population-level-changes-in-survival-of2022-01-29daily0.9 https://clinresonc-new.lhten.com/propensity-score-matching-study-of-chemotherapy-for-ipsilateral2022-01-30daily0.9 https://clinresonc-new.lhten.com/bevacizumab-plus-irinotecan-with-or-without-gamma-knife-radiosurgery2022-01-30daily0.9 https://clinresonc-new.lhten.com/first-line-tki-with-or-without-rt-for-synchronous-oligometastatic2022-01-31daily0.9 https://clinresonc-new.lhten.com/identification-of-a-subset-of-stage-i-colorectal-cancer-patients-with2022-01-31daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-for-previously-treated-advanced-anal-squamous-cell2022-02-01daily0.9 https://clinresonc-new.lhten.com/predictive-value-of-tumor-mutational-burden-for-pembrolizumab2022-02-01daily0.9 https://clinresonc-new.lhten.com/adoptive-cell-transfer-of-autologous-tils-in-metastatic-breast-cancer2022-02-02daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-atezolizumab-with-bevacizumab-for-advanced-non2022-02-02daily0.9 https://clinresonc-new.lhten.com/five-year-survival-outcomes-from-the-pacific-trial-of-durvalumab2022-02-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-first-line-nivolumab-combination2022-02-03daily0.9 https://clinresonc-new.lhten.com/use-of-compression-sleeves-for-prevention-of-arm-swelling-in-women-at2022-02-03daily0.9 https://clinresonc-new.lhten.com/ais-versus-tamoxifen-for-premenopausal-er-positive-early-stage-breast2022-02-04daily0.9 https://clinresonc-new.lhten.com/phase-2-3-study-of-trametinib-versus-standard-of-care-for-recurrent2022-02-04daily0.9 https://clinresonc-new.lhten.com/sex-differences-in-risk-of-severe-adverse-events-in-swog-cancer2022-02-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-niraparib-in-patients-with-mcrpc-and2022-02-05daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-of-palbociclib-monotherapy-for-retroperitoneal2022-02-07daily0.9 https://clinresonc-new.lhten.com/nanoparticle-assisted-axillary-staging-after-neoadjuvant-chemotherapy2022-02-07daily0.9 https://clinresonc-new.lhten.com/ncdb-analysis-of-impact-of-sex-on-survival-of-central-nervous-system2022-02-08daily0.9 https://clinresonc-new.lhten.com/palbociclib-plus-endocrine-therapy-compared-to-et-alone-for-hr-her22022-02-08daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-copanlisib-for-tumors-with-pik3ca-mutations2022-02-09daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-icis-for-stage-iii-melanoma-representativeness-of2022-02-09daily0.9 https://clinresonc-new.lhten.com/outcomes-from-opportunistic-salpingectomy-for-ovarian-cancer2022-02-09daily0.9 https://clinresonc-new.lhten.com/event-free-survival-with-pembrolizumab-in-early-stage-triple-negative2022-02-10daily0.9 https://clinresonc-new.lhten.com/survival-with-cemiplimab-in-recurrent-cervical-cancer2022-02-10daily0.9 https://clinresonc-new.lhten.com/follow-up-of-icaria-mm-study-of-isatuximab-plus-pomalidomide-and-low2022-02-11daily0.9 https://clinresonc-new.lhten.com/clinical-models-to-predict-immunotherapy-outcomes-in-metastatic2022-02-11daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-abemaciclib-for-p16ink4a-deficient-mesothelioma2022-02-12daily0.9 https://clinresonc-new.lhten.com/pain-and-health-related-quality-of-life-in-the-profound-trial2022-02-12daily0.9 https://clinresonc-new.lhten.com/long-term-results-of-perioperative-dual-anti-her2-therapy-for-her22022-02-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-praluzatamab-ravtansine-for-advanced2022-02-14daily0.9 https://clinresonc-new.lhten.com/blinatumomab-followed-by-pomp-maintenance-for-newly-diagnosed-ph2022-02-15daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-folfirinox-as-initial-treatment-for2022-02-15daily0.9 https://clinresonc-new.lhten.com/association-of-timing-of-adjuvant-hormone-therapy-with-os-among2022-02-15daily0.9 https://clinresonc-new.lhten.com/first-in-human-study-of-adagrasib-for-advanced-kras-g12c-mutated2022-02-16daily0.9 https://clinresonc-new.lhten.com/survival-outcomes-with-chemotherapy-for-resectable-gallbladder-cancer2022-02-16daily0.9 https://clinresonc-new.lhten.com/mortality-after-late-breast-cancer-recurrence-in-denmark2022-02-17daily0.9 https://clinresonc-new.lhten.com/capecitabine-maintenance-therapy-after-induction-chemotherapy-for-22022-02-17daily0.9 https://clinresonc-new.lhten.com/darolutamide-and-survival-in-metastatic-hormone-sensitive-prostate2022-02-18daily0.9 https://clinresonc-new.lhten.com/risk-of-cancer-following-primary-care-presentation-with-fatigue2022-02-18daily0.9 https://clinresonc-new.lhten.com/addition-of-navitoclax-to-ongoing-ruxolitinib-for-myelofibrosis2022-02-19daily0.9 https://clinresonc-new.lhten.com/pre-existing-autoimmune-disease-and-mortality-in-patients-treated2022-02-21daily0.9 https://clinresonc-new.lhten.com/comparison-of-three-paclitaxel-based-chemoradiotherapy-regimens-for2022-02-21daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-survival-impact-of-secondary-cytoreductive-surgery2022-02-22daily0.9 https://clinresonc-new.lhten.com/value-of-adjuvant-anthracyclines-in-intermediate-or-high-risk-her22022-02-22daily0.9 https://clinresonc-new.lhten.com/associations-of-intake-of-red-or-processed-meat-with-risk-of2022-02-22daily0.9 https://clinresonc-new.lhten.com/response-adapted-treatment-following-radiotherapy-for-locally2022-02-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-sintilimab-plus-anlotininib-for-pd-l12022-02-23daily0.9 https://clinresonc-new.lhten.com/3-year-survival-update-of-phase-1b-study-of-toripalimab-plus-axitinib2022-02-23daily0.9 https://clinresonc-new.lhten.com/recurrence-and-mortality-risk-of-merkel-cell-carcinoma-by-cancer2022-02-23daily0.9 https://clinresonc-new.lhten.com/upfront-peptide-receptor-radionuclide-therapy-versus-chemotherapy-or2022-02-24daily0.9 https://clinresonc-new.lhten.com/cost-effectiveness-analysis-of-pertuzumab-with-trastuzumab-in2022-02-24daily0.9 https://clinresonc-new.lhten.com/phase-3b-4-checkmate-920-trial-of-nivolumab-plus-ipilimumab-for2022-02-25daily0.9 https://clinresonc-new.lhten.com/ribociclib-plus-letrozole-for-hr-positive-her2-negative-breast-cancer2022-02-25daily0.9 https://clinresonc-new.lhten.com/survival-outcomes-after-breast-conserving-therapy-compared-with2022-02-26daily0.9 https://clinresonc-new.lhten.com/optimal-duration-of-adjuvant-endocrine-therapy-for-er-low-positive2022-02-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-perioperative-sox-versus-folfox-for2022-02-28daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-of-adding-pertuzumab-to-trastuzumab-plus2022-02-28daily0.9 https://clinresonc-new.lhten.com/randomized-phase-1-trial-of-nivolumab-ipilimumab-with-or-without-live2022-03-01daily0.9 https://clinresonc-new.lhten.com/association-of-plasma-ebv-dna-with-outcomes-of-anti-pd-1-therapy-for2022-03-01daily0.9 https://clinresonc-new.lhten.com/development-of-cancer-among-patients-with-pediatric-onset2022-03-01daily0.9 https://clinresonc-new.lhten.com/postoperative-weekly-cisplatin-plus-radiotherapy-for-high-risk2022-03-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-neoadjuvant-and-adjuvant-hd201-versus2022-03-03daily0.9 https://clinresonc-new.lhten.com/prospective-cardiovascular-surveillance-of-ici-based-combination2022-03-04daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-famitinib-with-camrelizumab-and-nab-paclitaxel-for2022-03-04daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-characteristics-surveillance-treatments-and-outcomes2022-03-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-adding-mesenchymal-stromal-cells-to2022-03-07daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-impact-of-oophorectomy-on-breast-cancer-survival2022-03-07daily0.9 https://clinresonc-new.lhten.com/high-burden-of-clonal-hematopoiese-in-first-responders-exposed-to-the2022-03-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-tebentafusp-for-previously-treated2022-03-08daily0.9 https://clinresonc-new.lhten.com/multicenter-population-based-prospective-cohort-study-of-one-off-low2022-03-09daily0.9 https://clinresonc-new.lhten.com/temozolomide-followed-by-low-dose-ipilimumab-plus-nivolumab-for-mss2022-03-09daily0.9 https://clinresonc-new.lhten.com/survival-after-hipec-with-primary-or-interval-crs-in-ovarian-cancer2022-03-09daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-ribociclib-plus-letrozole-in-advanced-breast2022-03-10daily0.9 https://clinresonc-new.lhten.com/thyroidectomy-with-versus-without-radioiodine-in-patients-with-low2022-03-10daily0.9 https://clinresonc-new.lhten.com/twenty-year-trends-in-grade-5-toxicity-and-response-in-phase-i-trials2022-03-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-testing-bortezomib-in-newly-diagnosed-t-all2022-03-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-pembrolizumab-for-classic-or-endemic2022-03-11daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-post-diagnostic-beta-blocker-use-and2022-03-14daily0.9 https://clinresonc-new.lhten.com/incidence-of-metastatic-prostate-cancer-before-and-after-the-uspstf2022-03-14daily0.9 https://clinresonc-new.lhten.com/rucaparib-versus-standard-chemotherapy-for-relapsed-brca1-or-brca22022-03-15daily0.9 https://clinresonc-new.lhten.com/risk-and-outcome-of-breakthrough-covid-19-infections-in-vaccinated2022-03-15daily0.9 https://clinresonc-new.lhten.com/european-precision-medicine-program-for-recurrent-malignancies-in2022-03-16daily0.9 https://clinresonc-new.lhten.com/adjuvant-versus-early-salvage-radiation-therapy-after-radical2022-03-16daily0.9 https://clinresonc-new.lhten.com/risk-of-colorectal-cancer-associated-with-lifetime-excess-weight2022-03-17daily0.9 https://clinresonc-new.lhten.com/manual-therapy-for-patients-with-radiation-associated-trismus-after2022-03-17daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-cabozantinib-plus-nivolumab-for-advanced-non-clear2022-03-18daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-oral-selinexor-as-maintenance-therapy-after-first2022-03-18daily0.9 https://clinresonc-new.lhten.com/real-world-efficacy-of-lenvatinib-plus-pd-blockade-in-advanced2022-03-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-avelumab-palbociclib-and-axitinib-for2022-03-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-axicabtagene-ciloleucel-as-first-line2022-03-21daily0.9 https://clinresonc-new.lhten.com/total-circulating-microrna-level-as-an-independent-prognostic-marker2022-03-22daily0.9 https://clinresonc-new.lhten.com/adjuvant-capecitabine-after-resection-of-biliary-tract-cancer-long2022-03-23daily0.9 https://clinresonc-new.lhten.com/durvalumab-and-tremelimumab-with-definitive-chemoradiotherapy-for2022-03-23daily0.9 https://clinresonc-new.lhten.com/trastuzumab-deruxtecan-versus-trastuzumab-emtansine-for-her2-positive-22022-03-24daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-lintuzumab-conjugated-to-actinium-225-for-relapsed2022-03-24daily0.9 https://clinresonc-new.lhten.com/laparoscopic-sentinel-node-navigation-surgery-for-stomach2022-03-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-dostarlimab-in-doublet-triplet2022-03-25daily0.9 https://clinresonc-new.lhten.com/association-of-pd-l1-combined-positive-score-with-efficacy-of2022-03-26daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-combination-of-bcma-and-cd19-car-t-cell2022-03-26daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-camrelizumab-plus-chemotherapy-for2022-03-26daily0.9 https://clinresonc-new.lhten.com/cumulative-burden-of-psychiatric-disorders-and-self-harm-across-262022-03-28daily0.9 https://clinresonc-new.lhten.com/suicide-risk-and-mortality-among-patients-with-cancer2022-03-28daily0.9 https://clinresonc-new.lhten.com/characteristics-and-prognosis-of-acquired-resistance-to-immune2022-03-29daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-egfr-inhibition-for-metastatic-or2022-03-30daily0.9 https://clinresonc-new.lhten.com/recipient-and-donor-outcomes-after-living-donor-liver-transplant-for2022-03-30daily0.9 https://clinresonc-new.lhten.com/association-of-ct-screening-with-lung-cancer-stage-shift-and-survival2022-03-31daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-stils-in-young-node-negative-chemotherapy-naive2022-03-31daily0.9 https://clinresonc-new.lhten.com/comparative-effectiveness-of-icis-versus-chemotherapy-by-tumor2022-03-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-pembrolizumab-versus-placebo-after-22022-04-01daily0.9 https://clinresonc-new.lhten.com/survival-with-adjuvant-chemotherapy-after-neoadjuvant-chemotherapy2022-04-01daily0.9 https://clinresonc-new.lhten.com/ncdb-analysis-of-adding-systemic-to-local-therapy-for-stage-i2022-04-02daily0.9 https://clinresonc-new.lhten.com/overall-survival-analysis-of-phase-3-olympia-study-of-adjuvant2022-04-02daily0.9 https://clinresonc-new.lhten.com/independent-roles-of-various-factors-in-the-risk-of-breast-cancer2022-04-03daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-perioperative-camrelizumab-plus-apatinib-for2022-04-04daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-c-reactive-protein-trajectories-and-the2022-04-04daily0.9 https://clinresonc-new.lhten.com/prognostic-impact-of-mrd-status-before-and-during-lenalidomide2022-04-05daily0.9 https://clinresonc-new.lhten.com/association-of-psychosocial-health-and-lifestyle-with-prognosis-after2022-04-06daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-hyperprogression-with-icis-versus-placebo-for2022-04-06daily0.9 https://clinresonc-new.lhten.com/risk-of-cardiovascular-disease-in-women-with-and-without-breast-cancer2022-04-07daily0.9 https://clinresonc-new.lhten.com/risk-factors-and-prognostic-implications-of-cancer-diagnosis-within2022-04-07daily0.9 https://clinresonc-new.lhten.com/atezolizumab-plus-bevacizumab-for-advanded-progressive-neuroendocrine2022-04-07daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-quality-of-life-in-older-adults-after-major2022-04-08daily0.9 https://clinresonc-new.lhten.com/breakthrough-sars-cov-2-infections-hospitalizations-and-mortality-in2022-04-08daily0.9 https://clinresonc-new.lhten.com/switch-maintenance-endocrine-therapy-after-induction-chemotherapy-for2022-04-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-3-study-of-selinexor-for-previously-treated2022-04-09daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-micrornas-as-biomarkers-and-radiosensitivity2022-04-10daily0.9 https://clinresonc-new.lhten.com/real-world-efficacy-and-safety-of-combination-of-pd-1-inhibition-and2022-04-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-neoadjuvant-chemoimmunotherapy-for2022-04-12daily0.9 https://clinresonc-new.lhten.com/endocrine-therapy-response-and-21-gene-expression-assay-for-therapy2022-04-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-fuzuloparib-maintenance-therapy-for2022-04-12daily0.9 https://clinresonc-new.lhten.com/overall-survival-analysis-of-keynote-177-pembrolizumab-versus2022-04-13daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-blood-based-tumor-mutational-burden-as-a2022-04-14daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-first-line-cabozantinib-for-metastatic-collecting2022-04-15daily0.9 https://clinresonc-new.lhten.com/overall-survival-analysis-of-arches-enzalutamide-for-metastatic2022-04-15daily0.9 https://clinresonc-new.lhten.com/incorporation-of-functional-status-frailty-comorbidities-and-co2022-04-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-first-line-sintilimab-chemotherapy2022-04-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-narsoplimab-for-hsct-associated2022-04-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-navicixizumab-plus-paclitaxel-for2022-04-20daily0.9 https://clinresonc-new.lhten.com/bempegaldesleukin-plus-nivolumab-as-first-line-treatment-for-advanced2022-04-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-addition-of-ivosidenib-to-azacitidine-22022-04-21daily0.9 https://clinresonc-new.lhten.com/association-of-pathogenic-variants-in-hereditary-cancer-genes-with2022-04-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-non-inferiority-study-of-segmentectomy-versus2022-04-22daily0.9 https://clinresonc-new.lhten.com/durvalumab-alone-or-in-combination-with-oleclumab-or-monalizumab-for2022-04-23daily0.9 https://clinresonc-new.lhten.com/characteristics-of-women-with-short-survival-after-diagnosis-of2022-04-24daily0.9 https://clinresonc-new.lhten.com/association-of-echocardiography-defined-pulmonary-hypertension-and2022-04-25daily0.9 https://clinresonc-new.lhten.com/phase-3-non-inferiority-trial-of-topical-imiquimod-versus-surgery-for2022-04-26daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-digital-remote-monitoring-of-patients-treated-with2022-04-26daily0.9 https://clinresonc-new.lhten.com/perioperative-breathomics-testing-for-identification-of-lung-cancer2022-04-27daily0.9 https://clinresonc-new.lhten.com/phase-1-2-study-of-topical-submicron-particle-paclitaxel-for2022-04-27daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-sbrt-plus-nivolumab-with-or-without2022-04-28daily0.9 https://clinresonc-new.lhten.com/outcomes-of-open-versus-robot-assisted-radical-cystectomy-for-bladder2022-04-28daily0.9 https://clinresonc-new.lhten.com/fase-2-study-of-organ-preservation-with-total-neoadjuvant-therapy-for2022-04-29daily0.9 https://clinresonc-new.lhten.com/icis-versus-chemotherapy-both-combined-with-rt-after-resection-of2022-04-29daily0.9 https://clinresonc-new.lhten.com/association-between-antibiotic-use-and-colon-and-rectal-cancer2022-04-30daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-addition-of-venetoclax-to-induction-chemotherapy2022-05-01daily0.9 https://clinresonc-new.lhten.com/association-between-androgen-deprivation-therapy-for-non-metastatic2022-05-01daily0.9 https://clinresonc-new.lhten.com/treatment-efficacy-score-to-compare-neoadjuvant-chemotherapy-efficacy2022-05-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-venetoclax-plus-3-72022-05-03daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analyses-of-electronic-health2022-05-03daily0.9 https://clinresonc-new.lhten.com/subsequent-primary-cancer-risk-among-five-year-survivors-of2022-05-04daily0.9 https://clinresonc-new.lhten.com/multcenter-phase-1-study-of-the-antibody-drug-conjugate-mrg003-for2022-05-05daily0.9 https://clinresonc-new.lhten.com/association-of-fam19a4-mir124-2-dna-methylation-and-clinical2022-05-06daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-first-line-anlotinib-plus-platinum-etoposide-for2022-05-08daily0.9 https://clinresonc-new.lhten.com/demographics-of-patients-receiving-car-t-cell-therapy-in-the-united2022-05-09daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-claudin18-2-specific-car-t-cells-for-previously2022-05-09daily0.9 https://clinresonc-new.lhten.com/three-year-follow-up-of-phase-1b-study-of-neoadjuvant-sintilimab-for2022-05-10daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-camrelizumab-plus-famitinib-for-advanced-metastatic2022-05-11daily0.9 https://clinresonc-new.lhten.com/hepatic-arterial-infusion-pump-chemotherapy-versus-resection-for2022-05-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-vistusertib-plus-anastrazole-for-hr2022-05-12daily0.9 https://clinresonc-new.lhten.com/addition-of-adt-and-pelvic-lymph-node-treatment-to-prostate-bed2022-05-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-fixed-duration-ibrutinib-venetoclax-in2022-05-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adding-adebrelimab-to-first-line2022-05-14daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-addition-of-tiragolumab-to-first-line2022-05-14daily0.9 https://clinresonc-new.lhten.com/overall-survival-in-phase-2-nadim-trial-of-neoadjuvant-nivolumab-plus2022-05-17daily0.9 https://clinresonc-new.lhten.com/racial-disparity-in-distant-recurrence-free-survival-in-patients-with2022-05-17daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-first-line-aumolertinib-versus-gefitinib-for2022-05-18daily0.9 https://clinresonc-new.lhten.com/ctdna-as-risk-stratifying-biomarker-in-stage-iii-and-iv-wilms-tumor2022-05-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-elacestrant-versus-standard-endocrine2022-05-19daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-response-2-study-of-ruxolitinib-for2022-05-19daily0.9 https://clinresonc-new.lhten.com/two-neoadjuvant-nab-paclitaxel-regimes-with-or-without-denosumab-for2022-05-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-lurbinectedin-for-relapsed-ewing2022-05-20daily0.9 https://clinresonc-new.lhten.com/overall-survival-of-patients-with-metastatic-breast-cancer-in-sweden2022-05-22daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-rcts-of-doacs-versus-lmwhs-for-treatment-of-cancer2022-05-22daily0.9 https://clinresonc-new.lhten.com/splenomegaly-predicts-survival-of-patients-receiving-immune2022-05-23daily0.9 https://clinresonc-new.lhten.com/intracranial-efficacy-and-safety-of-lorlatinib-for-alk-positive2022-05-24daily0.9 https://clinresonc-new.lhten.com/impact-of-adjuvant-metformin-versus-placebo-on-invasive-disease-free2022-05-24daily0.9 https://clinresonc-new.lhten.com/association-between-smoking-history-and-overall-survival-in-patients2022-05-25daily0.9 https://clinresonc-new.lhten.com/risk-of-hematologic-cancers-in-patients-with-undifferentiated-pruritus2022-05-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-study-of-olutasidenib-for-relapsed-or2022-05-26daily0.9 https://clinresonc-new.lhten.com/prospective-evaluation-of-taste-function-in-patients-receiving-imrt2022-05-26daily0.9 https://clinresonc-new.lhten.com/effect-of-supine-vs-prone-breast-radiotherapy-on-acute-skin-toxicity2022-05-26daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-in-soft-tissue-sarcomas-with-tertiary-lymphoid2022-05-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-upfront-folfoxiri-bevacizumaz-with-or2022-05-28daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-sintilimab-plus-anlotinib-for-recurrent-or-advanced2022-05-28daily0.9 https://clinresonc-new.lhten.com/bosutinib-versus-imatinib-for-newly-diagnosed-chronic-phase-chronic2022-05-29daily0.9 https://clinresonc-new.lhten.com/subsequent-treatments-beyond-progression-on-osimertinib-in-egfr2022-05-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-topical-pimecrolimus-for-early-stage2022-05-31daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-mrd-guided-stop-and-start-of-venetoclax2022-05-31daily0.9 https://clinresonc-new.lhten.com/addition-of-bevacizumab-to-first-line-erlotinib-for-egfr-mutated2022-06-01daily0.9 https://clinresonc-new.lhten.com/efficacy-of-epigallocatechin-3-gallate-in-preventing-dermatitis-in2022-06-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-durvalumab-plus-chemotherapy-for2022-06-02daily0.9 https://clinresonc-new.lhten.com/neoantigen-t-cell-receptor-gene-therapy-in-metastatic-pancreatic2022-06-02daily0.9 https://clinresonc-new.lhten.com/adjuvant-abemaciclib-plus-endocrine-therapy-after-neoadjuvant2022-06-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-first-line-furmonertinib-versus2022-06-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-ibrutinib-plus-bendamustine-and2022-06-03daily0.9 https://clinresonc-new.lhten.com/association-of-bariatric-surgery-with-cancer-risk-and-mortality-in2022-06-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-adagrasib-for-previously-treated-nsclc2022-06-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-abiraterone-plus-olaparib-for2022-06-04daily0.9 https://clinresonc-new.lhten.com/ramucirumab-plus-pembrolizumab-versus-standard-of-care-for-advanced2022-06-04daily0.9 https://clinresonc-new.lhten.com/fulvestrant-plus-capivasertib-for-aromatase-inhibitor-resistant-er2022-06-05daily0.9 https://clinresonc-new.lhten.com/circulating-tumor-dna-analysis-to-guide-adjuvant-therapy-in-stage-ii2022-06-05daily0.9 https://clinresonc-new.lhten.com/two-year-follow-up-of-ciltacabtagene-autoleucel-for-relapsed-or2022-06-05daily0.9 https://clinresonc-new.lhten.com/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast2022-06-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-teclistamab-for-relapsed-or2022-06-06daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-dostarlimab-for-mismatch-repair-deficient-locally2022-06-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-rucaparib-maintenance-after-primary2022-06-07daily0.9 https://clinresonc-new.lhten.com/association-of-physician-adenoma-detection-rates-with-postcolonoscopy2022-06-07daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-cabozantinib-versus-sunitinib-for-arcc-long2022-06-08daily0.9 https://clinresonc-new.lhten.com/cabozantinib-plus-atezolizumab-for-mcrpc-after-progression-on-novel2022-06-09daily0.9 https://clinresonc-new.lhten.com/breast-cancer-related-lymphedema-risk-factors-and-racial-or-ethnic2022-06-09daily0.9 https://clinresonc-new.lhten.com/association-of-low-and-intermediate-combined-positive-score-with2022-06-09daily0.9 https://clinresonc-new.lhten.com/imaging-response-to-contemporary-immuno-oncology-combination2022-06-10daily0.9 https://clinresonc-new.lhten.com/cancer-therapy-approval-timings-in-the-us-and-europe-2010-20192022-06-10daily0.9 https://clinresonc-new.lhten.com/ten-gene-ddr-pathway-gene-expression-signature-predicts-response-of2022-06-11daily0.9 https://clinresonc-new.lhten.com/impact-of-belantamab-mafodotin-induced-ocular-toxicity-on-outcomes-of2022-06-13daily0.9 https://clinresonc-new.lhten.com/literature-review-of-the-role-of-cesium-131-brachytherapy-in-brain2022-06-13daily0.9 https://clinresonc-new.lhten.com/molecular-international-prognostic-scoring-system-for-myelodysplastic2022-06-14daily0.9 https://clinresonc-new.lhten.com/impact-of-glycemic-status-on-association-between-light-to-moderate2022-06-14daily0.9 https://clinresonc-new.lhten.com/genomic-determinants-of-early-recurrences-in-low-stage-low-grade2022-06-14daily0.9 https://clinresonc-new.lhten.com/absolute-risk-of-oropharyngeal-cancer-after-an-hpv16-e6-serology-test2022-06-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-study-of-mri-guided-focused-ultrasound-focal2022-06-15daily0.9 https://clinresonc-new.lhten.com/prognostic-impact-of-obesity-in-newly-diagnosed-glioblastoma2022-06-15daily0.9 https://clinresonc-new.lhten.com/venetoclax-plus-clad-ldac-alternating-with-venetoclax-plus-5-aza-for2022-06-16daily0.9 https://clinresonc-new.lhten.com/treatment-of-anal-high-grade-squamous-intraepithelial-lesions-to2022-06-16daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-pegasparaginase-based-versus-l-asparaginase-based2022-06-16daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-study-of-addition-of-enzalutamide-to2022-06-16daily0.9 https://clinresonc-new.lhten.com/second-line-lisocabtagene-maraleucel-versus-standard-of-care-for2022-06-17daily0.9 https://clinresonc-new.lhten.com/final-overall-survival-analysis-of-gemcitabine-and-cisplatin2022-06-17daily0.9 https://clinresonc-new.lhten.com/direct-acting-antivirals-as-primary-treatment-for-hcv-associated2022-06-18daily0.9 https://clinresonc-new.lhten.com/association-of-healthy-lifestyle-after-endoscopic-polypectomy-with2022-06-19daily0.9 https://clinresonc-new.lhten.com/efficacy-and-tolerability-of-regorafenib-in-pretreated-patients-with2022-06-19daily0.9 https://clinresonc-new.lhten.com/ecological-study-of-regional-inequalities-of-tumor-size-at-diagnosis2022-06-20daily0.9 https://clinresonc-new.lhten.com/utility-of-hospital-frailty-risk-score-for-predicting-postoperative2022-06-21daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-eribulin-gemcitabine-combination-therapy-for2022-06-21daily0.9 https://clinresonc-new.lhten.com/differential-prognostic-effect-of-systemic-inflammation-in-nsclc2022-06-22daily0.9 https://clinresonc-new.lhten.com/long-term-survival-in-elderly-women-receiving-chemotherapy-for-non2022-06-22daily0.9 https://clinresonc-new.lhten.com/final-results-of-two-phase-3-studies-of-addition-of-pcv-chemotherapy2022-06-23daily0.9 https://clinresonc-new.lhten.com/long-term-morbidity-in-survivors-of-aml-treated-with-blood-or-marrow2022-06-23daily0.9 https://clinresonc-new.lhten.com/ipilimumab-versus-chemotherapy-combined-with-nivolumab-trastuzumab2022-06-23daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-study-of-first-line-olaparib-plus2022-06-24daily0.9 https://clinresonc-new.lhten.com/association-of-gut-microbiota-and-metabolites-with-outcomes-of-immune2022-06-24daily0.9 https://clinresonc-new.lhten.com/update-of-overall-survival-in-paloma-3-study-of-palbociclib-and2022-06-24daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-nivolumab-for-relapsed-or-refractory-peripheral-t2022-06-25daily0.9 https://clinresonc-new.lhten.com/exploratory-analysis-of-maintenance-phase-of-impower1332022-06-25daily0.9 https://clinresonc-new.lhten.com/four-year-follow-up-of-nivolumab-plus-low-dose-ipilimumab-for2022-06-26daily0.9 https://clinresonc-new.lhten.com/prevalence-and-predictors-of-adjuvant-chemotherapy-use-after2022-06-26daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-neoadjuvant-chemotherapy2022-06-27daily0.9 https://clinresonc-new.lhten.com/efficacy-of-subsequent-chemotherapy-after-progression-of-brca-mutated2022-06-27daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-taxane-maintenance-versus-surveillance-in-advanced2022-06-28daily0.9 https://clinresonc-new.lhten.com/multicenter-first-in-human-study-of-ezh2-inibition-for-relapsed-or2022-06-28daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-adjuvant-nivolumab-after-salvage-resection-for2022-06-28daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-atezolizumab-plus-anti-her2-therapy-and-chemotherapy-for2022-06-29daily0.9 https://clinresonc-new.lhten.com/persistent-disparities-in-uptake-of-colorectal-cancer-screening-in2022-06-29daily0.9 https://clinresonc-new.lhten.com/oncolytic-dnx-2401-virus-for-pediatric-diffuse-intrinsic-pontine2022-06-30daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-neoadjuvant-chemoimmunotherapy-for-locally-advanced2022-06-30daily0.9 https://clinresonc-new.lhten.com/association-of-abemaciclib-for-metastatic-breast-cancer-with-venous2022-06-30daily0.9 https://clinresonc-new.lhten.com/systematic-pan-cancer-analysis-of-mutation-treatment-interactions2022-06-30daily0.9 https://clinresonc-new.lhten.com/incidence-of-cardiovascular-events-in-patients-treated-with-immune2022-07-01daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-addition-of-apatinib-to-pegylated-liposomal2022-07-01daily0.9 https://clinresonc-new.lhten.com/three-versus-six-months-of-oxaliplatin-added-to-six-months-of2022-07-01daily0.9 https://clinresonc-new.lhten.com/three-versus-six-months-of-oxaliplatin-added-to-six-months-of-22022-07-01daily0.9 https://clinresonc-new.lhten.com/risk-of-second-brain-tumor-after-radiotherapy-for-pituitary-adenoma2022-07-01daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-circulating-protein-biomarkers-for-colorectal2022-07-03daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-neoadjuvant-niraparib-for-her2-negative-brca2022-07-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-first-line-cabozantinib-plus-22022-07-05daily0.9 https://clinresonc-new.lhten.com/efficacy-of-avapritinib-versus-best-available-therapy-for-advanced2022-07-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-mosunetuzumab-for-relapsed-or2022-07-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-immune-checkpoint-inhibitors-in-kidney2022-07-07daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-pertuzumab-and-trastuzumab-plus-atezolizumab-and2022-07-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-zanubrutinib-versus-bendamustine-and2022-07-08daily0.9 https://clinresonc-new.lhten.com/niraparib-plus-nivolumab-or-niraparib-plus-ipilimumab-maintenance-for2022-07-08daily0.9 https://clinresonc-new.lhten.com/niraparib-plus-nivolumab-or-niraparib-plus-ipilimumab-maintenance-for-22022-07-08daily0.9 https://clinresonc-new.lhten.com/long-term-morbidity-and-mortality-in-children-after-in-utero-exposure2022-07-08daily0.9 https://clinresonc-new.lhten.com/proton-craniospinal-irradiation-versus-photon-involved-field2022-07-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-trabectedin-to-first-line2022-07-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-post-hsct-eprenetapopt-plus-azacitidine2022-07-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-second-line-lisocabtagene-maraleucel-for2022-07-13daily0.9 https://clinresonc-new.lhten.com/long-term-benefits-of-tagraxofusp-for-patients-with-blastic2022-07-13daily0.9 https://clinresonc-new.lhten.com/multinational-trial-of-intensive-multimodality-therapy-for2022-07-13daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-brentuximab-vedotin-for-stage-iii-or-iv-hodgkin2022-07-14daily0.9 https://clinresonc-new.lhten.com/review-of-frontline-treatments-for-philadelphia-chromosome-positive2022-07-14daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-mfolfirinox-with-or-without-hypofractionated-radiotherapy2022-07-14daily0.9 https://clinresonc-new.lhten.com/overall-survival-in-polo-study-of-olaparib-maintenance-for-metastatic2022-07-15daily0.9 https://clinresonc-new.lhten.com/long-term-results-of-precis-study-of-radiotherapy-versus-autologous2022-07-15daily0.9 https://clinresonc-new.lhten.com/longitudinal-monitoring-of-circulating-tumor-dna-to-predict-treatment2022-07-15daily0.9 https://clinresonc-new.lhten.com/effect-of-clinical-trial-enrollment-on-overall-survival-in2022-07-16daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-toxicity-profiles-of-tyrosine-kinase-inhibitors-and2022-07-18daily0.9 https://clinresonc-new.lhten.com/clinical-outcomes-and-risk-stratification-of-early-stage-melanoma2022-07-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-venetoclax-plus-gilteritinib-for-flt32022-07-19daily0.9 https://clinresonc-new.lhten.com/final-overall-survival-data-from-orient-11-trial-of-first-line2022-07-20daily0.9 https://clinresonc-new.lhten.com/ten-year-outcomes-impact-of-downstaging-of-hepatocellular-carcinoma2022-07-20daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-intensive-versus-minimalist-follow-up-after2022-07-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-oral-paclitaxel-plus-encequidar-versus2022-07-21daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-pembrolizumab-plus-chemotherapy-for-advanced2022-07-21daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-intratumoral-oncolytic-herpes-virus-g47-for-residual2022-07-22daily0.9 https://clinresonc-new.lhten.com/twenty-year-benefit-from-adjuvant-goserelin-and-tamoxifen-for2022-07-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-lenvatinib-plus-pembrolizumab-for2022-07-23daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-modification-of-the-association-between-frequent2022-07-23daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-first-line-brentuximab-vedotin-plus2022-07-23daily0.9 https://clinresonc-new.lhten.com/analysis-of-circulating-cytokines-for-identification-of-malignant2022-07-25daily0.9 https://clinresonc-new.lhten.com/long-term-risk-of-cardiovascular-disease-mortality-among-classic2022-07-25daily0.9 https://clinresonc-new.lhten.com/deep-learning-vs-tradtional-breast-cancer-risk-models-to-support-risk2022-07-25daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-sbrt-and-in-situ-virus-gene-therapy-followed-by2022-07-26daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-long-term-risk-of-hospitalization2022-07-26daily0.9 https://clinresonc-new.lhten.com/outcomes-after-gamma-knife-radiosurgery-for-intraventricular2022-07-27daily0.9 https://clinresonc-new.lhten.com/salvage-resection-plus-cesium-131-brachytherapy-for-post-srs2022-07-28daily0.9 https://clinresonc-new.lhten.com/daily-insulin-dose-and-cancer-risk-among-patients-with-type-1-diabetes2022-07-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-talazoparib-plus-avelumab-for-recurrent2022-07-28daily0.9 https://clinresonc-new.lhten.com/risk-of-second-primary-cancer-after-primary-radiotherapy-versus2022-07-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-sintilimab-plus-ibi305-and-chemotherapy2022-07-29daily0.9 https://clinresonc-new.lhten.com/clinical-outcomes-by-race-in-a-phase-1-2-trial-of-neoadjuvant2022-07-29daily0.9 https://clinresonc-new.lhten.com/real-world-treatment-drop-off-among-recurrent-or-metastatic-cervical2022-07-30daily0.9 https://clinresonc-new.lhten.com/mendelian-randomization-analysis-of-causal-association-of-smoking-or2022-07-30daily0.9 https://clinresonc-new.lhten.com/impact-of-fertility-preservation-on-risk-of-recurrence-and-odds-of2022-07-31daily0.9 https://clinresonc-new.lhten.com/regrouping-of-luminal-b-her2-negative-breast-cancers2022-08-01daily0.9 https://clinresonc-new.lhten.com/circulating-tumor-dna-to-guide-rechallenge-with-panitumumab-in2022-08-01daily0.9 https://clinresonc-new.lhten.com/first-line-avelumab-for-pd-l1-positive-metastatic-urothelial-cancer2022-08-02daily0.9 https://clinresonc-new.lhten.com/prognosis-of-hpv-independent-and-hpv-associated-vulvar-squamous-cell2022-08-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-study-of-cediranib-plus-olaparib-for-recurrent2022-08-03daily0.9 https://clinresonc-new.lhten.com/therapeutic-value-of-sentinel-lymph-node-biopsy-in-patients-with2022-08-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-transarterial2022-08-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-cns-activitity-of-first-line2022-08-04daily0.9 https://clinresonc-new.lhten.com/association-between-psa-screening-and-prostate-cancer-mortality-among2022-08-04daily0.9 https://clinresonc-new.lhten.com/real-world-evaluation-of-immunotherapy-after-chemoradiation-for-stage2022-08-04daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-durvalumab-plus-tremelimumab-for-advanced-soft2022-08-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-radiation-doses-and-fractionation2022-08-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-atezolizumab-vemurafenib-and2022-08-06daily0.9 https://clinresonc-new.lhten.com/partial-versus-whole-breast-irradiation-after-breast-conserving2022-08-06daily0.9 https://clinresonc-new.lhten.com/real-life-analysis-of-use-of-icis-for-ansclc-in-france-and-germany2022-08-07daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-trastuzumab-deruxtecan-in-her2-positive-breast2022-08-08daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-galunisertib-plus-neoadjuvant-chemoradiotherapy-for2022-08-09daily0.9 https://clinresonc-new.lhten.com/end-of-life-use-of-systemic-therapy-in-patients-with-advanced2022-08-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-pazopanib-for-incurable-angiosarcoma2022-08-10daily0.9 https://clinresonc-new.lhten.com/physical-activity-in-stage-iii-colon-cancer-calgb-swog-807022022-08-10daily0.9 https://clinresonc-new.lhten.com/six-year-results-of-first-line-lenalidomide-rituximab-versus2022-08-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-ripretinib-versus-sunitinib-for2022-08-11daily0.9 https://clinresonc-new.lhten.com/analysis-of-trends-of-toxicity-and-response-in-national-cancer2022-08-12daily0.9 https://clinresonc-new.lhten.com/rituximab-lenalidomide-and-ibrutinib-before-chemotherapy-for-newly2022-08-12daily0.9 https://clinresonc-new.lhten.com/chest-ct-scan-plus-x-ray-versus-chest-x-ray-follow-up-after-complete2022-08-12daily0.9 https://clinresonc-new.lhten.com/rates-of-brain-metastases-and-association-with-breast-cancer-subtypes2022-08-12daily0.9 https://clinresonc-new.lhten.com/pan-cancer-efficacy-of-pralsetinib-in-patients-with-advanced-ret2022-08-13daily0.9 https://clinresonc-new.lhten.com/final-overall-survival-analysis-of-eloquent-3-elotuzumab-plus2022-08-13daily0.9 https://clinresonc-new.lhten.com/biomarker-selected-phase-2-trial-of-maintenance-rucaparib-after2022-08-13daily0.9 https://clinresonc-new.lhten.com/pralsetinib-in-ret-fusion-positive-non-small-cell-lung-cancer-update2022-08-14daily0.9 https://clinresonc-new.lhten.com/propensity-score-analysis-of-frontline-low-dose-versus-standard-dose2022-08-14daily0.9 https://clinresonc-new.lhten.com/seer-based-analysis-of-survival-benefits-with-primary-tumor-surgery2022-08-15daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-nivolumab-plus-ipilimumab-and-adjuvant-nivolumab-for2022-08-16daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-association-of-icis-with-patient-reported-outcomes2022-08-16daily0.9 https://clinresonc-new.lhten.com/extent-of-tumor-resection-and-survival-in-pedriatic-patients-with2022-08-16daily0.9 https://clinresonc-new.lhten.com/fgfr4-alterations-predict-efficacy-of-immune-checkpoint-inhibitors-in2022-08-17daily0.9 https://clinresonc-new.lhten.com/tumor-mutational-burden-as-predictor-of-first-line-ici-versus2022-08-18daily0.9 https://clinresonc-new.lhten.com/nivolumab-plus-rucaparib-for-metastatic-castration-resistant-prostate2022-08-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-cabazitaxel-in-metastatic-or2022-08-18daily0.9 https://clinresonc-new.lhten.com/global-burden-of-cancer-attributable-to-risk-factors-2010-20192022-08-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-neoadjuvant-chemotherapy-followed-by2022-08-19daily0.9 https://clinresonc-new.lhten.com/real-world-clinical-outcomes-with-avelumab-for-merkel-cell-carcinoma2022-08-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-ephrinb2-inhibition-plus-pd-1-blockade2022-08-20daily0.9 https://clinresonc-new.lhten.com/feasibility-of-adjuvant-enzalutamide-for-early-stage-androgen2022-08-21daily0.9 https://clinresonc-new.lhten.com/nomograms-and-scoring-system-for-forecasting-overall-and-cancer2022-08-22daily0.9 https://clinresonc-new.lhten.com/atezolizumab-versus-chemotherapy-in-advanced-or-metastatic-nsclc-with2022-08-22daily0.9 https://clinresonc-new.lhten.com/national-level-overall-survival-patterns-for-molecularly-defined2022-08-23daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-among-patients-with-systemic-mastocytosis2022-08-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-imrt-with-or-without-cisplatin-for-low2022-08-23daily0.9 https://clinresonc-new.lhten.com/role-of-genetic-predisposition-in-cardiovascular-risk-after-cancer2022-08-24daily0.9 https://clinresonc-new.lhten.com/outcomes-and-molecular-features-of-brain-metastasis-in2022-08-25daily0.9 https://clinresonc-new.lhten.com/relapse-rates-and-disease-specific-mortality-following-procedures-for2022-08-25daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-association-of-pd-l1-expression-and-other-variables2022-08-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-addition-of-cemiplimab-to-first-line2022-08-25daily0.9 https://clinresonc-new.lhten.com/aromatase-inhibitors-and-contralateral-breast-cancer-in-brca-mutation2022-08-26daily0.9 https://clinresonc-new.lhten.com/risk-of-central-nervous-system-metastases-in-patients-with-stage-ii2022-08-26daily0.9 https://clinresonc-new.lhten.com/sacituzumab-govitecan-in-hr-positive-her2-negative-endocrine2022-08-27daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-adjuvant-erlotinib-versus-vinorelbine-cisplatin2022-08-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-induction-chemotherapy-with-tp-versus2022-08-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-abbv-383-for-relapsed-or-refractory2022-08-28daily0.9 https://clinresonc-new.lhten.com/case-report-of-combination-strategy-for-osteosarcoma-with-cell-cycle2022-08-28daily0.9 https://clinresonc-new.lhten.com/association-of-diabetes-mellitus-with-risk-of-severe-adverse-events2022-08-29daily0.9 https://clinresonc-new.lhten.com/incident-comorbidities-after-adjuvant-tamoxifen-or-aromatase2022-08-29daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-comparing-two-step-versus-standard2022-08-30daily0.9 https://clinresonc-new.lhten.com/thirty-month-follow-up-of-adjuvant-pembrolizumab-post-nephrectomy-for2022-08-31daily0.9 https://clinresonc-new.lhten.com/assisted-reproductive-technology-and-risk-of-childhood-cancers2022-08-31daily0.9 https://clinresonc-new.lhten.com/association-of-retinoblastoma-mutation-status-and-function-with2022-09-01daily0.9 https://clinresonc-new.lhten.com/five-year-outcomes-with-folfirinox-versus-gemcitabine-as-adjuvant2022-09-01daily0.9 https://clinresonc-new.lhten.com/association-of-neurofilament-light-chain-levels-with-development-of2022-09-01daily0.9 https://clinresonc-new.lhten.com/correlation-between-recurrence-free-survival-and-overall-survival2022-09-02daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-sequential-immunotherapy-and-targeted2022-09-02daily0.9 https://clinresonc-new.lhten.com/phase-1-results-of-azacitidine-plus-venetoclax-for-high-risk2022-09-03daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-olaparib-versus-placebo-added-to2022-09-03daily0.9 https://clinresonc-new.lhten.com/association-of-immune-cells-in-mesothelioma-microenvironment-with2022-09-04daily0.9 https://clinresonc-new.lhten.com/multimodality-therapy-in-patients-with-primary-pericardial2022-09-05daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-rezvilutamide-plus-adt-versus-bicalutamide-plus-adt2022-09-06daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-tisagenlecleucel-for-r-r-b-cell2022-09-07daily0.9 https://clinresonc-new.lhten.com/effect-of-dexamethasone-on-dyspnea-in-patients-with-cancer2022-09-08daily0.9 https://clinresonc-new.lhten.com/interim-overall-survival-results-of-abemaciclib-plus-nonsteroidal2022-09-09daily0.9 https://clinresonc-new.lhten.com/final-overall-survival-results-of-paola-1-evaluating-maintance2022-09-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-tumor-infiltrating-lymphocytes-versus2022-09-09daily0.9 https://clinresonc-new.lhten.com/first-line-cabozantinib-plus-nivolumab-and-ipilimumab-for2022-09-10daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-xevinapant-plus-chemoradiotherapy-versus2022-09-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-camrelizumab-plus2022-09-10daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-the-optimal-duration-of-androgen-deprivation2022-09-11daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-immune-checkpoint-inhibition-in-locally-advanced-mmr2022-09-11daily0.9 https://clinresonc-new.lhten.com/avelumab-versus-standard-second-line-chemotherapy-for-msi-dmmr2022-09-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-sotarasib-for-previously-treated-nsclc2022-09-12daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-study-of-nivolumab-plus-ipilimumab2022-09-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-neoadjuvant-atezolizumab-for-resectable2022-09-12daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-cemipimab-for-stage-ii-to-iv-cutaneous-squamous-cell2022-09-13daily0.9 https://clinresonc-new.lhten.com/first-line-atezolizumab-versus-single-agent-chemotherapy-for-nsclc-in2022-09-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-pembrolizumab-versus-placebo2022-09-13daily0.9 https://clinresonc-new.lhten.com/toxicity-with-imrt-versus-sbrt-for-localized-prostate-cancer2022-09-14daily0.9 https://clinresonc-new.lhten.com/population-level-cure-patterns-for-cancer-patients-in-the-united2022-09-15daily0.9 https://clinresonc-new.lhten.com/short-term-outcomes-of-laparoscopic-versus-open-surgery-for-low2022-09-16daily0.9 https://clinresonc-new.lhten.com/outcomes-after-nonresponse-and-relapse-post-tisagenlecleucel-for-b2022-09-16daily0.9 https://clinresonc-new.lhten.com/pilot-study-of-oncos-102-and-pembrolizumab-for-anti-pd1-resistant2022-09-17daily0.9 https://clinresonc-new.lhten.com/mass-cytometry-based-peripheral-blood-analysis-as-a-novel-tool-for2022-09-17daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-association-of-reproductive-history-with2022-09-18daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-real-world-clinical-features-and-outcomes-of2022-09-18daily0.9 https://clinresonc-new.lhten.com/outcomes-of-allogeneic-hematopoietic-cell-transplant-for-relapsed2022-09-19daily0.9 https://clinresonc-new.lhten.com/risk-of-developing-a-second-primary-cancer-in-male-breast-cancer2022-09-19daily0.9 https://clinresonc-new.lhten.com/association-of-simultaneous-vs-delayed-resection-of-liver-metastasis2022-09-19daily0.9 https://clinresonc-new.lhten.com/selpercatinib-for-ret-fusion-positive-non-small-cell-lung-cancer2022-09-20daily0.9 https://clinresonc-new.lhten.com/gamma-knife-radiosurgery-for-meningiomas-of-the-confluence-of-the2022-09-20daily0.9 https://clinresonc-new.lhten.com/inflammation-and-clinical-decline-after-adjuvant-chemotherapy-in2022-09-21daily0.9 https://clinresonc-new.lhten.com/pik3ca-mutation-status-progression-and-survival-in-metastatic-hr-her22022-09-21daily0.9 https://clinresonc-new.lhten.com/margin-status-and-survival-outcomes-after-breast-cancer-conservation2022-09-22daily0.9 https://clinresonc-new.lhten.com/real-world-comparison-of-tisagenlecleucel-and-axicabtagene-ciloleucel2022-09-22daily0.9 https://clinresonc-new.lhten.com/outcomes-with-various-chemoradiotherapy-regimens-for-locally-advanced2022-09-22daily0.9 https://clinresonc-new.lhten.com/phase-1-2-study-of-anti-cll-based-car-t-therapy-for-relapsed-or2022-09-23daily0.9 https://clinresonc-new.lhten.com/ramucirumab-plus-atezolizumab-for-stage-iv-non-small-cell-lung-cancer2022-09-24daily0.9 https://clinresonc-new.lhten.com/scoring-system-to-predict-prognosis-of-resected-locally-advanced2022-09-25daily0.9 https://clinresonc-new.lhten.com/patient-derived-tumor-organoids-predict-responses-to-irinotecan-based2022-09-26daily0.9 https://clinresonc-new.lhten.com/cancer-risk-in-children-of-mothers-with-epilepsy-and-high-dose-folic2022-09-26daily0.9 https://clinresonc-new.lhten.com/adenoma-detection-rate-and-risk-of-interval-postcolonoscopy2022-09-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adding-serplulimab-to-first-line2022-09-27daily0.9 https://clinresonc-new.lhten.com/treatment-utilization-and-outcomes-for-locally-advanced-rectal-cancer2022-09-28daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-gprc5d-targeted-car-t-cells-for-heavily-pretreated2022-09-29daily0.9 https://clinresonc-new.lhten.com/circulating-tumor-dna-after-neoadjuvant-chemotherapy-in-breast-cancer2022-09-29daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-toxicities-of-stereotactic-ablative-radiotherapy-for2022-09-29daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-rising-esr1-mutation-guided-switch-from-aromatase2022-09-30daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-letrozole-plus-abemaciclib-for-estrogen-receptor2022-09-30daily0.9 https://clinresonc-new.lhten.com/association-of-elevated-crp-and-subsequent-cognitive-problems-in2022-10-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-perioperative-adebrelimab-plus2022-10-01daily0.9 https://clinresonc-new.lhten.com/preclinical-and-clinical-efficacy-of-trastuzumab-deruxtecan-in-breast2022-10-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-camrelizumab-plus-apatinib-and2022-10-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-orelabrutinib-for-relapsed-or-refractory2022-10-04daily0.9 https://clinresonc-new.lhten.com/long-term-oncologic-prognosis-with-minimal-access-breast-surgery-vs2022-10-05daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-intensity-modulated-radiotherapy-for2022-10-05daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-study-of-prognostic-value-of-plasma-circulating2022-10-06daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-meningioma-risk-following-treatment-for-childhood2022-10-06daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-cobimetinib-for-rosai-dorfman-disease2022-10-06daily0.9 https://clinresonc-new.lhten.com/association-between-polycystic-ovary-syndrome-and-risk-of-pancreatic2022-10-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-iberdomide-plus-dexamethasone-for2022-10-07daily0.9 https://clinresonc-new.lhten.com/survival-outcomes-after-radiotherapy-for-synchronous-oligometastatic2022-10-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-toripalimab-plus-chemotherapy-for2022-10-08daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-irinotecan-temozolomide-dinutuximab-gm-csf-for2022-10-08daily0.9 https://clinresonc-new.lhten.com/health-related-quality-of-life-with-ciltacabtagene-autoleucel-for2022-10-08daily0.9 https://clinresonc-new.lhten.com/short-term-outcomes-of-chemoradiotherapy-and-local-excision-versus2022-10-09daily0.9 https://clinresonc-new.lhten.com/association-of-colonoscopy-screening-with-risks-of-colorectal-cancer2022-10-10daily0.9 https://clinresonc-new.lhten.com/graded-cardiac-response-criteria-in-systemic-light-chain-amyloidosis2022-10-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-ii-trial-of-single-dose-carboplatin-followed-by2022-10-11daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-treatment-related-thoracic-soft-tissue2022-10-12daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-with-or-without-chemotherapy-for-r-m-hnscc-updated2022-10-12daily0.9 https://clinresonc-new.lhten.com/oncological-outcome-of-short-term-intensive-mitomycin-chemoresection2022-10-13daily0.9 https://clinresonc-new.lhten.com/early-radiologic-signal-of-responsiveness-to-immune-checkpoint2022-10-13daily0.9 https://clinresonc-new.lhten.com/adjuvant-capecitabine-following-concurrent-chemoradiotherapy-for2022-10-14daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-bemarituzumab-for-fgfr2b2022-10-14daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-incidence-of-cutaneous-adverse-events-with-adjuvant2022-10-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-lurbinectedin-plus-doxorubicin-for2022-10-15daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-first-line-pegylated-liposomal-doxorubicin-plus2022-10-15daily0.9 https://clinresonc-new.lhten.com/association-between-use-of-straighteners-and-other-hair-products-with2022-10-17daily0.9 https://clinresonc-new.lhten.com/combination-of-anlotinib-with-pd-l-1-inhibitors-for-previously2022-10-17daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-talazoparib-monotherapy-in-patients-with-wild-type2022-10-17daily0.9 https://clinresonc-new.lhten.com/distant-metastasis-free-survival-with-pembrolizumab-for-resected2022-10-18daily0.9 https://clinresonc-new.lhten.com/continuation-of-enzalutamide-after-progression-of-docetaxel-treated2022-10-18daily0.9 https://clinresonc-new.lhten.com/olaparib-with-or-without-cediranib-for-metastatic-castration2022-10-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-serplulimab-for-previously-treated-msi-h2022-10-19daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-reirradiation-to-bevacizumab2022-10-20daily0.9 https://clinresonc-new.lhten.com/association-of-high-levels-of-antidrug-antibodies-against2022-10-21daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-addition-of-low-dose-nivolumab-to-triple2022-10-21daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-frontline-hyper-cvad-followed-by-blinatumomab-for-ph2022-10-22daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-pet-adapted-therapy-for-bulky-stage-i-ii-classic2022-10-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-ciltacabtagene-autoleucel-for-relapsed2022-10-22daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-first-line-nivolumab-for-locally-advanced-or2022-10-24daily0.9 https://clinresonc-new.lhten.com/association-of-psa-screening-rates-with-subsequent-metastatic2022-10-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-eliminating-surgery-after-exceptional2022-10-26daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-relatlimab-plus-nivolumab-for-resectable2022-10-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-study-of-telisotuzumab-vedotin-plus-erlotinib2022-10-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-fak-inhibition-for-meningiomas-with2022-10-27daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-concurrent-olaparib-and-radiotherapy-for-triple2022-10-27daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-second-primary-malignancies-in-patients-with2022-10-28daily0.9 https://clinresonc-new.lhten.com/comparison-of-two-chemotherapy-regimens-in-patients-with-newly2022-10-28daily0.9 https://clinresonc-new.lhten.com/optimal-sequence-of-targeted-therapy-and-immunotherapy-for-advanced2022-10-28daily0.9 https://clinresonc-new.lhten.com/five-year-outcomes-with-first-line-pembrolizumab-versus-chemotherapy2022-10-29daily0.9 https://clinresonc-new.lhten.com/prognostic-impact-of-early-treatment-and-oxaliplatin-discontinuation2022-10-29daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-pyrotinib-combined-with-trastuzumab-plus2022-10-30daily0.9 https://clinresonc-new.lhten.com/trastuzumab-plus-folfox-for-her2-positive-biliary-tract-cancer2022-11-01daily0.9 https://clinresonc-new.lhten.com/addition-of-isatuximab-to-lenalidomide-bortzomib-dexamethasone2022-11-01daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-phase-2-and-3-studies-of-neoadjuvant-immunotherapy2022-11-02daily0.9 https://clinresonc-new.lhten.com/electroacupuncture-for-treatment-of-postoperative-ileus-after2022-11-02daily0.9 https://clinresonc-new.lhten.com/brentuximab-vedotin-with-chemotherapy-for-high-risk-hodgkin-s2022-11-03daily0.9 https://clinresonc-new.lhten.com/fracture-risk-among-older-cancer-survivors-compared-with-older-adults2022-11-03daily0.9 https://clinresonc-new.lhten.com/early-detection-and-prognosis-prediction-for-colorectal-cancer-by2022-11-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-combinations-of-durvalumab2022-11-04daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-moderately-hypofractionated-preoperative2022-11-05daily0.9 https://clinresonc-new.lhten.com/optimal-treatment-duration-of-bevacizumab-as-front-line-therapy-for2022-11-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-study-of-gedatolisib-in-combination-with-other2022-11-06daily0.9 https://clinresonc-new.lhten.com/outcomes-of-first-therapy-after-cd19-car-t-treatment-failure-in-large2022-11-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-coadministration-of-cd19-and-cd222022-11-09daily0.9 https://clinresonc-new.lhten.com/expression-of-hent1-predicts-response-of-advanced-pancreatic-ductal2022-11-09daily0.9 https://clinresonc-new.lhten.com/phase-1-results-of-a-phase-1-2-trial-of-olutasidenib-with-or-without2022-11-10daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-studies-of-cancer-risk-with-topical-calcineurin2022-11-10daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-circulating-tumor-dna-guided-therapy-in2022-11-11daily0.9 https://clinresonc-new.lhten.com/circulating-tumor-dna-as-a-marker-of-minimal-residual-disease-after2022-11-11daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-q-122-for-vasomotor2022-11-11daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-adding-enzalutamide-to-salvage-radiation-therapy-for2022-11-12daily0.9 https://clinresonc-new.lhten.com/premature-aging-as-an-accumulation-of-deficits-in-young-adult2022-11-13daily0.9 https://clinresonc-new.lhten.com/association-between-primary-care-use-prior-to-cancer-diagnosis-and2022-11-14daily0.9 https://clinresonc-new.lhten.com/phase-1-2-trial-of-trametinib-with-or-without-dabrafenib-for2022-11-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-zanidatamab-for-advanced-solid-tumors2022-11-16daily0.9 https://clinresonc-new.lhten.com/five-year-outcomes-after-stereotactic-ablative-body-radiotherapy-for2022-11-16daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-mre11-expression-by-mibc-tumors-and-mortality2022-11-16daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-ponatinib-plus-blinatumomab-for-philadelphia2022-11-17daily0.9 https://clinresonc-new.lhten.com/association-of-physical-activity-with-risk-of-mortality-among-breast2022-11-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-zanubrutinib-versus-ibrutinib-for2022-11-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-brentuximab-vedotin-plus-nivolumab-after2022-11-18daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-of-adjuvant-denosumab-in-postmenopausal-breast2022-11-19daily0.9 https://clinresonc-new.lhten.com/three-year-update-of-the-multinational-phase-2-eliana-trial-of-tisa2022-11-19daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-long-term-survival-with-first-line-nivolumab-plus2022-11-20daily0.9 https://clinresonc-new.lhten.com/impact-of-neoadjuvant-systemic-treatment-on-postoperative2022-11-20daily0.9 https://clinresonc-new.lhten.com/colorectal-cancer-stage-at-diagnosis-before-versus-during-the-covid2022-11-21daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-cobimetinib-plus-vemurafenib-for-colorectal-cancer2022-11-22daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2b-study-or-cannabidiol-oil-versus-placebo-for2022-11-22daily0.9 https://clinresonc-new.lhten.com/chemoradiotherapy-with-liposomal-paclitaxel-plus-cisplatin-for2022-11-22daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-daratumumab-bortezomib-and-dexamethasone-for2022-11-23daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-safety-and-efficacy-of-robotic-versus2022-11-23daily0.9 https://clinresonc-new.lhten.com/risk-factors-associated-with-first-and-secondary-primary-melanomas-in2022-11-23daily0.9 https://clinresonc-new.lhten.com/intraoperative-electron-radiotherapy-in-early-invasive-ductal-breast2022-11-24daily0.9 https://clinresonc-new.lhten.com/multinational-trial-of-perioperative-chemotherapy-in-colorectal2022-11-25daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-atezolizumab-plus-chemotherapy-for-transformed2022-11-25daily0.9 https://clinresonc-new.lhten.com/phase-1-1b-trial-of-neoadjuvant-sbrt-with-single-dose-durvalumab-for2022-11-26daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-anti-pd-1-consolidation-in2022-11-27daily0.9 https://clinresonc-new.lhten.com/adjuvant-endocrine-therapy-non-initiation-and-non-persistence-in2022-11-27daily0.9 https://clinresonc-new.lhten.com/mortality-among-pediatric-patients-with-acute-lymphoblastic-leukemia2022-11-28daily0.9 https://clinresonc-new.lhten.com/association-between-use-of-tamoxifen-for-premenopausal-breast-cancer2022-11-28daily0.9 https://clinresonc-new.lhten.com/risk-of-subsequent-primary-lymphoma-among-five-year-survivors-of2022-11-29daily0.9 https://clinresonc-new.lhten.com/association-between-various-types-of-plant-based-dietary-patterns-and2022-11-29daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-first-line-atezolizumab-vemurafenib-cobimetinib2022-11-30daily0.9 https://clinresonc-new.lhten.com/statin-use-and-survival-with-androgen-ablative-therapy-for-advanced2022-11-30daily0.9 https://clinresonc-new.lhten.com/association-of-smoking-behaviors-and-prognosis-in-patients-with-non2022-11-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-the-oral-combination-of-niraparib-and2022-12-01daily0.9 https://clinresonc-new.lhten.com/trastuzumab-capecitabine-with-tucatinib-or-placebo-for-pretreated2022-12-01daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-risk-factors-for-low-intensity-adjuvant2022-12-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-second-line-pembrolizumab-versus-placebo2022-12-02daily0.9 https://clinresonc-new.lhten.com/first-line-trifluridine-tipiracil-bevacizumab-versus-capecitabine2022-12-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-axatilimab-for-cgvhd-after-failure-of2022-12-03daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-pamiparib-for-advanced-her2-negative-breast-cancer2022-12-03daily0.9 https://clinresonc-new.lhten.com/first-line-pertuzumab-trastuzumab-docetaxel-for-her2-positive-locally2022-12-04daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-neoadjuvant-durvalumab-versus-durvalumab2022-12-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-the-wee1-inhibitor-adavosertib-in2022-12-06daily0.9 https://clinresonc-new.lhten.com/long-term-efficacy-and-safety-of-pembrolizumab-in-metastatic2022-12-06daily0.9 https://clinresonc-new.lhten.com/brain-cancer-after-radiation-exposure-from-ct-examinations-of2022-12-07daily0.9 https://clinresonc-new.lhten.com/abemaciclib-plus-endocrine-therapy-for-hr-positive-her2-negative-node2022-12-07daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-trastuzumab-deruxtecan-versus-trastuzumab2022-12-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-tumor-infiltrating-lymphocyte-therapy2022-12-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-capivasertib-plus-fulvestrant-for-ai2022-12-08daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-adjuvant-chemotherapy-after-multiagent-neoadjuvant2022-12-08daily0.9 https://clinresonc-new.lhten.com/clonal-hematopoiesis-and-risk-of-incident-lung-cancer2022-12-09daily0.9 https://clinresonc-new.lhten.com/validation-of-profile-for-the-omission-of-local-adjuvant-radiotherapy2022-12-09daily0.9 https://clinresonc-new.lhten.com/adjuvant-endocrine-therapy-in-premenopausal-breast-cancer-12-year2022-12-10daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-3-study-of-mepitel-film-for-the2022-12-10daily0.9 https://clinresonc-new.lhten.com/role-of-ibrutinib-in-first-line-treatment-of-mantle-cell-lymphoma-in2022-12-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-glofitamab-for-relapsed-or2022-12-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-zanubrutinib-versus-ibrutinib-for2022-12-12daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-association-between-genetic-risk-healthy2022-12-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-immediate-surgery-compared-with-short2022-12-13daily0.9 https://clinresonc-new.lhten.com/nivolumab-and-avd-for-early-stage-unfavorable-classical-hodgkin2022-12-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-nivolumab-plus-cabozantinib-with-or2022-12-14daily0.9 https://clinresonc-new.lhten.com/lifileucel-for-advanced-melanoma-after-progression-on-immune2022-12-14daily0.9 https://clinresonc-new.lhten.com/association-of-inflammatory-and-insulinemic-dietary-patterns-with2022-12-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-talquetemab-for-relapsed-or-refractory2022-12-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-atezolizumab-plus-bevacizumab2022-12-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2a-trial-of-survaxm-and-adjuvant-temozolomide-for2022-12-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-adjuvant-nab-paclitaxel-plus2022-12-16daily0.9 https://clinresonc-new.lhten.com/sequential-tace-and-sbrt-followed-by-immunotherapy-for-conversion-of2022-12-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-first-line-lorlatinib-versus2022-12-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-adjuvant-hepatic-artery-folfox-infusion2022-12-17daily0.9 https://clinresonc-new.lhten.com/long-term-morbidity-and-mortality-among-survivors-of-neuroblastoma2022-12-17daily0.9 https://clinresonc-new.lhten.com/shifting-incidence-and-survival-of-epithelial-ovarian-cancer-in-high2022-12-19daily0.9 https://clinresonc-new.lhten.com/long-term-incidence-of-esophageal-squamous-cell-carcinoma-in-patients2022-12-19daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-crizotinib-plus-chemotherapy-for-alk-positive2022-12-20daily0.9 https://clinresonc-new.lhten.com/effect-of-prior-treatments-on-post-cdk4-6-inhibitor-survival-in-hr2022-12-21daily0.9 https://clinresonc-new.lhten.com/high-dose-vitamin-d-for-the-management-of-toxic-erythema-of2022-12-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-sotorasib-for-kras-p-g12c-mutated2022-12-22daily0.9 https://clinresonc-new.lhten.com/circulating-tumor-dna-profiling-for-detection-risk-stratification-and2022-12-22daily0.9 https://clinresonc-new.lhten.com/adagrasib-with-or-without-cetuximab-for-metastatic-colorectal-cancer2022-12-22daily0.9 https://clinresonc-new.lhten.com/survival-after-minimally-invasive-versus-open-surgery-for-pancreatic2022-12-22daily0.9 https://clinresonc-new.lhten.com/outcomes-of-relapsed-medulloblastoma-in-young-children-after-initial2022-12-23daily0.9 https://clinresonc-new.lhten.com/dose-expansion-in-a-multinational-phase-1-2-trial-of-epcoritamab-for2022-12-23daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-first-line-nivolumab-plus-ipilimumab-versus2022-12-23daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-chemotherapy-in-advanced2022-12-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-intratumoral-oncolytic-virus-v937-plus2022-12-24daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-adjuvant-chemotherapy-for2022-12-25daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-treatment-and-outcomes-of-patients-with2022-12-25daily0.9 https://clinresonc-new.lhten.com/vascular-invasion-predicts-recurrence-in-stage-ia2-ib-lung2022-12-26daily0.9 https://clinresonc-new.lhten.com/cognitive-change-in-breast-cancer-patients-up-to-two-years-after2022-12-26daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-risks-of-cancer-in-women-aged-502022-12-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-ibrutinib-lenalidomide-rituximab-for2022-12-27daily0.9 https://clinresonc-new.lhten.com/association-of-degree-of-radiosensitivity-with-disease-specific2022-12-27daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-treatment-related-adverse-events-with-her2-targeted2022-12-28daily0.9 https://clinresonc-new.lhten.com/chemotherapy-plus-pembrolizumab-compared-with-chemotherapy-alone-for2022-12-28daily0.9 https://clinresonc-new.lhten.com/association-of-erbb2-mrna-expression-in-advanced-her2-positive-breast2022-12-29daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-covid-19-vaccination-with2022-12-29daily0.9 https://clinresonc-new.lhten.com/testing-for-egfr-variants-in-pleural-and-pericardial-effusion-cell2022-12-29daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-toripalimab-plus-chemotherapy-for-stage2022-12-30daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-ovarian-cancer-onset-across2022-12-30daily0.9 https://clinresonc-new.lhten.com/survival-in-male-breast-cancer-over-the-past-three-decades-22022-12-31daily0.9 https://clinresonc-new.lhten.com/proton-radiotherapy-for-idh-mutant-diffuse-glioma2022-12-31daily0.9 https://clinresonc-new.lhten.com/plasma-four-protein-signature-predicts-response-of-met-dysregulated2023-01-02daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-studies-of-options-for-advanced-thymic-carcinoma2023-01-03daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-lymphovascular-invasion-and-perineural-invasion2023-01-03daily0.9 https://clinresonc-new.lhten.com/breast-cancer-screening-among-women-with-intellectual-disability-in2023-01-03daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-characteristics-and2023-01-04daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-daratumumab-lenalidomide-dexamethasone-for2023-01-05daily0.9 https://clinresonc-new.lhten.com/development-and-validation-of-a-genomic-profile-for-the-omission-of2023-01-05daily0.9 https://clinresonc-new.lhten.com/association-of-tumor-mutational-burden-with-outcomes-of2023-01-05daily0.9 https://clinresonc-new.lhten.com/risk-of-psychiatric-disorders-among-spouses-of-patients-with-cancer2023-01-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-neoadjuvant-gemcitabine-plus-cisplatin2023-01-06daily0.9 https://clinresonc-new.lhten.com/outcomes-of-chronic-myeloid-leukemia-without-major-molecular-response2023-01-06daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-cisplatin-with-veliparib-or-placebo-for2023-01-07daily0.9 https://clinresonc-new.lhten.com/long-term-results-with-lenvatinib-plus-pembrolizumab-for-advanced2023-01-07daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-characteristics-and-outcomes-of-pregnancy2023-01-08daily0.9 https://clinresonc-new.lhten.com/facility-patient-volume-and-survival-among-patients-with-malignant2023-01-08daily0.9 https://clinresonc-new.lhten.com/healthy-eating-patterns-and-risk-of-total-and-cause-specific-mortality2023-01-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-high-dose-once-daily-thoracic2023-01-10daily0.9 https://clinresonc-new.lhten.com/real-world-results-with-idecabtagene-vicleucel-for-relapsed-or2023-01-10daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-pembrolizumab-for-localized-microsatellite-instability2023-01-10daily0.9 https://clinresonc-new.lhten.com/contralateral-breast-cancer-risk-among-carriers-of-germline2023-01-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-posoleucel-for-refractory-viral2023-01-11daily0.9 https://clinresonc-new.lhten.com/patient-reported-functional-impairment-due-cisplatin-based-hearing2023-01-11daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-risk-of-esophageal-and-gastric-cancer-after-bariatric2023-01-11daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-hemicolectomy-versus-appendectomy-for2023-01-12daily0.9 https://clinresonc-new.lhten.com/incidence-timing-and-factors-associated-with-suicide-among-patients2023-01-12daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-mri-guided-versus-ct-guided-stereotactic-body2023-01-12daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-carfilzomib-lenalidomide-dexamethasone-versus2023-01-13daily0.9 https://clinresonc-new.lhten.com/cognitive-and-behavioral-characteristics-of-9-year-old-children-after2023-01-13daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-first-line-chemotherapy-with-or-without2023-01-13daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-clinicobiologic-features-and2023-01-14daily0.9 https://clinresonc-new.lhten.com/phase-1-2b-trial-of-braf-and-egfr-inhibition-in-metastatic-colorectal2023-01-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-study-of-mdna55-for-recurrent-glioblastoma2023-01-15daily0.9 https://clinresonc-new.lhten.com/central-nervous-system-disease-in-patients-receiving-selpercatinib2023-01-16daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-molecular-residual-disease-and-efficacy-of2023-01-16daily0.9 https://clinresonc-new.lhten.com/prevalence-of-colorectal-neoplasia-10-or-more-years-after-a-negative2023-01-17daily0.9 https://clinresonc-new.lhten.com/association-of-expression-of-siglec-15-with-outcomes-of-neoadjuvant2023-01-17daily0.9 https://clinresonc-new.lhten.com/risk-of-major-psychiatric-disorders-among-children-and-adolescents2023-01-18daily0.9 https://clinresonc-new.lhten.com/association-between-surgical-quality-metric-adherence-and-overall2023-01-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-futibatinib-for-unresectable-or2023-01-19daily0.9 https://clinresonc-new.lhten.com/malignant-neoplasms-of-the-gastrointestinal-tract-after-blood-or2023-01-19daily0.9 https://clinresonc-new.lhten.com/survival-outcomes-with-first-line-targeted-therapy-for-metastatic2023-01-19daily0.9 https://clinresonc-new.lhten.com/trends-and-characteristics-of-potentially-preventable-emergency2023-01-19daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-neoadjuvant-chemotherapy-for2023-01-20daily0.9 https://clinresonc-new.lhten.com/efficacy-of-radiofrequency-ablation-after-tace-plus-sorafenib-for2023-01-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-s-1-versus-observation-after2023-01-21daily0.9 https://clinresonc-new.lhten.com/impact-of-dexrazoxane-on-long-term-heart-function-in-survivors-of2023-01-21daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-screening-for-multiple-cancers-during-one-visit2023-01-21daily0.9 https://clinresonc-new.lhten.com/survival-outcomes-with-contralateral-profylactic-mastectomy-in2023-01-22daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-risk-of-early-death-in-adolescents-and2023-01-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-allogeneic-bcma-targeting-car-t-cells2023-01-23daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-proton-therapy-reirradiation-for2023-01-23daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-adding-g-csf-and-decitabine-to-busulfan2023-01-24daily0.9 https://clinresonc-new.lhten.com/impact-of-antibiotic-treatment-on-efficacy-of-anti-pd-l-1-monotherapy2023-01-24daily0.9 https://clinresonc-new.lhten.com/late-health-outcomes-among-survivors-of-wilms-tumor-diagnosed-over2023-01-25daily0.9 https://clinresonc-new.lhten.com/genomic-characterization-of-hormone-receptor-positive-breast-cancer2023-01-25daily0.9 https://clinresonc-new.lhten.com/clinical-utility-of-circulating-tumor-dna-sequencing-with-a-large2023-01-25daily0.9 https://clinresonc-new.lhten.com/morbidity-and-mortality-among-childhood-medulloblastoma-survivors2023-01-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-combined-inhibition-of-pd-1-braf-and-mek2023-01-26daily0.9 https://clinresonc-new.lhten.com/association-between-age-and-survival-trends-in-advanced-non-small2023-01-26daily0.9 https://clinresonc-new.lhten.com/association-of-inflammatory-biomarkers-with-survival-among-patients2023-01-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-momelotinib-versus-danazol-in2023-01-27daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-adjuvant-temozolomide-with-or-without2023-01-27daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-docetaxel-as-radiosensitizer-in-cisplatin-ineligible2023-01-28daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-risk-of-endometrial-cancer-and2023-01-29daily0.9 https://clinresonc-new.lhten.com/prognostic-impact-of-extracranial-disease-control-in-patients-with2023-01-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-mirvetuximab-soravtansine-for-platinum2023-01-31daily0.9 https://clinresonc-new.lhten.com/racial-and-ethnic-disparities-in-childhood-and-young-adult-acute2023-01-31daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-gprc5d-targeted-car-t-cells-for-relapsed-or2023-01-31daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-the-association-of-ultra-processed-food2023-02-01daily0.9 https://clinresonc-new.lhten.com/updated-results-from-adaura-trial-of-adjuvant-osimertinib-versus2023-02-01daily0.9 https://clinresonc-new.lhten.com/effect-of-focal-versus-extended-irreversible-electroporation-for2023-02-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-apbi-using-brachytherapy-versus-wbi2023-02-02daily0.9 https://clinresonc-new.lhten.com/association-of-radiation-and-procarbazine-dose-with-risk-of2023-02-02daily0.9 https://clinresonc-new.lhten.com/breast-cancer-diagnosis-treatment-and-outcomes-of-patients-from-sex2023-02-02daily0.9 https://clinresonc-new.lhten.com/folfiri-with-or-without-bevacizumab-as-second-line-option-for2023-02-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-serplulimab-to-first-line2023-02-03daily0.9 https://clinresonc-new.lhten.com/association-of-anthracycline-with-heart-failure-in-patients-treated2023-02-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-first-line-camrelizumab-plus-pemetrexed2023-02-03daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-adjuvant-icotinib-versus-observation2023-02-04daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-camrelizumab-plus-apatinib-for-recurrent-or2023-02-04daily0.9 https://clinresonc-new.lhten.com/five-year-update-of-keynote-407-pembrolizumab-plus-chemotherapy-for2023-02-04daily0.9 https://clinresonc-new.lhten.com/nationwide-case-control-study-of-use-of-methotrexate-and-risk-of-skin2023-02-05daily0.9 https://clinresonc-new.lhten.com/role-of-defensive-information-processing-in-population-based2023-02-06daily0.9 https://clinresonc-new.lhten.com/prevalence-of-smoldering-multiple-myeloma-based-on-a-nationwide2023-02-06daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-medial-retropharyngeal-nodal-region-sparing2023-02-07daily0.9 https://clinresonc-new.lhten.com/dynamics-of-age-versus-therapy-related-clonal-hematopoiesis-in-long2023-02-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-sotorasib-versus-docetaxel-for2023-02-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-chemotherapy-to-gefitinib2023-02-08daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-darolutamide-maintenance2023-02-09daily0.9 https://clinresonc-new.lhten.com/lobar-or-sublobar-resection-for-peripheral-stage-ia-non-small-cell2023-02-09daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-oncolytic-t-vec-virotherapy-plus-neoadjuvant2023-02-09daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-allogeneic-hct-vs-standard-consolidation2023-02-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-nivolumab-plus-ipilimumab2023-02-10daily0.9 https://clinresonc-new.lhten.com/risks-of-second-non-breast-primaries-following-breast-cancer-in-women2023-02-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-idecabtagene-vicleucel-versus-standard2023-02-11daily0.9 https://clinresonc-new.lhten.com/addition-of-bortezomib-to-first-line-dexamethasone-rituximab-and2023-02-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-first-line-encorafenib-plus2023-02-11daily0.9 https://clinresonc-new.lhten.com/intraoperative-ultrasound-during-surgical-exploration-in-patients2023-02-12daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-cryotherapy-for-partial-gland-ablation-of2023-02-13daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-prevalence-of-comorbidities-in-cancer-patients2023-02-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2a-trial-of-nivolumab-plus-relatlimab-for2023-02-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-trial-of-temporary-treatment-cessation-versus2023-02-14daily0.9 https://clinresonc-new.lhten.com/five-year-clinical-outcomes-after-neoadjuvant-nivolumab-in-resectable2023-02-15daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-adding-avelumab-to2023-02-15daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-farmacokinetic-guided-individualized2023-02-15daily0.9 https://clinresonc-new.lhten.com/breast-conserving-surgery-with-or-without-irradiation-for-early-stage2023-02-16daily0.9 https://clinresonc-new.lhten.com/association-of-immune-related-adverse-events-with-efficacy-of2023-02-16daily0.9 https://clinresonc-new.lhten.com/validation-of-the-onkotev-risk-prediction-model-for-venous2023-02-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-rucaparib-or-physician-s-choice-for2023-02-17daily0.9 https://clinresonc-new.lhten.com/long-noncoding-rna-expression-indepently-predicts-outcome-in2023-02-17daily0.9 https://clinresonc-new.lhten.com/darolutamide-plus-androgen-deprivation-therapy-and-docetaxel-for2023-02-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-trial-of-neoadjuvant-osimertinib-for-egfr-mutant2023-02-17daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-of-metastatic-invasive-lobular-ductal-breast2023-02-18daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-primary-tumor-resesction-among-patients-with2023-02-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-trial-of-nivolumab-with-or-without2023-02-20daily0.9 https://clinresonc-new.lhten.com/evaluation-of-concomitant-systemic-therapy-in-older-adults-undergoing2023-02-20daily0.9 https://clinresonc-new.lhten.com/evaluation-of-maternal-infection-during-pregnancy-and-childhood2023-02-20daily0.9 https://clinresonc-new.lhten.com/adenoma-detection-rate-and-colorectal-cancer-risk-in-fecal2023-02-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-sitravatinib-combined-with-tislelizumab2023-02-21daily0.9 https://clinresonc-new.lhten.com/association-of-neighborhood-level-household-income-with-21-gene2023-02-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-savolitinib-plus-durvalumab-for2023-02-22daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-plus-pemetrexed-and-platinum-for-metastatic-nonsquamous2023-02-22daily0.9 https://clinresonc-new.lhten.com/high-grade-serous-carcinoma-at-risk-reducing-salpingo-oophorectomy-in2023-02-22daily0.9 https://clinresonc-new.lhten.com/phase-1-1b-trial-of-mitochondrially-targeted-tamoxifen-for-metastatic2023-02-23daily0.9 https://clinresonc-new.lhten.com/clinicopathologic-characteristics-and-prognosis-of-her2-low-breast2023-02-23daily0.9 https://clinresonc-new.lhten.com/randomized-phase-1-trial-of-perioperative-vorasidenib-or-ivosidenib2023-02-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-hyperfractionated-versus-standard2023-02-24daily0.9 https://clinresonc-new.lhten.com/systemic-treatments-of-small-intestinal-adenocarcinomas-systematic2023-02-24daily0.9 https://clinresonc-new.lhten.com/adjuvant-epirubicin-paclitaxel-versus-epirubicin-cyclophosphamide2023-02-24daily0.9 https://clinresonc-new.lhten.com/impact-of-antibiotic-exposure-before-immune-checkpoint-inhibitor2023-02-25daily0.9 https://clinresonc-new.lhten.com/conditional-relative-survival-in-non-metastatic-esophagogastric2023-02-26daily0.9 https://clinresonc-new.lhten.com/early-intervention-in-myelofibrosis-and-impact-on-outcomes-pooled2023-02-26daily0.9 https://clinresonc-new.lhten.com/time-interval-from-primary-melanoma-to-first-distant-recurrence-in2023-02-27daily0.9 https://clinresonc-new.lhten.com/psa-kinetics-and-association-between-psa-decline-and-clinical2023-02-27daily0.9 https://clinresonc-new.lhten.com/first-line-lenvatinib-plus-pembrolizumab-versus-sunitinib-for2023-02-28daily0.9 https://clinresonc-new.lhten.com/adjuvant-paclitaxel-and-trastuzumab-for-small-node-negative-her22023-02-28daily0.9 https://clinresonc-new.lhten.com/omission-of-radiotherapy-in-children-and-adolescents-with-classical2023-02-28daily0.9 https://clinresonc-new.lhten.com/tailored-immunotherapy-for-metastatic-urothelial-carcinoma-after2023-03-01daily0.9 https://clinresonc-new.lhten.com/multicenter-fase-1-2-trial-of-dinutuximab-beta-and-low-dose2023-03-01daily0.9 https://clinresonc-new.lhten.com/ncdb-analysis-of-optimal-time-interval-between-breast-cancer2023-03-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-adjuvant-versus-adjuvant2023-03-02daily0.9 https://clinresonc-new.lhten.com/codon-specific-kras-mutations-predict-survival-benefit-of2023-03-02daily0.9 https://clinresonc-new.lhten.com/systemic-review-and-meta-analysis-of-first-line-systemic-treatment2023-03-02daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-neoadjuvant-sintilimab-for-mismatch-repair-deficient2023-03-02daily0.9 https://clinresonc-new.lhten.com/adjuvant-chemotherapy-for-breast-cancer-association-of-obesity-with2023-03-03daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-braf-variants-with-disease2023-03-03daily0.9 https://clinresonc-new.lhten.com/health-related-quality-of-life-in-keynote-8262023-03-04daily0.9 https://clinresonc-new.lhten.com/prospective-multicenter-study-of-durvalumab-for-previously-treated2023-03-04daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-pegylated-liposomal-doxorubicin-or-epirubicin-based2023-03-05daily0.9 https://clinresonc-new.lhten.com/european-cancer-mortality-predictions-for-the-year-20232023-03-06daily0.9 https://clinresonc-new.lhten.com/impact-of-anatomic-stage-and-receptor-status-on-first-recurrence-of2023-03-06daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-pegylated-liposomal-doxorubicin-for-heavily2023-03-06daily0.9 https://clinresonc-new.lhten.com/single-arm-phase-3-study-of-segmentectomy-for-ground-glass-dominant2023-03-07daily0.9 https://clinresonc-new.lhten.com/dna-sequencing-to-detect-residual-disease-in-adults-with-acute2023-03-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-pelabresib-plus-ruxolitinib-for-janus2023-03-08daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-anti-gprc5d-car-t-cell-therapy-for-relapsed-or2023-03-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-frontline-magrolimab-plus-azacitidine2023-03-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-nirogacestat-for-desmoid-tumors2023-03-09daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-regorafenib-ipilimumab-and-nivolumab-for2023-03-09daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-alisertib-with-or-without-fulvestrant-for2023-03-09daily0.9 https://clinresonc-new.lhten.com/genomic-and-transcriptomic-determinants-of-exceptional-response-of2023-03-10daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-pembrolizumab-monotherapy-for-diffuse2023-03-10daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-axitinib-plus-avelumab-for-recurrent-or-metastatic2023-03-11daily0.9 https://clinresonc-new.lhten.com/outcomes-of-patients-with-pancreatic-neuroendocrine-tumors-treated-at2023-03-11daily0.9 https://clinresonc-new.lhten.com/fifteen-year-outcomes-after-monitoring-surgery-or-radiotherapy-for2023-03-12daily0.9 https://clinresonc-new.lhten.com/immune-priming-with-avelumab-and-rituximab-prior-to-r-chop-in-diffuse2023-03-12daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-delaying-surgery-after-neoadjuvant-chemotherapy-in2023-03-13daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-lenalidomide-maintance-after-response-of2023-03-13daily0.9 https://clinresonc-new.lhten.com/retroperitoneal-lymph-node-dissection-for-early-metastatic-testicular2023-03-14daily0.9 https://clinresonc-new.lhten.com/association-of-brenda-metastatic-recurrence-score-and-metastasis-free2023-03-14daily0.9 https://clinresonc-new.lhten.com/female-reproductive-and-hormonal-factors-and-lung-cancer-mortality2023-03-14daily0.9 https://clinresonc-new.lhten.com/low-dose-tamoxifen-to-prevent-recurrence-in-breast-noninvasive2023-03-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-the-menin-inhibitor-revumenib-in-kmt2a2023-03-15daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-chemotherapy-plus-nivolumab-with-or2023-03-16daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-pembrolizumab-plus-chemotherapy-for-relapsed-or2023-03-16daily0.9 https://clinresonc-new.lhten.com/trends-in-survival-rates-of-non-small-cell-lung-cancer-in-clinical2023-03-16daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-outcomes-of-therapy-related-and-de-novo2023-03-17daily0.9 https://clinresonc-new.lhten.com/interstitial-photodynamic-therapy-for-newly-diagnosed-glioblastoma2023-03-17daily0.9 https://clinresonc-new.lhten.com/real-world-validation-of-the-molecular-international-prognostic2023-03-18daily0.9 https://clinresonc-new.lhten.com/comparison-of-genomic-profiling-of-circulating-tumor-dna-in-plasma2023-03-18daily0.9 https://clinresonc-new.lhten.com/acute-leukemia-similar-outcomes-after-haploidentical-hct-from-non2023-03-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-garsorasib-for-non-small-cell-lung2023-03-20daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-adding-camrelizumab-and-radiotherapy-to-nab2023-03-20daily0.9 https://clinresonc-new.lhten.com/lung-cancer-brain-metastases-poor-karnofsky-status-is-no2023-03-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-isolated-hepatic-perfusion-with2023-03-21daily0.9 https://clinresonc-new.lhten.com/review-of-diagnosis-and-treatment-of-chronic-lymphocytic-leukemia2023-03-21daily0.9 https://clinresonc-new.lhten.com/novel-prognostic-staging-system-for-patients-with-de-novo-metastatic2023-03-22daily0.9 https://clinresonc-new.lhten.com/first-line-zolbetuximab-plus-capox-for-advanced-cldn18-2-her2-gastric2023-03-22daily0.9 https://clinresonc-new.lhten.com/overcoming-barriers-to-tumor-genomic-profiling-through-direct-to2023-03-22daily0.9 https://clinresonc-new.lhten.com/expansion-results-of-a-multinational-phase-1b-study-of-naporafenib2023-03-23daily0.9 https://clinresonc-new.lhten.com/phase-2b-nifty-trial-of-addition-of-liposomal-irinotecan-to-second2023-03-23daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-alternative-dose-regimens-of-exemestane-in2023-03-23daily0.9 https://clinresonc-new.lhten.com/overall-survival-and-response-with-nivolumab-and-relatlimab-for2023-03-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-niraparib-and-abiraterone-acetate-for2023-03-24daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-persistent-extramural-venous-invasion-after-total2023-03-25daily0.9 https://clinresonc-new.lhten.com/evaluating-colonoscopy-screening-intervals-in-patients-with-lynch2023-03-26daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-venetoclax-for-acute-myeloid-leukemia-in2023-03-26daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-systemic-anticoagulation-in-inpatients-with2023-03-26daily0.9 https://clinresonc-new.lhten.com/incidence-and-prognostic-impact-of-her2-positivity-loss-after-dual2023-03-27daily0.9 https://clinresonc-new.lhten.com/olaparib-for-germline-brca-mutated-her2-negative-metastatic-breast2023-03-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-dostarlimab-plus-chemotherapy-for2023-03-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-pembrolizumab-plus-chemotherapy-for2023-03-28daily0.9 https://clinresonc-new.lhten.com/association-of-stroke-at-young-age-with-new-cancer-in-the-years-after2023-03-28daily0.9 https://clinresonc-new.lhten.com/survival-following-surgical-resection-for-small-nonfunctional2023-03-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ficlatuzumab-with-or-without-cetuximab2023-03-29daily0.9 https://clinresonc-new.lhten.com/multicenter-trial-of-trastuzumab-deruxtecan-for-her2-expressing2023-03-29daily0.9 https://clinresonc-new.lhten.com/local-recurrence-after-breast-conserving-therapy-in-patients-with2023-03-29daily0.9 https://clinresonc-new.lhten.com/helicobacter-pylori-homologous-recombination-genes-and-gastric-cancer2023-03-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-neoadjuvant-trabectedin-plus2023-03-30daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-concurrent-intrathecal-and-intravenous-nivolumab-for2023-03-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-sugemalimab-monotherapy-for-relapsed-or2023-03-31daily0.9 https://clinresonc-new.lhten.com/association-of-pd-l1-expression-on-immune-cells-with-survival-of2023-03-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-belzutifan-plus-cabozantinib-for2023-04-01daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-toripalimab-plus-definitive-chemoradiotherapy-in2023-04-02daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-cancer-surveillance-as-an-alternative-to2023-04-02daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-testosterone-suppression-plus-enzalutamide-or2023-04-02daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-eprenetapopt-plus-venetoclax-and-azacitidine-in-tp532023-04-02daily0.9 https://clinresonc-new.lhten.com/consensus-definitions-for-immune-checkpoint-inhibitor-associated2023-04-02daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-enoblituzumab-for-localized-prostate2023-04-03daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-pembrolizumab-plus-cabozantinib-for-recurrent2023-04-03daily0.9 https://clinresonc-new.lhten.com/role-of-adrenalectomy-in-multidisciplinary-management-of-patients2023-04-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-maintenance-bevacizumab-for-nf2-related2023-04-04daily0.9 https://clinresonc-new.lhten.com/comprehensive-proteomics-and-platform-validation-of-urinary2023-04-05daily0.9 https://clinresonc-new.lhten.com/long-term-hypertension-and-cardiovascular-toxicity-with-ibrutinib-for2023-04-05daily0.9 https://clinresonc-new.lhten.com/transcriptomic-signature-and-microenvironment-of-early-neoplastic2023-04-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-gd2-cart01-for-relapsed-or-refractory2023-04-06daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-intermittent-hormone-therapy-with-or-without2023-04-06daily0.9 https://clinresonc-new.lhten.com/long-term-mortality-in-patients-diagnosed-with-cancer-during2023-04-06daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-survival-impact-of-prechirurgical2023-04-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-gumarontinib-for-advanced-nsclc-with2023-04-07daily0.9 https://clinresonc-new.lhten.com/postprogression-lenvatinib-with-or-without-pd-1-inhibitor-for2023-04-08daily0.9 https://clinresonc-new.lhten.com/surgery-and-proton-radiotherapy-for-pediatric-base-of-skull-chordomas2023-04-09daily0.9 https://clinresonc-new.lhten.com/pd-l1-blockade-in-combination-with-carboplatin-as-immune-induction-in2023-04-10daily0.9 https://clinresonc-new.lhten.com/immunogenomic-biomarker-analysis-of-tumors-from-pediatric-patients2023-04-10daily0.9 https://clinresonc-new.lhten.com/preliminary-clinical-outcomes-with-particle-beam-radiation-therapy2023-04-11daily0.9 https://clinresonc-new.lhten.com/low-value-prostate-specific-antigen-screening-in-older-males2023-04-11daily0.9 https://clinresonc-new.lhten.com/residual-risk-of-breast-cancer-after-bariatric-surgery2023-04-12daily0.9 https://clinresonc-new.lhten.com/association-of-excision-margin-size-with-locall-recurrence-and2023-04-12daily0.9 https://clinresonc-new.lhten.com/clinicopathologic-analysis-of-pineal-parenchymal-tumors-of2023-04-13daily0.9 https://clinresonc-new.lhten.com/individual-patient-data-meta-analysis-of-anthracycline-containing-and2023-04-13daily0.9 https://clinresonc-new.lhten.com/influence-of-germline-variations-in-drug-transporters-abcb1-and-abcg22023-04-14daily0.9 https://clinresonc-new.lhten.com/impact-of-biomarker-matched-therapies-on-outcomes-in-patients-with2023-04-14daily0.9 https://clinresonc-new.lhten.com/zolbetuximab-plus-mfolfox6-for-locally-advanced-unresectable-or2023-04-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-lenvatinib-plus-pembrolizumab-for2023-04-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-pembrolizumab-plus2023-04-16daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-adjuvant-atezolizumab-plus-bevacizumab-for2023-04-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-neoadjuvant-durvalumab-plus2023-04-16daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-personalized-mrna-vaccine-to2023-04-16daily0.9 https://clinresonc-new.lhten.com/association-of-ancestry-with-frequency-of-actionable-genomic2023-04-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-regn5459-for-relapsed-or-refractory2023-04-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-panitumumab-versus-bevacizumab-added-to2023-04-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pembrolizumab-monotherapy-for-metastatic2023-04-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-tislelizumab-plus2023-04-18daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-proton-therapy-and-limited-surgery-for2023-04-18daily0.9 https://clinresonc-new.lhten.com/avelumab-first-line-maintenance-for-advanced-urothelial-carcinoma2023-04-19daily0.9 https://clinresonc-new.lhten.com/anatomic-locations-of-procedurally-treated-keratinocyte-carcinomas-in2023-04-19daily0.9 https://clinresonc-new.lhten.com/race-and-ethnicity-adjusted-age-recommendation-for-initiating-breast2023-04-19daily0.9 https://clinresonc-new.lhten.com/risk-of-squamous-cell-carcinoma-of-the-breast-after-postmastectomy2023-04-19daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-nonalcoholic-fatty-liver-disease-as-risk2023-04-20daily0.9 https://clinresonc-new.lhten.com/early-detection-of-molecular-residual-disease-and-risk-stratification2023-04-20daily0.9 https://clinresonc-new.lhten.com/stereotactic-radiosurgery-versus-conventional-radiotherapy-for2023-04-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-trastuzumab-deruxtecan-versus2023-04-21daily0.9 https://clinresonc-new.lhten.com/association-of-overweight-obesity-and-recent-weight-loss-with2023-04-21daily0.9 https://clinresonc-new.lhten.com/association-of-overweight-obesity-and-recent-weight-loss-with-22023-04-21daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-statin-use-with-cancer-and2023-04-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-adjuvant-anastrazole-for-hr-positive2023-04-21daily0.9 https://clinresonc-new.lhten.com/effect-of-rituximab-on-immune-status-in-children-with-mature-b-cell2023-04-22daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-prevalence-and-survival-impact-of-low-skeletal2023-04-23daily0.9 https://clinresonc-new.lhten.com/impact-of-vitamin-d-levels-on-objective-response-rate-and-progression2023-04-24daily0.9 https://clinresonc-new.lhten.com/longitudinal-analysis-of-cancer-risk-in-children-and-adults-with2023-04-24daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-controlled-trial-of-allogeneic2023-04-25daily0.9 https://clinresonc-new.lhten.com/addition-of-selpercatinib-to-osimertinib-for-advanced-egfr-mutant2023-04-25daily0.9 https://clinresonc-new.lhten.com/changes-in-urological-cancer-surgical-volume-and-length-of-stay2023-04-25daily0.9 https://clinresonc-new.lhten.com/prediction-of-risk-for-myeloid-malignancy-in-clonal-hematopoiesis2023-04-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-quizartinib-plus-chemotherapy-for2023-04-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-efficacy-and-safety-of-intraoperative2023-04-26daily0.9 https://clinresonc-new.lhten.com/blinatumomab-plus-chemotherapy-for-kmt2a-rearranged-acute2023-04-27daily0.9 https://clinresonc-new.lhten.com/her2dx-pcr-score-for-predicting-pcr-with-deescalated-neoadjuvant2023-04-27daily0.9 https://clinresonc-new.lhten.com/longitudinal-analysis-of-change-in-mammographic-density-in-each2023-04-27daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-association-of-birth-by2023-04-27daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-anti-pd-1-therapy-with-or-without-chemotherapy2023-04-28daily0.9 https://clinresonc-new.lhten.com/long-term-safety-and-efficacy-of-selumetinib-for-inoperable-plexiform2023-04-28daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-outcomes-with-laparoscopic-versus-open-liver2023-04-28daily0.9 https://clinresonc-new.lhten.com/prostate-cancer-in-transgender-women-in-the-veterans-affairs-health2023-04-29daily0.9 https://clinresonc-new.lhten.com/association-of-geographic-origin-with-outcomes-of-hispanic-patients2023-04-30daily0.9 https://clinresonc-new.lhten.com/incidence-predictors-and-outcomes-of-febrile-neutropenia-and2023-05-01daily0.9 https://clinresonc-new.lhten.com/surgical-utilization-and-outcomes-for-patients-with-stage-iv-melanoma2023-05-01daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-low-versus-high-dose-lenalidomide-for2023-05-02daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-ruxolitinib-versus-best2023-05-02daily0.9 https://clinresonc-new.lhten.com/association-of-tumor-mutational-burden-with-outcomes-of-patients2023-05-02daily0.9 https://clinresonc-new.lhten.com/tucatinib-plus-trastuzumab-for-chemotherapy-refractory-her2-positive2023-05-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-ibrutinib-rituximab-versus2023-05-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-trifluridine-tipiracil-with-or-without2023-05-04daily0.9 https://clinresonc-new.lhten.com/multinational-trial-of-interrupting-endocrine-therapy-to-attempt2023-05-04daily0.9 https://clinresonc-new.lhten.com/childhood-acute-lymphoblastic-leukemia-results-of-the2023-05-05daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-a-multinational-randomized-phase-2-trial-of2023-05-05daily0.9 https://clinresonc-new.lhten.com/prediagnosis-smoking-cessation-and-overall-survival-among-patients2023-05-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-sintilimab-plus-chemotherapy-for-egfr2023-05-06daily0.9 https://clinresonc-new.lhten.com/validation-of-the-molecular-international-prognostic-scoring-system2023-05-06daily0.9 https://clinresonc-new.lhten.com/diagnostic-value-of-fdg-pet-ct-in-surveillance-after-curative2023-05-07daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-side-effects-of-standard-and-low-dose-tamoxifen2023-05-07daily0.9 https://clinresonc-new.lhten.com/quality-of-life-with-addition-of-cemiplimab-to-first-line2023-05-08daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-anlotinib-plus-pd-1-inhibitor-for-heavily-pretreated2023-05-09daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-allogeneic-hematopoietic-stem-cell2023-05-09daily0.9 https://clinresonc-new.lhten.com/adjuvant-nivolumab-versus-ipilimumab-after-complete-resection-of2023-05-10daily0.9 https://clinresonc-new.lhten.com/association-of-nativity-with-survival-among-adults-with2023-05-10daily0.9 https://clinresonc-new.lhten.com/association-of-body-mass-index-in-early-and-middle-adulthood-with2023-05-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-adjuvant-personalized-mrna-vaccine-plus2023-05-10daily0.9 https://clinresonc-new.lhten.com/first-line-cabozantinib-plus-nivolumab-and-ipilimumab-for-22023-05-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-venetoclax-combinations-in2023-05-11daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-endocrine-therapy-versus-de-escalated-chemotherapy-both2023-05-11daily0.9 https://clinresonc-new.lhten.com/absolute-and-conditional-number-of-life-years-lost-in-patients-with2023-05-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-dalpiciclib-plus-endocrine2023-05-12daily0.9 https://clinresonc-new.lhten.com/cumulative-burden-of-late-major-surgical-interventions-in-survivors2023-05-12daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-radical-cystectomy-versus-trimodality2023-05-13daily0.9 https://clinresonc-new.lhten.com/clinical-development-of-new-drugs-for-adults-and-children-with-cancer2023-05-13daily0.9 https://clinresonc-new.lhten.com/sleep-characteristics-and-cancer-recurrence-and-survival-after2023-05-14daily0.9 https://clinresonc-new.lhten.com/final-analysis-of-safron-ii-trial-of-single-versus-multifraction2023-05-15daily0.9 https://clinresonc-new.lhten.com/american-radium-society-appropriate-use-criteria-for-radiation2023-05-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-addition-of-ropeginterferon-to-standard2023-05-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-oncolytic-dnx-2401-virotherapy-plus2023-05-16daily0.9 https://clinresonc-new.lhten.com/association-of-prediagnostic-prescription-of-5-reductase-inhibitor2023-05-16daily0.9 https://clinresonc-new.lhten.com/safety-and-activitity-of-immune-checkpoint-inhibitors-for-cancer-in2023-05-17daily0.9 https://clinresonc-new.lhten.com/association-of-use-of-tyrosine-kinase-inhibitors-with-survival-and2023-05-17daily0.9 https://clinresonc-new.lhten.com/effectiveness-of-s-1-based-chemoradiotherapy-for-esophageal-squamous2023-05-17daily0.9 https://clinresonc-new.lhten.com/early-mortality-in-patients-with-cancer-treated-with-immune2023-05-18daily0.9 https://clinresonc-new.lhten.com/association-of-mgmt-promoter-methylation-with-survival-in-low-grade2023-05-18daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-anti-egfr-rechallenge-therapy2023-05-18daily0.9 https://clinresonc-new.lhten.com/interim-analysis-of-a-real-world-prospective-observational-study-of2023-05-19daily0.9 https://clinresonc-new.lhten.com/olaparib-plus-bevacizumab-first-line-maintenance-in-ovarian-cancer2023-05-19daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-association-of-bcg-vaccine-treatment-with2023-05-19daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-endocrine-therapy-with-or-without2023-05-20daily0.9 https://clinresonc-new.lhten.com/intratumoral-injection-of-oncolytic-virus-h01-in-combination-with2023-05-20daily0.9 https://clinresonc-new.lhten.com/palliative-care-referral-across-the-disease-trajectory-in-high-grade2023-05-20daily0.9 https://clinresonc-new.lhten.com/clinical-outcomes-and-prognostic-factors-in-triple-negative-invasive2023-05-21daily0.9 https://clinresonc-new.lhten.com/characteristics-and-clinical-outcomes-in-young-onset-versus-typical2023-05-22daily0.9 https://clinresonc-new.lhten.com/accumulation-of-chronic-disease-among-survivors-of-childhood-cancer2023-05-23daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-avapritinib-versus-placebo2023-05-24daily0.9 https://clinresonc-new.lhten.com/cancer-risk-following-surgical-removal-of-tonsils-and-adenoids2023-05-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-befotertinib-versus-icotinib2023-05-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-olvimulogene-nanivacirepvec-followed-by2023-05-25daily0.9 https://clinresonc-new.lhten.com/association-of-second-generation-antiandrogens-with-cognitive-and2023-05-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-cpx-351-for-higher-risk-myelodysplastic2023-05-26daily0.9 https://clinresonc-new.lhten.com/survival-after-introduction-of-adjuvant-treatment-for-stage-iii2023-05-26daily0.9 https://clinresonc-new.lhten.com/impact-of-use-of-pet-ct-versus-conventional-staging-in-patients-with2023-05-27daily0.9 https://clinresonc-new.lhten.com/multinational-case-control-study-of-risk-factors-for-primary-bone2023-05-27daily0.9 https://clinresonc-new.lhten.com/association-between-medically-diagnosed-postnatal-infection-and2023-05-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-comparing-ponatinib-versus-imatinib-for2023-05-28daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-the-association-between-statin-use2023-05-29daily0.9 https://clinresonc-new.lhten.com/treatment-free-remission-after-deep-molecular-response-of-chronic2023-05-30daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-cancer-risk-in-men-with-a-family-history-of2023-05-30daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-re-irradiation-for-high-grade-glioma2023-05-31daily0.9 https://clinresonc-new.lhten.com/late-onset-cognitive-impairment-and-modifiable-risk-factors-in-adult2023-05-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-fulvestrant-with-or-without2023-06-01daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-camrelizumab-plus-apatinib2023-06-01daily0.9 https://clinresonc-new.lhten.com/impact-of-pre-existing-depression-anxiety-or-both-on-survival-among2023-06-02daily0.9 https://clinresonc-new.lhten.com/direct-oral-anticoagulants-versus-low-molecular-weight-heparin-for2023-06-02daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-long-term-outcomes-with-bevacizumab-and2023-06-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2b-trial-of-zanidatamab-for-her2-amplified2023-06-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-pembrolizumab-for-early2023-06-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-talazoparib-plus2023-06-04daily0.9 https://clinresonc-new.lhten.com/association-between-duration-of-immunotherapy-and-overall-survival-in2023-06-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-vorasidenib-in-idh1-or-idh2-mutant-low2023-06-04daily0.9 https://clinresonc-new.lhten.com/overall-survival-results-from-phase-3-adaura-trial-adjuvant2023-06-05daily0.9 https://clinresonc-new.lhten.com/atezolizumab-plus-cabozantinib-versus-cabozantinib-alone-for-advanced2023-06-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-ciltacabtagene-autoleucel-versus2023-06-06daily0.9 https://clinresonc-new.lhten.com/germline-genetic-testing-after-cancer-diagnosis-in-california-and2023-06-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-survival-with-axicabtagene-ciloleucel2023-06-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-lisocabtagene-maraleucel-for-chronic2023-06-06daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-trial-of-safety-of-targeted-axillary2023-06-07daily0.9 https://clinresonc-new.lhten.com/long-term-prognosis-after-a-diagnosis-of-melanoma-in-situ2023-06-07daily0.9 https://clinresonc-new.lhten.com/impact-of-mgmt-promoter-methylation-on-treatment-benefit-in-patients2023-06-08daily0.9 https://clinresonc-new.lhten.com/risk-for-second-primary-cancers-after-imrt-versus-3dcrt-for-prostate2023-06-08daily0.9 https://clinresonc-new.lhten.com/risk-factors-for-progression-and-toxic-effects-after-preoperative2023-06-08daily0.9 https://clinresonc-new.lhten.com/association-of-her2dx-with-pathological-complete-response-and2023-06-09daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-eltrombopag-versus-placebo-for-low-risk2023-06-10daily0.9 https://clinresonc-new.lhten.com/association-of-multiple-high-risk-factors-with-real-world-outcomes2023-06-10daily0.9 https://clinresonc-new.lhten.com/associations-of-low-carbohydrate-diets-with-breast-cancer-survival2023-06-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-luspatercept-versus-epoetin-alfa-for2023-06-11daily0.9 https://clinresonc-new.lhten.com/epidemiology-of-cancer-associated-venous-thromboembolism-in-patients2023-06-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-nivolumab-ipilimumab-followed-by2023-06-13daily0.9 https://clinresonc-new.lhten.com/association-between-cardiac-substructure-radiation-dose-and-risk-of2023-06-13daily0.9 https://clinresonc-new.lhten.com/population-based-observational-cohort-study-of-breast-cancer2023-06-13daily0.9 https://clinresonc-new.lhten.com/isatuximab-bortezomib-lenalidomide-dexamethasone-in-patients-with2023-06-14daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-base-edited-car7-t-cells-for-relapsed-t-cell-acute2023-06-15daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-trastuzumab-deruxtecan-for-her2-postive-advanced-g2023-06-15daily0.9 https://clinresonc-new.lhten.com/first-line-systemic-treatment-strategies-for-initially-unresectable2023-06-15daily0.9 https://clinresonc-new.lhten.com/first-line-systemic-treatment-strategies-for-initially-unresectable-22023-06-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-sugemalimab-plus-chemotherapy2023-06-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-fruquintinib-versus-placebo-for2023-06-16daily0.9 https://clinresonc-new.lhten.com/intracranial-efficacy-of-adagrasib-in-patients-with-kras-g12c-mutated2023-06-17daily0.9 https://clinresonc-new.lhten.com/first-in-human-phase-1-trial-of-datopotamab-deruxtecan-for-advanced2023-06-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-anlotinib-plus-toripalimab-as-first-line2023-06-18daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-adjuvant-palbociclib-after-complete2023-06-18daily0.9 https://clinresonc-new.lhten.com/systematic-literature-review-of-epidemiology-clinical-characteristics2023-06-19daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-predictive-value-of-pcr-after-nac2023-06-19daily0.9 https://clinresonc-new.lhten.com/esmo-magnitude-of-clinical-benefit-scale-for-haematologic2023-06-19daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-risk-adapted-omission-of-neoadjuvant2023-06-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-busulfan-fludarabine-versus-busulfan2023-06-20daily0.9 https://clinresonc-new.lhten.com/multicancer-early-detection-test-in-symptomatic-patients-referred-for2023-06-21daily0.9 https://clinresonc-new.lhten.com/locoregional-recurrence-patterns-in-patients-with-different-molecular2023-06-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-post-tranplantation-cyclophosphamide2023-06-22daily0.9 https://clinresonc-new.lhten.com/severe-hepatopathy-in-national-wilms-tumor-studies-3-5-prevalence2023-06-22daily0.9 https://clinresonc-new.lhten.com/rates-of-and-factors-associated-with-patient-withdrawal-of-consent-in2023-06-22daily0.9 https://clinresonc-new.lhten.com/risk-of-cardiovascular-events-among-patients-with-head-and-neck-cancer2023-06-22daily0.9 https://clinresonc-new.lhten.com/seven-year-follow-up-of-the-phase-3-keynote-006-trial-pembrolizuamb2023-06-23daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-amcenestrant-versus2023-06-23daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-systemic-inflammation-and-body-composition-in2023-06-23daily0.9 https://clinresonc-new.lhten.com/treament-free-survival-after-nivolumab-versus-pembrolizumab-versus2023-06-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-camrelizumab-plus-famitinib-for2023-06-24daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-first-line-folfoxiri-plus-cetuximab2023-06-24daily0.9 https://clinresonc-new.lhten.com/association-of-diabetes-mellitus-with-efficacy-of-first-line2023-06-24daily0.9 https://clinresonc-new.lhten.com/trends-in-use-of-neoadjuvant-systemic-therapy-in-patients-with2023-06-25daily0.9 https://clinresonc-new.lhten.com/mortality-in-patients-with-nonfunctional-adrenal-tumors2023-06-26daily0.9 https://clinresonc-new.lhten.com/association-of-age-with-treatment-related-adverse-events-and-survival2023-06-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-relacorilant-plus-nab-paclitaxel-for2023-06-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-second-line-trastuzumab-plus2023-06-27daily0.9 https://clinresonc-new.lhten.com/association-of-body-mass-index-with-outcomes-among-patients-with-head2023-06-27daily0.9 https://clinresonc-new.lhten.com/plasma-epstein-bar-virus-dna-and-risk-of-future-nasopharyngeal-cancer2023-06-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-feasibility-trial-of-neoadjuvant-gemcitabine2023-06-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-gilteritinib-with-induction-and2023-06-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-perioperative-nivolumab-and-chemotherapy2023-06-29daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-association-of-cardiorespiratory-fitness-with2023-06-29daily0.9 https://clinresonc-new.lhten.com/long-term-patient-reported-outcomes-in-a-population-based-cohort2023-06-29daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2a-trial-of-zipalertinib-for-non-small-cell2023-06-30daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-association-of-daily-aspirin-use2023-06-30daily0.9 https://clinresonc-new.lhten.com/risk-of-male-breast-cancer-after-hodgkin-lymphoma2023-07-01daily0.9 https://clinresonc-new.lhten.com/predictors-of-quality-of-life-and-functional-recovery-in-older2023-07-01daily0.9 https://clinresonc-new.lhten.com/second-primary-cancer-among-colorectal-cancer-survivors-in-germany2023-07-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-niraparib-versus-placebo-added-to2023-07-02daily0.9 https://clinresonc-new.lhten.com/discordance-of-pik3ca-mutational-status-between-primary-and2023-07-02daily0.9 https://clinresonc-new.lhten.com/pathologic-complete-response-of-dcis-to-neoadjuvant-systemic-therapy2023-07-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-neoadjuvant-chemotherapy-plus-durvalumab2023-07-03daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-anakinra-for-icans-prophylaxis-in-cd19-car-t-cell2023-07-04daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-bcma-directed-car-t-cell-therapy-ari0002h-for2023-07-04daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-rcts-to-identify-mhspc-patient-groups-with-optimal2023-07-04daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-neoadjuvant-treatment-followed-by2023-07-05daily0.9 https://clinresonc-new.lhten.com/early-changes-in-circulating-tumor-dna-predict-response-of-kras-g12c2023-07-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-pirtobrutinib-after-a-covalent-btk2023-07-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-checkpoint-inhibitors-with-or-without2023-07-06daily0.9 https://clinresonc-new.lhten.com/radiotherapy-use-and-incidence-of-locoregional-recurrence-in2023-07-06daily0.9 https://clinresonc-new.lhten.com/high-tumor-mutational-burden-of-pdac-predicts-effectiveness-of-immune2023-07-07daily0.9 https://clinresonc-new.lhten.com/online-survey-of-long-term-effects-of-treatments-for-breast-cancer-in2023-07-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pembrolizumab-monotherapy-for-rare2023-07-08daily0.9 https://clinresonc-new.lhten.com/impact-of-black-race-on-bortezomib-induced-peripheral-neuropathy2023-07-08daily0.9 https://clinresonc-new.lhten.com/frontline-lenalidomide-plus-rituximab-for-dlbcl-in-elderly-frail2023-07-08daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-functional-and-survival-outcomes-after-primary2023-07-09daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-survival-impact-of-delay-of-adjuvant-radiotherapy2023-07-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-performance-of-liquid-biopsy-for2023-07-09daily0.9 https://clinresonc-new.lhten.com/personalized-oral-cancer-survival-calculator-to-estimate-risk-of2023-07-10daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-the-association-of2023-07-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-biomarker-directed-pembrolizumab-based2023-07-11daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-impact-of-concomitant-ppi-use-on2023-07-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-first-line-pembrolizumab-plus2023-07-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-adjuvant-nivolumab-versus-observation2023-07-12daily0.9 https://clinresonc-new.lhten.com/individual-participant-data-network-meta-analysis-of-neoadjuvant2023-07-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-braf-and-mek-inhibition-for-newly2023-07-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-niraparib-maintenance-therapy-among2023-07-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-metronomic-oral-vex-chemotherapy-versus2023-07-13daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-belzutifan-for-vhl-associated2023-07-14daily0.9 https://clinresonc-new.lhten.com/phase-1b-2-trial-of-tucatinib-letrozole-and-palbociclib-for2023-07-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-atezolizumab-vemurafenib-and-22023-07-15daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-differential-distribution-of2023-07-16daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-genomic-profiling-in2023-07-17daily0.9 https://clinresonc-new.lhten.com/concomitant-discontinuation-of-adjuvant-hormone-therapy-and2023-07-17daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-characteristics-and-outcomes-of-postradiation2023-07-17daily0.9 https://clinresonc-new.lhten.com/phase-1-2a-trial-of-yttrium-90-radioembolization-plus-durvalumab-for2023-07-18daily0.9 https://clinresonc-new.lhten.com/interim-analysis-of-oveall-survival-with-adjuvant-atezolizumab-after2023-07-18daily0.9 https://clinresonc-new.lhten.com/multisite-retrospective-study-of-synchronous-neoplasia-rates-at2023-07-18daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-stereotactic-ablative-radiotherapy-with2023-07-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-outcomes-of-cutaneous-squamous-cell-carcinoma2023-07-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-olaparib-plus-temozolomide-for-advanced2023-07-20daily0.9 https://clinresonc-new.lhten.com/association-of-lowering-the-recommended-colorectal-cancer-screening2023-07-20daily0.9 https://clinresonc-new.lhten.com/clinical-presentation-and-outcomes-of-patients-with-cancer-associated2023-07-21daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-concomitant-use-of2023-07-21daily0.9 https://clinresonc-new.lhten.com/optimal-regimen-of-short-term-mapk-pathway-inhibition-for2023-07-22daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-analysis-of-oncological-safety-of-radical2023-07-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-zanubrutinib-versus-ibrutinib-for-22023-07-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-lenalidomide-in-combination-with-r-eshap2023-07-24daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-bleeding-risk-with-concurrent2023-07-24daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-acute-toxicity-with-magnetic-resonance-guided2023-07-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-camrelizumab-plus-22023-07-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-trastuzumab-deruxtecan-for-metastatic2023-07-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-neoadjuvant-adebrelimab-for-locally2023-07-25daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-prognostic-factors-for-survival-after2023-07-26daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-studies-of-tumor-treating-fields-therapy-for-newly2023-07-27daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-toripalimab-plus-neoadjuvant2023-07-27daily0.9 https://clinresonc-new.lhten.com/association-of-wildfire-exposure-while-recovering-from-lung-cancer2023-07-27daily0.9 https://clinresonc-new.lhten.com/lead-time-to-recurrence-after-posttreatment-plasma-and-saliva-hpv-dna2023-07-27daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-prognostic-value-of-pathological-lymph-node2023-07-28daily0.9 https://clinresonc-new.lhten.com/association-between-availability-of-genotyping-results-and-overall2023-07-28daily0.9 https://clinresonc-new.lhten.com/clinical-outcomes-and-health-care-utilization-among-patients-with2023-07-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-everolimus-after-surgery-for2023-07-29daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-proton-beam-radiotherapy-versus-transarterial2023-07-29daily0.9 https://clinresonc-new.lhten.com/exploring-the-presence-of-bovine-leukemia-virus-among-breast-cancer2023-07-30daily0.9 https://clinresonc-new.lhten.com/value-of-vnpi-and-mskcc-nomogram-to-estimate-risk-of-ipislateral2023-07-31daily0.9 https://clinresonc-new.lhten.com/retrospective-cross-sectional-study-of-age-at-first-breast-cancer2023-07-31daily0.9 https://clinresonc-new.lhten.com/prevalence-of-pathogenic-or-likely-pathogenic-germline-variants-in2023-07-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-zolbetuximab-plus-capox-for-cldn18-22023-08-01daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-upfront-radiosurgery-versus-wait-and-scan-for2023-08-01daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-artificial-intelligence-supported-screen-reading2023-08-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-erdafinitinb-for-advanced-solid-tumors2023-08-02daily0.9 https://clinresonc-new.lhten.com/cross-sectional-assessment-of-changes-in-cancer-diagnoses-and-stage2023-08-02daily0.9 https://clinresonc-new.lhten.com/impact-of-thymectomy-on-all-cause-mortality-and-risk-of-cancer-in2023-08-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-avelumab-versus-standard-second-line2023-08-03daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-camrelizumab-to-neoadjuvant2023-08-03daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-neoadjuvant-cemiplimab-for-advanced2023-08-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-upfront-panitumumab-plus-mfolfox-or2023-08-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ak112-a-novel-pd1-vegf-bispecific2023-08-04daily0.9 https://clinresonc-new.lhten.com/time-to-deterioration-of-patient-reported-outcomes-as-a-surrogate-of2023-08-05daily0.9 https://clinresonc-new.lhten.com/registry-based-study-of-trends-in-cancer-incidence-by-socioeconomic2023-08-05daily0.9 https://clinresonc-new.lhten.com/outcomes-with-first-line-therapies-for-real-world-nsqnsclc-patients2023-08-06daily0.9 https://clinresonc-new.lhten.com/impact-of-race-and-ethnicity-on-overall-survival-of-patients2023-08-06daily0.9 https://clinresonc-new.lhten.com/retrospective-multicenter-study-of-chemoimmunotherapy-for-extensive2023-08-07daily0.9 https://clinresonc-new.lhten.com/prospective-associations-of-different-combinations-of-aerobic-and2023-08-07daily0.9 https://clinresonc-new.lhten.com/breast-cancer-overdiagnosis-after-screening-mammography-among-older2023-08-08daily0.9 https://clinresonc-new.lhten.com/radiation-facility-volume-and-survival-among-men-receiving-radiation2023-08-08daily0.9 https://clinresonc-new.lhten.com/consumption-of-sugar-sweetened-and-artificially-sweetened-beverages2023-08-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pyrotinib-plus-capecitabine-for2023-08-09daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-chemotherapy-plus-pd-l-1-blockade-as-first-line2023-08-09daily0.9 https://clinresonc-new.lhten.com/germline-variants-incidentally-detected-via-tumor-only-genomic2023-08-09daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-intermediate-endpoints-as-surrogates-for-outcomes-in2023-08-10daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-dual-anti-her2-therapy-with2023-08-10daily0.9 https://clinresonc-new.lhten.com/five-year-results-of-a-multinational-randomized-phase-2-trial-of2023-08-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-first-line-durvalumab-and2023-08-11daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-in-patients-with-tumors-with-high-tumor-mutational2023-08-11daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-anaplastic-lymphoma-kinase2023-08-11daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-addition-of-pd-l-1-inhibitor-to-first-line2023-08-12daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-study-of-clinicopathologic-features-and2023-08-12daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-immune-checkpoint-inhibitors-for2023-08-12daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-association-of-nasopharynx2023-08-13daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-evaluation-of-skin-toxicity-risk-factors-in2023-08-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-ibrutinib-maintenance-following-first2023-08-13daily0.9 https://clinresonc-new.lhten.com/mri-guided-salvage-focal-cryoablation-for-localized-recurrent2023-08-14daily0.9 https://clinresonc-new.lhten.com/first-line-cemiplimab-followed-by-continued-cemiplimab-plus2023-08-15daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-efficacy-and-safety-of-proton-therapy-versus-photon2023-08-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-elranatamab-for-relapsed-or-refractory2023-08-16daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-abiraterone-acetate-with-or2023-08-16daily0.9 https://clinresonc-new.lhten.com/patterns-in-cancer-incidence-among-people-younger-than-50-years-in2023-08-16daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-oncological-safety-of-omitting2023-08-17daily0.9 https://clinresonc-new.lhten.com/cdk4-6-inhibitors-versus-weekly-paclitaxel-for-er-her2-advanced2023-08-17daily0.9 https://clinresonc-new.lhten.com/health-related-quality-of-life-with-tislelizumab-versus-docetaxel-for2023-08-17daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-ipilimumab-with-or-without2023-08-18daily0.9 https://clinresonc-new.lhten.com/post-hoc-18-month-follow-up-of-a-phase-1-trial-of-idecabtagene2023-08-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-perioperative-chemoimmunotherapy-with2023-08-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-parsaclisib-for-relapsed-or-refractory2023-08-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-crs-hipec-versus-palliative-systemic2023-08-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-tislelizumab-plus-chemotherapy-for-egfr2023-08-20daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-tqb2450-with-or-without-anlotinib-for2023-08-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-mitotane-versus-surveillance2023-08-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-atezolizumab-plus-chemotherapy-for2023-08-22daily0.9 https://clinresonc-new.lhten.com/frequency-of-biopsy-and-tumor-grade-before-versus-after-introduction2023-08-22daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-adding-ovarian-suppression-to-tamoxifen-after2023-08-23daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-overall-survival-after-mohs-surgery2023-08-23daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-sacituzumab-govitecan-for-hr-positive2023-08-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-single-agent-divarasib-in-advanced2023-08-24daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-immune-checkpoint2023-08-24daily0.9 https://clinresonc-new.lhten.com/association-between-antibiotic-prescribing-and-time-to-diagnosis-of2023-08-24daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-nivolumab-plus-ipilimumab-for-advanced-salivary2023-08-25daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-impact-of-delayed-radiotherapy2023-08-25daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-immune-checkpoint-inhibition-and-cytotoxic2023-08-26daily0.9 https://clinresonc-new.lhten.com/final-analysis-of-the-dreamm-2-trial-of-single-agent-belantamab2023-08-26daily0.9 https://clinresonc-new.lhten.com/trends-in-severe-anal-intraepithelial-neoplasia-in-the-united-states2023-08-27daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-outcomes-of-patients-with-brain-only2023-08-27daily0.9 https://clinresonc-new.lhten.com/breast-screening-participation-and-degree-of-spread-of-invasive2023-08-27daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-randomized-trial-of-lifetime-gained-with-cancer2023-08-28daily0.9 https://clinresonc-new.lhten.com/prediction-model-for-early-stage-pancreatic-cancer-using-routinely2023-08-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ixazomib-daratumumab-and-low-dose2023-08-29daily0.9 https://clinresonc-new.lhten.com/matched-pair-analysis-of-survival-of-patients-with-cancer-with-dpyd2023-08-29daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-addition-of-nivolumab-versus-placebo-to-first-line2023-08-29daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-dabrafenib-plus-trametinib-for2023-08-30daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-neoadjuvant-palbociclib-plus-either2023-08-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-tumor-treating-fields-plus-standard2023-08-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-nimotuzumab-plus-gemcitabine-for-kras2023-08-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-mezigdomide-plus-dexamethasone-for2023-08-31daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-nivolumab-plus-ipilimumab-versus-nivolumab-alone-in2023-08-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-tisotumab-vedotin-based-combination2023-09-01daily0.9 https://clinresonc-new.lhten.com/pan-cancer-analysis-of-postdiagnosis-exercise-and-mortality2023-09-01daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-breast-cancer-and-incidence-of2023-09-01daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-first-line-regorafenib-with-nivolumab-and2023-09-02daily0.9 https://clinresonc-new.lhten.com/five-year-overall-survival-analysis-of-adjuvant-pemetrexed-cisplatin2023-09-02daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-impact-of-exercise-and-nutrition-intervention-on2023-09-02daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-the-association-of-leukocyte-telomere2023-09-03daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-gastric-score-for-prediction-of-overall-survival-and2023-09-03daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-study-of-chemotherapy-with-or-without2023-09-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-the-jak1-inhibitor-golidocitinib-for2023-09-05daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-prospective-studies-of-association-of-reproductive2023-09-05daily0.9 https://clinresonc-new.lhten.com/new-cancer-diagnoses-before-and-during-the-covid-19-pandemic-in2023-09-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-oral-selinexor-maintenance-after-first2023-09-06daily0.9 https://clinresonc-new.lhten.com/population-based-retrospective-study-of-antidepressant-use-and2023-09-06daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-cutaneous-adverse-events-and-cancer-survival2023-09-06daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-risk-of-second-primary-malignancies2023-09-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-atezolizumab-for-advanced-alveolar-soft2023-09-07daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-anlotinib-versus-placebo-for-locally2023-09-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-durvalumab-plus-concurrent-radiotherapy2023-09-07daily0.9 https://clinresonc-new.lhten.com/ncdb-analysis-of-de-escalation-of-postmastectomy-irridiation-in-hr2023-09-08daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-between-gastroesophageal-reflux-disease2023-09-08daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-prognostic-factors-for-relapse-in2023-09-09daily0.9 https://clinresonc-new.lhten.com/prospective-trial-of-artificial-intelligence-for-breast-cancer2023-09-09daily0.9 https://clinresonc-new.lhten.com/optimal-imaging-surveillance-interval-among-durable-progression-free2023-09-09daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-conventionally-fractionated-versus2023-09-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-patritumab-deruxtecan-for-egfr-mutated2023-09-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-trastuzumab-deruxtecan-for-her2-mutant2023-09-11daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-biochemical-recurrence-and-risk-of2023-09-11daily0.9 https://clinresonc-new.lhten.com/subsequent-female-breast-cancer-risk-associated-with-anthracycline2023-09-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-nalirifox-versus-nab2023-09-12daily0.9 https://clinresonc-new.lhten.com/ten-year-follow-up-results-of-phase-3-ovhipec-1-trial-crs-versus-crs2023-09-12daily0.9 https://clinresonc-new.lhten.com/final-analysis-of-phase-2-griffin-trial-of-addition-of-daratumumab-to2023-09-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-olaparib-to-first-line2023-09-13daily0.9 https://clinresonc-new.lhten.com/risk-of-subsequent-primary-malignancies-among-patients-with-merkel2023-09-13daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-the-association-of-non-erosive2023-09-14daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-long-term-incidence-of-hematological-cancer2023-09-14daily0.9 https://clinresonc-new.lhten.com/phase-2-nonrandomized-trial-of-individualized-stereotactic-ablative2023-09-14daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-survival-after-development-of-contralateral2023-09-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-axicabtagene-ciloleucel-for-large-b-cell2023-09-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-aminvantamab-plus-lazertinib-for-egfr2023-09-15daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-adjuvant-egfr-tkis-after-resection-of2023-09-15daily0.9 https://clinresonc-new.lhten.com/hrqol-with-nivolumab-plus-chemotherapy-versus-chemotherapy-alone-for2023-09-16daily0.9 https://clinresonc-new.lhten.com/hrqol-with-nivolumab-plus-chemotherapy-versus-chemotherapy-alone-for-22023-09-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-indoximod-based-chemo-immunotherapy-for2023-09-17daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-lurbinectedin-in-second-line-setting-and2023-09-17daily0.9 https://clinresonc-new.lhten.com/real-world-effectiveness-study-of-hpv-vaccination-and-anal-high-grade2023-09-18daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-cetuximab-maintenance-after-folfiri-plus2023-09-18daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-biomarker-directed-therapy-in-black-and2023-09-18daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-real-world-study-of-tyrosine-kinase2023-09-19daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-effect-of-invitation-letter-in-language-of-origin2023-09-20daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-studies-of-association-of-poor-oral-health-and2023-09-20daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-circulating-tumor-dna-dynamics-as2023-09-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-first-line-dabrafenib-plus-trametinib2023-09-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-anlotinib-as-maintenance-treatment-for2023-09-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-slnb-vs-no-axillary-surgery-for-small2023-09-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-risk-directed-ambulatory2023-09-21daily0.9 https://clinresonc-new.lhten.com/germline-sequencing-analysis-to-inform-clinical-gene-panel-testing2023-09-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-abiraterone-acetate-with-or-without2023-09-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-vemurafenib-plus-obinutuzumab-as2023-09-22daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-survivin-dendritic-cell-vaccine-for-high-risk2023-09-22daily0.9 https://clinresonc-new.lhten.com/ncdb-analysis-of-differential-response-to-neoadjuvant-endocrine2023-09-23daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-partial-breast-irradiation-or-intraoperative2023-09-23daily0.9 https://clinresonc-new.lhten.com/phase-1-2-trial-of-cd7-targeted-car-t-cell-therapy-for-relapsed-and2023-09-24daily0.9 https://clinresonc-new.lhten.com/false-suspicion-of-renal-insufficiency-with-mate-1-inhibiting2023-09-24daily0.9 https://clinresonc-new.lhten.com/comparison-of-post-chemoradiotherapy-pneumonitis-between-asian-and2023-09-25daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-incidence-risk-factors-and-management-of2023-09-25daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-age-at-new-onset-nonalcoholic-fatty2023-09-25daily0.9 https://clinresonc-new.lhten.com/mismatch-repair-system-deficiency-as-a-resistance-factor-for-locally2023-09-25daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-prophylactic-radiation2023-09-26daily0.9 https://clinresonc-new.lhten.com/nine-week-versus-one-year-trastuzumab-for-early-her2-positive-breast2023-09-26daily0.9 https://clinresonc-new.lhten.com/overall-survival-among-patients-with-de-novo-stage-iv-metastatic-and2023-09-26daily0.9 https://clinresonc-new.lhten.com/conditional-risks-of-biochemical-failure-and-prostate-cancer-specific2023-09-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-tucatinib-plus-trastuzumab-for2023-09-27daily0.9 https://clinresonc-new.lhten.com/cascade-testing-for-hereditary-cancer-using-multigene-panels2023-09-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-isatuximab-carfilzomib-lenalidomide-and2023-09-28daily0.9 https://clinresonc-new.lhten.com/lifetime-treatment-burden-of-patients-with-follicular-lymphoma-real2023-09-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-nonrandomized-trial-of-tiragolumab-with-or2023-09-28daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-study-of-tocilizumab-in-combination-with2023-09-29daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-trends-in-outcomes-of-philadelphia2023-09-29daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-overall-and-cervical-cancer-survival-of2023-09-29daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-vitamin-c-intake-and-colorectal-cancer-survival2023-09-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-fuzuloparib-plus-apatinib-for-advanced2023-09-30daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-survival-impact-of-quitting-smoking-after-a2023-10-01daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-combined-braf-mek-and-heat-shock-protein-902023-10-01daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-survival-trend-in-patients-with-de2023-10-02daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-effectiveness-of-a-decision-aid-plus-standard2023-10-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-organ-sparing-chemo-immunotherapy-for2023-10-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-elranatamab-for-relapsed-or-refractory2023-10-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-safety-and-activity-of-cadonilimab2023-10-03daily0.9 https://clinresonc-new.lhten.com/cancer-germline-predisposing-variants-and-late-mortality-from2023-10-03daily0.9 https://clinresonc-new.lhten.com/multinational-validation-study-of-the-immunoscore-biopsy-in-patients2023-10-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-rivoceranib-for-recurrent-or-metastatic2023-10-04daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-prophylactic-salpingo2023-10-04daily0.9 https://clinresonc-new.lhten.com/multinational-trial-of-pertuzumab-plus-trastuzumab-for-her2-altered2023-10-05daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-long-term-outcome-in-patients-with-nodal2023-10-05daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-subjective-and-objective-hearing-loss-among2023-10-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-tislelizumab-versus2023-10-05daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-blood-based-tests-for2023-10-06daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-second-line-lenvatinib-after-failure-of2023-10-06daily0.9 https://clinresonc-new.lhten.com/risk-factors-for-short-term-prostate-specific-antigen-recurrence2023-10-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-patritumab-deruxtecan-for-previously2023-10-07daily0.9 https://clinresonc-new.lhten.com/importance-of-low-and-moderate-grade-adverse-events-in-patients2023-10-07daily0.9 https://clinresonc-new.lhten.com/patterns-and-predictors-of-anxiety-and-depression-symptom2023-10-08daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-characteristics-of-patients-with2023-10-09daily0.9 https://clinresonc-new.lhten.com/nationwide-swedish-cohort-study-of-risks-of-non-ovarian-cancer2023-10-09daily0.9 https://clinresonc-new.lhten.com/intraoperative-or-postoperative-stereotactic-radiotherapy-for-brain2023-10-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ctdna-response-after-pembrolizumab-in2023-10-10daily0.9 https://clinresonc-new.lhten.com/cluster-randomized-trial-of-multilevel-primary-care-intervention-to2023-10-10daily0.9 https://clinresonc-new.lhten.com/phase-1b-2-trial-of-eribulin-in-combination-with-cyclophosphamide-in2023-10-10daily0.9 https://clinresonc-new.lhten.com/prospective-trial-of-radiofrequency-ablation-with-or-without2023-10-11daily0.9 https://clinresonc-new.lhten.com/ultra-fast-deep-learned-cns-tumor-classification-during-surgery2023-10-11daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-severe-oral-mucositis-after-intensity2023-10-11daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-global-variations-in-lung-cancer-incidence2023-10-12daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-berzosertib-plus-topotecan-versus2023-10-12daily0.9 https://clinresonc-new.lhten.com/oncologic-outcome-in-advanced-oral-squamous-cell-carcinoma-after2023-10-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-intratumoral-toll-like-receptor-42023-10-12daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-the-association-of-obesitas-with-risk2023-10-13daily0.9 https://clinresonc-new.lhten.com/value-of-systemic-chemotherapy-in-patients-treated-with-crs-hipec-for2023-10-13daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-second-or-third-line-pembrolizumab2023-10-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-nivolumab-with-or-without-nivolumab2023-10-14daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-first-line-palbociclib-plus-aromatase2023-10-14daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-long-term-risks-of-supplemental-surgery-after2023-10-15daily0.9 https://clinresonc-new.lhten.com/predictive-value-of-pretreatment-pan-immune-inflammation-value-for2023-10-15daily0.9 https://clinresonc-new.lhten.com/impact-of-patient-specific-clinical-features-on-real-world2023-10-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-osimertinib-for-advanced-non-small2023-10-16daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-radiologic-identification-of2023-10-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-nivolumab-after-resection-of2023-10-17daily0.9 https://clinresonc-new.lhten.com/neoplasia-risk-in-patients-with-lynch-syndrome-treated-with-immune2023-10-17daily0.9 https://clinresonc-new.lhten.com/prospective-randomized-trial-of-adjuvant-selenium-and-vitamin-e-for2023-10-17daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-long-term-outcomes-and-risk-of2023-10-17daily0.9 https://clinresonc-new.lhten.com/analysis-of-expension-of-clinical-actionability-for-cancer-patients2023-10-18daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-sequential-cd19-and-cd22-car-t-cell-therapy-for2023-10-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-cosibelimab-for-metastatic-cutaneous2023-10-18daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2a-study-of-bispecific-cs1-bcma-car-t-cells-for2023-10-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-enzalutamide-androgen-deprivation2023-10-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-perioperative-chemotherapy-plus-immune2023-10-19daily0.9 https://clinresonc-new.lhten.com/cancers-attributable-to-infections-in-the-us-in-20172023-10-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-dental-extractions-before2023-10-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-tebotelimab-with-or-without2023-10-20daily0.9 https://clinresonc-new.lhten.com/disparities-in-breast-cancer-screening-rates-among-adults-with-and2023-10-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-the-combination-of-gt90001-and2023-10-20daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-hereditary-cancer-testing-in-a-diverse-sample2023-10-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-erdafitinib-versus-chemotherapy-for2023-10-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-tarlatamab-for-patients-with2023-10-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-selpercatinib-or2023-10-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-selpercatinib-versus2023-10-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-amivantamab-plus-chemotherapy-for2023-10-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-tebentafusp-for-metastatic-uveal2023-10-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-nivolumab-plus-gemcitabine-cisplatin2023-10-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-pembrolizumab-plus-chemotherapy-for2023-10-23daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-neoadjuvant-cemiplimab-and-surgery-for2023-10-23daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-durvalumab-for2023-10-23daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-chemotherapy-related-toxic-effects2023-10-23daily0.9 https://clinresonc-new.lhten.com/germline-egfr-mutations-and-familial-lung-cancer2023-10-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-cldn6-specific-car-t-cells-plus2023-10-24daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-impact-of-recent-bendamustine2023-10-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-zimberelimab-monotherapy-in-patients2023-10-25daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-short-term-outcomes-after-laparoscopic-versus2023-10-25daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-pharmaceutical-industry-payments-and2023-10-26daily0.9 https://clinresonc-new.lhten.com/case-control-study-of-fetal-and-newborn-outcomes-after-anti-her22023-10-26daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-life-expectancy-after-a-diagnosis2023-10-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-metronomic-antiangiogenic-regimen-for2023-10-26daily0.9 https://clinresonc-new.lhten.com/binational-phase-3-trial-of-biweekly-versus-triweekly-cabazitaxel-for2023-10-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-inotuzumab-ozogamicin-induction-therapy2023-10-27daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-the-response-adjusted-therapy-for-advanced2023-10-27daily0.9 https://clinresonc-new.lhten.com/long-term-results-of-phase-2-opra-trial-of-organ-preservation-with2023-10-27daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-outcomes-in-children-adolescents-and-youg2023-10-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-screening-mammography-performance-by-race-and2023-10-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-dietary-patterns-with-kidney2023-10-28daily0.9 https://clinresonc-new.lhten.com/two-year-follow-up-of-lisocabtagene-maraleucel-in-relapsed-or2023-10-28daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-contralateral-breast-cancer-risk-among2023-10-29daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-long-term-risk-of-carotid-stenosis2023-10-29daily0.9 https://clinresonc-new.lhten.com/cerebrospinal-fluid-circulating-tumor-dna-genotyping-in-lung2023-10-29daily0.9 https://clinresonc-new.lhten.com/impact-of-helicobacter-pylori-infection-status-on-outcomes-with2023-10-30daily0.9 https://clinresonc-new.lhten.com/multinational-cohort-study-of-association-of-dcis-size-and-margin2023-10-30daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-temporal-trend-in-overall-survival-after-treatment2023-10-30daily0.9 https://clinresonc-new.lhten.com/analysis-of-association-between-pathologic-response-and-event-free2023-10-31daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-tenofovir-versus-entecavir-after2023-10-31daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-impact-of-timing-of2023-10-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-survival-impact-of-addition-of-hipec-to2023-11-01daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-dabrafenib-trametinib-versus2023-11-01daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-single-dose-lu-177-psma-617-followed-by-maintenance2023-11-01daily0.9 https://clinresonc-new.lhten.com/overall-survival-in-a-multinational-phase-3-trial-of-first-line2023-11-02daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-first-line-lenvatinib-plus-toripalimab-and-folfox2023-11-02daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-incidence-and-survival-of-peritoneal2023-11-02daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-breast-cancer-incidence-after-a2023-11-02daily0.9 https://clinresonc-new.lhten.com/three-year-survival-results-from-a-phase-2-trial-of-neoadjuvant2023-11-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-dostarlimab-monotherapy-for-mismatch2023-11-03daily0.9 https://clinresonc-new.lhten.com/five-year-results-of-a-randomized-trial-of-adjuvant-hipec-for-locally2023-11-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-chemotherapy-with-or-without2023-11-04daily0.9 https://clinresonc-new.lhten.com/individual-patient-data-meta-analysis-of-14-324-women-in-16-trials-of2023-11-04daily0.9 https://clinresonc-new.lhten.com/diagnostic-outcomes-of-concurrent-dna-and-rna-sequencing-in2023-11-04daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-cancer-mortality-after2023-11-05daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-correlation-between-preoperative-mri-and2023-11-05daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-factors-driving-breast-cancer-chemotherapy2023-11-05daily0.9 https://clinresonc-new.lhten.com/association-between-prediagnostic-psa-level-and-prostate-cancer2023-11-06daily0.9 https://clinresonc-new.lhten.com/survival-improvements-in-advanced-hepatocellular-carcinoma-with2023-11-06daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-guideline-based-follow-up-outcomes-in-patients2023-11-06daily0.9 https://clinresonc-new.lhten.com/colonoscopy-ascertained-prevalence-of-advanced-neoplasia-according-to2023-11-07daily0.9 https://clinresonc-new.lhten.com/four-year-follow-up-of-multinational-phase-3-trial-of-first-line2023-11-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ipilimumab-once-every-twelve-versus2023-11-07daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-circulating-tumor-cell-count-drive2023-11-07daily0.9 https://clinresonc-new.lhten.com/retrospective-database-analysis-of-treatments-and-overall-survival2023-11-08daily0.9 https://clinresonc-new.lhten.com/analysis-of-sex-related-differences-in-cancer-incidence-among-solid2023-11-08daily0.9 https://clinresonc-new.lhten.com/database-analysis-of-survival-outcomes-in-premenopausal-patients-with2023-11-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-osimertinib-with-or-without2023-11-09daily0.9 https://clinresonc-new.lhten.com/case-description-of-severe-immune-related-enteritis-after-in-utero2023-11-09daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-trends-in-organ-preservation-among-rectal2023-11-09daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-global-stage-distribution-of2023-11-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-trastuzumab-plus-gemcitabine2023-11-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-second-line-docetaxel-ramucirumab-after2023-11-10daily0.9 https://clinresonc-new.lhten.com/risk-of-hematological-malignancies-from-ct-radiation-exposure-in2023-11-10daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-impact-of-patient-age-on-outcomes-with-addition2023-11-11daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-impact-of-a-pain-monitoring-app-for-children-with2023-11-11daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-toripalimab-plus-axitinib-in-resectable2023-11-12daily0.9 https://clinresonc-new.lhten.com/analysis-of-dyslipidemia-and-cardiovascular-disease-among-childhood2023-11-12daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-with-first-line-durvalumab-with-or-without2023-11-12daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-fecal-microbiota-transplantation-plus2023-11-13daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-pooled-analysis-of-studies-of-postoperative2023-11-13daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-induction-toripalimab-and-chemotherapy-for-organ2023-11-13daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-the-association-between-pretreatment-emotional2023-11-14daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-second-line-lenvatinib-after-first-line2023-11-14daily0.9 https://clinresonc-new.lhten.com/incidence-of-infections-in-patients-receiving-teclistamab-for2023-11-14daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-acupuncture-versus-massage-for-cancer2023-11-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-trial-of-addition-of-atezolizumab-to-flot2023-11-15daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-the-phase-3-profound-trial-olaparib-for-patients2023-11-15daily0.9 https://clinresonc-new.lhten.com/prediction-of-adjuvant-gemcitabine-sensitivity-in-resectable2023-11-15daily0.9 https://clinresonc-new.lhten.com/risk-of-second-primary-lung-cancer-among-lung-cancer-survivor-who2023-11-15daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-impact-of-pathologic-features-of-axillary2023-11-16daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-first-line-blinatumomab-for-b-all-in2023-11-16daily0.9 https://clinresonc-new.lhten.com/nationwide-cohort-study-of-trends-in-incidence-of-recurrence-and-time2023-11-16daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-nivolumab-for-prevention-of-oral-squamous-carcinoma2023-11-16daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-hpv-circulating-tumor-dna-for-early2023-11-17daily0.9 https://clinresonc-new.lhten.com/case-control-analysis-of-cumulative-absolute-risk-of-colorectal2023-11-17daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-systemic-therapy-with-or2023-11-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-tovorafenib-for-relapsed-or-refractory2023-11-18daily0.9 https://clinresonc-new.lhten.com/early-results-with-particle-beam-radiotherapy-for-who-grade-2-and-32023-11-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-real-world-outcomes-with-osimertinib-for-egfr2023-11-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-prednisone-vinblastine2023-11-19daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-bendaeam-versus-beam-as2023-11-20daily0.9 https://clinresonc-new.lhten.com/increasing-risk-of-hepatocellular-carcinoma-in-successive-generations2023-11-20daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-survival-of-patients-with-head-and2023-11-20daily0.9 https://clinresonc-new.lhten.com/phase-1b-trial-of-ponsegromab-in-patients-with-cancer-and-cachexia2023-11-20daily0.9 https://clinresonc-new.lhten.com/phase-1b-trial-of-ponsegromab-in-patients-with-cancer-and-cachexia-22023-11-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-first-line-pyrotinib-plus-camrelizumab2023-11-21daily0.9 https://clinresonc-new.lhten.com/nationwide-study-of-potential-clinical-utility-of-circulating-tumor2023-11-21daily0.9 https://clinresonc-new.lhten.com/propensity-score-matched-analysis-of-impact-of-neoadjuvant2023-11-21daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-two-phase-2-trials-of-disitamab-vedotin-for-her22023-11-22daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-trial-of-risk-adapted-radioimmunotherapy-for2023-11-22daily0.9 https://clinresonc-new.lhten.com/database-analysis-of-association-of-surgeon-patient-sex-concordance2023-11-22daily0.9 https://clinresonc-new.lhten.com/two-center-phase-2-trial-of-neoadjuvant-pembrolizumab-plus2023-11-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-osimertinib-for-metastatic2023-11-22daily0.9 https://clinresonc-new.lhten.com/predictive-value-of-minimal-residual-disease-status-after-induction2023-11-23daily0.9 https://clinresonc-new.lhten.com/association-of-body-mass-index-with-cancer-risk-among-adults-with-and2023-11-23daily0.9 https://clinresonc-new.lhten.com/impact-of-intrathecal-pemetrexed-on-survival-of-patients-with2023-11-23daily0.9 https://clinresonc-new.lhten.com/impact-of-intrathecal-pemetrexed-on-survival-of-patients-with-22023-11-23daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-prevalence-and-prognosis-of-diabetes2023-11-24daily0.9 https://clinresonc-new.lhten.com/new-predictive-score-of-outcomes-with-first-line-atezolizumab-plus2023-11-24daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-traes-in-patients-receiving2023-11-25daily0.9 https://clinresonc-new.lhten.com/physical-activity-and-checkpoint-inhibition-association-with-toxicity2023-11-25daily0.9 https://clinresonc-new.lhten.com/cross-sectional-analysis-of-prevalence-of-targetable-genomic2023-11-25daily0.9 https://clinresonc-new.lhten.com/impact-of-age-and-comorbidities-on-efficacy-and-tolerability-of2023-11-26daily0.9 https://clinresonc-new.lhten.com/impact-of-body-composition-factors-on-outcomes-with-first-line-immune2023-11-26daily0.9 https://clinresonc-new.lhten.com/registry-based-retrospective-study-of-outcomes-of-allogeneic2023-11-27daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-clinicopathologic-predictors-of-recurrence-and2023-11-27daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-serum-sodium-levels-with2023-11-27daily0.9 https://clinresonc-new.lhten.com/adherence-to-the-2018-wcrf-aicr-cancer-prevention-recommendations-and2023-11-28daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-long-term-outcomes-of-addition-of-immunotherapy-to2023-11-28daily0.9 https://clinresonc-new.lhten.com/uk-biobank-analysis-of-the-association-of-circulating-levels-of2023-11-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-chemotherapy-with-or-without2023-11-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-sbrt-with-or-without-avasopasem-for2023-11-29daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-metronomic-chemotherapy-with-or-without2023-11-29daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-risk-of-cervical-cancer-among2023-11-30daily0.9 https://clinresonc-new.lhten.com/multinational-analysis-of-risk-reducing-mastectomy-and-breast-cancer2023-11-30daily0.9 https://clinresonc-new.lhten.com/kras-sequence-variation-as-prognostic-marker-in-patients-with-early2023-11-30daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-lu-psma-617-versus-cabazitaxel-for-mcrpc-in-the2023-12-01daily0.9 https://clinresonc-new.lhten.com/case-control-analysis-of-the-association-of-inflammatory-tongue2023-12-01daily0.9 https://clinresonc-new.lhten.com/platinum-ineligibility-and-survival-outcomes-in-patients-with2023-12-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-chemotherapy-plus2023-12-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-atezolizumab-plus-bevacizumab-and2023-12-02daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-cumulative-incidence-of-second2023-12-02daily0.9 https://clinresonc-new.lhten.com/cns-efficacy-of-osimertinib-with-or-without-chemotherapy-in-egfr2023-12-03daily0.9 https://clinresonc-new.lhten.com/propensity-score-weighted-analysis-of-overall-survival-with-first2023-12-03daily0.9 https://clinresonc-new.lhten.com/peripheral-blood-based-model-to-predict-response-of-metastatic2023-12-04daily0.9 https://clinresonc-new.lhten.com/risk-of-chronic-health-conditions-in-lesbian-gay-and-bisexual2023-12-04daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-the-association-of-exposure-to-agent-orange-and2023-12-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-talazoparib-with2023-12-05daily0.9 https://clinresonc-new.lhten.com/urinary-protein-signature-combined-with-clinical-information-for2023-12-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-sintilimab-plus-chemotherapy-for2023-12-05daily0.9 https://clinresonc-new.lhten.com/preoperative-breast-mri-to-identify-candidates-for-omission-of2023-12-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-trial-of-divarasib-plus-cetuximab-for-kras2023-12-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-mirvetuximab-soravtansine-in-fr2023-12-07daily0.9 https://clinresonc-new.lhten.com/case-control-analysis-of-the-effect-of-baseline-estradiol-serum2023-12-07daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-cohort-study-of-feasibility-and-safety-of2023-12-07daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-trial-of-omission-of-radiotherapy-after2023-12-08daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-addition-of-immune-checkpoint-inhibitors-to-first2023-12-08daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-association-between-prediabetes-and-breast-cancer2023-12-08daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-by-sex-and-hiv-status-in2023-12-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-second-line-cemiplimab-after-failure2023-12-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-tislelizumab-plus-zanubrutinib-for2023-12-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-golidocitinib-for-relapsed-or2023-12-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-ibrutinib-plus-venetoclax-versus-fcr-for2023-12-10daily0.9 https://clinresonc-new.lhten.com/phase-1b-2-trial-of-mosunetuzumab-plus-polatuzumab-vedotin-for2023-12-11daily0.9 https://clinresonc-new.lhten.com/multicenter-trial-of-neoadjuvant-sacituzumab-govitecan-for-localized2023-12-11daily0.9 https://clinresonc-new.lhten.com/trastuzumab-deruxtecan-for-previously-treated-her2-positive2023-12-11daily0.9 https://clinresonc-new.lhten.com/multinational-pooled-analysis-of-leisure-time-physical-activity-and2023-12-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-daratumumab-to-vrd-in-ndmm2023-12-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-venetoclax-to-ibrutinib2023-12-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-sunvozertinib-for-locally-advanced-or2023-12-13daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-the-association-between-metabolic-syndrome-and2023-12-13daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-primary-care-utilization-and-cardiovascular2023-12-13daily0.9 https://clinresonc-new.lhten.com/prediabetes-and-associated-risk-of-cardiovascular-events-and-chronic2023-12-14daily0.9 https://clinresonc-new.lhten.com/discordance-between-ca-125-progression-and-recist-progression-in-the2023-12-14daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-carboplatin-with-or-without2023-12-14daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-or-placebo-plus-chemotherapy-with-or-without2023-12-14daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-sbrt-to-standard-of-care2023-12-15daily0.9 https://clinresonc-new.lhten.com/prospective-analysis-of-minimal-residual-disease-status-as-predictor2023-12-15daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-early-kinetics-of-crp-for-cancer-agnostic2023-12-15daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-global-burden-of-non-hodgkin-lymphoma-attributable2023-12-16daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-sotorasib-for-kras-g12c-mutated-advanced-non2023-12-16daily0.9 https://clinresonc-new.lhten.com/retrospective-real-world-study-of-risk-factors-for-primary-resistance2023-12-16daily0.9 https://clinresonc-new.lhten.com/discordance-of-mutational-signatures-between-pretreatment-tumor2023-12-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-efbemalenograstim-alfa-for-reducing2023-12-17daily0.9 https://clinresonc-new.lhten.com/use-and-outcomes-of-surgery-for-locally-advanced-pancreatic-cancer2023-12-18daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-treatment-related-adverse-events-among-men-receiving2023-12-18daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-rituximab-maintenance-in-young-patients-with2023-12-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-cadonilimab-plus-anlotinib-as-first2023-12-19daily0.9 https://clinresonc-new.lhten.com/godrevy-project-virtual-reality-for-symptom-control-and-well-being-in2023-12-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-pembrolizumab-plus2023-12-20daily0.9 https://clinresonc-new.lhten.com/women-s-health-initative-analysis-of-the-association-of-hysterectomy2023-12-20daily0.9 https://clinresonc-new.lhten.com/association-of-pik3ca-mutation-with-pcr-and-outcome-by-hormone2023-12-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-cabozantinib-plus-atezolizumab-for2023-12-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-donor-derived-anti-cd19-car-t-cells-for2023-12-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-oral-decitabine-cedazuridine-versus2023-12-21daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-beep-induction-therapy-before-wbrt-for-previously2023-12-21daily0.9 https://clinresonc-new.lhten.com/allogeneic-hematopoietic-cell-transplantation-for-patients-with-acute2023-12-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-olaparib-plus-ramucirumab-for2023-12-23daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-prognostic-value-of-nodal-status-before-and2023-12-23daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-multimodal-primary-treatment-of-localized2023-12-24daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-docetaxel-based-neoadjuvant-chemotherapy2023-12-24daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-risk-factors-for-recurrence-among-patients2023-12-25daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-nivolumab-monotherapy-for-advanced2023-12-25daily0.9 https://clinresonc-new.lhten.com/long-term-impact-of-chemotherapy-and-radiotherapy-on-dental-health-of2023-12-26daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-impt-versus-imrt-in-concurrent2023-12-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-odm-208-for-heavily-pretreated2023-12-26daily0.9 https://clinresonc-new.lhten.com/validation-of-the-rsclin-risk-calculator-in-the-national-cancer2023-12-27daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-palonosetron-for-prevention-of-delayed-chemotherapy2023-12-27daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-survival-impact-of-local-therapy-for-early2023-12-28daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-association-of-perioperative-dexamethasone-with2023-12-28daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-association-of-b-cell-infiltration2023-12-28daily0.9 https://clinresonc-new.lhten.com/potential-of-genetics-in-identifying-women-at-lower-risk-of-breast2023-12-29daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-mesenchymal-stem-cells-for2023-12-29daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-real-life-outcomes-with-pazopanib-for2023-12-30daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-factors-affecting-recurrence-and-survival2023-12-30daily0.9 https://clinresonc-new.lhten.com/comparison-of-clinicopathologic-phenotypes-of-her2-low-versus-her22023-12-30daily0.9 https://clinresonc-new.lhten.com/novel-comprehensive-hepatocellular-carcinoma-outcome-prognostic2023-12-31daily0.9 https://clinresonc-new.lhten.com/defining-the-biology-of-estrogen-receptor-low-positive-breast-cancer2024-01-01daily0.9 https://clinresonc-new.lhten.com/incidence-and-risk-factors-of-immune-related-adverse-events-induced2024-01-02daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-concomitant-antihypertensive2024-01-02daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-perioperative-toripalimab-and2024-01-03daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-microwave-ablation-versus2024-01-03daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-prophylactic-cranial2024-01-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-camrelizumab-plus-apatinib2024-01-04daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-bevacizumab-and-gamma-knife2024-01-04daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-brain-radiotherapy-combined-with2024-01-04daily0.9 https://clinresonc-new.lhten.com/phase-1b-trial-of-sotorasib-plus-panitumumab-for-chemotherapy2024-01-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-belantamab-mafodotin-with-pomalidomide2024-01-05daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-immunotherapy-initiation-at-the-end-of2024-01-05daily0.9 https://clinresonc-new.lhten.com/post-hoc-ctdna-analysis-explains-response-of-gist-to-ripretinib2024-01-06daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-rpfs-and-cpfs-as-surrogates-for-os-in-metastatic2024-01-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-disitamab-vedotin-plus-toripalimab-for2024-01-06daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-management-of-non-metastatic2024-01-07daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-effectiveness-and-toxicity-of2024-01-07daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-prognostic-value-of-variant2024-01-07daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-analysis-of-bone-marrow-graft-versus2024-01-08daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-first-line-nalirifox-folfirinox-or-gem-nabp-for2024-01-08daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-atezolizumab-plus-chemotherapy-for2024-01-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-toripalimab-plus-nab2024-01-09daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-first-line-subtype-based-therapy-for2024-01-09daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-adjuvant-abemaciclib-with-endocrine-therapy2024-01-10daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-two-rituximab-dosing-strategies-for-low-tumor2024-01-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-repotrectinib-for-advanced-ros12024-01-11daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-actinium-225-psma-radioligand2024-01-11daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-impact-of-adjuvant-chemotherapy-on2024-01-11daily0.9 https://clinresonc-new.lhten.com/value-of-gls-and-nt-probnp-for-prediction-of-cardiomyopathy-in2024-01-12daily0.9 https://clinresonc-new.lhten.com/assocation-of-body-mass-index-with-risk-of-multiple-myeloma-in-the2024-01-12daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-trial-of-streptococcus-salivarius-k12-for2024-01-13daily0.9 https://clinresonc-new.lhten.com/single-center-phase-3-trial-of-low-dose-versus-standard-dose2024-01-13daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-with-first-line-enfortumab-vedotin-with-or2024-01-13daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-prognostic-impact-of-adjuvant2024-01-14daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-review-of-presentation-and-outcomes-of2024-01-15daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-neoadjuvant-folfirinox2024-01-16daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-addition-of-toripalimab-to2024-01-16daily0.9 https://clinresonc-new.lhten.com/first-line-lenvatinib-plus-pembrolizumab-versus-sunitinib-for-22024-01-17daily0.9 https://clinresonc-new.lhten.com/single-center-prospective-trial-of-autologous-dendritic-cell-therapy2024-01-17daily0.9 https://clinresonc-new.lhten.com/case-control-study-of-survival-impact-of-adjuvant-radiotherapy-after2024-01-17daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-patient-specific-markers-of-measurable-residual2024-01-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-gemcitabine-with-or-without-paclitaxel2024-01-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-sacituzumab-govitecan-for-advanced2024-01-18daily0.9 https://clinresonc-new.lhten.com/retrospective-observational-cohort-study-of-immune-related-adverse2024-01-18daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2b-trial-of-addition-of-individualized-neoantigen2024-01-19daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-optimal-timing-of-initiation-of-adjuvant2024-01-19daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-adjuvant-sintilimab-in2024-01-19daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-chemo-immunotherapy-for-potentially2024-01-20daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-real-world-analysis-of-teclistamab-for2024-01-20daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-olaparib-versus-paclitaxel2024-01-21daily0.9 https://clinresonc-new.lhten.com/seer-analysis-of-survival-difference-between-secondary-and-de-novo2024-01-21daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-prognostic-impact-of-mismatch2024-01-21daily0.9 https://clinresonc-new.lhten.com/observational-study-of-invasive-cervical-cancer-incidence-following2024-01-22daily0.9 https://clinresonc-new.lhten.com/survey-of-determinants-of-active-surveillance-uptake-in-a-cohort-of2024-01-22daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-concurrent-tissue-and-ctdna-molecular-profiling2024-01-22daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-cemiplimab-for-advanced-cutaneous2024-01-23daily0.9 https://clinresonc-new.lhten.com/association-between-recent-weigth-loss-and-cancer-diagnoses-among2024-01-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-second-line-ramucirumab-avelumab-and2024-01-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nab-paclitaxel-plus-gemcitabine-and2024-01-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-intensification-of-androgen-blockade-for2024-01-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-second-line-sacituzumab-govitecan-plus2024-01-24daily0.9 https://clinresonc-new.lhten.com/fdg-pet-ct-imaging-one-week-after-a-single-dose-of-pembrolizumab-can2024-01-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-iruplinalkib-versus-crizotinib-for-alk2024-01-25daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-invasive-breast-cancer-and-breast2024-01-25daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-genetic-alterations-associated-with2024-01-25daily0.9 https://clinresonc-new.lhten.com/efficacy-and-safety-of-radiotherapy-dose-escalation-among-pediatric2024-01-26daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-efficacy-and-safety-of-nab2024-01-26daily0.9 https://clinresonc-new.lhten.com/phase-1-2-trial-of-azacitidine-venetoclax-and-gilteritinib-for-newly2024-01-27daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-treatment-free-remission-after2024-01-27daily0.9 https://clinresonc-new.lhten.com/association-between-health-related-quality-of-life-and-overall2024-01-28daily0.9 https://clinresonc-new.lhten.com/prospective-pilot-study-of-cesium-131-brachytherapy-for-rapidly2024-01-28daily0.9 https://clinresonc-new.lhten.com/european-union-cancer-mortality-predictions-for-the-year-20242024-01-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-ficonalkib-for-advanced-alk-positive2024-01-29daily0.9 https://clinresonc-new.lhten.com/prospective-observational-study-of-biomarkers-of-adjuvant2024-01-30daily0.9 https://clinresonc-new.lhten.com/association-between-high-til-levels-and-pcr-in-patients-receiving2024-01-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-high-dose-chemotherapy-and-autohsct-for2024-01-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-high-dose-chemotherapy-and-autohsct-for-22024-01-30daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-prognostic-value-of-intratumoral-immune2024-01-31daily0.9 https://clinresonc-new.lhten.com/comment-in-nature-the-naming-of-cancers-need-to-change2024-01-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-penpulimab-plus-chemotherapy2024-02-01daily0.9 https://clinresonc-new.lhten.com/prospective-trial-of-association-of-skin-microbiome-dynamics-with2024-02-01daily0.9 https://clinresonc-new.lhten.com/retrospective-database-analysis-of-survival-impact-of-radiotherapy2024-02-01daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-circulating-tumor-dna-posttreatment-measurement-and2024-02-01daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-with-adjuvant-olaparib-for-gbrca1-2-mutated2024-02-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-sugemalimab-plus-chemotherapy-22024-02-02daily0.9 https://clinresonc-new.lhten.com/nationwide-retrospective-cohort-study-of-risk-of-venous2024-02-03daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-study-of-oral-decitabine-plus-cedazuridine2024-02-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-monalizumab-plus-durvalumab-for2024-02-03daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-efficacy-of-immune-checkpoint-inhibitors-in2024-02-04daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-clinical-outcomes-of-icis-with-or-without-srs2024-02-04daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-effect-of-surgery-versus-chemotherapy-in2024-02-04daily0.9 https://clinresonc-new.lhten.com/preoperative-ca-19-9-predicts-disease-progression-after-crs-hipec-for2024-02-04daily0.9 https://clinresonc-new.lhten.com/multinational-cross-sectional-study-of-long-term-health-related2024-02-05daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-allogeneic-stem-cell2024-02-05daily0.9 https://clinresonc-new.lhten.com/mia-calculator-for-predicting-recurrence-free-and-overall-survival-of2024-02-06daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-the-association-of-smoking-status-with-survival2024-02-06daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-the-association-between-post-diagnostic2024-02-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-induction-sintilimab-plus-chemotherapy2024-02-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-myc-targeting-by-omo-103-in-metastatic2024-02-07daily0.9 https://clinresonc-new.lhten.com/repeated-prostate-cancer-screening-using-psa-testing-and-mri-in-the2024-02-07daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-incidence-of-late-recurrence-and-second2024-02-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-induction-chemotherapy-followed-by2024-02-08daily0.9 https://clinresonc-new.lhten.com/association-of-tumor-mutational-burden-in-metastatic-castration2024-02-08daily0.9 https://clinresonc-new.lhten.com/multinational-randomised-phase-2-trial-of-enobosarm-for-ar-positive2024-02-09daily0.9 https://clinresonc-new.lhten.com/modelling-study-of-cost-effectiveness-of-gene-specific-prevention2024-02-09daily0.9 https://clinresonc-new.lhten.com/population-based-prospective-study-of-mtfit-versus-fit-in-a2024-02-10daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-mental-disorders-among-adolescents-and-young2024-02-10daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-five-studies-of-onc201-dordaviprone-for-recurrent2024-02-10daily0.9 https://clinresonc-new.lhten.com/multinational-observational-study-of-safety-and-effectiveness-of2024-02-11daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-concomitant-use-of-ppis-and-cdk4-62024-02-11daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-association-of-excess-body-weight-with2024-02-11daily0.9 https://clinresonc-new.lhten.com/trend-in-survival-of-patients-with-advanced-melanoma-in-the2024-02-12daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-studies-of-diffuse-midline-h3k27-altered-gliomas2024-02-12daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-studies-of-stereotactic-body-versus-conventional2024-02-12daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-nivolumab-plus-ipilimumab-plus-chemotherapy-for2024-02-13daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-stroke-risk-in-survivors-of-head-and-neck2024-02-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-chemotherapy-after2024-02-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-umbrella-trial-of-biomarker-directed-targeted2024-02-14daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-implementation-of-best-practices-in-pancreatic2024-02-14daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1b-trial-of-entinostat-nivolumab-and-ipilimumab2024-02-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-3-trial-of-addition-of-pegargiminase-to-first2024-02-15daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-a-phase-2-trial-of-2-induction-courses-of-bcg2024-02-15daily0.9 https://clinresonc-new.lhten.com/prospective-trial-of-nivolumab-plus-ipilimumab-for-previously-treated2024-02-15daily0.9 https://clinresonc-new.lhten.com/development-and-validation-of-a-prediction-model-of-outcomes-with2024-02-16daily0.9 https://clinresonc-new.lhten.com/association-of-height-with-survival-among-patients-with-resectable2024-02-16daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-association-between-doxorubicin-exposure-and2024-02-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-olaparib-in-patients-with-advanced2024-02-17daily0.9 https://clinresonc-new.lhten.com/association-between-neighborhood-opportunity-allostatic-load-and-all2024-02-17daily0.9 https://clinresonc-new.lhten.com/oncological-safety-of-skipping-alnd-in-patients-undergoing-mastectomy2024-02-18daily0.9 https://clinresonc-new.lhten.com/retrospective-real-world-comparison-of-dacomitinib-and-afatinib-for2024-02-19daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-outcomes-of-salvage-treatment-after-bcma2024-02-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-ki-67-labeling-index-with2024-02-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-regorafenib-plus-nivolumab2024-02-20daily0.9 https://clinresonc-new.lhten.com/four-year-overall-survival-update-from-the-multinational-phase-32024-02-20daily0.9 https://clinresonc-new.lhten.com/nationwide-retrospective-cohort-study-of-gastric-and-duodenal-cancer2024-02-20daily0.9 https://clinresonc-new.lhten.com/de-novo-her2-positive-metastatic-breast-cancer-time-trends-in-real2024-02-21daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-use-of-cancer-directed-therapy-at-the2024-02-21daily0.9 https://clinresonc-new.lhten.com/cytogenetic-and-molecular-associations-with-outcomes-of-hmas-plus2024-02-21daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-total-neoadjuvant-therapy-with-pd-12024-02-21daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-chemotherapy-for-advanced-gastroesophageal2024-02-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-rusfertide-for-control-of-erythrocytosis2024-02-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-camrelizumab-plus-famitinib2024-02-22daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-sunitinib-for-progressive2024-02-23daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-eribulin-plus-pembrolizumab-for-metastatic-soft2024-02-23daily0.9 https://clinresonc-new.lhten.com/variables-associated-with-odds-of-severe-covid-19-among-vaccinated2024-02-23daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-belzutifan-for-von-hippel-lindau2024-02-24daily0.9 https://clinresonc-new.lhten.com/ncdb-analysis-of-racial-ethnic-disparities-in-outcomes-with2024-02-24daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-study-of-sapanisertib-in-combination-with-ziv2024-02-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-dual-ctla-4-checkpoint-blockade-with-pd2024-02-26daily0.9 https://clinresonc-new.lhten.com/phase-1b-study-of-zilovertamab-plus-paclitaxel-for-locally-advanced2024-02-26daily0.9 https://clinresonc-new.lhten.com/single-center-fase-2-3-trial-of-gallium-68-rm2-pet-mri-for-evaluation2024-02-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-pivekimab-sunirine-for-relapsed-or2024-02-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-stereotactic-ablative-body-radiotherapy2024-02-27daily0.9 https://clinresonc-new.lhten.com/single-center-phase-3-trial-of-topical-diclofenac-versus-placebo-for2024-02-28daily0.9 https://clinresonc-new.lhten.com/primary-tumor-resection-before-systemic-therapy-in-patients-with2024-02-28daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-incidence-of-and-risk-factors-for-second-primary2024-02-28daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-associations-of-serum-tumor-markers2024-02-28daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-simple-versus-radical-hysterectomy2024-02-29daily0.9 https://clinresonc-new.lhten.com/observational-cohort-study-of-mortality-risk-over-20-years-in-men2024-02-29daily0.9 https://clinresonc-new.lhten.com/multinational-longitudinal-cohort-study-of-the-association-of2024-02-29daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-association-of-mri-surveillance2024-02-29daily0.9 https://clinresonc-new.lhten.com/sacituzumab-govitecan-for-metastatic-triple-negative-breast-cancer-22024-03-01daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-adding-of-immunotherapy-to-first-line-chemotherapy2024-03-01daily0.9 https://clinresonc-new.lhten.com/association-between-patient-ethnicity-and-prostate-cancer-diagnosis2024-03-02daily0.9 https://clinresonc-new.lhten.com/effectiveness-of-glutamine-for-the-treatment-of-radiodermatitis-in2024-03-02daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-impact-of-helicobacter-pylori-infection2024-03-03daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-phase-2-ampect-trial-of-nab-sirolimus-for2024-03-03daily0.9 https://clinresonc-new.lhten.com/trastuzumab-plus-pertuzumab-for-non-breast-gastroesophageal-her22024-03-04daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-parenteral-nutrition-for-patients-with2024-03-04daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-the-association-of-socioeconomic-status2024-03-04daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-sintilimab-plus-chidamide-with-or-without2024-03-05daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-survival-among-patients-with-high-risk2024-03-05daily0.9 https://clinresonc-new.lhten.com/prospective-real-world-outcomes-with-cemiplimab-for-locally-advanced2024-03-06daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-immune-checkpoint-inhibitors-in2024-03-06daily0.9 https://clinresonc-new.lhten.com/response-and-survival-impact-of-pd-l1-status-in-metastatic-urothelial2024-03-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-enfortumab-vedotin-plus2024-03-07daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-immunotherapy-or2024-03-07daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-neoadjuvant-adjuvant-versus-neoadjuvant-only-pd-l-12024-03-07daily0.9 https://clinresonc-new.lhten.com/prospective-trial-of-stereotactic-radiation-therapy-in-patients-with2024-03-07daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-versus-placebo-after-resection-of-stage-iib-or-iic2024-03-08daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-incidence-of-nonkeratinocyte-skin-cancer2024-03-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3b-trial-of-venetoclax-for-relapsed-or-refractory2024-03-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-trifluridine-tipiracil-with-or-without2024-03-09daily0.9 https://clinresonc-new.lhten.com/predictive-and-prognostic-value-of-her2-gene-expression-levels-in2024-03-09daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-tucidinostat-plus-exemestane-for-early2024-03-10daily0.9 https://clinresonc-new.lhten.com/longitudinal-cohort-study-of-long-term-outcomes-of-pediatric-patients2024-03-11daily0.9 https://clinresonc-new.lhten.com/prospective-analysis-of-association-of-metabolic-syndrome-scores2024-03-11daily0.9 https://clinresonc-new.lhten.com/time-trends-in-prognosis-of-screen-detected-and-interval-cancers-in2024-03-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-cemiplimab-once-every-four-weeks-for2024-03-12daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-overall-survival-in-patients-with-de-novo2024-03-12daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-prognostic-value-of-psa-level-at-6-months-after2024-03-13daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-gilterinib-as-post-transplant2024-03-13daily0.9 https://clinresonc-new.lhten.com/impact-of-center-volume-on-outcomes-of-adverse-events-after-immune2024-03-13daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-trends-in-cancer-incidence-and-mortality2024-03-14daily0.9 https://clinresonc-new.lhten.com/performance-of-a-cell-free-dna-blood-based-test-for-colorectal-cancer2024-03-14daily0.9 https://clinresonc-new.lhten.com/noninferiority-of-hypofractionated-versus-conventionally-fractionated2024-03-14daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-sintilimab-plus-anlotinib-for2024-03-15daily0.9 https://clinresonc-new.lhten.com/prognostic-and-predictive-value-of-immunoscore-in-stage-iii2024-03-15daily0.9 https://clinresonc-new.lhten.com/danish-population-based-study-of-the-association-of-congenital-tooth2024-03-15daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-thromboembolic-risk-with-krd-versus-vrd-for-newly2024-03-16daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-real-world-study-of-first-line2024-03-16daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-clinical-impact-of-biopsy-preceding2024-03-17daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-severe-sepsis-during-treatment-for-childhood-leukemia2024-03-18daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-prognostic-significance-of-lymph-node2024-03-18daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-mri-guided-sabr-versus-ct-guided-ire2024-03-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-zandelisib-plus-zanubrutinib-for2024-03-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-zandelisib-plus-zanubrutinib-for-22024-03-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-neoadjuvant-pembrolizumab-plus2024-03-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-neoadjuvant-nivolumab-or-nivolumab-plus2024-03-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-pembrolizumab-plus-chemoradiotherapy2024-03-21daily0.9 https://clinresonc-new.lhten.com/seer-medicare-database-analysis-of-toxicity-of-proton-beam-therapy2024-03-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-ribociclib-plus-endocrine-therapy-in2024-03-21daily0.9 https://clinresonc-new.lhten.com/improvements-in-posttransplant-outcomes-in-older-aml-patients-in-the2024-03-22daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-neoadjuvant-chemoimmunotherapy2024-03-22daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-fulvestrant-palbociclib-and2024-03-22daily0.9 https://clinresonc-new.lhten.com/clinical-epidemiologic-and-pathologic-significancer-of-her2-low2024-03-23daily0.9 https://clinresonc-new.lhten.com/patient-advocate-led-survey-of-side-effects-of-real-world-treatments2024-03-23daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-high-dose-vitamin-d-to-attenuate-bone2024-03-24daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-the-association-of2024-03-24daily0.9 https://clinresonc-new.lhten.com/trends-in-mortality-due-tocolorectal-cancer-in-the-united-states-from2024-03-25daily0.9 https://clinresonc-new.lhten.com/comparison-of-long-term-oncologic-outcomes-of-central-lumpectomy-and2024-03-25daily0.9 https://clinresonc-new.lhten.com/nomogram-for-predicting-pathological-response-to-neoadjuvant2024-03-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-trastuzumab-deruxtecan-for-her22024-03-26daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-the-association-between-exclusive2024-03-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-pazopanib-versus-placebo-in-patients2024-03-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-gedatolisib-in-combination-with2024-03-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-afamitresgene-autoleucel-for-advanced2024-03-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-sintilimab-plus-pegaspargase2024-03-28daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-impact-of-anti-helicobacter2024-03-28daily0.9 https://clinresonc-new.lhten.com/extended-follow-up-of-phase-1-2-study-of-mosunetuzumab-for-relapsed2024-03-29daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-oxaliplatin-based-adjuvant-chemotherapy-for-stage2024-03-29daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-cognitive-behavioral-therapy-for-insomina-to2024-03-30daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-anti-cd19-car-t-cell-therapy-for2024-03-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-atezolizumab-plus-cabozantinib-versus2024-03-30daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-non-comparative-phase-2-trial-of-first-line2024-03-31daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-study-of-load703-plus-chemotherapy-for2024-03-31daily0.9 https://clinresonc-new.lhten.com/development-and-validation-of-a-model-to-predict-recurrence-free-and2024-04-01daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-association-of-exposure-to-polybrominated2024-04-01daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-impact-of-postoperative-radiotherapy-on2024-04-02daily0.9 https://clinresonc-new.lhten.com/association-of-tumor-infiltrating-lymphocyte-abundance-with-survival2024-04-02daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-mental-health-care-utilization-among-parents2024-04-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-neoadjuvant-mfolfox6-or-capox-versus2024-04-03daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-addition-of-transarterial-chemoembolization-to2024-04-03daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-tucatinib-plus-trastuzumab-and-capecitabine-after2024-04-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-pet-based-pcr-adapted-chemotherapie-de2024-04-04daily0.9 https://clinresonc-new.lhten.com/recurrence-free-survival-in-a-multinational-noninferiority-trial-of2024-04-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-second-line-folfiri-plus-durvalumab-with2024-04-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-cisplatin-plus-gemcitabine-and-imrt-for2024-04-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-mri-based-versus-psa-based2024-04-05daily0.9 https://clinresonc-new.lhten.com/prevalence-of-functional-disability-among-us-cancer-survivors-20172024-04-05daily0.9 https://clinresonc-new.lhten.com/fifteen-year-follow-up-of-cap-trial-of-association-between-psa2024-04-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-mri-guided-optimization-of-neoadjuvant2024-04-06daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-camrelizumab-chemotherapy2024-04-06daily0.9 https://clinresonc-new.lhten.com/prognostic-impact-of-number-of-induction-courses-to-attain-complete2024-04-07daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-cancer-stage-compared-with-mortality-as-end-points2024-04-08daily0.9 https://clinresonc-new.lhten.com/clinical-benefit-and-regulatory-outcomes-of-cancer-drugs-receiving2024-04-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-the-combination-of-personalized2024-04-08daily0.9 https://clinresonc-new.lhten.com/trajectories-of-health-care-contact-days-for-patients-with-stage-iv2024-04-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-perioperative-versus-adjuvant-s-1-plus2024-04-09daily0.9 https://clinresonc-new.lhten.com/population-based-retrospective-trial-of-clinical-factors-associated2024-04-09daily0.9 https://clinresonc-new.lhten.com/secondary-analysis-of-paola-1-trial-of-addition-of-olaparib-to2024-04-10daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-cabozantinib-for-unresectable-and2024-04-10daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-cabozantinib-monotherapy-for-advanced2024-04-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-alectinib-versus-chemotherapy-after2024-04-11daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-risk-of-second-primary-breast-cancer-in-young2024-04-11daily0.9 https://clinresonc-new.lhten.com/international-prognostic-index-for-marginal-zone-lymphomas-requiring2024-04-12daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-anlotinib-plus2024-04-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-metformin-for-prevention-of-alpelisib2024-04-12daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-lutetium-177-psma-617-plus-enzalutamide2024-04-13daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-first-line-chemotherapy-with-or2024-04-13daily0.9 https://clinresonc-new.lhten.com/retrospective-long-term-evaluation-of-conventional-transarterial2024-04-14daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-trends-and-predictors-of-quality2024-04-15daily0.9 https://clinresonc-new.lhten.com/omission-of-postmastectomy-radiotherapy-for-patients-with-clinically2024-04-15daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-burden-of-childhood-cancer-and2024-04-15daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-covid-19-mortality-risk-in-us-cancer2024-04-16daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-neoadjuvant-chemo2024-04-16daily0.9 https://clinresonc-new.lhten.com/cytology-based-deep-learning-method-for-prediction-of-tumor-origin-in2024-04-17daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-tolerability-and-efficacy-of2024-04-17daily0.9 https://clinresonc-new.lhten.com/vigibase-analysis-of-association-between-ici-use-during-pregnancy-and2024-04-17daily0.9 https://clinresonc-new.lhten.com/adjuvant-pembrolizumab-versus-placebo-for-renal-cell-carcinoma2024-04-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-vismodegib-plus-radiation-therapy-for2024-04-18daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-adherence-to-american-cancer-society2024-04-18daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-clonal-hematopoiesis-and-therapy2024-04-19daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-postpartum-breast-cancer-and-survival-in-women2024-04-19daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-controlled-trial-of-laparoscopic-versus-open2024-04-20daily0.9 https://clinresonc-new.lhten.com/risk-based-lung-cancer-screening-performance-in-a-universal2024-04-20daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-safety-and-efficacy-of2024-04-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1a-trial-of-ivonescimab-in-patients-with-advanced2024-04-21daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-bendamustine-lymphodepletion2024-04-22daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-biomarker-versus-mri-enhanced-strategies-for2024-04-22daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-durvalumab-consolidation-after2024-04-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-liposomal-irinotecan-versus-topotecan2024-04-23daily0.9 https://clinresonc-new.lhten.com/cross-over-study-of-suppression-of-serum-estrogens-during-neoadjuvant2024-04-23daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-value-of-neoadjuvant-chemo-immunotherapy-for2024-04-23daily0.9 https://clinresonc-new.lhten.com/nivolumab-for-mismatch-repair-deficient-gynecological-cancers-single2024-04-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-datopotamab-deruxtecan-for-advanced-or2024-04-24daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-salvage-reirradiation-for-locally-recurrent2024-04-24daily0.9 https://clinresonc-new.lhten.com/sequential-cd7-car-t-cell-therapy-and-allogeneic-stem-cell2024-04-25daily0.9 https://clinresonc-new.lhten.com/sequential-cd7-car-t-cell-therapy-and-allogeneic-stem-cell-22024-04-25daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-postoperative-hypofractionated-intensity-modulated2024-04-25daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-radiation-therapy-with-or-without2024-04-26daily0.9 https://clinresonc-new.lhten.com/prospective-pilot-study-of-low-dose-lenvatinib-plus-anti-pd-1-therapy2024-04-26daily0.9 https://clinresonc-new.lhten.com/gene-expression-markers-in-peripheral-blood-and-outcomes-of-platinum2024-04-27daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-cell-free-hpv-dna-as-biomarker-for-prognosis-and2024-04-27daily0.9 https://clinresonc-new.lhten.com/safety-and-feasibility-of-chemotherapy-followed-by-liver2024-04-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-bortezomib-to-rituximab2024-04-28daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-studies-reporting-on-progression-free-survival2024-04-29daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-study-of-aspirin-versus-placebo-as-adjuvant2024-04-29daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-hepatocellular-carcinoma-screening-in-a2024-04-29daily0.9 https://clinresonc-new.lhten.com/phase-1b-study-of-unesbulin-plus-dacarbazine-for-the-treatment-of2024-04-30daily0.9 https://clinresonc-new.lhten.com/matched-cohort-study-of-cancer-incidence-treatment-and-survival-in2024-04-30daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-in-the-phase-3-topaz-1-trial-of-durvalumab2024-04-30daily0.9 https://clinresonc-new.lhten.com/modeling-study-to-compare-different-breast-cancer-screening-strategies2024-04-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-nivolumab-with-or-without2024-05-01daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-in-destiny-breast02-trastuzumab-deruxtecan2024-05-01daily0.9 https://clinresonc-new.lhten.com/longitudinal-observational-cohort-study-of-association-of-plant-based2024-05-01daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-the-association-of-national-health-expenditure2024-05-02daily0.9 https://clinresonc-new.lhten.com/elective-pelvic-lymph-node-radiation-and-risk-of-death-in-patients2024-05-02daily0.9 https://clinresonc-new.lhten.com/longer-interval-between-first-colonoscopy-with-negative-findings-for2024-05-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-immunochemotherapy-with-or2024-05-03daily0.9 https://clinresonc-new.lhten.com/associations-between-circulating-eosinophils-and-cancer-risk-in-the2024-05-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-trastuzumab-deruxtecan-for-metastatic2024-05-04daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-psychological2024-05-05daily0.9 https://clinresonc-new.lhten.com/impact-of-initial-treatment-strategy-for-metastatic-renal-cell-cancer2024-05-05daily0.9 https://clinresonc-new.lhten.com/impact-of-quality-of-life-on-survival-in-a-prospective-study-of2024-05-06daily0.9 https://clinresonc-new.lhten.com/clinical-and-molecular-predictors-of-very-late-recurrence-in-er2024-05-06daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-kras-allelic-variants-in-biliary-tract-cancers2024-05-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-pemigatinib-for-previously-treated2024-05-07daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-first-line-icis-plus-anti-vegf2024-05-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-niraparib-maintenance-for-platinum2024-05-08daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-impact-of-exercise-on-chemotherapy-induced2024-05-08daily0.9 https://clinresonc-new.lhten.com/phase-1b-study-of-transarterial-chemoembolization-followed-by2024-05-08daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-network-meta-analysis-of-prognostic-value-of2024-05-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-frontline-ponatinib-versus-imatinib2024-05-09daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-dose-escalation-study-of-dose-adjusted-epoch2024-05-09daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-tumor-stroma-immune-interactions-on2024-05-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-first-line-nivolumab-and-relatlimab2024-05-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-pembrolizumab-monotherapy-for-high2024-05-11daily0.9 https://clinresonc-new.lhten.com/ductal-carcinoma-in-situ-and-breast-cancer-specific-mortality-in2024-05-11daily0.9 https://clinresonc-new.lhten.com/disparities-in-cancer-incidence-among-women-by-sexual-orientation2024-05-12daily0.9 https://clinresonc-new.lhten.com/cancer-among-adolescents-and-young-adults-in-the-usa2024-05-12daily0.9 https://clinresonc-new.lhten.com/interstitial-pneumonitis-following-sequential-use-of-pd-l-12024-05-12daily0.9 https://clinresonc-new.lhten.com/cemiplimab-plus-chemotherapy-versus-chemotherapy-alone-for-advanced2024-05-13daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-analysis-of-folh1-expression-in-renal-cell2024-05-13daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-study-of-acupuncture-for-chronic-radiation2024-05-13daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-association-between-pretreatment-emotional2024-05-14daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-cohort-studies-of-survival2024-05-14daily0.9 https://clinresonc-new.lhten.com/survey-study-of-clinician-level-knowledge-and-barriers-to2024-05-14daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-dabrafenib-and-trametinib2024-05-15daily0.9 https://clinresonc-new.lhten.com/real-world-experiences-with-idecabtagene-vicleucel-for-relapsed-or2024-05-15daily0.9 https://clinresonc-new.lhten.com/nonrandomized-controlled-trial-of-breast-cancer-risk-after-bariatric2024-05-15daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-liver-resection-versus2024-05-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-nivolumab-for-resectable2024-05-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-senaparib-as-first-line-maintenance2024-05-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pertuzumab-plus-trastuzumab-for-advanced2024-05-16daily0.9 https://clinresonc-new.lhten.com/health-related-quality-of-life-with-first-line-sintilimab-plus2024-05-17daily0.9 https://clinresonc-new.lhten.com/value-of-addition-of-six-months-of-androgen-deprivation-therapy-to2024-05-17daily0.9 https://clinresonc-new.lhten.com/long-course-versus-short-course-androgen-deprivation-therapy-with2024-05-17daily0.9 https://clinresonc-new.lhten.com/long-term-analysis-of-rtog-0415-trial-of-conventional-fractionated2024-05-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-carboplatin-weekly-paclitaxel-and-pembolizumab2024-05-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-frailty-on-survival-of-patients-with2024-05-19daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-beta-blockers-use-in-patients-with2024-05-20daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-survival-benefit-associated2024-05-20daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-risk-factors-and-mortality-among-women-with2024-05-20daily0.9 https://clinresonc-new.lhten.com/outcomes-of-pirtobrutinib-for-relapsed-or-refractory-mantle-cell2024-05-21daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-observational-study-of-the-prognostic2024-05-21daily0.9 https://clinresonc-new.lhten.com/randomized-controlled-trial-of-infrared-laser-moxibustion-for-cancer2024-05-21daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-tattoos-as-a-risk-factor-for2024-05-22daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-ribociclib-plus-endocrine-therapy-vs2024-05-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-cadonilimab-plus-chemotherapy-for2024-05-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-and-randomized-phase-2-trial-of-ruxolitinib-with2024-05-23daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-accuracy-of-salivary2024-05-23daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-pembrolizumab-plus-low-dose-single2024-05-24daily0.9 https://clinresonc-new.lhten.com/hector-prediction-of-recurrence-risk-in-endometrial-cancer-with2024-05-24daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-red-flag-signals-and-symptoms2024-05-24daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-two-trials-of-safety-and-efficacy-of-ct041-in2024-05-25daily0.9 https://clinresonc-new.lhten.com/simplified-risk-stratification-model-for-patients-with-waldenstrom2024-05-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ibrutinib-followed-by-ofatumumab2024-05-26daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-induction-immunochemotherapy2024-05-26daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-post-trastuzumab-deruxtecan2024-05-27daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-analysis-of-real-world-efficacy-of2024-05-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-clinicopathological-features-and-survival2024-05-28daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-of-the-phase-iii-himalaya-study-of2024-05-29daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-oral-azacitidine-versus-standard2024-05-29daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-open-versus-minimally-invasive2024-05-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-bl-b01d1-for-locally-advanced-or2024-05-30daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-trial-of-fertility-preservation-and2024-05-30daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-long-term-outcomes-with2024-05-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-induction-concurrent-chemoradiotherapy2024-05-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2a-study-of-iadademstat-plus-azacitidine-for-newly2024-05-31daily0.9 https://clinresonc-new.lhten.com/prospective-analysis-of-impact-of-burden-of-cardiovascular-disease-on2024-05-31daily0.9 https://clinresonc-new.lhten.com/prospective-analysis-of-impact-of-burden-of-cardiovascular-disease-on-22024-05-31daily0.9 https://clinresonc-new.lhten.com/four-year-follow-up-of-gaia-cll13-first-line-venetoclax-combinations2024-06-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-ivonescimab-plus-chemotherapy-for-non2024-06-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-asciminib-for-newly-diagnosed-chronic2024-06-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-taletrectinib-for-non-small-cell-lung2024-06-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-nivolumab-plus-relatlimab-for2024-06-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-belantamab-mafodotin-bortezomib-and2024-06-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-fruquintinib-plus-paclitaxel-for2024-06-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-trial-of-first-line-mitazalimab-plus2024-06-03daily0.9 https://clinresonc-new.lhten.com/personalized-circulating-tumor-dna-for-monitoring-disease-status-in2024-06-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-neoadjuvant-nivolumab-and-ipilimumab2024-06-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-osimertinib-after-chemoradiotherapy2024-06-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-isatuximab-bortezomib-lenalidomide-and2024-06-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-vimseltinib-versus-placebo-for2024-06-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-osimertinib-for-egfr-mutated-nsclc-with2024-06-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-belantamab-mafodotin-pomalidomide-and2024-06-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-immunotherapy-in-locally2024-06-06daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-cardiac-dysfunction-among-breast-cancer2024-06-06daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-study-of-ramucirumab-plus-pembrolizumab-for2024-06-06daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-nivolumab-plus2024-06-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-oncolytic-adenoviral-therapy-plus2024-06-07daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-camrelizumab-plus-apatinib-for-locally2024-06-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-telisotuzumab-vedotin-for-previously2024-06-07daily0.9 https://clinresonc-new.lhten.com/predictive-impact-of-tumor-mutational-burden-on-real-world-outcomes2024-06-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ramucirumab-plus-chemotherapy-for2024-06-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-toripalimab-plus-bevacizumab2024-06-08daily0.9 https://clinresonc-new.lhten.com/population-based-registry-study-of-relative-risk-of-second-malignant2024-06-09daily0.9 https://clinresonc-new.lhten.com/overall-survival-results-of-the-multinational-phase-3-ruby-trial-of2024-06-10daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-androgen-deprivation-therapy-and2024-06-10daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-stereotactic-body-radiotherapy-as-a2024-06-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-garsorasib-for-kras-g12c-mutated-non2024-06-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-lazertinib-plus-subcutaneous-versus2024-06-11daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-addition-of-palbociclib-to-endocrine-therapy-for2024-06-11daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-doublet-chemotherapy-triplet-chemotherapy-or-doublet2024-06-12daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-optimal-timing-of-adjuvant-chemotherapy-after2024-06-12daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-neighborhood-deprivation-and-breast2024-06-12daily0.9 https://clinresonc-new.lhten.com/off-label-brigatinib-in-alk-positive-alcl-after-failure-of2024-06-13daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-stereotactic-ablative-radiotherapy2024-06-13daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-circulating-tumor-dna-guided-de-escalation-of2024-06-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-botensilimab-plus-balstilimab-for2024-06-14daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-association-of-germline2024-06-14daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-impact-of-sarcopenic-obesity2024-06-14daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-phase-2-trial-of-sbrt-plus-nivolumab-with-or2024-06-15daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-ipilimumab-nivolumab-or-the-combination-in-patients2024-06-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-epcoritamab-for-relapsed-or-refractory2024-06-16daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-phase-3-cassiopeia-trial-of-d-vtd-versus-vtd2024-06-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-linvoseltamab-for-relapsed-or2024-06-17daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-skeletal-related-events-in-patients-with-bone2024-06-17daily0.9 https://clinresonc-new.lhten.com/phase-1b-2a-trial-of-duvelisib-plus-romidepsin-for-relapsed-or2024-06-18daily0.9 https://clinresonc-new.lhten.com/multinational-observational-cohort-study-of-pathological-complete2024-06-18daily0.9 https://clinresonc-new.lhten.com/population-based-retrospective-cohort-study-of-survival-with-extended2024-06-18daily0.9 https://clinresonc-new.lhten.com/survival-outcomes-with-addition-of-celecoxib-to-adjuvant-chemotherapy2024-06-19daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-demographic-and-clinical2024-06-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-combination-therapy-with-immune-checkpoint2024-06-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-3-study-of-entrectenib-in-ros1-positive2024-06-20daily0.9 https://clinresonc-new.lhten.com/final-results-of-the-multinational-phase-3-combi-ad-trial-of-adjuvant2024-06-20daily0.9 https://clinresonc-new.lhten.com/final-results-of-the-multinational-phase-3-combi-ad-trial-of-adjuvant-22024-06-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-sorafenib-to-transarterial2024-06-20daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-perioperative-mfolfirinox-for2024-06-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-shr-a1811-for-heavily-pretreated-her22024-06-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-brigatinib-in-nf2-related2024-06-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-pembrolizumab-dabrafenib-and2024-06-21daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-camrelizumab-plus-apatinib-for2024-06-22daily0.9 https://clinresonc-new.lhten.com/multicenter-observational-cohort-study-of-mogamulizumab-for-sezary2024-06-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nab-paclitaxel-plus-cisplatin-and2024-06-23daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-randomized-trials-of-acupuncture-for-hot-flashes2024-06-24daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-robotic-versus-laparoscopic-hepatectomy-for-liver2024-06-25daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-outcomes-of-prostate-cancer-among-black2024-06-25daily0.9 https://clinresonc-new.lhten.com/clinical-outcomes-with-breast-conserving-therapy-for-breast-cancer-in2024-06-25daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-association-between-social2024-06-26daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-real-world-outcomes-with-first-vs-second2024-06-26daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-irinotecan-temozolomide-with-or-without-dasatinib2024-06-26daily0.9 https://clinresonc-new.lhten.com/impact-of-protocol-waivers-on-safety-and-outcome-in-the-drug2024-06-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-amivantamab-plus-lazertinib-for2024-06-27daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-imrt-versus-3d-crt-for-locally-advanced-lung2024-06-27daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-impact-of-stil-level-on-outcomes-of-stage-i2024-06-27daily0.9 https://clinresonc-new.lhten.com/long-term-efficacy-of-adjuvant-trastuzumab-emtansine-for-stage-i-her22024-06-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-watch-and-wait-in-locally-advanced-rectal2024-06-28daily0.9 https://clinresonc-new.lhten.com/temporal-trends-in-outcomes-with-pancreatoduodenectomy-for-pancreatic2024-06-28daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-phase-1-trial-of-first-line-cabozantinib-and2024-06-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-finotonlimab-with-chemotherapy-in2024-06-29daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-molecular-expression-assay-for2024-06-29daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-alkylating-chemoradiotherapy-versus-radiotherapy2024-06-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-local-radiotherapy-and-mrd-guided2024-07-01daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-preventive-impact-of-neuromuscular2024-07-01daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-fluorine-18-psma-1007-pet-ct-versus-multiparametric2024-07-01daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-immunotherapy-based-total2024-07-02daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-dendritic-cell-based-immunotherapy2024-07-02daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-epigenic-age-acceleration-in-non-hispanic2024-07-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-neoadjuvant-chemotherapy-with-or-without2024-07-03daily0.9 https://clinresonc-new.lhten.com/comparative-cohort-study-of-survival-of-surveillance-detected-pdac2024-07-03daily0.9 https://clinresonc-new.lhten.com/population-based-analysis-of-survival-impact-of-obesity-among2024-07-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-tisotumab-vedotin-as-second-or-third2024-07-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-pet-guided-brecadd-versus2024-07-04daily0.9 https://clinresonc-new.lhten.com/dna-ploidy-and-pten-protein-expression-as-biomarkers-for-predicting2024-07-04daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-trastuzumab-deruxtecan-for-her-22024-07-05daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-disparities-in-biomarker-testing-among2024-07-05daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-glucagon-like-peptide-1-receptor-agonists-and2024-07-05daily0.9 https://clinresonc-new.lhten.com/multicenter-bayesian-adaptive-randomized-phase-2-trial-of-metronomic2024-07-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neratinib-plus-trastuzumab-emtansine-for2024-07-06daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-radiotherapy-versus-surgical2024-07-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-total-neoadjuvant-therapy-with2024-07-08daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-nonrelapse-mortality-after-car2024-07-09daily0.9 https://clinresonc-new.lhten.com/association-of-bone-pain-at-metastatic-hormone-sensitive-prostate2024-07-09daily0.9 https://clinresonc-new.lhten.com/single-center-dose-finding-phase-1-study-of-cd22-directed-car-t-cell2024-07-10daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-overall-survival-with-screening-for2024-07-10daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-3-trial-of-first-line-benmelstobart2024-07-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-ruxolitinib-for-treatment-naive-or2024-07-11daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-response-adapted-low-dose-radiation2024-07-11daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-association-of-measurable2024-07-11daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-nab-paclitaxel-plus-s-1-versus-nab2024-07-12daily0.9 https://clinresonc-new.lhten.com/ethnic-disparities-in-erbb2-amplification-among-patients-with-gastric2024-07-12daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-trial-of-robotic-assisted-versus-video2024-07-13daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-neoadjuvant-docetaxel-oxaliplatin-and-s-12024-07-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-gx-188e-dna-vaccine-plus-pembrolizumab2024-07-14daily0.9 https://clinresonc-new.lhten.com/prevalence-of-cancer-survivors-in-the-united-states-as-of-january-12024-07-14daily0.9 https://clinresonc-new.lhten.com/hidden-genome-classifier-to-quantify-heterogeneity-of-intrahepatic2024-07-15daily0.9 https://clinresonc-new.lhten.com/quality-improvement-study-of-surgeon-skill-and-perioperative-outcomes2024-07-15daily0.9 https://clinresonc-new.lhten.com/retrospective-multicohort-study-of-multi-organ-immune-related-adverse2024-07-16daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-alzheimer-disease-and-related-dementia2024-07-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-celiac-plexus-radiosurgery-for-main2024-07-17daily0.9 https://clinresonc-new.lhten.com/multicenter-non-inferiority-phase-3-trial-of-health-related-quality2024-07-17daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-the-associations-of-endometriosis2024-07-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-tailored-dose-dense-versus-standard2024-07-18daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-immunotherapy-versus-best2024-07-18daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-neoadjuvant-exercise-therapy-in2024-07-18daily0.9 https://clinresonc-new.lhten.com/efficacy-and-safety-of-pirtobrutinib-in-the-richter-transformation2024-07-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-low-dose-lenalidomide-in-non2024-07-19daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-studies-of-the-association-of-pre-diagnosis-tea2024-07-19daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-association-of-participating2024-07-19daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-effects-of-once-only-flexible-sigmoidoscopy2024-07-20daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-paclitaxel-ifosfamide-cisplatin-as2024-07-20daily0.9 https://clinresonc-new.lhten.com/efficacy-and-safety-of-anti-pd-1-immune-checkpoint-inhibition-plus2024-07-21daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-survival-impact-of-adjuvant-chemotherapy2024-07-21daily0.9 https://clinresonc-new.lhten.com/liquid-biopsies-for-minimal-residual-disease-detection-after2024-07-22daily0.9 https://clinresonc-new.lhten.com/change-in-trust-in-us-government-health-agencies-for-cancer2024-07-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-4-trial-of-first-line-pembrolizumab-plus2024-07-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-a-curative-strategy-for-high-risk2024-07-23daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-intratumoral-escherichia-on-outcomes2024-07-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-foritinib-for-advanced-ros1-rearranged2024-07-24daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-anti-bcma-gprc5d-bispecific-car-t2024-07-24daily0.9 https://clinresonc-new.lhten.com/preoperative-model-for-predicting-futility-of-upfront-resection-for2024-07-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-blinatumomab-for-mrd-negative-acute2024-07-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-atezolizumab-before-and-after2024-07-25daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-bcma-cd19-dual-targeting-car-t-cell2024-07-25daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-exercise-in-metastatic-breast2024-07-26daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-trial-of-site-specific-therapy-guided-by-902024-07-26daily0.9 https://clinresonc-new.lhten.com/multicenter-placebo-controlled-phase-2-study-of-nanvuranlat-for2024-07-26daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-anthracycline-followed-by2024-07-27daily0.9 https://clinresonc-new.lhten.com/single-center-prospective-study-of-supplemental-screening-with2024-07-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-vebreltinib-for-advanced-non-small-cell2024-07-27daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-lenalidomide-plus-obinutuzumab-for2024-07-28daily0.9 https://clinresonc-new.lhten.com/single-center-prospective-trial-of-prevention-of-taxane-induced-nail2024-07-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ipilimumab-plus-nivolumab-for2024-07-29daily0.9 https://clinresonc-new.lhten.com/single-center-experience-with-trastuzumab-deruxtecan-for2024-07-29daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-impact-of-obesity-on-early-onset-breast2024-07-29daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-addition-of-targeted-agents2024-07-30daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-prognostic-relevance-of-patient-derived2024-07-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-second-line-tepotinib-plus-osimertinib2024-07-30daily0.9 https://clinresonc-new.lhten.com/cluster-randomized-controlled-trial-of-gastric-cancer-prevention-by2024-07-31daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-low-versus-high-dose-5-fu-in-triplet2024-07-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-sacituzumab-govitecan-for-metastatic2024-08-01daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-molecularly-guided-therapy2024-08-01daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-association-of-aspirine-use-and-incidence2024-08-01daily0.9 https://clinresonc-new.lhten.com/multcenter-phase-2-trial-of-trastuzumab-deruxtecan-for-advanced-solid2024-08-02daily0.9 https://clinresonc-new.lhten.com/causal-attribution-of-hpv-genotypes-to-invasive-cervical-cancer2024-08-02daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-impact-of-body-mass-index2024-08-02daily0.9 https://clinresonc-new.lhten.com/preoperative-chemoradiotherapy-and-preoperative-and-or-perioperative2024-08-02daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-standard-of-care-axicabtagene-ciloleucel-for2024-08-03daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-selpercatinib-for-ret-activated-thyroid-cancer2024-08-03daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-ipilimumab-versus-sunitinib-for-advanced2024-08-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-atezolizumab-plus-chemotherapy-for2024-08-04daily0.9 https://clinresonc-new.lhten.com/development-of-a-scoring-system-to-predict-local-recurrence-after2024-08-05daily0.9 https://clinresonc-new.lhten.com/temporal-trends-in-overall-survival-of-metastatic-lung-cancer2024-08-05daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-trastuzumab-deruxtecan-for2024-08-06daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-metastasis-directed-therapy2024-08-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-trastuzumab-deruxtecan-for-her22024-08-06daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-3-trial-of-olanzapine-as-antiemetic2024-08-06daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-association-between-ambient-air2024-08-07daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-primary-care-use-and-90-day-mortality2024-08-07daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-prognostic-genome-and-transcriptome2024-08-07daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-impact-of-corticosteroids-for-immune-related2024-08-08daily0.9 https://clinresonc-new.lhten.com/discontinuation-versus-continuation-of-imatinib-for-advanced-gist2024-08-08daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-the-association-of-cannabis2024-08-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ibi351-monotherapy-for-advanced-non2024-08-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-study-of-chiauranib-with-or-without2024-08-09daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-drivers-of-overall-rating-of-cancer-care-by2024-08-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-revumenib-for-kmt2a-rearranged2024-08-10daily0.9 https://clinresonc-new.lhten.com/molecular-and-clinicopathologic-impact-of-gnas-variants-across-solid2024-08-10daily0.9 https://clinresonc-new.lhten.com/extension-of-a-phase-3-trial-of-survival-with-atezolizumab-plus2024-08-11daily0.9 https://clinresonc-new.lhten.com/retrospective-single-center-study-of-real-world-outcomes-with2024-08-11daily0.9 https://clinresonc-new.lhten.com/apixaban-versus-aspirin-in-patients-with-cancer-and-cryptogenic2024-08-12daily0.9 https://clinresonc-new.lhten.com/burden-of-30-cancers-among-men-global-statistics-in-2022-and2024-08-12daily0.9 https://clinresonc-new.lhten.com/long-term-hrqol-impact-of-adjuvant-pembrolizumab-versus-placebo-after2024-08-13daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-incidence-of-cancer-and2024-08-13daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-impact-of-integration-of-proms2024-08-13daily0.9 https://clinresonc-new.lhten.com/indirect-comparison-of-first-line-nivolumab-plus-relatlimab-or2024-08-14daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-long-term-survival-among-clinical-practice-patients2024-08-14daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-minimal-access-versus2024-08-14daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-impact-of-neoadjuvant2024-08-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-lazertinib-for-egfr-variant-non-small2024-08-15daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-suicide-attempts-and-suicide-deaths2024-08-15daily0.9 https://clinresonc-new.lhten.com/dna-liquid-biopsy-based-prediction-of-cancer-associated-venous2024-08-16daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-clinical-and-molecular-features2024-08-16daily0.9 https://clinresonc-new.lhten.com/retrospective-comparison-of-outcomes-with-abiraterone-acetate-or2024-08-16daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-immune-checkpoint-inhibitors-for-advanced-egfr2024-08-17daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-dose-reduction-stategy-of2024-08-17daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-case-control-studies-of-associations-of-aspirin-or2024-08-18daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-tranexamic-acid-in-patients2024-08-19daily0.9 https://clinresonc-new.lhten.com/population-based-retrospective-study-of-outcomes-with-immune2024-08-19daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-incidence-and-survival-outcomes-of2024-08-19daily0.9 https://clinresonc-new.lhten.com/efficacy-and-safety-of-bosutinib-for-previously-treated-chronic2024-08-20daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-body-mass-index-and-risk-of-over-100-cancer-types-in2024-08-20daily0.9 https://clinresonc-new.lhten.com/outcome-adaptive-randomized-platform-trial-of-androgen-receptor2024-08-21daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-incidence-of-medication-related2024-08-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-vimseltinib-for-csf1r-inhibition-in2024-08-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-belzutifan-versus-everolimus-for2024-08-22daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-effect-of-breast-cancer2024-08-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-olaparib-without-androgen-deprivation2024-08-22daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-women-s-health-initiative-randomized-trials-of2024-08-23daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-association-between-body-mass2024-08-23daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-real-world-cardiotoxicity-with2024-08-23daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-tislelizumab-plus2024-08-24daily0.9 https://clinresonc-new.lhten.com/seer-registry-analysis-of-hr-positive-metastatic-breast-cancer2024-08-24daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-capmatinib-for-non-small-cell-lung2024-08-25daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-outcomes-of-low-risk-ductal2024-08-25daily0.9 https://clinresonc-new.lhten.com/adjuvant-chemotherapy-plus-nine-weeks-or-one-year-of-adjuvant2024-08-26daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-clinicopathological-features2024-08-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-sacituzumab-govitecan-for-metastatic2024-08-27daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-association-of-use-of-5-reductase2024-08-27daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-comparison-of-androgen-receptor-inhibitors2024-08-27daily0.9 https://clinresonc-new.lhten.com/prospective-trial-of-immunologic-signatures-of-response-to-immune2024-08-28daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-body-mass-index-and-risk-of-colorectal-cancer2024-08-28daily0.9 https://clinresonc-new.lhten.com/a-phase-ii-placebo-controlled-study-of-the-effect-and-safety-of2024-08-28daily0.9 https://clinresonc-new.lhten.com/clinical-outcomes-and-histologic-findings-in-patients-with-durable-pr2024-08-29daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-neoadjuvant-immune-checkpoint2024-08-29daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-radiotherapy-versus-surgery2024-08-29daily0.9 https://clinresonc-new.lhten.com/update-of-the-multinational-phase-1-dellphi-300-trial-of-tarlatamab2024-08-30daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-nivolumab-maintenance-after-severe-immune2024-08-30daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-racial-disparities-in-cancer-stage-at2024-08-30daily0.9 https://clinresonc-new.lhten.com/long-term-survival-in-the-phase-2-ec-crt-001-study-of-toripalimab2024-08-31daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-endpoint-surrogacy-in-first-line-chronic2024-08-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-first-line-cediranib-plus-etoposide-and2024-09-01daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-addition-of-trilaciclib-to2024-09-01daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-2-belzutifan-doses-for2024-09-02daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-prognostic-significane-of-low2024-09-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-reduced-dose-chemotherapy-and2024-09-03daily0.9 https://clinresonc-new.lhten.com/case-series-of-fratricide-resistant-cd7-car-t-cells-in-t-cell-acute2024-09-03daily0.9 https://clinresonc-new.lhten.com/single-center-phase-3-trial-of-neoadjuvant-paclitaxel-plus-platinum2024-09-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-dose-ranging-study-of-liposomal-irinotecan-as2024-09-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-bladder-preserving-trimodality-treatment2024-09-04daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-association-of-growth-rate-of2024-09-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-doxorubicin-trabectedin-with2024-09-05daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-inpatient-care-and-outcomes-among-people2024-09-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-circulating-tumor-dna-and2024-09-05daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-3-study-of-palliative-radiotherapy2024-09-06daily0.9 https://clinresonc-new.lhten.com/multicenter-first-in-human-study-of-cinrebafusp-alfa-for-previously2024-09-06daily0.9 https://clinresonc-new.lhten.com/seer-22-registries-database-analysis-of-impact-of-covid-19-pandemic2024-09-06daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-nivolumab-and-nab2024-09-07daily0.9 https://clinresonc-new.lhten.com/randomized-controlled-trial-of-adding-electroacupuncture-to-standard2024-09-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-ixazomib-consolidation-and-maintenance2024-09-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-tas-102-with-irinotecan-and-bevacizumab2024-09-08daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-clinical-features-and-response2024-09-08daily0.9 https://clinresonc-new.lhten.com/matched-pair-analysis-of-differences-in-prognosis-and-recurrence2024-09-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-plinabulin-plus-docetaxel-for-egfr2024-09-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-fedratinib-for-myelofibrosis-in2024-09-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-datopotamab-deruxtecan-versus2024-09-10daily0.9 https://clinresonc-new.lhten.com/avelumab-for-metastatic-merkel-cell-carcinoma-biomarker-analyses-of2024-09-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-tislelizumab-plus2024-09-11daily0.9 https://clinresonc-new.lhten.com/multicenter-placebo-controlled-trial-of-naldemedine-for-opioid2024-09-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-sintilimab-plus-bevacizumab-for-relapsed2024-09-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-atezolizumab-venetoclax-and-obinutuzumab2024-09-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-datopotamab-deruxtecan-versus-22024-09-13daily0.9 https://clinresonc-new.lhten.com/association-between-lorlatinib-serum-concentration-and-adverse-events2024-09-13daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-trial-of-impact-of-androgen-deprivation2024-09-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-pembrolizumab-plus-22024-09-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-durvalumab-versus-placebo-after2024-09-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-ponsegromab-for-the-treatment-of2024-09-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-pembrolizumab-versus2024-09-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-trastuzumab-deruxtecan-after-endocrine2024-09-15daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-nivolumab-plus-relatlimab2024-09-15daily0.9 https://clinresonc-new.lhten.com/final-overall-survival-analysis-of-the-phase-3-checkmate-067-trial-of2024-09-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-durvalumab-with2024-09-16daily0.9 https://clinresonc-new.lhten.com/final-overall-survival-results-of-the-multinational-phase-3-keynote2024-09-16daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-two-trials-of-zolbetuximab-in-gastric-or2024-09-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-cabozantinib-for-previously-treated2024-09-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-darolutamide-plus-androgen-deprivation2024-09-17daily0.9 https://clinresonc-new.lhten.com/cohortstudie-van-associatie-tussen-overgewicht-en-risico-van-tweede2024-09-18daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-a-psychological-intervention-for-caregivers-of2024-09-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-linperlisib-for-relapsed-and-or2024-09-19daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-car-t-cells-targeting-cd19-and-gcc-in2024-09-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-sbrt-versus-hypofractionated2024-09-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-glutaminase-inhibition-in-combination2024-09-20daily0.9 https://clinresonc-new.lhten.com/randomized-phase-3-trial-of-iodine-131-apamistamab-before-allohct-for2024-09-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-biomarker-study-of-adding-radiotherapy-to2024-09-20daily0.9 https://clinresonc-new.lhten.com/wearable-device-based-intervention-for-promoting-physical-actvity2024-09-20daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-trends-in-incidence-prevalence-and2024-09-20daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-liver-transplantation-plus2024-09-21daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-pyrotinib-plus-capecitabine-for-her2-positive2024-09-21daily0.9 https://clinresonc-new.lhten.com/single-center-phase-3-trial-of-neoadjuvant-chemoradiotherapy-versus2024-09-22daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-prognostic-impact-of-tumor-deposits-in2024-09-22daily0.9 https://clinresonc-new.lhten.com/cardiovascular-disease-and-stroke-following-cancer-and-cancer2024-09-23daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-role-of-hospital-connectedness-in-brain-metastasis2024-09-23daily0.9 https://clinresonc-new.lhten.com/association-of-circulating-tryptophan-kynurenine-pathway-metabolites2024-09-23daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-crossover-study-of-oral-decitabine2024-09-24daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-trends-in-survival-outcomes-of-patients2024-09-24daily0.9 https://clinresonc-new.lhten.com/impact-of-sequence-of-checkpoint-inhibitors-and-braf-mek-inhibitors2024-09-24daily0.9 https://clinresonc-new.lhten.com/single-center-analysis-of-stereotactic-radiosurgery-for-spinal2024-09-25daily0.9 https://clinresonc-new.lhten.com/epcoritamab-for-relapsed-or-refractory-large-b-cell-lymphoma-two-year2024-09-25daily0.9 https://clinresonc-new.lhten.com/prospective-locommotion-study-of-real-life-standards-of-care-in2024-09-25daily0.9 https://clinresonc-new.lhten.com/population-based-randomized-trial-of-results-after-four-years-of2024-09-26daily0.9 https://clinresonc-new.lhten.com/case-control-analysis-of-the-association-between-oral-microbiome-and2024-09-26daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-of-unresectable-locally-advanced-hepatocellular2024-09-26daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-consolidative-stereotactic-radiotherapy-for-oligo2024-09-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nivolumab-in-patients-with-metastatic2024-09-27daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-hepatic-artery-infusion-chemotherapy-for2024-09-28daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-toripalimab-plus-concurrent2024-09-28daily0.9 https://clinresonc-new.lhten.com/survey-study-of-breastfeeding-experiences-among-young-breast-cancer2024-09-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-basket-trial-of-ipilimumab-plus-nivolumab-for2024-09-29daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-screening-for-helicobacter-pylori-to-prevent2024-09-30daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-two-prospective-studies-of-association-of-tumor2024-09-30daily0.9 https://clinresonc-new.lhten.com/capmatinib-for-met-exon-14-mutated-non-small-cell-lung-cancer-final2024-10-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-ziftomenib-for-relapsed-or2024-10-01daily0.9 https://clinresonc-new.lhten.com/two-center-phase-1-trial-of-c-car066-after-failure-of-anti-cd19-car-t2024-10-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-roxadustat-for-anemia-in-patients2024-10-02daily0.9 https://clinresonc-new.lhten.com/cluster-randomized-trial-of-impact-of-epstein-barr-virus-serology2024-10-02daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-tranexamic-acid-during-open-radical2024-10-02daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-long-term-risk-of-subsequent-neoplasms2024-10-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-the-combination-of-doxorubicin2024-10-03daily0.9 https://clinresonc-new.lhten.com/population-based-retrospective-cohort-study-of-fracture-risk2024-10-03daily0.9 https://clinresonc-new.lhten.com/denmark-wide-cohort-study-of-risk-of-recurrence-in-early-onset-versus2024-10-04daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-whole-pelvis-radiation-versus2024-10-04daily0.9 https://clinresonc-new.lhten.com/retrospective-population-based-cohort-study-of-brain-metastasis2024-10-04daily0.9 https://clinresonc-new.lhten.com/multicenter-real-world-study-of-ciltacabtagene-autoleucel-for2024-10-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-regorafenib-for-refractory-advanced2024-10-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-glofitamab-for-relapsed-or-22024-10-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-toripalimab-plus-the-anti-ctla-42024-10-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-afatinib-plus-bevacizumab-after2024-10-06daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-association-between-dietary2024-10-06daily0.9 https://clinresonc-new.lhten.com/circulating-tumor-cell-count-and-overall-survival-in-patients-with2024-10-07daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-cardiovascular-events-after-car-t-therapy-for2024-10-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-addition-of-thoracic-radiotherapy-to2024-10-08daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-association-between-aerobic2024-10-08daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-osimertinib-with-or-without2024-10-09daily0.9 https://clinresonc-new.lhten.com/long-term-cure-rates-with-adjuvant-nivolumab-or-ipilimumab-after2024-10-09daily0.9 https://clinresonc-new.lhten.com/association-of-air-pollution-and-breast-cancer-incidence-in-the2024-10-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-perioperative-camrelizumab-plus2024-10-10daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-outcomes-of-melanoma-among2024-10-10daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-nadunolimab-plus-chemotherapy-in-patients-with2024-10-10daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-study-of-bms-986156-with-ipilimumab-or2024-10-11daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-real-world-immune-related2024-10-11daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-cranial-stereotactic-radiosurgery-for-pediatric2024-10-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-simlukafusp-alfa-plus-atezolizumab-for2024-10-12daily0.9 https://clinresonc-new.lhten.com/three-year-follow-up-of-adjuvant-nivolumab-versus-placebo-for-high2024-10-12daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-lung-cancer-screening-by-low-dose-ct-scan-in2024-10-13daily0.9 https://clinresonc-new.lhten.com/census-based-cohort-study-of-residential-exposure-to-solar2024-10-13daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-adherence-to-guidelines-recommending-testing-for2024-10-14daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-the-association-of-ultra-processed-food2024-10-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-nadim-trial-five-year-outcomes-with-perioperative2024-10-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-standard-chemoradiotherapy-with-or2024-10-15daily0.9 https://clinresonc-new.lhten.com/impact-of-prior-local-therapy-on-efficacy-of-first-line-apalutamide2024-10-15daily0.9 https://clinresonc-new.lhten.com/development-and-validation-of-tnbc-dx-genomic-test-in-early-stage2024-10-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-cadonilimab-plus-chemotherapy2024-10-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-pembrolizumab-or-placebo-plus-adjuvant2024-10-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-nivolumab-plus-avd-for-advanced-stage2024-10-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-stereotactic-body-radiotherapy-for2024-10-17daily0.9 https://clinresonc-new.lhten.com/association-of-diet-quality-and-risk-of-prostate-cancer-grade2024-10-17daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-brexucabtagene-autoleucel-as-standard-therapy2024-10-18daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-association-of-diet-quality-with-survival2024-10-18daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-pyrotinib-plus-metronomic-etoposide-in2024-10-18daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-atezolizumab-plus2024-10-19daily0.9 https://clinresonc-new.lhten.com/validation-of-the-polar-breast-cancer-assay-for-radiotherapy-omission2024-10-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-second-line-avelumab-plus-gemcitabine2024-10-19daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-pathological-response-after-neoadjuvant-immune2024-10-20daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-attrition-between-lines-of-therapy-and-real-world2024-10-20daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-3-versus-6-cycles-of-adjuvant-chemotherapy-for2024-10-21daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-treatment-patterns-and-survival2024-10-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2a-trial-of-first-line-dkn-01-plus-tislelizumab-and2024-10-22daily0.9 https://clinresonc-new.lhten.com/quality-of-life-after-stereotactic-radiosurgery-for-brain-metastasis2024-10-22daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-in-denmark-of-risk-of-type-2-diabetes2024-10-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-zabrutinib-obinutuzumab-and-venetoclax2024-10-23daily0.9 https://clinresonc-new.lhten.com/modelling-study-of-long-term-outcomes-with-psma-pet-imaging-of2024-10-23daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-trastuzumab-duocarmazine-for2024-10-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-a-multigene-signature-for-tailoring2024-10-24daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-atezolizumab-plus-targeted-therapy-for2024-10-24daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-comorbid-depression-in-patients-with2024-10-24daily0.9 https://clinresonc-new.lhten.com/three-year-follow-up-of-a-multinational-phase-1-2-trial-of2024-10-25daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-study-of-irinotecan-and-tas-102-plus2024-10-25daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-real-world-comparison-of-the-efficacy-and2024-10-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-zuberitamab-plus-chop-versus2024-10-26daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-anlotinib-plus-the-anti-pd-l1-antibody2024-10-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-pembrolizumab-plus2024-10-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-first-line-ivonescimab-plus-etoposide2024-10-27daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-clinical-trials-of-sacituzumab-govitecan-in2024-10-27daily0.9 https://clinresonc-new.lhten.com/secondary-hematological-dysplasia-after-car-t-for-acute-lymphoblastic2024-10-28daily0.9 https://clinresonc-new.lhten.com/association-of-timing-of-palliative-care-with-end-of-life-quality2024-10-28daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-risk-of-distant-metastasis-after-organ2024-10-29daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-ischemic-cardiotoxicity-of-aromatase2024-10-29daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-camizestrant-versus2024-10-29daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-valemetostat-for-relapsed-or2024-10-30daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-first-line-nivolumab-ipilimumab-versus-chemotherapy2024-10-30daily0.9 https://clinresonc-new.lhten.com/second-primary-cancer-risks-after-breast-cancer-in-brca1-and-brca22024-10-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-inavolisib-based-therapy-for-pik3ca2024-10-31daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-with-or-without-chemotherapy-for-advanced-urothelial2024-10-31daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-cancer-chemotherapy-during-pregnancy2024-10-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-second-line-onvansertib-plus2024-11-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-enfortumab-vedotin-in-patients-with2024-11-01daily0.9 https://clinresonc-new.lhten.com/association-of-physical-activity-during-adolescence-and-early2024-11-02daily0.9 https://clinresonc-new.lhten.com/profile-and-predictors-of-severe-infectious-complications-with2024-11-03daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-histopathological-prognostic-factors-in-surgically2024-11-03daily0.9 https://clinresonc-new.lhten.com/review-of-evidence-regarding-car-t-cells-and-t-cell-therapies-for2024-11-04daily0.9 https://clinresonc-new.lhten.com/review-of-evidence-regarding-car-t-cells-and-t-cell-therapies-for-22024-11-04daily0.9 https://clinresonc-new.lhten.com/detection-of-actionable-structural-variants-in-advanced-non-small2024-11-04daily0.9 https://clinresonc-new.lhten.com/case-report-of-response-of-her2-expressing-prostate-cancer-to2024-11-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-safety-and-efficacy-of-pd-l-12024-11-05daily0.9 https://clinresonc-new.lhten.com/safety-and-efficacy-of-crizotinib-for-met-mutated-advanced-non-small2024-11-05daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-overall-survival-with-routine2024-11-06daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-psoriasis-risk-with-immune-checkpoint2024-11-06daily0.9 https://clinresonc-new.lhten.com/prospective-multi-cohort-study-of-predictive-value-of-a-5-gene2024-11-06daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-long-term-outcomes-with-nivolumab-plus-ipilimumab2024-11-07daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-long-term-adverse-effects-and2024-11-07daily0.9 https://clinresonc-new.lhten.com/phase-1b-2-trial-of-equecabtagene-autoleucel-in-patients-with2024-11-07daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-phase-2-trial-of-neoadjuvant-and-adjuvant2024-11-08daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-nodal-burden-and-oncologic-outcomes-in2024-11-08daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-body-mass-index-and-type-2-diabetes2024-11-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-trial-of-mirdametinib-for-symptomatic2024-11-09daily0.9 https://clinresonc-new.lhten.com/efficacy-of-subsequent-therapies-in-patients-with-advanced-ovarian2024-11-09daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1b-trial-of-neoadjuvant-oncolytic-immunotherapy2024-11-10daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-comparison-of-first-line-options-for2024-11-10daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-child-outcomes-after-prenatal2024-11-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-iparomlimab-ql1604-for-msi-h-or-dmmr2024-11-11daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-overtreatment-of-prostate-cancer-among-men-with2024-11-11daily0.9 https://clinresonc-new.lhten.com/network-meta-analysis-of-first-line-chemotherapy-regimens-for2024-11-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-trbc1-directed-car-t-cell-therapy2024-11-12daily0.9 https://clinresonc-new.lhten.com/retrospective-seer-medicare-study-of-recent-changes-in-treatment2024-11-12daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-addition-of-pembrolizumab-to2024-11-13daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-travel-to-high-volume-centers-with2024-11-13daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-intravenous-and-intracranial-gd2-car-t-cells-for2024-11-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-hyperthermic-intraperitoneal2024-11-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-toripalimab-to-first-line2024-11-14daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-chemoradiotherapy-and2024-11-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-glofitamab-plus-chemotherapy-versus2024-11-15daily0.9 https://clinresonc-new.lhten.com/retrospective-population-based-cohort-study-of-racial-and-ethnic2024-11-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-ramucirumab-plus-paclitaxel-as-switch2024-11-16daily0.9 https://clinresonc-new.lhten.com/retrospective-real-world-data-of-immunotherapy-benefits-for-large2024-11-16daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-patient-reported-persistent-lymphedema-and2024-11-17daily0.9 https://clinresonc-new.lhten.com/multicenter-cross-sectional-study-of-frequency-and-clinical2024-11-17daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-first-line-r-chop-plus-the-pde42024-11-18daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-trends-in-hepatocellular-carcinoma-mortality2024-11-18daily0.9 https://clinresonc-new.lhten.com/database-study-of-trends-of-incidence-and-mortality-of-pancreatic2024-11-19daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-treatment-intensification-after-not-achieving-mrd2024-11-19daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-impact-of-bone-metastasis-in-stage-iv-nsclc2024-11-19daily0.9 https://clinresonc-new.lhten.com/case-series-of-intralesional-t-vec-in-combination-with-topical2024-11-20daily0.9 https://clinresonc-new.lhten.com/phase-2-basket-trial-of-ipilimumab-plus-nivolumab-for-rare-tumors2024-11-20daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-temporal-trends-in-active-surveillance-or2024-11-20daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-study-of-ror1-specific-car-t-cells-for-advanced2024-11-21daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-first-cycle-toxicity-and-survival-in-patients2024-11-21daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-1b-trial-of-olverembatinib-after2024-11-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-prostate-radiotherapy-in-de-novo2024-11-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-perioperative-tislelizumab2024-11-22daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-atezolizumab-with-or-without-human2024-11-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-intermittent-versus-continuous-first2024-11-23daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-sintilimab-plus-decitabine2024-11-23daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-high-grade-serous-carcinoma-after-risk-reducing2024-11-24daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-centralized-colorectal-cancer-screening-outreach2024-11-25daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-obesity-with-outcomes-of2024-11-25daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-oxaliplatin-versus-alkylating2024-11-26daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-disparities-in-treatment-and-outcomes2024-11-26daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-four-prospective-studies-of-plasma-prolactin2024-11-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-neoadjuvant-nab-paclitaxel-versus2024-11-27daily0.9 https://clinresonc-new.lhten.com/selection-of-patients-with-early-stage-breast-cancer-for-extended2024-11-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-early-versus-deferred-use-of-cdk4-62024-11-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-nivolumab-plus-ipilimumab-for-msi-h-or2024-11-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-obecabtagene-autoleucel-for-b-cell2024-11-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-ibrutinib-versus-placebo-for-early-stage2024-11-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-dose-escalation-study-of-ctx130-for-relapsed-or2024-11-29daily0.9 https://clinresonc-new.lhten.com/five-years-outomes-of-a-multicenter-phase-3-study-of-first-line2024-11-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-sintilimab-plus-hpv-vaccine-for2024-11-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1a-1b-trial-of-the-bispecific-antibody-ibi3182024-11-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-third-or-later-line-mirvetuximab2024-11-30daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-time-of-day-of-radiotherapy-and2024-12-01daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-impact-of-prehabilitation-on-outcomes-of-major2024-12-01daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-incidence-treatment-patterns-and-mortality2024-12-02daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-home-based-exercise-and-self-management2024-12-02daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-3-trial-of-hr20013-for-prevention-of2024-12-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-alpelisib-plus-fulvestrant-in-pik3ca2024-12-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-tremelimab-plus-durvalumab-as2024-12-03daily0.9 https://clinresonc-new.lhten.com/french-nationwide-cross-sectional-study-of-pain-prevalence-in-cancer2024-12-04daily0.9 https://clinresonc-new.lhten.com/differential-long-term-tamoxifen-benefit-by-menopausal-status-in2024-12-04daily0.9 https://clinresonc-new.lhten.com/plasma-arginine-as-predictive-biomarker-for-outcomes-with-immune2024-12-05daily0.9 https://clinresonc-new.lhten.com/update-of-a-phase-1-trial-of-gprc5d-targeted-car-t-cell-therapy2024-12-05daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-cardiac-events-and-survival-among2024-12-05daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-intratumoral-dendritic-cells-before2024-12-05daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-of-a-multinational-phase-3-trial-of-adjuvant2024-12-06daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-neoadjuvant-chemotherapy-22024-12-06daily0.9 https://clinresonc-new.lhten.com/global-burden-of-disease-database-analysis-of-worldwide-incidence2024-12-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-trametinib-alone-and-in-combination-with2024-12-07daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-perioperative-sintilimab-plus-platinum-based2024-12-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-acalabrutinib-venetoclax-and2024-12-08daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-loncastuximab-tesirine-plus-rituximab2024-12-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-blinatumomab-for-standard-risk-b-cell2024-12-08daily0.9 https://clinresonc-new.lhten.com/first-line-zanubrutinib-versus-bendamustine-rituximab-for-cll-sll2024-12-09daily0.9 https://clinresonc-new.lhten.com/oncological-outcomes-of-patients-with-localized-primary-head-and-neck2024-12-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-weekly-cisplatin-cycles-and-outcomes2024-12-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-daratumumab-versus-active-monitoring2024-12-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-basket-trial-of-durvalumab-plus-tremelimumab-in2024-12-10daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-anti-bcma-car-t-cell-therapy-for-relapsed-or2024-12-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-tafasitamab-plus-lenalidomide-and2024-12-11daily0.9 https://clinresonc-new.lhten.com/longitudinal-cohort-study-of-genotype-and-associated-cancer-risk-in2024-12-11daily0.9 https://clinresonc-new.lhten.com/national-inpatient-sample-analysis-of-use-of-metastasectomy-in-the2024-12-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-imlunestrant-with-or-without2024-12-12daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-nivolumab-plus-avd-as-frontline-therapy-in-older2024-12-12daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-active-monitoring-versus-guideline2024-12-12daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-axillary-surgery-as-part-of-breast-conserving2024-12-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-neoadjuvant-camrelizumab-versus-placebo2024-12-13daily0.9 https://clinresonc-new.lhten.com/nivolumab-plus-relatlimab-for-advanced-melanoma-three-year-follow-up2024-12-14daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-high-omega-3-and-low-omega-6-diet-with2024-12-14daily0.9 https://clinresonc-new.lhten.com/prognostic-impact-of-number-of-adjuvant-chemotherapy-cycles-after2024-12-15daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-network-meta-analysis-of-treatments-for2024-12-15daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-3-trial-to-evaluate-the-clinical2024-12-16daily0.9 https://clinresonc-new.lhten.com/observational-study-of-association-of-improved-adenoma-detection2024-12-16daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-cannabidiol-for-scan-related-anxiety-in2024-12-16daily0.9 https://clinresonc-new.lhten.com/multi-cohort-study-of-primary-mismatch-repair-deficient-gliomas-in2024-12-17daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-risk-enabled-therapy-after-neoadjuvant2024-12-17daily0.9 https://clinresonc-new.lhten.com/real-world-prognostic-index-for-patients-with-kras-mutated-nsclc-and2024-12-17daily0.9 https://clinresonc-new.lhten.com/first-line-avelumab-plus-axitinib-versus-sunitinib-for-advanced-renal2024-12-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-addition-of-immunotherapy-to-perioperative2024-12-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-incidence-of-and-risk-factors-for-cutaneous2024-12-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-abemaciclib-plus-fulvestrant-for2024-12-19daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-radiofrequency-ablation-versus-stereotactic-body2024-12-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-sorafenib-versus-stereotactic2024-12-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-histologic-and-immunologic-factors-associated2024-12-20daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-survival-and-quality-of-life-after2024-12-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-denileukin-diftitox-cxdl-for-relapsed-or2024-12-20daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-first-line-nivolumab-plus-ipilimumab-for2024-12-21daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-association-of-iraes-with-efficacy-in2024-12-21daily0.9 https://clinresonc-new.lhten.com/nationwide-cohort-study-in-the-netherlands-of-outcomes-of-endometrial2024-12-22daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-case-control-studies-of-the-association-of-coffee2024-12-23daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-immune-checkpoint-inhibitor2024-12-23daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-neoadjuvant-hypofractionated2024-12-23daily0.9 https://clinresonc-new.lhten.com/single-center-prospective-trial-of-circulating-tumor-hpv-dna-for2024-12-24daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-association-of-consumption-of-red-meat2024-12-24daily0.9 https://clinresonc-new.lhten.com/seer-medicare-database-analysis-of-statin-use-with-immune-checkpoint2024-12-25daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-immune-checkpoint-inhibitors-for-advanced2024-12-25daily0.9 https://clinresonc-new.lhten.com/three-year-follow-up-of-phase-ii-trial-of-neoadjuvant-atezolizumab2024-12-26daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-association-of-patterns-of-progressive-disease2024-12-26daily0.9 https://clinresonc-new.lhten.com/global-burden-of-male-breast-cancer-systematic-analysis-from-the2024-12-27daily0.9 https://clinresonc-new.lhten.com/single-center-pilot-study-of-neoadjuvant-and-adjuvant-osimertinib-in2024-12-27daily0.9 https://clinresonc-new.lhten.com/clinical-value-of-surveillance-with-serial-circulating-tumor-dna2024-12-27daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-depression-risk-among-breast2024-12-28daily0.9 https://clinresonc-new.lhten.com/retrospective-clinicopathologic-study-of-secretory-breast-carcinoma2024-12-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-perioperative-benzodiazepine2024-12-29daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-prognostic-significance-of-interim-pet-ct-in2024-12-29daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-survival-impact-of-metastatic2024-12-30daily0.9 https://clinresonc-new.lhten.com/nationwide-case-control-study-of-risk-of-childhood-brain-tumors-after2024-12-30daily0.9 https://clinresonc-new.lhten.com/case-control-study-of-breast-cancer-susceptibility-gene-sequence2024-12-30daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-odronextamab-monotherapy-after-car-t-cell2024-12-31daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-second-primary-non-myeloid2024-12-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-avelumab-for-high-grade-neuroendocrine2024-12-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-integrated-genomics-and-avatar-models2025-01-01daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-association-of-adiposity-and-risks-of2025-01-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-transplant-free-approach-for-relapsed2025-01-02daily0.9 https://clinresonc-new.lhten.com/case-control-study-of-association-of-cardiovascular-disease-and2025-01-02daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-amivantamab-plus-lazertinib-for2025-01-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adding-metronomic-capecitabine-to2025-01-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-belzutifan-plus-cabozantinib2025-01-03daily0.9 https://clinresonc-new.lhten.com/post-hoc-retrospective-cross-sectional-analysis-of-psma-pet-ct2025-01-03daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-of-a-multinational-phase-3-trial-of-cilta2025-01-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-brain-radiotherapy-plus2025-01-04daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-pulmonary-stereotactic-body2025-01-05daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-real-world-outcomes-of-adjuvant2025-01-05daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-demographic-and-clinical-trends2025-01-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-iberdomide-with-ixazomib-and2025-01-06daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-racial-ethnic-differences-in-trends-of2025-01-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-datopotamab-deruxtecan-in-advanced-or2025-01-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-trial-of-glecirasib-for-locally-advanced-or2025-01-07daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-neoadjuvant-chemoradiation2025-01-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-brentuximab-vedotin-lenalidomide-and2025-01-08daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-surgical-deescalation-within2025-01-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adding-durvalumab-with-or-without2025-01-09daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-t-cell-malignancies-after-car-t-cell2025-01-09daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-relapse-and-disease-free-survival2025-01-09daily0.9 https://clinresonc-new.lhten.com/melanoma-among-adult-survivors-of-childhood-cancer-in-the-childhood2025-01-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-noninferiority-trial-of-eribulin-versus-taxane2025-01-10daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-studies-of-venous-thromboembolism-in-patients2025-01-10daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-hpv-circulating-cell-free-dna-kinetic-in2025-01-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-trial-of-epcoritamab-plus-gemox-in2025-01-11daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-the-oral-stat3-inhibitor-tti-101-in-patients-with2025-01-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-study-of-telisotuzumab-vedotin-plus2025-01-12daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-cns-outcomes-of-osimertinib-plus2025-01-12daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-neoadjuvant-therapy-for-left2025-01-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-atezolizumab-to-first-line2025-01-13daily0.9 https://clinresonc-new.lhten.com/health-related-quality-of-life-with-androgen-receptor-pathway2025-01-13daily0.9 https://clinresonc-new.lhten.com/ultrasensitive-ctdna-detection-for-preoperative-disease2025-01-14daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-esophageal-candida2025-01-14daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-trial-of-initial-multiparametric-mri-versus2025-01-15daily0.9 https://clinresonc-new.lhten.com/follow-up-of-the-multinational-phase-3-katherine-trial-of-trastuzumab2025-01-16daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-pembrolizumab-with-or-without-bevacizumab2025-01-16daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-intratumoral-injection-of-mrna-27522025-01-16daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-the-association-of-central-obesity-with2025-01-16daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-efficacy-and-tolerability-of-neoadjuvant-talimogene2025-01-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-atezolizumab-plus-dual-her22025-01-17daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-mortality-after-cancer-diagnosis-among2025-01-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-basket-trial-of-tucatinib-plus-trastuzumab-for2025-01-18daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-bms-986299-as-monotherapy-and-in-combination-with2025-01-18daily0.9 https://clinresonc-new.lhten.com/longitudinal-cohort-study-of-long-term-use-of-low-dose-aspirin-for2025-01-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-overall-survival-impact-of-adjuvant2025-01-19daily0.9 https://clinresonc-new.lhten.com/pan-tumor-analysis-of-the-obesity-paradox-in-immune-checkpoint2025-01-20daily0.9 https://clinresonc-new.lhten.com/prognostic-and-clinical-significance-of-contrast-enhancement-on2025-01-20daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-studies-of-cryotherapy-for-prevention-of-peripheral2025-01-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-noninferiority-trial-of-thermal-ablation-versus2025-01-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-ramucirumab-plus-somatostatin-analog2025-01-21daily0.9 https://clinresonc-new.lhten.com/external-validation-of-a-5-factor-risk-model-for-breast-cancer2025-01-21daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-1b-2-study-of-addition-of-tiragolumab2025-01-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-pembrolizumab-and-chemotherapy-for2025-01-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-neoadjuvant-nivolumab-plus2025-01-22daily0.9 https://clinresonc-new.lhten.com/reanalysis-of-urothelial-cancer-chemoimmunotherapy-trial-with2025-01-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-perioperative-chemotherapy-versus2025-01-23daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-first-line-cadonilimab-plus-chemotherapy-for-her22025-01-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-3-year-disease-free-rates-after2025-01-23daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-impact-of-adjuvant2025-01-23daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-a-therapeutic-vaccine-for-hpv16-positive-high-grade2025-01-24daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-brain-mri-surveillance-among2025-01-24daily0.9 https://clinresonc-new.lhten.com/hrqol-and-symptoms-in-phase-3-orient-11-trial-of-first-line2025-01-24daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-proof-of-concept-study-of-digoxin-for2025-01-25daily0.9 https://clinresonc-new.lhten.com/final-overall-survival-analysis-of-phase-3-trial-of-pertuzumab2025-01-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-nivolumab-plus-ipilimumab-versus2025-01-26daily0.9 https://clinresonc-new.lhten.com/three-year-follow-up-of-a-multinational-phase-3-trial-of-first-line2025-01-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-encorafenib-with-cetuximab-and2025-01-27daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-trends-in-prostate-cancer-incidence-and-mortality2025-01-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-trifluridine-tipiracil-for-previously2025-01-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-botensilimab-plus-balstilimab-in2025-01-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-time-dependency-of-hpv-ctdna-detection-after2025-01-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-dna-damage-response-and-repair2025-01-29daily0.9 https://clinresonc-new.lhten.com/seer-and-medicare-databases-analysis-of-outcomes-after-surgical2025-01-29daily0.9 https://clinresonc-new.lhten.com/secondary-analysis-of-a-randomized-trial-of-superficial-curettage-and2025-01-29daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-mobocertinib-versus2025-01-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-atezolizumab-for-early-stage2025-01-30daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-urinary-dna-methylation-test-for2025-01-30daily0.9 https://clinresonc-new.lhten.com/first-in-human-phase-1-study-of-a-novel-cd19-ixx-chimeric-antigen2025-01-31daily0.9 https://clinresonc-new.lhten.com/surrogate-endpoints-for-overall-survival-in-neoadjuvant-randomized2025-01-31daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-survival-among-patients-with-her2-positive2025-01-31daily0.9 https://clinresonc-new.lhten.com/multicenter-noninferiority-phase-3-trial-of-annual-versus-less2025-02-01daily0.9 https://clinresonc-new.lhten.com/multinational-nonrandomized-phase-1-2-study-of-nivolumab-with-or2025-02-01daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-immune-checkpoint-inhibitors2025-02-01daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-impact-of-delayed-surgery-on-outcomes-of2025-02-02daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-the-association-of-diet-quality-and2025-02-02daily0.9 https://clinresonc-new.lhten.com/outcomes-of-adjuvant-pembrolizumab-in-stage-ii-melanoma-post-hoc2025-02-02daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-adjuvant-radiotherapy-for2025-02-03daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-pathologic-complete-response-rates-with2025-02-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-first-line-rezivertinib-versus-gefitinib2025-02-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-ibrutinib-plus-venetoclax-versus2025-02-04daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-efficacy-and-safety-of-brigatinib-in-patients-with2025-02-04daily0.9 https://clinresonc-new.lhten.com/secondary-analysis-of-prognostic-value-of-combined-assessment-of2025-02-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-perioperative-pembrolizumab-in-early2025-02-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-ablative-therapies-for-primary2025-02-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-acalabruinib-combinations2025-02-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-zenocutuzumab-monotherapy-for-advanced2025-02-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pembrolizumab-for-previously-treated2025-02-07daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-return-to-work-up-to-5-years-after-the-end-of2025-02-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-d-vrd-versus-vrd-voor-transplant2025-02-07daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-cumulative-excess-body2025-02-07daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-adjuvant-anlotinib-versus-placebo-for2025-02-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-vodobatinib-for-ph-positive-cml2025-02-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-car-macrophage-therapy-for-her22025-02-08daily0.9 https://clinresonc-new.lhten.com/associations-between-degree-of-industrial-food-processing-and2025-02-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-segmentectomy-with-or-without2025-02-09daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-real-world-outcomes-with-tisagenlecleucel-for2025-02-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-lurbinectedin-plus-pembrolizumab-for2025-02-10daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-incidence-of-newly-diagnosed-cancer2025-02-10daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-fear-of-cancer-recurrence-and-health-care2025-02-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-sacituzumab-govitecan-in-advanced2025-02-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-ipilimumab-nivolumab-and-panitumumab-for2025-02-12daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-perioperative-or-postoperative-sox-versus2025-02-12daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-long-term-survival-by-number-of-immune-checkpoint2025-02-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ensartinib-for-advanced-or-metastatic2025-02-13daily0.9 https://clinresonc-new.lhten.com/car-t-cell-lymphoma-after-cilta-cel-therapy-for-relapsed-or2025-02-13daily0.9 https://clinresonc-new.lhten.com/ten-year-analysis-of-shorther-trial-association-between-tumor2025-02-13daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-enzalutamide-with-or-without2025-02-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-studies-of-allogeneic-car-t-cell-products-allo2025-02-14daily0.9 https://clinresonc-new.lhten.com/retrospective-pooled-analysis-of-racial-and-ethnic-survival2025-02-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-durvalumab-plus-chemotherapy2025-02-15daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-association-between-exposure-to2025-02-15daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-vascular-targeted-photodynamic2025-02-16daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-chemo-immunotherapy-versus2025-02-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-bladder-preservation-with-durvalumab2025-02-17daily0.9 https://clinresonc-new.lhten.com/systematic-literature-review-and-network-meta-analysis-of-anti-pd-l-12025-02-17daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-calcium-intake-and-risk-of-colorectal2025-02-17daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-of-a-phase-1-trial-of-gd2-directed-car-t-cell2025-02-18daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-nivolumab-with-or-without2025-02-18daily0.9 https://clinresonc-new.lhten.com/palbociclib-plus-endocrine-therapy-versus-capecitabine-for2025-02-18daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-pulmonary-embolism-related-mortality-in-patients-with2025-02-18daily0.9 https://clinresonc-new.lhten.com/retrospective-comparison-of-standard-of-care-idecabtagene-vicleucel2025-02-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-study-of-cabozantinib-plus-atezolizumab-for-22025-02-19daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-mohs-surgery-versus-wide-local-excision2025-02-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-atezolizumab-after-definitive2025-02-20daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-novel-combination-immunotherapy-for2025-02-20daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-estimated-lithium-exposure-in-drinking-water-and2025-02-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-pembrolizumab-for-msi-h-dmmr-advanced2025-02-21daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-overall-survival-according-to-time-of-day-of2025-02-21daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-survival-following-progression-of2025-02-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-selpercatinib-in-ret-fusion-positive2025-02-22daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-neoadjuvant-therapy-in-t3-and-t4-colon2025-02-22daily0.9 https://clinresonc-new.lhten.com/association-of-location-of-brca-mutation-and-efficacy-of-parp2025-02-23daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-distribution-of-malignant-peripheral-nerve2025-02-23daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-boswellia-serrate-for-cerebral-radiation2025-02-23daily0.9 https://clinresonc-new.lhten.com/analysis-of-the-association-of-physical-activity-with-survival-in2025-02-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-sugemalimab-plus-chemotherapy-32025-02-24daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-clinical-behavior-of-breast2025-02-25daily0.9 https://clinresonc-new.lhten.com/outcomes-following-complete-response-of-hepatocellular-carcinoma-to2025-02-25daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-late-adverse-events-after-car2025-02-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-trastuzumab-rezetecan-for-previously2025-02-26daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-analysis-of-association-of-5-reductase2025-02-26daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-racial-differences-in-ctdna-profiles2025-02-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-cladribine-to-idarubicin2025-02-27daily0.9 https://clinresonc-new.lhten.com/analysis-of-structural-inequities-in-the-availability-of-prostate2025-02-27daily0.9 https://clinresonc-new.lhten.com/academic-community-partnership-in-acute-promyelocytic-leukemia-and2025-02-27daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-cabozantinib-for-locally2025-02-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-her2-loss-after-trastuzumab-deruxtecan-for2025-02-28daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-physical-health-decline-after2025-02-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pirtobrutinib-for-relapsed-or-refractory2025-03-01daily0.9 https://clinresonc-new.lhten.com/retrospective-seer-medicare-database-analysis-of-use-of-adjuvant2025-03-01daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-incidence-and-prognostic-relevance-of2025-03-02daily0.9 https://clinresonc-new.lhten.com/adjuvant-chemotherapy-in-localized-resectable-extremity-and-truncal2025-03-02daily0.9 https://clinresonc-new.lhten.com/identification-of-candidate-alterations-mediatin-kras-g12c-inhibitor2025-03-03daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-rural-urban-disparities-in-cervical-cancer2025-03-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1a-trial-of-zongertinib-for-advanced-solid-tumors2025-03-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-atezolizumab-plus-carboplatin-and2025-03-04daily0.9 https://clinresonc-new.lhten.com/cost-effectivenes-of-addition-of-pembrolizumab-to-chemoradiotherapy2025-03-04daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-phase-2-trial-of-addition-of-adt-to-sbrt-for2025-03-05daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-neoadjuvant-shr-a1811-with-or-without2025-03-05daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-anlotinib-versus-placebo2025-03-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-chemotherapy-plus-dual2025-03-06daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-trial-of-hand-cooling-and-compression-for2025-03-06daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-nivolumab-plus-chemotherapy-followed-by2025-03-06daily0.9 https://clinresonc-new.lhten.com/two-institution-phase-2-trial-of-pembrolizumab-plus-bevacizumab-for2025-03-07daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-association-between-statin-use2025-03-07daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-associations-of2025-03-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-ivonescumab-versus-pembrolizumab-for-pd2025-03-08daily0.9 https://clinresonc-new.lhten.com/circulating-tumor-dna-analysis-guiding-adjuvant-therapy-in-stage-ii2025-03-08daily0.9 https://clinresonc-new.lhten.com/long-term-survival-outcomes-with-maintenance-chemotherapy-for-high2025-03-08daily0.9 https://clinresonc-new.lhten.com/impact-of-donor-leukocyte-telomere-length-and-shortening-post-allohct2025-03-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-statin-use-and-risk-of2025-03-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-study-of-cofetuzumab-pelidotin-monotherapy-for2025-03-10daily0.9 https://clinresonc-new.lhten.com/association-of-radiotherapy-use-and-time-to-second-cancer-in-children2025-03-10daily0.9 https://clinresonc-new.lhten.com/review-article-prostate-cancer2025-03-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-pelabresib-plus-ruxolitinib-for-jak2025-03-11daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-enfortumab-vedotin-with-or2025-03-11daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-bowel-disorder-incidence-and-rectal2025-03-11daily0.9 https://clinresonc-new.lhten.com/european-cancer-mortality-predictions-for-the-year-20252025-03-12daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-trial-of-bevaciumab-for-radiation2025-03-12daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-prognostic-value-of2025-03-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-camrelizumab-for-locoregionally2025-03-13daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-adjuvant-chemoradiotherapy-versus2025-03-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-1b-trial-of-the-b7h3-targeting-antibody-drug2025-03-14daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-neoadjuvant-durvalumab-plus-dos-chemotherapy2025-03-14daily0.9 https://clinresonc-new.lhten.com/temporal-trends-in-incidence-and-mortality-of-colorectal-cancer-in2025-03-14daily0.9 https://clinresonc-new.lhten.com/phase-3-noninferiority-trial-of-efbemalenograstim-alfa-versus2025-03-15daily0.9 https://clinresonc-new.lhten.com/protein-profiles-predict-treatment-responses-of-chronic-lymphocytic2025-03-15daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-aumolertinib-plus2025-03-16daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-antiangiogenic-therapy-in2025-03-16daily0.9 https://clinresonc-new.lhten.com/case-control-study-of-risk-of-head-and-neck-cancer-after-allergic2025-03-17daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-statin-use-with-risk-of-hepatocellular2025-03-17daily0.9 https://clinresonc-new.lhten.com/multicenter-non-inferiority-phase-3-trial-of-neoadjuvant2025-03-18daily0.9 https://clinresonc-new.lhten.com/health-related-quality-of-life-with-belzutifan-versus-everolimus-for2025-03-18daily0.9 https://clinresonc-new.lhten.com/clinical-and-genomic-characterization-of-secondary-rectal-cancer2025-03-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-tazemetostat-plus-r-chop-for2025-03-19daily0.9 https://clinresonc-new.lhten.com/multicenter-analysis-of-neoadjuvant-chemoradiotherapy-versus2025-03-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nivolumab-adjuvant-to-chemoradiation-for2025-03-20daily0.9 https://clinresonc-new.lhten.com/simulation-modeling-study-of-risk-of-chronic-conditions-due-to2025-03-20daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-cancer-antigen125-levels-at-time2025-03-20daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-sex-specific-associations-between-sleep2025-03-21daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-riluzole-in-combination-with-mfolfox62025-03-21daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-presymptomatic-awareness2025-03-22daily0.9 https://clinresonc-new.lhten.com/clinical-outcomes-and-genomic-alterations-in-gleason-score-102025-03-22daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-prognostic-value-of-baseline-eortc-qlq-c30-scores2025-03-22daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-microultrasonography-guided-versus2025-03-23daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-after-lobectomy-or-sublobar-resection-for-stage2025-03-23daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-local-anesthetic-transperineal-biopsy2025-03-24daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-neoadjuvant-bms-813160-nivolumab-and2025-03-24daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-temporal-trends-in-use-and2025-03-25daily0.9 https://clinresonc-new.lhten.com/real-world-retrospective-cohort-study-of-treatment-patterns-and2025-03-25daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-autologous-cik-cell-therapy-plus2025-03-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-adjuvant-mfolfox6-after-resection-of2025-03-26daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-patient-characteristics-and-treatment2025-03-26daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-adherence-to-lifestyle-accomodations-after-cancer2025-03-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-first-in-human-study-of-for46-fg-3246-for2025-03-27daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-smoking-status-of-the-us-cancer2025-03-28daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-late-onset-immune-related-adverse2025-03-28daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-noninferiority-trial-of-effect-of-invitation2025-03-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-selective-elimination-of-breast-surgery2025-03-29daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-long-term-safety-and-efficacy-of-bcma-car-t-cell2025-03-29daily0.9 https://clinresonc-new.lhten.com/real-world-correlation-of-invasive-disease-free-survival-and-overall2025-03-30daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-perioperative-chemotherapy-for2025-03-30daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-outcomes-of-multiple-myeloma2025-03-31daily0.9 https://clinresonc-new.lhten.com/retrospective-database-analysis-of-the-genomic-landscape-of-small2025-03-31daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-patient-navigation-to-improve-colonoscopy2025-04-01daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-adaptive-manufactured-lentiviral2025-04-01daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-from-the-mirasol-trial-mirvetuximab2025-04-01daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-from-talapro-2-first-line-talazoparib-plus2025-04-02daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-ipilimumab-nivolumab-versus-standard-of2025-04-02daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-appendiceal-tumor-prevalence-in2025-04-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-neoadjuvant-mogamulizumab-plus-nivolumab2025-04-03daily0.9 https://clinresonc-new.lhten.com/adherence-to-the-american-cancer-society-guideline-for-cancer2025-04-03daily0.9 https://clinresonc-new.lhten.com/multinational-cohort-study-of-prognostic-impact-of-chromosome-1p-loss2025-04-04daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-ctdna-clearance-as-predictive-biomarker-of-pcr-to2025-04-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-glofitamab-in-refractory-or-relapsed2025-04-04daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-allogeneic-natural-killer-cells-with-a2025-04-05daily0.9 https://clinresonc-new.lhten.com/pooled-results-of-two-phase-2-studies-of-talectrectinib-for-ros12025-04-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-topical-imiquimod-and-local2025-04-06daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-de-novo-colorectal-cancer2025-04-06daily0.9 https://clinresonc-new.lhten.com/swedish-cohort-studies-of-association-between-anti-inflammatory-diet2025-04-06daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-cytokine-storms-in-covid2025-04-07daily0.9 https://clinresonc-new.lhten.com/secondary-analysis-of-association-of-comorbidity-in-midlife-with2025-04-07daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-adjuvant-therapy-for-stage-iiia2025-04-08daily0.9 https://clinresonc-new.lhten.com/comparative-observational-study-of-real-world-outcomes-with-first2025-04-08daily0.9 https://clinresonc-new.lhten.com/placebo-controlled-phase-2-trial-of-regorafenib-maintenance-after2025-04-09daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-bevacizumab-plus2025-04-09daily0.9 https://clinresonc-new.lhten.com/single-center-cohort-study-of-symptomatic-necrosis-with-dual-immune2025-04-09daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-use-of-a-polygenic-risk-score-in-screening-for2025-04-10daily0.9 https://clinresonc-new.lhten.com/final-analysis-of-alcyone-d-vmp-versus-vmp-for-newly-diagnosed2025-04-10daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-nonoperative-management-of-technically2025-04-10daily0.9 https://clinresonc-new.lhten.com/multinational-first-in-human-phase-1-study-of-the-hif-2-inhibitor2025-04-11daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-pretest-video-education-versus-genetic-counseling2025-04-11daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-association-of-perioperative2025-04-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-sacituzumab-tirumotecan-for-previously2025-04-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-belzutifan-for-von-hippel-lindau2025-04-12daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-anti-gprc5d-car-t-cell-therapy-for2025-04-12daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-secondary-malignancies-after2025-04-13daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-prognostic-impact-of-cohesin-mutations-in-patients2025-04-13daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-stereotactic-body-radiation-therapy-for-spinal2025-04-14daily0.9 https://clinresonc-new.lhten.com/modeling-study-of-projected-lifetime-cancer-risks-from-current2025-04-14daily0.9 https://clinresonc-new.lhten.com/temporal-trends-in-incidence-of-pancreas-and-colorectal2025-04-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-trispecific-cb307-in-patients-with2025-04-15daily0.9 https://clinresonc-new.lhten.com/seer-medicare-database-analysis-of-association-of-screening-history2025-04-15daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-health-care-contact-day-and-outcomes-in2025-04-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-neoadjuvant-chemotherapy-followed-by2025-04-16daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-reduced-elective-dose-in-definitive2025-04-16daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-first-line-afatinib-versus2025-04-17daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-a-dna-methylation-marker-for-risk2025-04-17daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-addition-of-atezolizumab-to2025-04-17daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-dasatinib-plus-car-t-cell-therapy-for2025-04-18daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-dasatinib-plus-car-t-cell-therapy-for-22025-04-18daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-survival-in-melanoma-patients-with-brain2025-04-18daily0.9 https://clinresonc-new.lhten.com/two-center-retrospective-study-of-factors-associated-with-disease2025-04-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-4-1bb-co-stimulated-cd19-specific-car-nk2025-04-19daily0.9 https://clinresonc-new.lhten.com/final-outcomes-of-a-phase-2-trial-of-high-dose-versus-standard-dose2025-04-20daily0.9 https://clinresonc-new.lhten.com/final-outcomes-of-phase-2-trial-of-high-dose-versus-standard-dose-of2025-04-20daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-first-line-osimertinib-versus-afatinib-for2025-04-20daily0.9 https://clinresonc-new.lhten.com/retrospective-two-center-study-of-image-guided-hypofractionated2025-04-21daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-stereotactic-reirradiation-for2025-04-21daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-identification-of-early-stage-breast-cancer-with2025-04-21daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-neoadjuvant-chemotherapy2025-04-22daily0.9 https://clinresonc-new.lhten.com/single-center-cohort-study-of-patterns-in-symptoms-preceding-acute2025-04-22daily0.9 https://clinresonc-new.lhten.com/single-center-phase-3-trial-of-induction-versus-concurrent2025-04-23daily0.9 https://clinresonc-new.lhten.com/multinational-phase-iib-study-of-adavosertib-for-recurrent-or2025-04-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-tfox-versus-folfox-for2025-04-24daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-impact-of-intravenous2025-04-24daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-risk-of-myeloid-neoplasms-after-cd19-directed2025-04-24daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-onset-and-progression-of-atherosclerosis-in2025-04-25daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-survival-outcomes-after-first2025-04-25daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-geographic-variation-of-racial-and2025-04-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-modakafusp-alfa-monotherapy-for2025-04-26daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-impact-of-tp53-co-mutation-on2025-04-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-the-next-generation-nectin-4-targeting2025-04-26daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-nonoperative-management-of-mismatch2025-04-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-perioperative2025-04-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-zoldonrasib-for-kras-g12d-mutated-non2025-04-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-zoldonrasib-for-kras-g12d-mutated-non-22025-04-27daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-ctdna-analysis-to-detect-recurrence-after2025-04-28daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-digital-histopathology-for2025-04-28daily0.9 https://clinresonc-new.lhten.com/multinational-multicohort-phase-1-trial-of-zongertinib-for-previously2025-04-28daily0.9 https://clinresonc-new.lhten.com/combined-tissue-and-liquid-biopsy-improves-outcomes-in-advanced-solid2025-04-29daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-d3s-001-in-advanced-solid-tumors-with2025-04-29daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1b-study-of-nivolumab-plus-stereotactic2025-04-30daily0.9 https://clinresonc-new.lhten.com/long-term-results-of-a-phase-3-trial-of-eary-rituximab-monotherapy2025-04-30daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-risk-of-secondary-cancer-among-patients-with-primary2025-04-30daily0.9 https://clinresonc-new.lhten.com/association-between-parental-cancer-history-and-in-vitro2025-05-01daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-antimicrobial-resistance-in2025-05-01daily0.9 https://clinresonc-new.lhten.com/deep-learning-model-of-primary-tumor-and-metastatic-cervical-lymph2025-05-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-acalabrutinib-plus2025-05-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-chemotherapy-free-neoadjuvant2025-05-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-low-dose-moderate-hypofractionated2025-05-03daily0.9 https://clinresonc-new.lhten.com/individual-patient-data-meta-analysis-of-neoadjuvant2025-05-03daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-real-world-outcomes-of-treatments2025-05-04daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-thyroid-radiation-dose-with2025-05-04daily0.9 https://clinresonc-new.lhten.com/short-term-outcomes-of-a-multicenter-randomized-phase-2-trial-of2025-05-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-impact-of-radiotherapy2025-05-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2a-study-of-zanidatamab-plus-palbociclib-and2025-05-06daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-salvage-metastasis-directed-therapy-versus-elective2025-05-06daily0.9 https://clinresonc-new.lhten.com/prospective-multicenter-cohort-study-of-developmen-of-12-and-15-year2025-05-06daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-durvalumab-restart-after-moderate2025-05-07daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-neoadjuvant-radiotherapy-versus-upfront2025-05-07daily0.9 https://clinresonc-new.lhten.com/secondary-analysis-of-enzalutamide-and-psa-levels-in-metastatic2025-05-07daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-study-of-enhanced-car-t-cell-therapy-for2025-05-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-nivolumab-plus-ipilimumab2025-05-08daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-long-term-health-outcomes-of-bilateral2025-05-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-anlotinib-plus-penpulimab2025-05-09daily0.9 https://clinresonc-new.lhten.com/prospective-analysis-of-sex-differences-in-cancer-incidence-in-the-uk2025-05-09daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-second-line-camrelizumab-plus-apatinib2025-05-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-lazertinib-for-advanced-non-small-cell2025-05-10daily0.9 https://clinresonc-new.lhten.com/long-term-risk-of-major-cardiac-events-after-imrt-or-3d-crt-for2025-05-10daily0.9 https://clinresonc-new.lhten.com/long-term-risk-of-major-cardiac-events-after-imrt-or-3d-crt-for-22025-05-10daily0.9 https://clinresonc-new.lhten.com/patient-reported-outcomes-from-destiny-breast04-trastuzumab2025-05-11daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-pulsed-electrical-fields-in-the2025-05-11daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-addition-of-bevacizumab-to-first-line2025-05-12daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-somatic-tumor-next-generation2025-05-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-the-combination-of-kn046-and-kn026-for2025-05-12daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-first-line-nab-paclitaxel-and-gemcitabine2025-05-13daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-neoadjuvant-chemotherapy-for-organ-preservation2025-05-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-trial-of-neoadjuvant-chemotherapy-with-or2025-05-13daily0.9 https://clinresonc-new.lhten.com/prospective-analysis-of-associations-of-preclinical-and-clinical2025-05-14daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-chronic-opioid-use-and-related-outcomes-among2025-05-14daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-long-term-oncological2025-05-14daily0.9 https://clinresonc-new.lhten.com/long-term-update-of-a-phase-3-trial-of-hypofractionated-dose2025-05-15daily0.9 https://clinresonc-new.lhten.com/two-center-phase-2-study-of-patient-reported-outcomes-with2025-05-15daily0.9 https://clinresonc-new.lhten.com/barriers-to-car-t-cell-therapy-among-patients-with-hematologic2025-05-15daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-a-phase-2-trial-of-neoadjuvant-pembrolizumab2025-05-16daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-study-of-niraparib-for-previously-treated2025-05-16daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-low-intensity-vibration-for-chemotherapy-induced2025-05-16daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-alectinib-plus-bevacizumab2025-05-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-nivolumab-plus-low-dose2025-05-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-folfirinox-versus-gemcitabine-for2025-05-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-low-dose-radiotherapy-plus2025-05-18daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-mental-health-trajectories-among-us-survivors-of2025-05-19daily0.9 https://clinresonc-new.lhten.com/validation-of-a-vaginal-cervical-cancer-screening-self-collection2025-05-19daily0.9 https://clinresonc-new.lhten.com/retrospective-population-based-matched-cohort-study-of-risk-of2025-05-19daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-real-world-outcomes-with-furmonertinib-for2025-05-20daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-capecitabine-maintenance-therapy-for2025-05-20daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-factors-associated-with-reaching-maintenance2025-05-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-toripalimab-plus-bevacizumab2025-05-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-organ-preservation-after-total2025-05-21daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-association-of-a-circulating-lipid-panel-with2025-05-21daily0.9 https://clinresonc-new.lhten.com/interim-results-of-a-randomized-controlled-trial-of-supplemental2025-05-22daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-tomosynthesis-versus-digital-mammography-screening-in2025-05-22daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-neoadjuvant-pd-1-or-pd-l1-blockade-with2025-05-22daily0.9 https://clinresonc-new.lhten.com/cthpvdna-detection-and-recurrence-risk-in-hpv-positive-opscc2025-05-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-niraparib-plus-aromatase-inhibitor-for2025-05-23daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-1b-trial-of-db-020-intratympanic2025-05-23daily0.9 https://clinresonc-new.lhten.com/observational-retrospective-study-of-value-of-timely-germline-brca2025-05-24daily0.9 https://clinresonc-new.lhten.com/observational-retrospective-study-of-value-of-timely-germline-brca-22025-05-24daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1a-1b-trial-of-anlotinib-in-children-with-high2025-05-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-ramucirumab-plus-irinotecan-versus2025-05-24daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-siumple-hysterectomy-as-alternative-to2025-05-25daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-skeletal-muscle-density-as-predictive2025-05-25daily0.9 https://clinresonc-new.lhten.com/a-novel-transcriptomic-signature-for-prediction-of-response-to2025-05-26daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-long-term-clinical-outcome-of-metastatic-melanome2025-05-26daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-the-effect-of-bivalent-hpv-vassination2025-05-27daily0.9 https://clinresonc-new.lhten.com/hrqol-pain-and-symptomatic-skeletal-events-with-lu-psma-617-for2025-05-27daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-adverse-event-costs-and-cost-effectiveness2025-05-27daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-alcohol-use-disorder-treatment-initiation-among-u-s2025-05-28daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-concurrent-versus-sequential2025-05-28daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-diagnostic-intervals-for-children-and-young2025-05-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-chemoradiotherapy-and-local-excision2025-05-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-dose-escalation-study-of-bexmarilimab-plus2025-05-29daily0.9 https://clinresonc-new.lhten.com/twenty-year-survival-outcomes-with-imatinib-for-advanced-gist2025-05-29daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-trial-of-acupuncture-for-nocturia-in2025-05-29daily0.9 https://clinresonc-new.lhten.com/population-based-survey-study-of-the-association-between-alcohol-use2025-05-29daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-targeted-therapy-induction2025-05-30daily0.9 https://clinresonc-new.lhten.com/contributions-of-cancer-treatment-and-genetic-predisposition-to-risk2025-05-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-patritumab-deruxtecan-in2025-05-31daily0.9 https://clinresonc-new.lhten.com/atezolizumab-after-chemotherapy-in-resected-stage-ib-iiia-nsclc-five2025-05-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-encorafenib-cetuximab-and2025-05-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-second-line-t-dxd-versus-ramucirumab2025-05-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-inavolisib-for-pik3ca-mutated-locally2025-06-01daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-cldn18-2-specific-car-t-cell2025-06-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-tumor-treating-fields-to2025-06-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-durvalumab-in-gastric2025-06-01daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-cetuximab-to-avelumab-for2025-06-02daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-predictors-of-withdrawal-of-anticancer2025-06-02daily0.9 https://clinresonc-new.lhten.com/first-line-camizestrant-for-emerging-esr1-mutated-advanced-breast2025-06-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-tarlatamab-in-small-cell-lung-cancer2025-06-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-maintenance-lurbinectedin2025-06-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-overall-survival-after-neoadjuvant2025-06-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-relacorilant-plus-nab-paclitaxel-for2025-06-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-hbm4003-plus-toripalimab-for-high-grade2025-06-04daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-cilta-cel-for-heavily-pretreated-relapsed-or2025-06-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-omitting-regional-nodal-irradiation2025-06-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-atezolizumab-plus-paclitaxel2025-06-05daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-analysis-of-body-mass-index-physical-activity2025-06-05daily0.9 https://clinresonc-new.lhten.com/real-world-utilization-and-outcomes-of-immunotherapy-for-distantly2025-06-05daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-sacituzumab-tirumotecan2025-06-06daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-neoadjuvant-bms-813160-plus2025-06-06daily0.9 https://clinresonc-new.lhten.com/association-between-antihypertensive-medication-use-and-kidney-cancer2025-06-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-pirtobrutinib-for-covalent-btk2025-06-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-oncolytic-virus-ovv-01-in-patients-with2025-06-07daily0.9 https://clinresonc-new.lhten.com/single-center-prospective-study-of-minimally-invasive-keyhole2025-06-08daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-focal-radiotherapy-versus-whole2025-06-08daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-real-world-outcomes-with-adjuvant2025-06-09daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-studies-of-impact-of-patient-navigation-services-for2025-06-09daily0.9 https://clinresonc-new.lhten.com/individual-participant-data-meta-analysis-of-efficacy-of-immune2025-06-10daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-incidence-of-appendiceal-adenocarcinoma-in2025-06-10daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-biomarker-specific-survival-and2025-06-10daily0.9 https://clinresonc-new.lhten.com/long-term-follow-up-of-multicenter-phase-2-trial-of-transoral-surgery2025-06-11daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-her2-low-expression-by-race-and2025-06-11daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-resistance-training-and2025-06-11daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-real-world-outcomes-with-molecular-tumor-board2025-06-12daily0.9 https://clinresonc-new.lhten.com/ten-year-outcomes-from-a-non-inferiority-phase-3-trial-of-partial2025-06-12daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-long-term-effectiveness-of-early-age-start2025-06-12daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-cancer-incidence-and-trends-in-us-adults-with-hiv2025-06-12daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-pep-cmv-vaccine-for-recurrent-high-grade-glioma-in2025-06-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-first-line-azacitidine-venetoclax-and2025-06-13daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-ai-assisted-versus-ai-unassisted2025-06-13daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-gvhd-prophylaxis-with-cyclophosphamide-and2025-06-14daily0.9 https://clinresonc-new.lhten.com/first-line-sugemalimab-versus-placebo-in-combination-with2025-06-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-cabozantinib-plus-atezolizumab-for2025-06-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-retifanlimab-plus-chemotherapy-for2025-06-15daily0.9 https://clinresonc-new.lhten.com/overall-survival-in-propensity-score-matched-prospective-study-of2025-06-15daily0.9 https://clinresonc-new.lhten.com/denmark-wide-study-of-long-term-cancer-risk-in-users-of-glp-12025-06-15daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-occurrence-rates-of-delirium2025-06-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-ibrutinib-venetoclax-ibrutinib-alone-or2025-06-16daily0.9 https://clinresonc-new.lhten.com/nivolumab-avd-versus-brentuximab-vedotin-avd-for-advanced-stage2025-06-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-post-transplant-cyclophosphamide-based2025-06-17daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-treatments-and-outcomes-after-platinum2025-06-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-chemotherapy-with-or-without2025-06-18daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-local-cranial-radiation-plus-third-generation2025-06-18daily0.9 https://clinresonc-new.lhten.com/early-ctdna-and-survival-in-dmmr-msi-h-mcrc-treated-with-icis2025-06-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-perioperative-22025-06-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-glofitamab-with-pola-r-chp-or2025-06-19daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-bevacizumab-plus-erlotinib-for2025-06-19daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-study-of-anlotinib-plus-irinotecan-as-second2025-06-20daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-durvalumab-plus-chemotherapy-followed-by-adjuvant2025-06-20daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-risk-of-alzheimer-disease-among-breast2025-06-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-first-line-limertinib-versus-gefitinib2025-06-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-impact-of-lean-body-mass-based-adjuvant2025-06-21daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-the-assocation-of-area-deprivation-index-and2025-06-22daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-acute-cardiotoxicity-with-tyrosine-kinase2025-06-22daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-salvage-stereotactic-radiotherapy-for2025-06-23daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-the-association-between-atopy-and-survival-and2025-06-23daily0.9 https://clinresonc-new.lhten.com/microsimulation-model-study-of-cost-effectiveness-of-trimodal-therapy2025-06-23daily0.9 https://clinresonc-new.lhten.com/individual-participant-data-meta-analysis-of-outcomes-with-icis-for2025-06-24daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-inpatient-palliative-care2025-06-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-mibg-plus-dinutuximab-with-or-without2025-06-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-patritumab-deruxtecan-in-previously2025-06-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-tislelizumab-plus-bevacizumab-and2025-06-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-total-neoadjuvant-therapy-with-long2025-06-25daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-study-of-camrelizumab-with-or-without2025-06-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-utidelone-plus-bevacizumab-for-her22025-06-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-high-dose-aumolertinib-for-untreated2025-06-26daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-pembrolizumab-maintenance-with-or-without2025-06-27daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-risk-of-new-onset-hypertension-with2025-06-27daily0.9 https://clinresonc-new.lhten.com/retrospective-real-world-study-of-first-line-taxane-platinum-with-or2025-06-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-defactinib-plus-avutometinib-in-patients2025-06-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-bo-112-plus-pembrolizumab-for-anti-pd-12025-06-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-venetoclax-or-placebo-combined-with2025-06-28daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-cml-outcomes-according-to-baseline2025-06-29daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-ifosfamide-induced-encephalopathy-in-children2025-06-29daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-incidence-and-outcomes-of-de-novo-renal-cell2025-06-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-basket-trial-of-pembrolizumab-plus-vorinostat-for2025-06-30daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-clinical-outcomes-with-perioperative2025-06-30daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-olverembatinib-plus2025-07-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ipilimumab-plus-nivolumab-for-pancreatic2025-07-01daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-cd19-car-t-therapy-for-central2025-07-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-study-of-gfh018-plus-toripalimab-for-recurrent2025-07-02daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-dendritic-cell-vaccination-to2025-07-02daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-apalutamide-plus-stereotactic-body2025-07-02daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-linperlisib-plus-chidamide-for2025-07-02daily0.9 https://clinresonc-new.lhten.com/population-based-study-and-meta-analysis-of-the-association-of-oral2025-07-03daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-adherence-to-breast-screening2025-07-03daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-first-line-therapy-for-non2025-07-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nivolumab-plus-ipilimumab-for-advanced2025-07-03daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-adverse-events-with-neoadjuvant2025-07-04daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-impact-of-molecular-alterations2025-07-04daily0.9 https://clinresonc-new.lhten.com/prognostic-significance-of-early-circulating-tumor-dna-during2025-07-05daily0.9 https://clinresonc-new.lhten.com/fixed-ratio-combination-versus-sequential-infusion-of-nivolumab-and2025-07-05daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-clinical-features-and-survival2025-07-06daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-germline-brca1-2-pathogenic-variants-in2025-07-06daily0.9 https://clinresonc-new.lhten.com/rising-rates-of-colorectal-and-uterine-cancers-in-us-females-under2025-07-07daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-immune-checkpoint-inhibitors-and2025-07-07daily0.9 https://clinresonc-new.lhten.com/global-lifetime-estimates-of-expected-and-preventable-gastric-cancers2025-07-07daily0.9 https://clinresonc-new.lhten.com/three-year-follow-up-of-the-phase-3-transform-study-of-lisocabatagene2025-07-08daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-safety-of-intralesional-nivolumab-for2025-07-08daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-real-world-outcomes-with-teclistamab-for2025-07-09daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-phase-2-trial-of-addition-of-sintilimab-to2025-07-09daily0.9 https://clinresonc-new.lhten.com/survival-trends-in-metastatic-urothelial-cancer-before-and-after2025-07-09daily0.9 https://clinresonc-new.lhten.com/risk-of-malignant-neoplasms-with-ixekizumab-for-psoriasis-psoriatric2025-07-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-single-agent-divarasib-for-kras-g12c2025-07-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-blb01d1-for-previously-treated2025-07-10daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-adjuvant-chemoradiation-and2025-07-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-second-line-dkn-01-plus-tislelizumab-for2025-07-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-plus-adjuvant-relatlimab2025-07-11daily0.9 https://clinresonc-new.lhten.com/fertility-with-brecadd-versus-ebeacopp-for-advanced-classic-hodgkin2025-07-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-avutometinib-with-or-without2025-07-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-stereotactic-radiosurgery-for-patients2025-07-12daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-pelvic-exenteration-for-advanced-gynecologic2025-07-13daily0.9 https://clinresonc-new.lhten.com/multicenter-fase-2-trial-of-transcutaneous-auricular-vagus-nerve2025-07-13daily0.9 https://clinresonc-new.lhten.com/impact-of-a-mainstream-genetic-testing-pathway-and-socioeconomic2025-07-14daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-nadunolimab-plus-platinum2025-07-14daily0.9 https://clinresonc-new.lhten.com/population-based-matched-case-control-study-of-diabetes-and2025-07-15daily0.9 https://clinresonc-new.lhten.com/individual-patient-level-meta-analysis-of-association-of-her2dx-score2025-07-15daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-consolidation-durvalumab2025-07-15daily0.9 https://clinresonc-new.lhten.com/belantamab-mafadotin-plus-bortezomib-and-dexamethasone-for-relapsed2025-07-16daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-the-association-of-childhood-residence-near-the2025-07-16daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-the-association-between2025-07-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-ibi343-for-advanced-gastric-or2025-07-17daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-covid-19-vaccine-booster-uptake-and2025-07-17daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-risk-factors-for-covid-19-related2025-07-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pet-guided-first-line-brecadd-for2025-07-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-overall-survival-with-proton-beam-radiation2025-07-18daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-impact-of-glp-1ras-sglt2i-and2025-07-18daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-abemaciclib-plus-endocrine-therapy2025-07-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-carmrelizumab-plus2025-07-19daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-safety-and-efficacy-of2025-07-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-de-escalated-neoadjuvant-nab-paclitaxel2025-07-20daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-frequent-missed-opportunities-for2025-07-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-trial-of-safety-and-efficacy-of-tarlatamab-in2025-07-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-response-adapted-surgery-and2025-07-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-value-of-mediastinal-lymph-node2025-07-22daily0.9 https://clinresonc-new.lhten.com/retrospective-trial-of-mortality-after-emergency-department-use-prior2025-07-22daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-prediagnostic-serum-syndecan-4-level2025-07-23daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-long-term-locoregional-outcomes-of2025-07-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-stereotactic-ablative-radiotherapy-for2025-07-24daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-ctdna-analysis-during-treatment-of-locally2025-07-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-sequential-versus-induction-plus2025-07-24daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-outcomes-of-vaccines-for2025-07-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-obrixtamig-for-dll3-positive-small2025-07-25daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-neoadjuvant-chemotherapy-case-volume-and2025-07-25daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-an-online-mindfulness-program-to2025-07-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-obinutuzumab-induction-and-maintenance2025-07-26daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-analysis-of-cumulative-incidence-and2025-07-27daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-ql1706-plus-chemotherapy-and-bevacizumab-for-egfr2025-07-27daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-axillary-dissection-in-ct1n0-triple-negative2025-07-28daily0.9 https://clinresonc-new.lhten.com/incidence-and-outcomes-of-interval-colorectal-cancer-in-a-fecal2025-07-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-study-of-first-line-s-1-plus-irinotecan-and2025-07-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nivolumab-plus-ipilimumab-for-metastatic2025-07-29daily0.9 https://clinresonc-new.lhten.com/two-center-phase-2-trial-of-neoadjuvant-sintilimab-and-chemotherapy2025-07-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-precemtabart-tocentecan-for-metastatic2025-07-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2b-trial-of-tar-200-for-bcg-unresponsive-high2025-07-31daily0.9 https://clinresonc-new.lhten.com/multicenter-first-in-human-phase-1-2-trial-of-fhnd-9041-in-patients2025-07-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-tibremciclib-plus-fulvestrant-or-placebo2025-07-31daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-grade-group-1-prostate-cancer-outcome2025-07-31daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-clinical-presentation-and-outcome-of2025-08-01daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-split-dose-chemotherapy-plus-atezolizumab-for2025-08-01daily0.9 https://clinresonc-new.lhten.com/five-year-survival-and-biomarker-analyses-of-pembrolizumab-plus2025-08-02daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-dendrimer-nanoparticle-delivery-of-sn-38-in2025-08-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-hormone-therapy-with-or-without2025-08-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-intratumoral-vidutolimod-with-or2025-08-03daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-colorectal-cancer-screening-strategies-in-adults2025-08-04daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-colorectal-cancer-incidence-in-us-adults2025-08-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-focal-boost-to-ebrt-for2025-08-05daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-pembrolizumab-for-resectable-non-small2025-08-05daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-timing-of-recurrence-after-neoadjuvant-chemo2025-08-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-abemaciclib-plus-fulvestrant-for-hr2025-08-06daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-socioeconomic-disparities-in-incidence2025-08-06daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-age-threshold-for-oxaliplatin-benefit2025-08-06daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-risk-of-digestive-system2025-08-07daily0.9 https://clinresonc-new.lhten.com/single-center-phase-3-trial-of-bacterial-decolonization-with2025-08-07daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-frontline-acalabrutinib-lenalidomide2025-08-08daily0.9 https://clinresonc-new.lhten.com/differences-in-prostate-cancer-biochemical-recurrence-between-rural2025-08-08daily0.9 https://clinresonc-new.lhten.com/patient-level-meta-analysis-of-extending-duration-of-endocrine2025-08-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adagrasib-versus-docetaxel-for2025-08-09daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-osteonecrosis-in-pediatric-all2025-08-10daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-real-world-outcomes-with-second-line2025-08-10daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-prolonged-car-t-apheresis-to2025-08-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-lymph-node-targeted-mkras-specific2025-08-11daily0.9 https://clinresonc-new.lhten.com/health-outcomes-beyond-age-50-years-in-survivors-of-childhood-cancer2025-08-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-trial-of-neurocognition-impact-of-hippocampal2025-08-12daily0.9 https://clinresonc-new.lhten.com/decision-analytical-model-study-of-cervical-cancer-screening-hpv2025-08-12daily0.9 https://clinresonc-new.lhten.com/observational-study-of-change-in-adenoma-detection-rate-after2025-08-13daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-neoadjuvant-toripalimab-plus-chemotherapy-in2025-08-13daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-incidence-of-second-primary-cancers-in2025-08-13daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-chemoradiotherapy-versus-chemotherapy2025-08-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pembrolizumab-for-unresectable2025-08-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-sintilimab-plus-axitinib-for-treatment2025-08-14daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-outcomes-with-subsequent-treatment-regimens2025-08-15daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-cervical-cancer-outcomes-in-women-with-hiv-in2025-08-15daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-electronic-patient-reported-outcomes-and-vital2025-08-15daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-study-of-neoadjuvant-cadonilimab-plus2025-08-16daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-reproductive-factors-and-risk-of2025-08-16daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-carboplatin-with-or-without-everolimus2025-08-17daily0.9 https://clinresonc-new.lhten.com/comparative-study-of-neoadjuvant-chemoradiotherapy-chemotherapy-or2025-08-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-b-trial-of-anti-pd-1-antibody-sct-i10a-plus-anti2025-08-18daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-symptom-burden-in-adolescents-and-young2025-08-18daily0.9 https://clinresonc-new.lhten.com/two-prospective-studies-of-mifamurtide-for-nonmetastatic-high-grade2025-08-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-arsenic-trioxide-and-all-trans2025-08-19daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-use-of-depression-and-anxiety-medications-by2025-08-19daily0.9 https://clinresonc-new.lhten.com/germline-pathogenic-likely-pathogenic-mutations-and-subsequent2025-08-20daily0.9 https://clinresonc-new.lhten.com/phase-3-study-of-perioperative-pembrolizumab-plus-chemotherapy-for2025-08-20daily0.9 https://clinresonc-new.lhten.com/impact-of-statin-use-on-outcomes-with-apalutamide-for-advanced2025-08-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-sacituzumab-tirumotecan-plus2025-08-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-toripalimab-combination-therapy-without2025-08-21daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-between-use-of-glp-12025-08-21daily0.9 https://clinresonc-new.lhten.com/model-for-predicting-chronic-kidney-disease-after-cisplatin-treatment2025-08-21daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-etiologies-and-outcomes-of-diabetic2025-08-22daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-temporal-trends-in-use-of2025-08-22daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-addition-of-ipilimumab-plus-nivolumab-to-neadjuvant2025-08-22daily0.9 https://clinresonc-new.lhten.com/ten-year-survival-rates-by-psa-nadir-in-patients-with-metastatic2025-08-23daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-association-between-food-intake-and2025-08-23daily0.9 https://clinresonc-new.lhten.com/birth-cohort-effects-in-increase-of-early-onset-colorectal-cancer-in2025-08-24daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-outcomes-with-neoadjuvant2025-08-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-one-time-autologous-til-cell-therapy-for2025-08-25daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-the-association-of-traumatic-brain-injury-and-risk-of2025-08-25daily0.9 https://clinresonc-new.lhten.com/matched-cohort-study-of-resignation-in-working-japanese-women-after2025-08-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-prognostic-relevance-of-baseline-ctc2025-08-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-pemigatinib-for-myeloid-lymphoid2025-08-26daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-work-status-absenteeism-work-performance-and2025-08-26daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-osimertinib-plus-consolidative-radiotherapy-for2025-08-27daily0.9 https://clinresonc-new.lhten.com/dynamic-prognostic-models-for-colorectal-cancer-with-liver-metastases2025-08-27daily0.9 https://clinresonc-new.lhten.com/population-based-observational-cohort-study-of-second-cancers-in2025-08-28daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-addition-of-tar-200-to2025-08-28daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-survival-after-fertility2025-08-28daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-iodine-seed-marking-protocol-for-response-guided2025-08-28daily0.9 https://clinresonc-new.lhten.com/association-of-circulating-kidney-injury-molecule-1-with-outcome-of2025-08-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-avelumab-versus-observation-after2025-08-29daily0.9 https://clinresonc-new.lhten.com/incidence-and-temporal-trends-of-depression-and-anxiety-following2025-08-29daily0.9 https://clinresonc-new.lhten.com/bicenter-phase-2-trial-of-conversion-therapy-of-tislelizumab-plus2025-08-30daily0.9 https://clinresonc-new.lhten.com/nomogram-to-predict-development-of-brain-metastasis-in-non-small-cell2025-08-30daily0.9 https://clinresonc-new.lhten.com/examining-adherence-to-asco-s-language-of-respect-guidelines-in2025-08-30daily0.9 https://clinresonc-new.lhten.com/case-control-study-of-predictors-of-pdac-in-electronic-health-records2025-08-31daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-predictive-biomarkers-for-regression2025-08-31daily0.9 https://clinresonc-new.lhten.com/relmacabtagene-autoleucel-for-relapsed-or-refractory-follicular2025-09-01daily0.9 https://clinresonc-new.lhten.com/single-center-study-of-anti-angiogenic-therapy-with-or-without-immune2025-09-01daily0.9 https://clinresonc-new.lhten.com/randomized-controlled-trial-of-effect-of-personalized-risk-messages2025-09-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-benmelstobart-plus-anlotinib2025-09-02daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-metastases-directed-therapy2025-09-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-lenvatinib-plus-pembrolizumab-for2025-09-03daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-targeting-dormant-tumor-cells-to-prevent2025-09-03daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-local-recurrence-and-survival-in2025-09-03daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-de-escalated-versus-standard-adjuvant-radiotherapy2025-09-04daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-pazopanib-versus-placebo-for2025-09-04daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-patritumab-deruxtecan-for-hr-positive-her2-negative2025-09-04daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-proton-craniospinal2025-09-04daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-metastasis-directed-radiotherapy2025-09-05daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-acalabrutinib-monotherapy-for-cll-in-elderly-and2025-09-05daily0.9 https://clinresonc-new.lhten.com/phase-1-2a-umbrella-trial-of-molecularly-matched-targeted-therapies2025-09-06daily0.9 https://clinresonc-new.lhten.com/ten-year-results-of-a-multinational-phase-3-trial-of-adjuvant2025-09-06daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-first-line-amivantamab-lazertinib-for-egfr2025-09-07daily0.9 https://clinresonc-new.lhten.com/individual-participant-data-meta-analysis-of-association-between2025-09-07daily0.9 https://clinresonc-new.lhten.com/observational-study-of-impact-of-opioid-use-associated-with-curative2025-09-08daily0.9 https://clinresonc-new.lhten.com/population-based-model-to-estimate-potential-impact-of-glucagon-like2025-09-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-study-of-tarlatamab-plus-a-pd-l1-inhibitor-as2025-09-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-perioperative-nivolumab-with-or-without2025-09-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-studye-of-broad-spectrum-antibiotic-use-at-the2025-09-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-sunvozertinib-for-platinum-pretreated2025-09-10daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-concomitant-comedications-and-survival-with2025-09-10daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-prediction-of-invasive-melanoma-risk2025-09-10daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-first-line-mfolfirinox-versus2025-09-11daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-patient-reported-outcomes-as2025-09-11daily0.9 https://clinresonc-new.lhten.com/oral-lachnoanaerobaculum-levels-and-survival-in-patients-with-head2025-09-11daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-methylcobalamin-for-capecitabine-induced-hand-foot2025-09-11daily0.9 https://clinresonc-new.lhten.com/increased-risk-of-infections-in-smoldering-multiple-myeloma-in-the2025-09-12daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-stereotactic-radiosurgery-for2025-09-12daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-circulating-tumor-dna-and-tissue2025-09-12daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-toripalimab-with-or-without-celecoxib2025-09-13daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-survival-impact-of-non-adherence-to2025-09-13daily0.9 https://clinresonc-new.lhten.com/treatment-free-survival-after-nivolumab-with-or-without-relatlimab2025-09-14daily0.9 https://clinresonc-new.lhten.com/retrospective-real-world-study-of-neoadjuvant-immunochemotherapy2025-09-14daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-prevalence-of-brca1-and-brca2-variants-in-an2025-09-15daily0.9 https://clinresonc-new.lhten.com/seer-medicare-database-analysis-of-association-of-frailty-with2025-09-15daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-accuracy-benefits-and-harms-of-multicancer2025-09-16daily0.9 https://clinresonc-new.lhten.com/clinical-trial-of-m1-c6v1-oncolytic-virus-plus-camrelizumab-and2025-09-16daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-survival-by-treatment-recommendation-and2025-09-16daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-de-escalated-adjuvant-therapy-for-early2025-09-17daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-nicotinamide-for-skin-cancer-prevention2025-09-17daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-low-dose-aspirin-for-pi3k-altered-localized2025-09-18daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-impact-of-anthracyclines-in-genomic-high-risk2025-09-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pembrolizumab-plus-platinum-based2025-09-18daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-oral-bacterial-and-fungal-microbiome2025-09-18daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-salvage-therapies-for-immune-checkpoint2025-09-19daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-long-term-outcomes-of-alternative-donor2025-09-19daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-chemoradiotherapy-with-or-without-simultaneous2025-09-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-retifanlimab-plus-platinum2025-09-20daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-impact-of-glycemic-control-on2025-09-20daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-safety-of-omitting-radiotherapy-after-breast2025-09-21daily0.9 https://clinresonc-new.lhten.com/ncdb-analysis-of-addition-of-radiotherapy-to-hormonal-therapy-for-de2025-09-21daily0.9 https://clinresonc-new.lhten.com/five-year-outcomes-of-a-phase-2-trial-of-sabrt-for-unresectable2025-09-22daily0.9 https://clinresonc-new.lhten.com/alcohol-consumption-and-upper-aerodigestive-tract-squamous-cell2025-09-22daily0.9 https://clinresonc-new.lhten.com/patient-derived-organoids-predict-treatment-response-in-metastatic2025-09-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-study-of-talquetamab-plus-daratumumab-for2025-09-23daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-surgical-outcomes-after-implementation2025-09-23daily0.9 https://clinresonc-new.lhten.com/survival-after-fertility-sparing-surgery-for-early-stage-cervical2025-09-24daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced2025-09-24daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-sunburn-and-cutaneous-squamous-cell-carcinoma2025-09-24daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-first-mammography-screening2025-09-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-trial-of-neoadjuvant-combinations-of-immune2025-09-25daily0.9 https://clinresonc-new.lhten.com/four-year-outcomes-after-three-years-ribociclib-plus-endocrine2025-09-25daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-600-vs-400-mg-first-line2025-09-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-ziftomenib-for-relapsed-or-refractory2025-09-26daily0.9 https://clinresonc-new.lhten.com/nationwide-population-based-study-of-transformation-and-survival-of2025-09-26daily0.9 https://clinresonc-new.lhten.com/association-of-adherence-to-american-cancer-society-guideline-for2025-09-26daily0.9 https://clinresonc-new.lhten.com/real-world-study-of-amivantamab-for-egfr-exon-20-mutant-non-small2025-09-27daily0.9 https://clinresonc-new.lhten.com/trends-in-breast-cancer-death-rates-from-ductal-carcinoma-in-situ2025-09-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-chidamide-plus-chemotherapy2025-09-28daily0.9 https://clinresonc-new.lhten.com/real-world-retrospective-study-of-prognostic-biomarkers-in-patients2025-09-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-durvalumab-plus-carboplatin2025-09-29daily0.9 https://clinresonc-new.lhten.com/rise-in-early-onset-cancer-in-the-us-population-apparent-or-real2025-09-29daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-genomically-matched-therapy2025-09-30daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-long-term-overall-survival-with-pd-l1-blockade-with2025-09-30daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-electroacupuncture-for-early-urinary-incontinence2025-09-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-inotuzumab-ozogamicin2025-10-01daily0.9 https://clinresonc-new.lhten.com/first-line-immunotherapy-with-or-without-chemotherapy-versus-braf2025-10-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-a-dexamethasone-sparing-regimen-with2025-10-01daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-use-of-proteomic-aging-clocks-to-predict-risk-of2025-10-02daily0.9 https://clinresonc-new.lhten.com/nationwide-south-korean-case-control-study-of-the-association-of2025-10-02daily0.9 https://clinresonc-new.lhten.com/retrospective-population-based-study-of-contemporary-incidence-and2025-10-02daily0.9 https://clinresonc-new.lhten.com/randomized-phase-1-2-trial-of-addition-of-low-dose-endoxifen-to2025-10-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-mosunetuzumab-plus-polatuzumab-vedotin2025-10-03daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-screen-detected-breast-cancer-outcomes-by2025-10-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-3-trial-of-first-line-ibrutinib-plus-rituximab2025-10-04daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-sirolimus-and-cyclosporine-with-post-transplant2025-10-04daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-association-of-socioeconomics-with2025-10-05daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-first-line-hepatic-artery-infusion-chemotherapy-with2025-10-05daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-flot-versus-sox2025-10-06daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-daily-exemestane-in-women-with-endometrial2025-10-06daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-envafolimab-plus2025-10-07daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-efficacy-and-safety-of-brigatinib-after-alectinib2025-10-07daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-gprc5d-targeted-car-t-cell-therapy-for2025-10-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-niraparib-plus-abiraterone-prednisone2025-10-08daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-after-minimally-invasive-versus-open-left2025-10-08daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-prostate-specific-antigen-retesting2025-10-09daily0.9 https://clinresonc-new.lhten.com/single-center-randomized-phase-2-trial-of-neoadjuvant-ipilimumab-and2025-10-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-bl-b01d1-for-locally-advanced-or2025-10-09daily0.9 https://clinresonc-new.lhten.com/case-control-study-of-risk-factors-for-valvulopathy-among-childhood2025-10-09daily0.9 https://clinresonc-new.lhten.com/pathogenic-variants-family-history-and-cumulative-risk-of-breast2025-10-10daily0.9 https://clinresonc-new.lhten.com/role-of-dna-damage-repair-genes-in-pediatric-cancer-risk2025-10-10daily0.9 https://clinresonc-new.lhten.com/french-nationwide-cohort-study-of-pd-l1-inhibitors-plus-chemotherapy2025-10-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pembrolizumab-plus-chemotherapy-without2025-10-11daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-omacetaxine-and-azacitidine-for2025-10-11daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-durvalumab-doxorubine-and-ifosfamide2025-10-12daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-causes-of-death-among-individuals-with2025-10-12daily0.9 https://clinresonc-new.lhten.com/outcomes-with-intensity-modulated-proton-therapy-in-patients-with-non2025-10-12daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-cdk4-6-inhibitors-for-hr-her2-metastatic2025-10-13daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-determinants-and2025-10-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-hepatic-arterial-infusion-pump2025-10-14daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-quizartinib-versus-placebo2025-10-14daily0.9 https://clinresonc-new.lhten.com/longitudinal-cohort-study-of-quality-of-cancer-care-among-people-with2025-10-14daily0.9 https://clinresonc-new.lhten.com/impact-of-loneliness-and-social-isolation-on-mortality-among-cancer2025-10-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-ifinatamab-deruxtecan-for-previously2025-10-15daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-a-skin-cancer-surveillance-program-for2025-10-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-ruxolitinib-versus-best-available2025-10-16daily0.9 https://clinresonc-new.lhten.com/multicenter-noninferiority-trial-of-sentinel-lymph-node-biopsy-alone2025-10-16daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-ai-detected-tils-as-biomarkers-for2025-10-16daily0.9 https://clinresonc-new.lhten.com/active-monitoring-surgery-and-radiotherapy-for-cribriform-positive2025-10-16daily0.9 https://clinresonc-new.lhten.com/axicabtagene-ciloleucel-for-relapsed-or-refractory-indolent-non2025-10-17daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-il-10-expressing-anti-cd19-car-t-cells2025-10-17daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-adjuvant-endocrine-therapy-with-or-without2025-10-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-osimertinib-plus2025-10-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-sevabertinib-in-advanced-her2-mutant2025-10-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-belzutifan-for-advanced2025-10-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-nivolumab-versus-ipilimumab-for2025-10-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-sacituzumab-govitecan-for2025-10-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-sacituzumab-tirumotecan-for-egfr-tki2025-10-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-disitamab-vedotin-plus-toripalimab-in2025-10-20daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-enzalutamide-in-biochemically-recurrent2025-10-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-ctdna-guided-adjuvant-atezolizumab-in2025-10-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-continuous-nirogacestat-treatment-in2025-10-21daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-addition-of-carboplatin-to-neoadjuvant-sequential2025-10-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-trial-of-glofitamab-plus-polatuzumab-vedotin2025-10-21daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-stereotactic-radiosurgery-for-brain2025-10-22daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-osimertinib-plus-savolitinib-after-first-line2025-10-22daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-neoadjuvant-t-dxd-alone-or-followed-by-thp-for-high2025-10-22daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-the-anti-gprc5d-car-t-cell-therapy-rd118-for2025-10-22daily0.9 https://clinresonc-new.lhten.com/real-world-analysis-of-first-line-enfortumab-vedotin-plus2025-10-23daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-valemetostat-for-relapsed-or-refractory2025-10-23daily0.9 https://clinresonc-new.lhten.com/longitudinal-cohort-study-of-a-risk-prediction-model-for-development2025-10-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-trop-2-targeting-antibody-drug-conjugate2025-10-24daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-first-line-anlotinib-plus-anthracyclines-and2025-10-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-amivantamab-plus-lazertinib-for2025-10-24daily0.9 https://clinresonc-new.lhten.com/updated-estimates-ofincidence-of-oropharyngeal-cancer-in-the-united2025-10-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nab-paclitaxel-plus-bevacizumab-for2025-10-25daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-pattern-of-brain-metastases-and2025-10-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-zanubrutinib-lenalidomide-plus-r-chop2025-10-25daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-the-association-of-22025-10-25daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-the-association-between-county-level2025-10-26daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-overall-survival-in-patients-with-non2025-10-26daily0.9 https://clinresonc-new.lhten.com/retr-ospective-study-of-associations-of-supramaximal-resection-with2025-10-26daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-postoperative-single-fraction2025-10-27daily0.9 https://clinresonc-new.lhten.com/prospective-validation-study-of-nutritional-and-immunological2025-10-27daily0.9 https://clinresonc-new.lhten.com/clinical-obesity-and-all-cause-and-cancer-specific-mortality-in-the2025-10-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-patritumab-deruxtecan-in-patients-with2025-10-28daily0.9 https://clinresonc-new.lhten.com/cell-of-origin-subtype-predicts-response-to-polatuzumab-vedotin-in2025-10-28daily0.9 https://clinresonc-new.lhten.com/identifying-patients-most-likely-to-benefit-from-routine2025-10-28daily0.9 https://clinresonc-new.lhten.com/trends-in-the-use-of-neoadjuvant-systemic-therapy-for-head-and-neck2025-10-28daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-electro-acupuncture-for-quality-of-life-during2025-10-29daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-one-year-mortality-after-hepatectomy-defining2025-10-29daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-trends-over-time-in-patients2025-10-29daily0.9 https://clinresonc-new.lhten.com/retrospective-head-to-head-comparison-of-first-line-tki-and-ici2025-10-30daily0.9 https://clinresonc-new.lhten.com/prognostic-and-predictive-impact-of-circulating-tumor-dna-levels-in2025-10-30daily0.9 https://clinresonc-new.lhten.com/multicenter-case-control-study-of-association-of-statin-and-other2025-10-30daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-hormonal-contraceptive-formulations2025-10-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-trastuzumab-deruxtecan-plus-pertuzumab2025-10-31daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-psa-testing-for-prostate-cancer-23-year-follow-up2025-10-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-whole-body-imaging-during-follow-up2025-11-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-patritumab-deruxtecan-in-patients-with-22025-11-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-abemaciclib-plus-abiraterone-in2025-11-01daily0.9 https://clinresonc-new.lhten.com/modelling-study-of-deep-inspiration-breath-hold-for-breast-cancer2025-11-02daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-patterns-of-failure-and-post-progression2025-11-02daily0.9 https://clinresonc-new.lhten.com/updated-meta-analysis-of-phase-3-trial-of-addition-of-cdk4-62025-11-02daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-cryoablation-plus-sintilimab-and2025-11-03daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-network-meta-analysis-of-systemic-therapies-for2025-11-03daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-neoadjuvant-therapy-for-invasive-intraductal2025-11-03daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-the-association-of-kidney2025-11-03daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-incidence-of-non-colorectal-endometrial2025-11-04daily0.9 https://clinresonc-new.lhten.com/molecular-characterization-to-predict-outcomes-of-patients-with2025-11-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-randomized-trial-of-neoadjuvant-camrelizumab-plus2025-11-04daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-abiraterone-versus-enzalutamide-among2025-11-04daily0.9 https://clinresonc-new.lhten.com/ezabenlimab-and-induction-chemotherapy-followed-by-adaptive2025-11-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nimotuzumab-plus-radiotherapy-for2025-11-05daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-prognostic-value-of-preoperative-ctdna-and2025-11-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-parp-inhibitor-maintenance2025-11-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-postmastectomy-chest-wall-irradiation-in2025-11-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-enfortumab-vedotin-for-previously2025-11-06daily0.9 https://clinresonc-new.lhten.com/phase-1b-trial-of-polypepi1018-cancer-vaccine-plus-tas-102-for2025-11-06daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-association-of-unrelated-donor-age-with2025-11-06daily0.9 https://clinresonc-new.lhten.com/histopathological-response-after-neoadjuvant-chemotherapy-for-high2025-11-07daily0.9 https://clinresonc-new.lhten.com/phase-1b-study-of-ianalumab-plus-ibrutinib-in-patients-with-chronic2025-11-07daily0.9 https://clinresonc-new.lhten.com/dose-escalation-part-of-a-multinational-phase-1-2-study-of2025-11-07daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-pirfenidone-for-grade-2-32025-11-07daily0.9 https://clinresonc-new.lhten.com/real-world-study-of-clinical-and-genomic-factors-associated-with2025-11-08daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-impact-of-immune-related-and-non-immune2025-11-08daily0.9 https://clinresonc-new.lhten.com/atorvastatin-and-aortic-stiffness-during-anthracycline-based2025-11-09daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-management-and-survival-of-patients-with2025-11-09daily0.9 https://clinresonc-new.lhten.com/increased-risk-of-early-onset-gastric-cancer-among-adults-aged-20-492025-11-09daily0.9 https://clinresonc-new.lhten.com/lung-cancer-risk-in-females-versus-males-in-a-large-married-couples2025-11-09daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-cardiotoxic-effects-of-antibody-drug-conjugates2025-11-10daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-factors-associated-with-provider2025-11-10daily0.9 https://clinresonc-new.lhten.com/multinational-population-based-study-of-age-and-sex-differentials-in2025-11-10daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-bowel-related-symptoms-and-dietary-fiber2025-11-10daily0.9 https://clinresonc-new.lhten.com/reducing-daunorubicin-in-induction-therapy-in-children-with-low-risk2025-11-11daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-association-of-liver-fat-with-clinical-outcomes2025-11-11daily0.9 https://clinresonc-new.lhten.com/a-10-year-microsimulation-model-of-the-impact-of-multicancer-early2025-11-11daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-e-health-intervention-for-fear-of-cancer2025-11-11daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-and-mendelian-randomization-analysis-of-use2025-11-12daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-trastuzumab-deruxtecan-for-her2-mutant-metastatic2025-11-12daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-laparoscopic-versus-open-distal2025-11-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-camrelizumab-plus2025-11-13daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-neoadjuvant-psma-targeting2025-11-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nivolumab-plus-ipilimumab-for-advanced-22025-11-13daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-the-association-of-ultraprocessed-food2025-11-13daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-peg-gcsf-neutropenia-prophylaxis-in2025-11-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-axicabtagene-ciloleucel-plus2025-11-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-cetuximab-plus-nivolumab-for-recurrent2025-11-14daily0.9 https://clinresonc-new.lhten.com/retrospective-population-based-cohort-study-of-pancreatic-ductal2025-11-14daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-trial-of-ablative-preoperative-single-fraction2025-11-14daily0.9 https://clinresonc-new.lhten.com/matched-cohort-study-of-cancer-related-outcomes-in-people-with-a2025-11-15daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-her2-positivity-as-a-prognostic2025-11-15daily0.9 https://clinresonc-new.lhten.com/contralateral-breast-cancer-after-radiotherapy-and-hormone-therapy-in2025-11-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-andamertinib-for-pretreated-advanced-non2025-11-16daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-pathological-risk-parameters-in-predicting2025-11-16daily0.9 https://clinresonc-new.lhten.com/clinical-significance-of-mtap-deletions-and-their-overlap-with2025-11-17daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-association-of-arsenic-exposure-reduction2025-11-17daily0.9 https://clinresonc-new.lhten.com/a-novel-14-gene-expression-signature-associated-with-prostate-cancer2025-11-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-tucatinib-plus-trastuzumab-emtansine2025-11-18daily0.9 https://clinresonc-new.lhten.com/multicenter-non-inferiority-phase-3-trial-of-early-pet-response2025-11-18daily0.9 https://clinresonc-new.lhten.com/association-of-type-and-location-of-germline-brca1-2-pvs-lpvs-with2025-11-18daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-by-best-confirmed-response-to-trastuzumab-deruxtecan2025-11-18daily0.9 https://clinresonc-new.lhten.com/individual-patient-data-meta-analysis-of-consensus-molecular-subtypes2025-11-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-tisagenlecleucel-for-relapsed2025-11-19daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-network-meta-analysis-of-targeted-therapies-in2025-11-19daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-chemotherapy-plus-tislelizumab-in2025-11-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2b-trial-of-zanidatamab-for-her2-positive2025-11-20daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-cohort-study-of-the-impact-tool-to-risk2025-11-20daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-optimal-duration-of-androgen-deprivation-therapy2025-11-20daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-faceage-as-a-biomarker-for-prognosis-and2025-11-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-preoperative-mfolfirinox-versus-paxg-for2025-11-21daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-neoadjuvant-immune-checkpoint2025-11-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-sacituzumab-tirumotecan-for-advanced2025-11-21daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-adverse-effects-of-scalp2025-11-21daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-real-world-effectiveness-of-avelumab2025-11-21daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-induction-chemotherapy-plus-camrelizumab-followed-by2025-11-22daily0.9 https://clinresonc-new.lhten.com/denmark-wide-cohort-study-of-association-between-body-mass-index-and2025-11-22daily0.9 https://clinresonc-new.lhten.com/phase-1b-study-of-intratumoral-tamilogene-laherparepvec-in2025-11-22daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-profiling-tumor-infiltrating-immune2025-11-23daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-trial-of-non-invasive-predictors-of-response2025-11-23daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-axl-expression-to-predict2025-11-23daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-a-therapeutic-peptide-vaccine-for-fibromellar2025-11-24daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-the-association-of-perinatal2025-11-24daily0.9 https://clinresonc-new.lhten.com/preclinical-study-of-gene-editing-strategy-to-engineer-allogeneic2025-11-24daily0.9 https://clinresonc-new.lhten.com/multinational-real-world-study-of-effectiviness-of-gilteritinib2025-11-24daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-pembrolizumab-plus-lenvatinib-as-second-line2025-11-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-fuzuloparib-with-or-without-apatinib-for2025-11-25daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-noninferiority-study-of-minimally-invasive2025-11-25daily0.9 https://clinresonc-new.lhten.com/individual-patient-data-meta-analysis-of-the-association-between2025-11-25daily0.9 https://clinresonc-new.lhten.com/validation-of-a-risk-score-for-cancer-associated-thrombosis-using-usa2025-11-25daily0.9 https://clinresonc-new.lhten.com/ten-year-outcomes-of-metronomic-capecitabine-as-extended-adjuvant2025-11-26daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-neoadjuvant-tqb2102-in2025-11-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-lorlatinib-in-tki-naive-advanced-ros12025-11-26daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-osteoradionecrosis-after-intensity2025-11-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-camrelizumab-plus-32025-11-27daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-distant-disease-free-survival-as-surrogate2025-11-27daily0.9 https://clinresonc-new.lhten.com/evaluating-post-trastuzumab-deruxtecan-treatment-strategies-in-her22025-11-27daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-real-world-outcomes-of-early-stage-her22025-11-27daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-adjuvant-camrelizumab-plus2025-11-28daily0.9 https://clinresonc-new.lhten.com/impact-of-time-to-colonoscopy-after-a-positive-fit-result-on2025-11-28daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-first-line-firmonertinib-plus2025-11-28daily0.9 https://clinresonc-new.lhten.com/monitoring-of-circulating-tumor-dna-allows-early-detection-of-disease2025-11-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2a-trial-of-glecirasib-plus-sitneprotafib-for2025-11-29daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-examining-suicide2025-11-29daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-jak-inhibitors-for-treatment-of-life2025-11-29daily0.9 https://clinresonc-new.lhten.com/multinational-real-world-study-of-combination-immunotherapy-sequences2025-11-29daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-real-world-analysis-of-first-line2025-11-30daily0.9 https://clinresonc-new.lhten.com/randomized-phase-3-trial-of-impact-of-nutritional-interventions-on2025-11-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-total-neoadjuvant-therapy-followed-by2025-12-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-microbubble-enhanced-transcranial2025-12-01daily0.9 https://clinresonc-new.lhten.com/long-term-recurrence-risk-after-resection-of-intracranial-meningiomas2025-12-01daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-statewide-medicaid-expansion-with2025-12-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-1b-trial-of-amivantamab-plus-lazertinib-for2025-12-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-lomustine-with-or-without-eflornithine2025-12-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-venetoclax-plus-azacitidine-for-relapsed2025-12-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-ib-2-study-of-first-line-zanidatamab-plus2025-12-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-perioperative-tislelizumab-plus2025-12-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-tinengotinib-for-previously-treated2025-12-03daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-letrozole-abemaciclib-and-metformin-in-er-positive2025-12-03daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-travel-time-to-treating2025-12-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-neoadjuvant-cetrelimab-with-or-without2025-12-04daily0.9 https://clinresonc-new.lhten.com/predictive-role-of-ctdna-in-stage-iii-colon-cancer-treated-with2025-12-04daily0.9 https://clinresonc-new.lhten.com/case-control-trial-of-association-of-use-of-angiogenesis-inhibitor2025-12-04daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-serum-metabolomics-for-prognostic2025-12-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-serplulimab-plus-chemotherapy2025-12-05daily0.9 https://clinresonc-new.lhten.com/multi-institutional-retrospective-analysis-of-her2-positivity-as2025-12-05daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-trabectedin-with-or-without2025-12-05daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-two-multinational-phase-1-2-trial-of-garsorasib2025-12-05daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-cancer-mortality-rates-by-detailed2025-12-06daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-spop-mutation-on-clinical-outcomes2025-12-06daily0.9 https://clinresonc-new.lhten.com/impact-of-ras-mapk-pathway-genetic-alterations-on-radiotherapy2025-12-06daily0.9 https://clinresonc-new.lhten.com/multicenter-multi-cohort-phase-2-study-of-vebreltinib-in-met2025-12-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-fixed-duration-versus-continuous2025-12-07daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-envafolimab-for-mismatch2025-12-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-talquetamab-plus-teclistamab-for2025-12-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-epcoritamab-to2025-12-08daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-pirtobrutinib-versus-ibrutinib-in2025-12-08daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-preoperative-weight-loss-in-patients2025-12-08daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-trial-of-epcoritamab-monotherapy-for-richter2025-12-09daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-adjuvant-benmelstobart-plus-anlotinib-after2025-12-09daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-risk-of-secondary-cancer2025-12-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-health-care-contact-days-in-older2025-12-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-teclistamab-plus-daratumumab-in2025-12-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-epirubicin-plus2025-12-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-pirtobrutinib-versus-bendamustine-plus2025-12-10daily0.9 https://clinresonc-new.lhten.com/patterns-of-iraes-and-treatment-responses-in-aya-patients-with2025-12-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-postneoadjuvant-trastuzumab-deruxtecan2025-12-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-tucatinib-versus-placebo-in2025-12-11daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-sintilimab-based-induction-therapy-in2025-12-11daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-pembrolizumab-plus2025-12-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-proton-versus-photon-radiotherapy-for2025-12-12daily0.9 https://clinresonc-new.lhten.com/cognitive-impairment-with-chemoendocrine-versus-endocrine-therapy-for2025-12-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-lbl-007-plus-tislelizumab-and2025-12-12daily0.9 https://clinresonc-new.lhten.com/risk-of-residual-cancer-after-immediate-surgery-or-nonoperative2025-12-12daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-risk-based-versus-annual-breast-cancer2025-12-13daily0.9 https://clinresonc-new.lhten.com/germline-pathogenic-variants-among-women-without-a-history-of-breast2025-12-13daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-effects-of-proton-therapy-on-cognition-in-adult2025-12-13daily0.9 https://clinresonc-new.lhten.com/compression-sleeves-for-prevention-and-treatment-of-breast-cancer2025-12-14daily0.9 https://clinresonc-new.lhten.com/cancer-risks-in-lynch-syndrome-carriers-systematic-review-and-meta2025-12-14daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-real-world-effectiveness-of-parp2025-12-14daily0.9 https://clinresonc-new.lhten.com/post-hoc-analysis-of-patients-with-advanced-ampullary-cancer-in-the2025-12-15daily0.9 https://clinresonc-new.lhten.com/case-control-study-for-genomic-ascertainment-of-chek2-related-cancer2025-12-15daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-multidisciplinary-team-support-for-patients2025-12-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-tislelizumab-plus-nab2025-12-16daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-radical-cystectomy-versus-bladder-sparing2025-12-16daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-trimodal-therapy-versus2025-12-16daily0.9 https://clinresonc-new.lhten.com/longitudinal-cohort-study-of-time-burden-in-patients-with-metastatic2025-12-16daily0.9 https://clinresonc-new.lhten.com/prognostic-potential-of-ultrasensitive-analysis-of-ctdna-dynamics2025-12-17daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-local-tumor-control-of-liver-tumors-after2025-12-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-bevacizumab-plus-erlotinib-in-advanced2025-12-17daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-five-day-preoperative-radiation2025-12-17daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-tumor-recurrence-risk-in-patients2025-12-17daily0.9 https://clinresonc-new.lhten.com/randomized-noninferiority-trial-of-a-liberalized-diet-versus2025-12-18daily0.9 https://clinresonc-new.lhten.com/benefits-harms-and-burden-of-colorectal-cancer-screening-among2025-12-18daily0.9 https://clinresonc-new.lhten.com/single-center-clinical-trial-of-intensity-modulated-radiotherapy-and2025-12-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-postoperative-sbrt-efficacy-and-late2025-12-18daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-sbrt-plus-sintilimab-and-bevacizumab2025-12-19daily0.9 https://clinresonc-new.lhten.com/performance-of-multicancer-early-detection-blood-test-in-cancer2025-12-19daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-pathologic-response-and2025-12-19daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-quadrivalent-human-papillomavirus2025-12-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-capivasertib-plus2025-12-20daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-durable-complete-response2025-12-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-addition-of-ipatasertib-to-dual-anti2025-12-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-chemotherapy-with-or-without-22025-12-21daily0.9 https://clinresonc-new.lhten.com/association-of-race-with-survival-of-prostate-cancer-patients-treated2025-12-21daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-sitravatinib-plus-tislelizumab-in-locally-recurrent2025-12-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-fruquintinib-plus-sintilimab-for2025-12-22daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-serplulimab-plus2025-12-22daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-atezolizumab-bevacizumab-versus-locoregional2025-12-22daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-liver-metastases-and-survival-among2025-12-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-adding-nivolumab-to-adjuvant2025-12-23daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-car-t-cell-therapy-and2025-12-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-the-her3-monoclonal-antibody2025-12-23daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-adjuvant-chemotherapy-use-for-hr2025-12-23daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-adjuvant-carboplatin-intensified-chemotherapy-versus2025-12-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-datopotamab-deruxtecan-versus-32025-12-24daily0.9 https://clinresonc-new.lhten.com/breast-cancer-incidence-among-brca-mutated-ovarian-cancer-patients2025-12-24daily0.9 https://clinresonc-new.lhten.com/pubertal-timing-and-incident-uterine-cancer-in-the-sister-study-cohort2025-12-24daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-outcomes-with-or-without-alnd-in-breast-cancer2025-12-25daily0.9 https://clinresonc-new.lhten.com/efficacy-of-everolimus-plus-endocrine-therapy-after-cdk4-6-inhibitors2025-12-25daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-patterns-of-lung-cancer-diagnosed-in2025-12-25daily0.9 https://clinresonc-new.lhten.com/pd-1-or-pd-l1-agent-induced-diabetes-across-national-cancer-institute2025-12-26daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-association-of-baseline-fatigue-with-severe-toxic2025-12-26daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-outcomes-with-adjuvant-anastrozole-letrozole-or2025-12-26daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-patients-reported-outcomes-across-treatment2025-12-26daily0.9 https://clinresonc-new.lhten.com/prospective-clinical-study-of-tislelizumab-plus-chemotherapy-for2025-12-27daily0.9 https://clinresonc-new.lhten.com/population-based-swedish-matched-cohort-study-of-lifetime-risk-of2025-12-27daily0.9 https://clinresonc-new.lhten.com/multicenter-real-world-study-of-efficacy-and-relapse-profiles-of-pola2025-12-27daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-first-line-toripalimab-in-combination-with2025-12-28daily0.9 https://clinresonc-new.lhten.com/impact-of-kras-codon-specific-mutations-on-survival-in-metastatic2025-12-28daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-preoperative-conversion-therapy-of-camrelizumab-with2025-12-29daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-brentuximab-vedotin-for-advanced-stage2025-12-29daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-stereotactic-body-radiotherapy2025-12-29daily0.9 https://clinresonc-new.lhten.com/survey-study-of-association-between-medical-misinformation-and-fear2025-12-29daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-lay-health-worker-led-symptom-intervention-and2025-12-30daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-lay-health-worker-led-symptom-intervention-and-22025-12-30daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-treatment-patterns-and-survival2025-12-30daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-accelerated-brain-aging-atherogenicity-and2025-12-30daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-masofaniten-plus-enzalutamide-for2025-12-31daily0.9 https://clinresonc-new.lhten.com/cross-sectional-analysis-of-the-assocation-between-body-mass-index2025-12-31daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-pet-ct-guided-management-of2025-12-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-first-line-tiragolumab-plus2026-01-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-concurrent-and-adjuvant-temozolomide2026-01-01daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-versus-chemotherapy-in-chinese-patients-with-nsclc-and2026-01-01daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-1b-2-trial-of-first-line-tiragolumab2026-01-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-iberdomide-plus-low-dose2026-01-02daily0.9 https://clinresonc-new.lhten.com/cross-sectional-analysis-of-adherence-to-healthy-dietary-patterns-and2026-01-02daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-three-year-outcomes-of-neoadjuvant2026-01-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-toripalimab-versus2026-01-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-erubulin-for-metastatic-angiosarcoma2026-01-03daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1-2-trial-of-autologous-multiantigen-targeted-t2026-01-03daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-first-line-sintilimab-plus2026-01-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nivolumab-with-definitive2026-01-04daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-analysis-of-survival-impact-of-acid2026-01-04daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-efficacy-and-safety-of-teclistamab-in-triple-class2026-01-05daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-analysis-of-circulating-tumor-dna-to-inform2026-01-05daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-neoadjuvant-chemoradiotherapy-with-surgery-versus2026-01-05daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-racial-and-ethnic-disparaties-in2026-01-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-trial-of-letrozole-with-or-without-megestrol-for2026-01-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-axicabtagene-ciloleucel-plus-rituximab2026-01-06daily0.9 https://clinresonc-new.lhten.com/deep-learning-derived-sarcopenia-marker-predicts-benefit-from-anti2026-01-06daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-the-global-clinical-trial-landscape-for2026-01-06daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-palbociclib-trastuzumab-and-endocrine-therapy-for2026-01-07daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-induction-chemoimmunotherapy-followed-by-concurrent2026-01-07daily0.9 https://clinresonc-new.lhten.com/randomized-clinical-trial-of-music-therapy-versus-cognitive2026-01-07daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-association-of-risk-reducing2026-01-07daily0.9 https://clinresonc-new.lhten.com/cilta-cel-in-lenalidomide-refractory-multiple-myeloma-updated2026-01-08daily0.9 https://clinresonc-new.lhten.com/soluble-madcam-1-as-a-biomarker-in-metastatic-renal-cell-carcinoma2026-01-08daily0.9 https://clinresonc-new.lhten.com/association-of-use-of-sodium-glucose-cotransporter-2-inhibitors-with2026-01-08daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-the-association-of-clonal-hematopoiesis-with2026-01-08daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-blinatumomab-for-infants-with-kmt2a2026-01-09daily0.9 https://clinresonc-new.lhten.com/upfront-modified-folfoxiri-plus-panitumumab-for-ras-braf-wild-type2026-01-09daily0.9 https://clinresonc-new.lhten.com/single-center-phase-3-trial-of-pegylated-liposomal-doxorubicin-for2026-01-09daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-perioperative-tislelizumab-plus2026-01-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-outcomes-among-patients-with-colon2026-01-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-stereotactic-body-radiation-therapy-plus2026-01-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-suvemcitug-plus-chemotherapy-for2026-01-10daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-simultaneous-focal-boost-with-stereotactic2026-01-11daily0.9 https://clinresonc-new.lhten.com/three-year-follow-up-of-nivolumab-avd-versus-brentuximab-vedotin-avd2026-01-11daily0.9 https://clinresonc-new.lhten.com/three-versus-six-months-of-adjuvant-oxaliplatin-fluoropyrimidime2026-01-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-tucatinib-plus-trastuzumab-for-22026-01-12daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-mortality-prediction-by-sarcopenia2026-01-12daily0.9 https://clinresonc-new.lhten.com/pooled-post-hoc-analysis-of-two-phase-2-trials-of-durvalumab-based2026-01-12daily0.9 https://clinresonc-new.lhten.com/quantitative-counseling-after-genetic-testing-in-breast-cancer-the2026-01-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-linavonkibart-and-pembrolizumab-in2026-01-13daily0.9 https://clinresonc-new.lhten.com/prognostic-model-for-predicting-long-term-risk-for-prostate-cancer2026-01-13daily0.9 https://clinresonc-new.lhten.com/serum-cytokines-predict-response-and-survival-in-esophageal-squamous2026-01-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-savolitinib-plus-osimertinib-versus2026-01-14daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-the-association-of-genetic-predisposition-to-excess2026-01-14daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-first-line-osimertinib-with2026-01-14daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-atezolizumab-with-or-without-tiragolumab2026-01-14daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-lymph-node-dissection-guideline-adherence2026-01-15daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-incidentally-detected-splenomegaly-and2026-01-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ctdna-guided-immunotherapy-following2026-01-15daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-cohort-study-of-adverse-events-after2026-01-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pembrolizumab-plus-lenvatinib-for2026-01-16daily0.9 https://clinresonc-new.lhten.com/improved-survival-with-delayed-surgery-at-high-volume-centers-versus2026-01-16daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-air-pollution-and-cardiac-remodeling-and2026-01-16daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-erdafitinib-with-or-without-cetrelimab2026-01-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-abemaciclib-in-meningiomas-with-somatic2026-01-17daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-docetaxel-rechallenge2026-01-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-study-of-pembrolizumab-olaparib-for-advanced2026-01-17daily0.9 https://clinresonc-new.lhten.com/real-world-study-of-clinical-impact-of-egfr-mutation-subtypes-on2026-01-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-cabozantinib-plus-temozolomide-for2026-01-18daily0.9 https://clinresonc-new.lhten.com/presurgical-window-of-opportunity-study-of-pharmacodynamics-of2026-01-18daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-effects-of-preoperative2026-01-18daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-toripalimab-plus-concurrent2026-01-19daily0.9 https://clinresonc-new.lhten.com/comparison-of-mri-and-endoscopy-for-detection-of-nasopharyngeal2026-01-19daily0.9 https://clinresonc-new.lhten.com/european-cancer-mortality-predictions-for-the-year-20262026-01-19daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-outcomes-with-durvalumab2026-01-19daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-inter-rater-reliabiliby-of-ctcae2026-01-20daily0.9 https://clinresonc-new.lhten.com/motor-development-in-toddlers-prenatally-exposed-to-maternal-cancer2026-01-20daily0.9 https://clinresonc-new.lhten.com/five-year-absolute-risk-based-and-age-based-breast-cancer-screening2026-01-20daily0.9 https://clinresonc-new.lhten.com/toripalimab-plus-chemotherapy-for-advanced-esophageal-squamous-cell2026-01-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-gemcitabine-plus-selinexor-in-selected2026-01-21daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-crizotinib-for-tumors-with-met-amplification-or2026-01-21daily0.9 https://clinresonc-new.lhten.com/decision-analytical-model-of-esophagectomy-versus-active-surveillance2026-01-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-sacituzumab-govitecan-plus2026-01-22daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-long-term-use-of-proton-pump2026-01-22daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-iparomlimab-and-tuvonralimab-with2026-01-22daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-prognostic-value-of-circulating-tumor-dna-in2026-01-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-pembrolizumab-and-paclitaxel-in-hr-her22026-01-23daily0.9 https://clinresonc-new.lhten.com/cost-effectiveness-of-proton-therapy-compared-with-photon-therapy-for2026-01-23daily0.9 https://clinresonc-new.lhten.com/incidence-of-breast-implant-associated-anaplastic-large-cell-lymphoma2026-01-23daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-glucose-6-phosphate-dehydrogenase-deficiency-in2026-01-23daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-prospective-trials-of-robotic2026-01-24daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-addition-of-carboplatin-to-neoadjuvant-taxane2026-01-24daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-threshold-dose-response-association-between-alcohol2026-01-24daily0.9 https://clinresonc-new.lhten.com/event-free-survival-and-complete-response-rate-as-surrogate-endpoints2026-01-25daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-cohort-study-of-real-world-effectiveness2026-01-25daily0.9 https://clinresonc-new.lhten.com/association-of-alcohol-intake-over-the-lifetime-with-colorectal2026-01-26daily0.9 https://clinresonc-new.lhten.com/real-world-occurrence-of-severe-gastrointestinal-bleeding-in-patients2026-01-26daily0.9 https://clinresonc-new.lhten.com/multicenter-real-world-study-of-effectiveness-and-safety-of-pegylated2026-01-26daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-oxybutynin-versus-placebo-for-hot-flashes-in2026-01-27daily0.9 https://clinresonc-new.lhten.com/ctdna-dynamics-and-recurrence-patterns-after-organ-sparing2026-01-27daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-phase-1-and-phase-2-trials-of-izalontamab2026-01-27daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-the-association-of-medicaid-expansion2026-01-27daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-dalpiciclib-plus-cetuximab-for-hpv-negative-anti-pd2026-01-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-olaparib-and-irinotecan-for2026-01-28daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-simultaneous-resection-in2026-01-28daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-incidence-trends-of-cutaneous-squamous-cell2026-01-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-addition-of-palbociclib-to-first-line2026-01-29daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-ipilimumab-plus-nivolumab-in-melanoma-five-year-outcomes2026-01-29daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-efficacy-and-safety-of-ultra-low-dose-immunotherapy2026-01-29daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-olaparib-monotherapy-for-patients-with-metastatic2026-01-29daily0.9 https://clinresonc-new.lhten.com/thromboembolic-events-during-perioperative-therapy-for-resectable-and2026-01-30daily0.9 https://clinresonc-new.lhten.com/five-year-outcome-of-camrelizumab-plus-chemotherapy-for-recurrent-or2026-01-30daily0.9 https://clinresonc-new.lhten.com/community-based-cohort-study-of-association-of-low-dose-aspirin-with2026-01-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-intratumoral-radioenhancer2026-01-30daily0.9 https://clinresonc-new.lhten.com/colorectal-cancer-screening-among-individuals-with-intellectual2026-01-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-pd-1-blockade-in-surgically2026-01-31daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-circulating-tumor-dna-in-a-phase-3-trial-of2026-01-31daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-neoadjuvant-modified-folfirinox-plus-nivolumab-for2026-02-01daily0.9 https://clinresonc-new.lhten.com/neurocognitive-impairment-and-financial-hardship-in-adult-survivors2026-02-01daily0.9 https://clinresonc-new.lhten.com/modelled-impact-of-a-multi-cancer-early-detection-screening-program2026-02-01daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-leukocyte-telomere-length2026-02-02daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-risk-of-interstitial-lung2026-02-02daily0.9 https://clinresonc-new.lhten.com/opportunistic-salpingectomy-for-prevention-of-tubo-ovarian-carcinoma2026-02-02daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-biomarkers-of-20-year-prostate-cancer-risk-in-men2026-02-02daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-3-trial-of-impact-of-time-of-day-of2026-02-03daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-addition-of-metastasis2026-02-03daily0.9 https://clinresonc-new.lhten.com/evaluation-of-progression-free-status-at-24-months-as-surrogate2026-02-03daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-subsequent-primary-cancer-risks-among2026-02-03daily0.9 https://clinresonc-new.lhten.com/global-and-regional-cancer-burden-attributable-to-modifiable-risk2026-02-04daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-associations-between-reproductive-factors-and-ovarian2026-02-04daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-early-recurrence-and-prognosis2026-02-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-varnimcabtagene-autoleucel-for-relapsed2026-02-04daily0.9 https://clinresonc-new.lhten.com/cross-sectional-population-based-study-of-testing-menstrual-blood-for2026-02-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-repotrectinib-in-ntrk-fusion2026-02-05daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-survival-outcomes-with-or-without-risk2026-02-05daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-resminostat-versus-placebo2026-02-05daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-survival-of-patients-diagnosed-with-cancer2026-02-06daily0.9 https://clinresonc-new.lhten.com/trends-in-the-hidden-burden-of-cancer-in-an-autopsy-based-study-over2026-02-06daily0.9 https://clinresonc-new.lhten.com/ten-year-outcomes-of-a-multicenter-phase-3-noninferiority-trial-of2026-02-06daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-impact-of-immunotherapy-on-incidence-of2026-02-06daily0.9 https://clinresonc-new.lhten.com/target-trial-emulation-study-of-transarterial-chemoembolization-with2026-02-07daily0.9 https://clinresonc-new.lhten.com/population-based-cross-sectional-study-of-women-s-preferences-for2026-02-07daily0.9 https://clinresonc-new.lhten.com/overestimation-of-multiple-myeloma-survival-from-cancer-registry-data2026-02-07daily0.9 https://clinresonc-new.lhten.com/meta-epidemiological-study-of-control-arm-overperformance-in-phase-32026-02-08daily0.9 https://clinresonc-new.lhten.com/individual-patient-data-meta-analysis-of-correlation-of-biochemical2026-02-08daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-amrubicin-plus-cisplating-and-concurrent-accelerated2026-02-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-apatinib-plus-docetaxel-and-s2026-02-09daily0.9 https://clinresonc-new.lhten.com/the-association-between-pre-existing-type-2-diabetes-and-mortality2026-02-09daily0.9 https://clinresonc-new.lhten.com/population-based-retrospective-cohort-study-of-stage-at-diagnosis-and2026-02-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-outcomes-with-influenza-vaccination2026-02-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-r2-gemox-pd1i-in-relapsed-or-refractory2026-02-10daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-prevalence-of-her2-low2026-02-10daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-endometrial-cancer-risk-with-progestins2026-02-10daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-loboplatin-versus-cisplatin-added-to-fluorouracil2026-02-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-pembrolizumab-plus-lenvatinib2026-02-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-standard-chemoradiotheray-with2026-02-11daily0.9 https://clinresonc-new.lhten.com/danish-cohort-study-of-severe-toxicity-free-survival-following-acute2026-02-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-pivekimab-sunirine-in-blastic2026-02-12daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-chemotherapy-for-advanced-gastroesophageal-22026-02-12daily0.9 https://clinresonc-new.lhten.com/phase-2a-trial-of-tunlametinib-in-adults-with-inoperable2026-02-12daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-cohort-study-of-salvage-focal-therapy2026-02-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-lisocabtagene-maraleucel-for-relapsed2026-02-13daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2b-study-of-intismeran-autogene-plus-pembrolizumab2026-02-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-nintedanib-plus-nivolumab-in2026-02-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-nivolumab-ipilimumab-for-62026-02-13daily0.9 https://clinresonc-new.lhten.com/prognostic-role-of-early-ctdna-dynamics-in-advanced-melanoma-patients2026-02-14daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-ceralasertib-in-patients-with-arid1a2026-02-14daily0.9 https://clinresonc-new.lhten.com/association-of-medicaid-expansion-with-diagnosis-treatment-and2026-02-14daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-pancreatic-cystic-neoplasm-risk-among-individuals2026-02-14daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-long-term-outcomes-with-first-line-bortezomib2026-02-15daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-sodium-glucose-cotransporter-22026-02-15daily0.9 https://clinresonc-new.lhten.com/validation-of-the-2025-ims-imwg-risk-classification-in-patient2026-02-16daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-short-term-global-health-score-decline-after-lung2026-02-16daily0.9 https://clinresonc-new.lhten.com/cost-effectiveness-of-mepitel-film-for-prevention-of-acute-radiation2026-02-16daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-effectiveness-of-electronic-health-record2026-02-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-mri-based-personlisation-of-neoadjuvant2026-02-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-load703-induced-tumor-microenvironment2026-02-17daily0.9 https://clinresonc-new.lhten.com/noninferiority-randomized-trial-of-hypofractionated-split-course2026-02-17daily0.9 https://clinresonc-new.lhten.com/risk-of-developing-subsequent-cutaneous-malignant-neoplasms-with2026-02-17daily0.9 https://clinresonc-new.lhten.com/multinational-first-in-human-phase-1-study-of-volrustomig-for2026-02-18daily0.9 https://clinresonc-new.lhten.com/population-based-analysis-of-ten-year-outcomes-with-guideline2026-02-18daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-anlotinib-plus-chemotherapy-for2026-02-18daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-coronary-plaque-progression-after2026-02-18daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-enfortumab-vedotin-and2026-02-19daily0.9 https://clinresonc-new.lhten.com/first-line-cabozantanib-plus-nivolumab-and-ipilimumab-for-advanced2026-02-19daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-nivolumab-ipilimumab-chemotherapy2026-02-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-stereotactic-radiation-versus2026-02-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-overall-survival-with-first-line-versus2026-02-20daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-capox-versus-chemoradiation-for-locally-advanced-rectal2026-02-20daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-immunotherapy-prescribing-patterns-and2026-02-20daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-survival-impact-of-prior2026-02-20daily0.9 https://clinresonc-new.lhten.com/adjunctive-ultrasonography-and-cumulative-incidence-of-advanced2026-02-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-3-trial-of-axitinib-and-long-acting-octreotide2026-02-21daily0.9 https://clinresonc-new.lhten.com/erythrocyte-anti-pd1-conjugates-for-advanced-solid-tumors-resistant2026-02-21daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-bronchoscopic-pulsed-electric2026-02-22daily0.9 https://clinresonc-new.lhten.com/impact-of-trimester-of-diagnosis-on-tumor-characteristics-and2026-02-22daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-nab-paclitaxel-plus-pd-1-inhibitor-for2026-02-22daily0.9 https://clinresonc-new.lhten.com/optimal-duration-of-adjuvant-targeted-immunotherapy-after-successful2026-02-23daily0.9 https://clinresonc-new.lhten.com/identifying-patients-with-high-risk-stage-i-nsclc-using-tumor2026-02-23daily0.9 https://clinresonc-new.lhten.com/a-reversible-non-covalent-bruton-s-tyrosine-kinase-epi-inhibitor-for2026-02-23daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-or-colorectal-or-pancreatic2026-02-24daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-maintenance-parp-inhibitor-rechallenge-plus2026-02-24daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-real-world-outcomes-of-pembrolizumab2026-02-24daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-real-world-outcomes-with2026-02-24daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-transarterial2026-02-25daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-ipilimumab-versus-chemotherapy-for2026-02-25daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-trifluridine-tipiracil-with-and-without2026-02-25daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-club-cell-secretory-protein-serum-concentration2026-02-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-the-p53-reactivator-rezatapopt-for-tp532026-02-26daily0.9 https://clinresonc-new.lhten.com/post-hoc-pooled-analysis-of-five-prospective-trials-of-stereotactic2026-02-26daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-analysis-of-neoadjuvant-radiotherapy-for2026-02-26daily0.9 https://clinresonc-new.lhten.com/nationwide-registry-based-study-of-temporal-trends-in-opioid-use2026-02-26daily0.9 https://clinresonc-new.lhten.com/individual-patient-data-meta-analysis-of-hormone-therapy-use-and2026-02-27daily0.9 https://clinresonc-new.lhten.com/first-line-tislelizumab-plus-chemotherapy-for-recurrent-or-metastatic2026-02-27daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-adjuvant-imatinib-versus-observation-after2026-02-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-amivantamab-for-recurrent-or-metastatic2026-02-27daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-sacituzumab-govitecan-plus-pembrolizumab2026-02-28daily0.9 https://clinresonc-new.lhten.com/case-control-study-of-erythropoiesis-stimulating-agents-and2026-02-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-ipilimumab-and-nivolumab-followed-by2026-02-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-a-small-molecule-inverse-agonist-of-ppar2026-03-01daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-risk-of-breast-cancer-after-ovarian-cancer-in2026-03-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-osimertinib-plus-dapopotamab-deruxtecan2026-03-02daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-early-stage-lung-cancer-treatment2026-03-02daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-use-of-complementary-and-alternative-medicine-in-the2026-03-02daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-adding-ipilimumab-and-nivolumab-to2026-03-03daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-pembrolizumab-in-sorafenib-treated-and-treatment2026-03-03daily0.9 https://clinresonc-new.lhten.com/systematic-analysis-of-global-regional-and-national-burden-of-breast2026-03-03daily0.9 https://clinresonc-new.lhten.com/england-wide-case-control-study-of-the-association-of-recurrent2026-03-03daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-nivolumab-with-or-without-22026-03-04daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-real-world-outcomes-with2026-03-04daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-locally-ablative-therapies-in2026-03-04daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-preventing-hand2026-03-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-trial-of-neoadjuvant-golp-for-resectable-high2026-03-05daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-adebrelimab-with-bevacizumab-and-cisplatin-or2026-03-05daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-clinical-and-pathological-factors-in2026-03-05daily0.9 https://clinresonc-new.lhten.com/phase-1b-study-of-izalontamab-brengitecan-for-la-m-nsclc-with-genomic2026-03-05daily0.9 https://clinresonc-new.lhten.com/outcomes-of-older-adults-with-advanced-cancer-who-prefer-quality-of2026-03-06daily0.9 https://clinresonc-new.lhten.com/multinational-placebo-controlled-phase-3-trial-of-pimicotinib-for2026-03-06daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-survival-benefit-from-sentinel2026-03-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1a-b-trial-of-hs-20093-a-b7-h3-targeted-antibody2026-03-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-hypofractionated-locoregional2026-03-07daily0.9 https://clinresonc-new.lhten.com/bellmunt-risk-score-as-prognostic-tool-in-metastatic-castration2026-03-07daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-association-of-antibiotic2026-03-07daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-tolerability-and-efficacy-of-chemosaturation2026-03-08daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-venetoclax-or-pirtobrutinib-in-relapsed-or2026-03-08daily0.9 https://clinresonc-new.lhten.com/nationwide-retrospective-study-of-association-of-autoimmune-diseases2026-03-08daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-of-immunotherapy-rechallenge-in-extensive-stage2026-03-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-outcomes-and-safety-of-chemotherapy2026-03-09daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-prevalence-and-size-based-risk2026-03-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-gedatolisib-plus-fulvestrant-with-or2026-03-10daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-prognostic-significance-of-pretreatment-kras2026-03-10daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-anlotinib-plus-toripalimab-maintenance-therapy-in2026-03-10daily0.9 https://clinresonc-new.lhten.com/role-of-adiposity-and-lipid-biomarkers-in-postmenopausal-breast2026-03-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-benmelstobart-plus-anlotinib-22026-03-11daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-tumor-targeted-il-12-with-hepatic-artery-infusion2026-03-11daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-ultrasensitive-circulating-tumor-dna2026-03-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-risk-adaptive-therapy-guided-by-dynamic2026-03-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-romiplostim-versus-placebo-for2026-03-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-carfilzomib-lenalidomide-dexamethasone2026-03-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-camrelizumab-plus-capox-with2026-03-12daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-cancer-risk-in-solid-organ-transplant-recipients-with2026-03-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-pembrolizumab-with-or2026-03-13daily0.9 https://clinresonc-new.lhten.com/preliminary-safety-and-efficacy-of-tarlatamab-in-previously-treated2026-03-13daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-efficacy-and-safety-of-neoadjuvant2026-03-13daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-one-versus-three-fractions-of2026-03-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-of-oral-paclitaxel-versus-intravenous-weekly2026-03-14daily0.9 https://clinresonc-new.lhten.com/residual-absolute-volume-of-blastema-as-a-predictor-of-clinical2026-03-14daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-effect-of-reminder-phone-calls-in-language-of2026-03-14daily0.9 https://clinresonc-new.lhten.com/phase-3-compassion-16-trial-of-first-line-cadonilimab-plus2026-03-15daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-pooled-analysis-of-single-arm-studies-of-carbon2026-03-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-pyrotinib-plus-trastuzumab-and-docetaxel2026-03-16daily0.9 https://clinresonc-new.lhten.com/multinational-case-control-study-of-the-association-of-metformin-use2026-03-16daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-tumor-debulking-with-chemotherapy-in2026-03-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-first-line-zolbetuximab-plus-mfolfox62026-03-17daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-durvalumab-and-cediranib-with-or-without-olaparib-in2026-03-17daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-new-prognostic-molecular-markers2026-03-17daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-timing-of-detection-of-liver-metastases2026-03-17daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-phase-3-studies-of-first-line2026-03-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-association-of-intratumoral-microbiota-with2026-03-18daily0.9 https://clinresonc-new.lhten.com/association-between-circulating-levels-of-mirnas-and-pancreatic2026-03-18daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-prognostic-stratification-of2026-03-18daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-tucatinib-trastuzumab-capecitabine-for2026-03-19daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-aspirin-for-prevention-of2026-03-19daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-cemiplimab-for-locally-advanced2026-03-19daily0.9 https://clinresonc-new.lhten.com/association-of-circulating-t-cell-and-tumor-microenvironment-profiles2026-03-19daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-colorectal-cancer-risk-with-negative2026-03-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-bireociclib-plus-fulvestrant-in-advanced2026-03-20daily0.9 https://clinresonc-new.lhten.com/multicenter-observational-cohort-study-of-second-line-chemotherapy2026-03-20daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-sglt2-inhibitors-in2026-03-20daily0.9 https://clinresonc-new.lhten.com/individual-patient-data-meta-analysis-of-randomized-trials-of2026-03-21daily0.9 https://clinresonc-new.lhten.com/real-world-clinical-utility-of-tumor-whole-genome-sequencing2026-03-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-savolitinib-plus-durvalumab-for2026-03-21daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-fullerene-versus-trolamine-for-reducing2026-03-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-late-functional-patient-reported-disease2026-03-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-trial-of-datopotamab-deruxtecan-plus2026-03-22daily0.9 https://clinresonc-new.lhten.com/individual-participant-data-meta-analysis-of-studies-of-the2026-03-23daily0.9 https://clinresonc-new.lhten.com/two-center-real-world-retrospective-study-of-impact-of-g-csf-on2026-03-23daily0.9 https://clinresonc-new.lhten.com/cross-sectional-survey-of-knowledge-attitudes-and-behaviors-toward2026-03-23daily0.9 https://clinresonc-new.lhten.com/multinational-cohort-study-of-dynamic-risk-stratification-of2026-03-24daily0.9 https://clinresonc-new.lhten.com/final-results-of-a-multicenter-confirmatory-phase-3b-study-of2026-03-24daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-early-phase-studies-of-zanidatamab-for2026-03-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-etrumadenant-based-therapy-versus2026-03-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-nivolumab-plus-folfoxiri-and2026-03-25daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-urothelial-carcinoma-diagnostic-performance-of2026-03-25daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-conversion-surgery-after-induction-therapy-for2026-03-25daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-oncological-risk-of2026-03-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-atezolizumab-plus-mfolfox6-for-stage-iii2026-03-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-transdermal-estradiol-patches-in-locally2026-03-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-setidegrasib-in-advanced-non-small2026-03-26daily0.9 https://clinresonc-new.lhten.com/socioeconomic-disparities-in-treatment-and-survival-of-esophageal-and2026-03-26daily0.9 https://clinresonc-new.lhten.com/development-and-validation-of-a-risk-stratification-model-for2026-03-27daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-mirvetuximab-soravtansine-plus-pembrolizumab-in2026-03-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-pralsetinib-for-advanced-ret-fusion2026-03-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-irinotecan-cisplatin-versus-etoposide2026-03-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-gotistobart-versus-docetaxel-for2026-03-28daily0.9 https://clinresonc-new.lhten.com/systematic-analysis-of-locoregional-delivery-of-car-t-cells-in-high2026-03-28daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-tislelizumab-plus-anlotinib-as-first-line-treatment2026-03-28daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-frontline-zanubrutinib-rituximab-followed-by2026-03-29daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-perioperative-circulating-tumor-dna-levels2026-03-29daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-adjuvant-immunotherapy-after-neoadjuvant2026-03-29daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-survival-impact-of-idh2-and-tp53-mutations-in2026-03-30daily0.9 https://clinresonc-new.lhten.com/association-of-neighborhood-socioeconomic-status-with-risk-of-lung2026-03-30daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-atra-plus-arsenic-trioxide2026-03-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-telisotuzumab-adizutecan-a-novel-c-met2026-03-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-the-anti-sirp-antibody-lm-101-for2026-03-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-dhp107-oral-paclitaxel-versus2026-03-31daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-adjuvant-capecitabine-in-women-with-tnbc-and2026-03-31daily0.9 https://clinresonc-new.lhten.com/assocation-of-significant-incidental-findings-in-the-national-lung2026-04-01daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-chemotherapy-with-or-without2026-04-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-robot-assisted-versus-conventional2026-04-01daily0.9 https://clinresonc-new.lhten.com/nationwide-population-based-cohort-study-of-risk-of-skin-cancer-among2026-04-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-trial-of-first-line-fulzerasib-plus2026-04-02daily0.9 https://clinresonc-new.lhten.com/dose-escalation-results-from-a-phase-1-2-trial-of-ifinatamab2026-04-02daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-study-of-177lu-psma-617-versus-standard-of-care2026-04-03daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-determinants-of-circulating-tumor-hpv2026-04-03daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-pretreatment-mri-as-a2026-04-03daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-surgical-outcomes-after-risk-reducing-mastectomy2026-04-04daily0.9 https://clinresonc-new.lhten.com/multicenter-real-world-study-of-adjuvant-therapy-after-pathologic2026-04-04daily0.9 https://clinresonc-new.lhten.com/systematic-analysis-of-global-burden-of-cancer-in-children-and2026-04-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-datopotamab-deruxtecan-for-untreated2026-04-05daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-study-of-neoadjuvant-tyrosine-kinase-plus2026-04-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-single-arm-meta-analysis-of-her2-targeted2026-04-05daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-single-nucleotide-polymorfisms-in-pdcd1-impact2026-04-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-atezolizumab-plus-chemotherapy-with-or2026-04-06daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-adjuvant-chemotherapy-outcomes-in-older2026-04-06daily0.9 https://clinresonc-new.lhten.com/longitudinal-patterns-of-symptoms-in-patients-undergoing-chemotherapy2026-04-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-isatuximab-carfilzomib-lenalidomide2026-04-07daily0.9 https://clinresonc-new.lhten.com/phase-1-2-trial-of-il15-activated-cytokine-induced-killer-cells-after2026-04-07daily0.9 https://clinresonc-new.lhten.com/japanese-population-based-study-of-increasing-incidence-and-changing2026-04-07daily0.9 https://clinresonc-new.lhten.com/trends-and-disparities-in-the-use-of-next-generation-sequencing-in2026-04-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-tobemstomig-a-pd1-lag3-bispecific2026-04-08daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-outcomes-of-immunotherapy-in-medulloblastoma2026-04-08daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-multimodal-assessment-of-biological-age2026-04-08daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-hormone-therapy-and-breast2026-04-08daily0.9 https://clinresonc-new.lhten.com/retrospective-comparison-of-belzutifan-versus-natural-history-control2026-04-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-atezolizumab-plus-obinutuzumab-and-pet2026-04-09daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-subsequent-treatments-and2026-04-09daily0.9 https://clinresonc-new.lhten.com/implementation-of-enhanced-recovery-after-surgery-in-crs-plus-hipec2026-04-09daily0.9 https://clinresonc-new.lhten.com/pain-and-health-related-quality-of-life-outcomes-with-darolutamide-in2026-04-10daily0.9 https://clinresonc-new.lhten.com/bespoke-ctdna-testing-for-diagnosis-surveillance-and-treatment2026-04-10daily0.9 https://clinresonc-new.lhten.com/multicenter-analysis-of-prognostic-factors-for-efficacy-and-safety-of2026-04-10daily0.9 https://clinresonc-new.lhten.com/performance-of-three-breast-cancer-risk-assessment-tools-in-us-black2026-04-10daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-pembrolizumab-plus-weekly-paclitaxel2026-04-11daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-relacorilant-plus-nab-paclitaxel-for-22026-04-11daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-the-association-of-residential-radon2026-04-11daily0.9 https://clinresonc-new.lhten.com/prospective-observational-study-to-develop-and-validate-a-risk2026-04-11daily0.9 https://clinresonc-new.lhten.com/real-world-results-with-parp-inhibitor-use-for-her2-negative-advanced2026-04-12daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-tislelizumab-with-induction2026-04-12daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-neoadjuvant-twelve-week-paclitaxel-carboplatin2026-04-12daily0.9 https://clinresonc-new.lhten.com/age-at-first-pregnancy-adult-weight-gain-and-postmenopausal-breast2026-04-13daily0.9 https://clinresonc-new.lhten.com/allogeneic-cd19-car-t-with-anti-rejection-cd70-car-to-overcome2026-04-13daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-between-tailored-exercise-strategies-and2026-04-13daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-lung-cancer-diagnosis-rates-in-early2026-04-13daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-study-of-real-world-outcomes-with-radiation2026-04-14daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-cardiovascular-adverse-events2026-04-14daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-geriatric-covariates-on-metronomic2026-04-14daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-barriers-to-health-care-with-cancer2026-04-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-perioperative-pembrolizumab-in-dmmr-msi2026-04-15daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-elraglusib-and-chemotherapy2026-04-15daily0.9 https://clinresonc-new.lhten.com/pik3ca-mutations-predict-her2-targeted-therapy-resistance-in-primary2026-04-15daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-bayesian-network-meta-analysis-of-first-line2026-04-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1a-1b-trial-of-first-line-zongertinib-in-advanced2026-04-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-trabectedin-and-low-dose-irinotecan-in2026-04-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-dual-ctla-4-and-pd-1-blockade-in-rare2026-04-16daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-chemotherapy-with-or-without-anlotinib2026-04-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-lenalidomide-plus-rituximab-for-r-r2026-04-17daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-early-fdg-pet-for-estimating-outcomes2026-04-17daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-prognostic-value-of-baseline-inflammatory2026-04-17daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-oral-serds-in-hr-positive-her22026-04-17daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-datopotamab-deruxtecan-in-advanced-non2026-04-18daily0.9 https://clinresonc-new.lhten.com/american-college-of-physicians-guidance-statement-on-breast-cancer2026-04-18daily0.9 https://clinresonc-new.lhten.com/provider-level-facilitators-and-barriers-towards-neoadjuvant2026-04-18daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-prospective-studies-of-the-association-of-body2026-04-18daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-atezolizumab-for-alveolar-soft-part-sarcoma-long2026-04-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-a-rituximab-methotrexate-and-thiotepa-based2026-04-19daily0.9 https://clinresonc-new.lhten.com/awake-salvage-resection-for-local-recurrence-or-radiation-necrosis2026-04-19daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-gemcitabine-plus-nivolumab-with-carboplatin-or2026-04-20daily0.9 https://clinresonc-new.lhten.com/updated-phase-1-results-of-zoldonrasib-for-kras-g12d-mutant-non-small2026-04-20daily0.9 https://clinresonc-new.lhten.com/review-of-bio-magnetic-nanomedicine-for-targeted-drug-delivery-in2026-04-20daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-financial-hardship-end-of-life-health-care-use-and2026-04-20daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-sigvotagug-vedotin-for-advanced-non2026-04-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-durvalumab-plus-chemotherapy-22026-04-21daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-ciltcabtagene-autoleucel-in-high-risk-smoldering2026-04-21daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-bright-ideas-ya-skills-training-and-psychosocial2026-04-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-io102-io103-immune-modulatory-cancer2026-04-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-taletrectinib-for-ros1-non-small-cell2026-04-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-study-of-aminvantamab-in-chemorefractory-ras2026-04-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-tucidinostat-to-first-line-r2026-04-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-duvelisib-for-peripheral-t-cell2026-04-23daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-hepatic-arterial-infusion-of-oxaliplatin2026-04-23daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-allogeneic-hematopoietic-cell-transplantation-in2026-04-23daily0.9 https://clinresonc-new.lhten.com/national-cancer-database-analysis-of-radiation-treatment-patterns-for2026-04-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-jyp0322-for-non-small-cell-lung-cancer2026-04-24daily0.9 https://clinresonc-new.lhten.com/real-world-retrospective-study-of-tarlatamab-for-relapsed-extensive2026-04-24daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-deintensified-chemoradiotherapy-for-hpv-associated2026-04-24daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-incidence-and-survival-of-early-onset2026-04-24daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-efficacy-and-safety-of-177lu-psma-617-for2026-04-25daily0.9 https://clinresonc-new.lhten.com/predicting-radiation-induced-esophagitis-in-locally-advanced-nsclc2026-04-25daily0.9 https://clinresonc-new.lhten.com/tumor-specific-expansion-cohorts-of-a-first-in-human-phase-1-trial-of2026-04-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-nivolumab-plus-ipilimumab-in-advanced2026-04-25daily0.9 https://clinresonc-new.lhten.com/impact-of-guideline-concordance-on-survival-in-non-small-cell-lung2026-04-26daily0.9 https://clinresonc-new.lhten.com/acute-myeloid-leukemia-after-myeloproliferative-neoplasms-recent-real2026-04-26daily0.9 https://clinresonc-new.lhten.com/real-world-cohort-study-of-clinical-molecular-and-immunologic2026-04-26daily0.9 https://clinresonc-new.lhten.com/review-on-targeting-mek-in-cancer-and-beyond2026-04-26daily0.9 https://clinresonc-new.lhten.com/anti-cd19-car-t-cell-therapy-for-relapsed-or-refractory-mantle-cell2026-04-27daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-first-line-pd1-inhibitors-for2026-04-27daily0.9 https://clinresonc-new.lhten.com/imlunestrant-with-or-without-abemaciclib-in-advanced-breast-cancer2026-04-27daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-risk-of-cancer-in-patients-with-first-time-seizure2026-04-27daily0.9 https://clinresonc-new.lhten.com/single-center-phase-1b-trial-of-ipatasertib-plus-endocrine-therapy2026-04-28daily0.9 https://clinresonc-new.lhten.com/ipd-meta-analysis-of-phase-3-trials-of-endocrine-therapy-with-or2026-04-28daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-from-five-randomized-trial-of-lymph-node-surgery-and2026-04-28daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-olaparib-plus-pembrolizumab-for-recurrent-copy2026-04-28daily0.9 https://clinresonc-new.lhten.com/next-generation-ai-model-for-visually-occult-pancreatic-cancer2026-04-29daily0.9 https://clinresonc-new.lhten.com/two-center-phase-2-trial-of-one-or-two-preoperative-cycles-of2026-04-29daily0.9 https://clinresonc-new.lhten.com/chemotherapy-declination-among-patients-with-early-stage-hr-positive2026-04-29daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-the-association-of-mental-health2026-04-29daily0.9 https://clinresonc-new.lhten.com/safety-and-efficacy-of-intravenous-nivolumab-with-either-intratumoral2026-04-30daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-histotripsy-for2026-04-30daily0.9 https://clinresonc-new.lhten.com/cross-sectional-analysis-of-neurocognitive-impairment-and-substance2026-04-30daily0.9 https://clinresonc-new.lhten.com/real-world-study-of-vebreltinib-plus-egfr-tki-for-egfr-mutated-nsclc2026-04-30daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-local-salvage-therapy-alone2026-05-01daily0.9 https://clinresonc-new.lhten.com/long-term-outcomes-with-maintenance-rucaparib-for-brca-of-palb22026-05-01daily0.9 https://clinresonc-new.lhten.com/seer-database-analysis-of-trends-in-long-term-survival-among-patients2026-05-01daily0.9 https://clinresonc-new.lhten.com/randomized-placebo-controlled-trial-of-b-cell-depletion-for2026-05-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-pirtobrutinib-for-relapsed-or2026-05-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-nilotinib-with-or-without2026-05-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-telisotuzumab-adizutecan-for-late-line2026-05-02daily0.9 https://clinresonc-new.lhten.com/patient-level-meta-analysis-of-effects-of-ovarian-ablation-or2026-05-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-very-early-fdg-pet-guided-targeted2026-05-03daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-impact-of-daytime-light2026-05-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-ramucirumab-plus-erlotinib2026-05-04daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-psychological-distress-trajectories-and2026-05-04daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-long-term-effects-of-colonoscopy2026-05-05daily0.9 https://clinresonc-new.lhten.com/multinational-cohort-study-of-survival-impact-of-extended-endocrine2026-05-05daily0.9 https://clinresonc-new.lhten.com/real-world-study-of-treatment-patterns-and-outcomes-in-patients-with2026-05-05daily0.9 https://clinresonc-new.lhten.com/retrospective-target-trial-emulation-of-efficacy-of-renin-angiotensin2026-05-05daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-retifanlimab-plus2026-05-06daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-impact-of-time-of-day2026-05-06daily0.9 https://clinresonc-new.lhten.com/perioperative-toripalimab-plus-chemotherapy-versus-chemotherapy-alone2026-05-06daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-neoadjuvant-single-cycle-pembrolizumab-for-stage2026-05-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-daraxonrasib-in-previously-treated2026-05-07daily0.9 https://clinresonc-new.lhten.com/multinational-study-to-identify-prognostic-risk-factors-in-adult2026-05-07daily0.9 https://clinresonc-new.lhten.com/emulated-target-trial-of-osimertinib-versus-second-gnerations-egfr2026-05-07daily0.9 https://clinresonc-new.lhten.com/exploratory-phase-2-trial-of-risk-adapted-therapy-guided-by-hpv-ctdna2026-05-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-radium-223-with-or-without-olaparib-for2026-05-08daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-rates-of-systemic-treatment-for-metastatic2026-05-08daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-tumor-infiltrating-clonal-hematopoiesis2026-05-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-penpulimab-and-gemcitabine-with-or2026-05-08daily0.9 https://clinresonc-new.lhten.com/preclinical-study-of-cd84-as-specific-target-for-acute-myeloid2026-05-09daily0.9 https://clinresonc-new.lhten.com/expansion-cohort-of-a-multicenter-phase-1-1b-trial-of-first-line2026-05-09daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-axitinib-plus-avelumab-for-recurrent-metastatic2026-05-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-nivolumab-plus-ipilimumab-for2026-05-09daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-anti-pd-1-plus-nab-paclitaxel-and-bevacizumab-as2026-05-10daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-curative-intent-metastasectomy-in-colorectal2026-05-10daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-risk-factors-and-metastatic-sites-in-her22026-05-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-tinengotinib-as-monotherapy-or2026-05-11daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-comparative-real-world-effectiveness-of2026-05-11daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-testosterone-replacement-therapy-in2026-05-11daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-and-recurrence-with-glp-12026-05-11daily0.9 https://clinresonc-new.lhten.com/twenty-three-year-follow-up-of-a-randomized-trial-of-sigmoidoscopy2026-05-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-concurrent-versus-sequential-dose2026-05-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-tobemstomig-for-immune-checkpoint2026-05-12daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-time-trends-in-incidence-and-survival-of-individuals2026-05-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-adjuvant-personalized-multivalent2026-05-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-crispr-cas9-cd33-deleted-allohct-with2026-05-13daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-docetaxel-plus-ramucirumab-after-immunotherapy-in2026-05-13daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-rural-urban-disparities-in-hepatocellular-carcinoma2026-05-13daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-camrelizumab-plus-apatinib-for-refractory-chordoma2026-05-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-trial-of-maveropepimut-s-pembrolizumab-and2026-05-14daily0.9 https://clinresonc-new.lhten.com/emulated-randomized-trial-of-morning-versus-afternoon-administration2026-05-14daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-nimotuzumab-with-concurrent-curative-radiotherapy2026-05-14daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-mri-guided-adaptive-radiotherapy-for2026-05-15daily0.9 https://clinresonc-new.lhten.com/surveillance-study-of-temporal-trends-in-lung-cancer-cases-diagnosed2026-05-15daily0.9 https://clinresonc-new.lhten.com/prospective-population-based-cohort-study-of-age-dependent-interplay2026-05-15daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-second-line-strategies-for-extensive2026-05-15daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-overall-survival-with-external-beam-radiotherapy2026-05-16daily0.9 https://clinresonc-new.lhten.com/first-in-human-phase-1-trial-of-the-her2-biparatopic-antibody-drug2026-05-16daily0.9 https://clinresonc-new.lhten.com/prolonged-follow-up-of-a-phase-3-superiority-trial-of-addition-of2026-05-16daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-sbrt-plus-atezolizumab-and-tiragolumab2026-05-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-long-term-outcomes-with-reduced-dose2026-05-17daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-addition-of-nivolumab-to2026-05-17daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-perioperative-pembrolizumab-plus-lenvatinib-for2026-05-17daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-metastases-directed-treatment-in2026-05-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-bone-sparing-chemoradiotherapy-for-anal2026-05-18daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-a-phase-2-trial-of-reduced-dose-radiotherapy2026-05-18daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-trastuzumab-pertuzumab-plus-endocrine-versus-chemotherapy2026-05-19daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-durvalumab-plus-haic-folfox-and-durvalumab2026-05-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-alk-inhibitors-in-patients-with-nonlung2026-05-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-trial-of-repotrectinib-plus-osimertinib-for-egfr2026-05-19daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-tebentafusp-for-metastatic-uveal-22026-05-20daily0.9 https://clinresonc-new.lhten.com/longitudinal-transcriptomic-profiling-identifies-predictors-of2026-05-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-trametinib-for-pediatric-patients-with2026-05-20daily0.9 https://clinresonc-new.lhten.com/first-line-datopotamab-deruxtecan-plus-durvalumab-for-unresectable2026-05-20daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-impact-of-multimodal-prehabilitation-on2026-05-21daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-pancreatic-cancer-risk-in2026-05-21daily0.9 https://clinresonc-new.lhten.com/nonrandomized-phase-2-trial-of-pembrolizumab-with-or-without2026-05-21daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-the-association-of-meat-consumption-with-risk-of2026-05-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adding-intraperitoneal-paclitaxel-to2026-05-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-radiotherapy-versus-observation2026-05-22daily0.9 https://clinresonc-new.lhten.com/peripheral-measurable-residual-multiple-myeloma-disease-activity2026-05-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-camrelizumab-plus-famitinib-for2026-05-22daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-survival-impact-of-systemic2026-05-23daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-pandemic-related-disruptions-in2026-05-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-autologous-t-cell-antigen-coupler2026-05-23daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-moderately-hypofractionated-prostate-boost-with2026-05-24daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-comparative-fall-risk-of2026-05-24daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-efficacy-and-safety-of2026-05-24daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-addition-of-anlotinib-to-durvalumab2026-05-25daily0.9 https://clinresonc-new.lhten.com/development-of-a-clinical-prediction-model-for-interstitial-lung2026-05-25daily0.9 https://clinresonc-new.lhten.com/study-cohort-characteristics-and-design-of-the-wisdom-trial-comparing2026-05-25daily0.9 https://clinresonc-new.lhten.com/britsh-society-of-breast-radiology-annual-scientific-meeting-abstracts2026-05-25daily0.9 https://clinresonc-new.lhten.com/run-in-phase-trial-of-gemcitabine-plus-nab-paclitaxel-with-or-without2026-05-26daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-real-world-first-line-treatment-patterns-and2026-05-26daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-studies-of-psychosocial-interventions-for2026-05-26daily0.9 https://clinresonc-new.lhten.com/multicenter-study-comparing-prognostic-markers-in-primary-pulmonary2026-05-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-neoadjuvant-ddmvac-plus-durvalumab-with2026-05-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-camrelizumab-plus-apatinib-in-advanced2026-05-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-rogaratinib-for-succinate-dehydrogenase2026-05-27daily0.9 https://clinresonc-new.lhten.com/randomized-study-of-every-six-month-versus-single-dose-adjuvant2026-05-27daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-zanidatamab-with-and2026-05-28daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-capecitabine-in-advanced-cutaneous-squamous-cell2026-05-28daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-observation-for-low-risk-and-radiotherapy-for2026-05-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-spartalizumab-plus-low-dose-pazopanib2026-05-28daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-trial-of-interrupting-breast-cancer2026-05-29daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-longitudinal-risk-for-suicidal-self-directed-violence2026-05-29daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-sintilimab-plus-chemotherapy-in-egfr2026-05-29daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-intrathecal-allogeneic-b7-h3-targeted-car-t-cells2026-05-29daily0.9 https://clinresonc-new.lhten.com/teclistamab-in-multiple-myeloma-with-one-to-three-previous-lines-of2026-05-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-sunvozertinib-in-nsclc-with2026-05-30daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-concomitant-use-of-pcsk9-inhibitors-versus-statins2026-05-30daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-financial-hardship-and-nonadherence-to2026-05-30daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-cancer-diagnostic-delay-rates-associated2026-05-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-parp-and-androgen-signaling-inhibition2026-05-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-sacituzumab-tirumotecan-to2026-05-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-selpercatinib-in-early-stage-ret2026-06-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-apalutamide-in-high-risk2026-06-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-daraxonrasib-or-chemotherapy-in2026-06-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-neoadjuvant-sacituzumab-govitecan-for2026-06-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-study-of-amivantamab-in-recurrent-metastatic2026-06-01daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-fovinaciclib-as-first-line-therapy-for2026-06-02daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-antibody-drug2026-06-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-pemigatinib-for2026-06-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2b-trial-of-addition-of-intismeran-autogene-to2026-06-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-selinexor-plus-ruxolitinib-for-jak2026-06-03daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-the-association-of-statin-use-with2026-06-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-lu-177-dotatate-versus-sunitinib-for2026-06-03daily0.9 https://clinresonc-new.lhten.com/real-world-analysis-of-impact-of-trastuzumab-on-survival-outcomes-of2026-06-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-all-oral-treatment-for-acute-myeloid2026-06-04daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-duke-pancreatic-monocolonal2026-06-04daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-incidence-and-survival-of-gastro-entero2026-06-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-izalontamab-brengitecan-for-unresectable2026-06-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-serplulimab-in-extensive2026-06-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-phase-3-rcts-of-first-line2026-06-05daily0.9 https://clinresonc-new.lhten.com/retrospective-population-based-study-of-treatment-delays-in-early-age2026-06-05daily0.9 https://clinresonc-new.lhten.com/phase-1-study-of-guanylyl-cyclase-2c-targeted-car-t-cell-therapy-in2026-06-05daily0.9 https://clinresonc-new.lhten.com/multimodal-artificial-intelligence-prediction-of-abiraterone-efficacy2026-06-06daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-the-prognostic-impact-of-common-molecular2026-06-06daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-biopsy-alone-versus-laser-interstitial-thermal2026-06-06daily0.9 https://clinresonc-new.lhten.com/osimertinib-after-definitive-crt-in-unresectable-stage-iii-egfr2026-06-06daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-salivary-cytokines-as-biomarkers-for2026-06-07daily0.9 https://clinresonc-new.lhten.com/hypertension-use-of-antihypertensive-medication-and-breast-cancer2026-06-07daily0.9 https://clinresonc-new.lhten.com/platinum-pemetrexed-following-first-line-nivolumab-and-ipilimumab-in2026-06-07daily0.9 https://clinresonc-new.lhten.com/target-trial-emulation-of-the-association-of-glp-1-receptor-agonist2026-06-08daily0.9 https://clinresonc-new.lhten.com/comparative-performance-of-shape-sensing-robotic-assisted2026-06-08daily0.9 https://clinresonc-new.lhten.com/high-throughput-geocoding-to-assess-association-of-short-term-air2026-06-08daily0.9 https://clinresonc-new.lhten.com/migration-associated-variation-in-gastric-cancer-risk-in-the-united2026-06-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-post-adjuvant-chemotherapy-in-ctdna2026-06-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1b-2-trial-of-first-line-durvalumab-plus-t-dxd2026-06-09daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-intravenous-vcn-01-oncolytic-adenovirus-and2026-06-09daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-survival-outcomes-and-molecular-predictors-in2026-06-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-chemoradiotherapy-to2026-06-10daily0.9 https://clinresonc-new.lhten.com/first-line-sacituzumab-govitecan-plus-pembrolizumab-and-carboplatin2026-06-10daily0.9 https://clinresonc-new.lhten.com/breast-cancer-patient-perspectives-on-approval-speed-versus2026-06-10daily0.9 https://clinresonc-new.lhten.com/transcriptome-based-prediction-model-for-treatment-free-remission-in2026-06-10daily0.9 https://clinresonc-new.lhten.com/phase-1-2-study-of-the-all-oral-combination-of-revumenib-decitabine2026-06-11daily0.9 https://clinresonc-new.lhten.com/impact-of-population-skin-cancer-screening-on-melanoma-mortality-rates2026-06-11daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-prospective-studies-of-artificially-sweetened-and2026-06-11daily0.9 https://clinresonc-new.lhten.com/prospective-analysis-of-association-of-depression-with-risk-of2026-06-11daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-high-dose-methotrexate-as-cns-prophylaxis-in-ultra2026-06-12daily0.9 https://clinresonc-new.lhten.com/target-trial-emulation-of-second-generation-versus-first-generation2026-06-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-first-line-avelumab-plus-methotrexate2026-06-12daily0.9 https://clinresonc-new.lhten.com/surgical-removal-of-residual-tumor-masses-in-patients-undergoing2026-06-12daily0.9 https://clinresonc-new.lhten.com/meta-analysis-of-treatment-related-adverse-events-of-cd3-based-t-cell2026-06-13daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-cardiometabolic-health-on-chemo2026-06-13daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-long-term-outcomes-of-adjuvant-proton2026-06-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-cadonilimab-plus-chemotherapy2026-06-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-talquetamab-daratumumab-in-relapsed-or2026-06-14daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-prognostic-significance-of-lymphovascular-and2026-06-14daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-diagnostic-utility-of-liquid-biopsy-in-pediatric2026-06-14daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adding-mezigdomide-to-carfilzomib-and2026-06-15daily0.9 https://clinresonc-new.lhten.com/real-world-burden-of-cardiovascular-events-after-immune-checkpoint2026-06-15daily0.9 https://clinresonc-new.lhten.com/cemiplimab-plus-chemotherapy-versus-chemotherapy-for-advanced-nsclc-52026-06-15daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-risk-of-new-vestibulopathy-after-semicircular2026-06-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-liposomal-mitoxantrone-plus2026-06-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-chemoradiotherapy-versus2026-06-16daily0.9 https://clinresonc-new.lhten.com/real-world-time-trends-of-survival-after-post-transplant-relapse-of2026-06-16daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-utility-of-recurrence-based2026-06-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-aumolertinib-with-or-without2026-06-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-mrna-2752-with-or-without-durvalumab2026-06-17daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-study-of-the-mek1-2-inhibitor-luvometinib-in2026-06-17daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-adding-cyclophosphamide-to2026-06-17daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-spatial-distribution-of-the-proteome-in-the2026-06-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-ivonescimab-to-chemotherapy2026-06-18daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-becotatug-vedotin-for-recurrent-or2026-06-18daily0.9 https://clinresonc-new.lhten.com/population-based-analysis-of-cervical-cancer-mortality-trends2026-06-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-single-fraction-stereotactic-body2026-06-19daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-second-primary-malignant2026-06-19daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-pembrolizumab-plus-quad-shot2026-06-19daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-durvalumab-plus-etoposide-platinum-for-egfr-mutated2026-06-19daily0.9 https://clinresonc-new.lhten.com/multinational-first-in-human-study-of-lomvastomig-for-advanced-or2026-06-20daily0.9 https://clinresonc-new.lhten.com/individual-participant-data-meta-analyses-of-associations-of2026-06-20daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-selinexor-combined-with-azacitidine2026-06-20daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-radium-223-with-or-without-olaparib-for-22026-06-20daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-sacituzumab-govitecan-with-or-without2026-06-21daily0.9 https://clinresonc-new.lhten.com/multicenter-observational-study-of-sex-disparities-in-lung-cancer2026-06-21daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-impact-of-neurofibromatosis-1-on-cancer2026-06-21daily0.9 https://clinresonc-new.lhten.com/prospective-analysis-of-the-association-of-dietary-inflammatory-index2026-06-22daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-demographic-birth-and-parental2026-06-22daily0.9 https://clinresonc-new.lhten.com/analysis-of-tumor-informed-ctdna-for-prediction-of-nodal-metastases2026-06-22daily0.9 https://clinresonc-new.lhten.com/target-trial-emulation-of-benefits-and-harms-of-immediate-versus2026-06-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-later-line-trifluridine-tipiracil-plus2026-06-23daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-investigational-clinical-trial-agents-versus2026-06-23daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-ctdna-based-mrd-detection-in-stage2026-06-23daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-reporting-of-rurality-deprivation-and2026-06-24daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-liposomal-irinotecan-plus-fluoruracil-and2026-06-24daily0.9 https://clinresonc-new.lhten.com/french-nationwide-population-based-study-of-comparative-atrial2026-06-24daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-pd-l-1-blockade-in-nsclc-without-actionable2026-06-24daily0.9 https://clinresonc-new.lhten.com/ten-year-outcomes-after-tisagenlecleucel-t-cell-therapy-for-relapsed2026-06-25daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-nonoperative-management-of-locally-advanced2026-06-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-aumolertinib-as-switch-therapy-in2026-06-25daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-long-term-outcomes-and-late-effects-of2026-06-25daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-neoadjuvant-sbrt-with-durvalumab-and2026-06-26daily0.9 https://clinresonc-new.lhten.com/multinational-study-of-donor-selection-and-hla-loss-leukemia-relapse2026-06-26daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-long-term-outcomes-in-patients2026-06-26daily0.9 https://clinresonc-new.lhten.com/neoadjuvant-paclitaxel-trastuzumab-and-pertuzumab-for-stage-ii-iii2026-06-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-disitamab-vedotin2026-06-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-trial-of-adjuvant-crt-with-3-weekly-cisplatin2026-06-27daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-adjuvant-chemotherapy-after-pelvic-exenteration2026-06-27daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-serum-ca19-9-for-detecting2026-06-27daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-vibecotamab-for-measurable-residual-disease-in-aml2026-06-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-effect-of-neoadjuvant-therapy-on-post2026-06-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-weight-loss-on-adverse-events-during2026-06-28daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-prevalence-and-characteristics-of-ntrk-fusions2026-06-29daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-prognostic-impact-of-proliferative2026-06-29daily0.9 https://clinresonc-new.lhten.com/multicenter-preclinical-study-identifies-akt-as-a-novel-therapeutic2026-06-29daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-treatment-patters-and2026-06-29daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-addition-of-sbrt-to2026-06-30daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-analysis-of-ultra-processed-food-consumption-and2026-06-30daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-graft-versus-host-disease2026-06-30daily0.9 https://clinresonc-new.lhten.com/retrospective-cross-sectional-study-of-differences-in-cascade-genetic2026-06-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-adjuvant-metronomic-capecitabine-in2026-07-01daily0.9 https://clinresonc-new.lhten.com/tailoring-radiotherapy-in-ct1-2n1-breast-cancer-to-nodal-response-on2026-07-01daily0.9 https://clinresonc-new.lhten.com/phase-2-study-of-camrelizumab-plus-apatinib-and-radiotherapy-in2026-07-01daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-prognostic-relevance-of-kras-mutant-ctdna2026-07-01daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-pembrolizumab-plus-belzutifan2026-07-02daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-first-line-enfortumab-vedotin-plus2026-07-02daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-addition-of-celecoxib-to2026-07-02daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-zenocutuzumab-for-advanced-nrg1-fusion2026-07-02daily0.9 https://clinresonc-new.lhten.com/years-of-life-lost-in-patients-with-a-false-negative-diagnosis-of2026-07-03daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-cardiac-risk-after-heart-sparing2026-07-03daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-equity-and-cancer-survival2026-07-03daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-circulating-methylated-sept9-for-detection-of2026-07-03daily0.9 https://clinresonc-new.lhten.com/impact-of-proton-pump-inhibitors-or-antibiotics-on-immunotherapy2026-07-04daily0.9 https://clinresonc-new.lhten.com/circulating-tumor-dna-status-and-adjuvant-chemotherapy-after2026-07-04daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-real-world-results-with2026-07-04daily0.9 https://clinresonc-new.lhten.com/phase-1b-trial-of-personalized-neoantigen-pulsed-autologous-dendritic2026-07-05daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-prognostic-relevance-of-preoperative2026-07-05daily0.9 https://clinresonc-new.lhten.com/systematic-review-of-studies-of-body-image-following-ostomy-surgery2026-07-05daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-practices-of-pancreatic-neck-margin-testing2026-07-06daily0.9 https://clinresonc-new.lhten.com/oncologic-safety-of-preoperative-controlled-ovarian-stimulation-for2026-07-06daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-germline-mutations2026-07-06daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-psa-screening-patterns-and-metastatic2026-07-06daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-polatuzumab-vedotin-plus-rituximab2026-07-07daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-presenting-features-and-outcomes-to-standard2026-07-07daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-feasibility-and-safety-of-ifosfamide2026-07-07daily0.9 https://clinresonc-new.lhten.com/comparative-efficacy-of-car-t-cell-therapy-versus-historical2026-07-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-expansion-cohort-of-first-line2026-07-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-oral-b440-vaccine-in-patients-with2026-07-08daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-trial-of-patient-centered-approach-to2026-07-08daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-incidence-and-predictors-of-hemorrhage-in2026-07-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-study-of-ensartinib-after-resection-of-alk2026-07-09daily0.9 https://clinresonc-new.lhten.com/single-center-prospective-study-of-lung-transplant-for-refractory2026-07-09daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-ctdna-versus-merkel-virus-antibody-for2026-07-09daily0.9 https://clinresonc-new.lhten.com/worldwide-population-based-age-standardized-five-year-breast-cancer2026-07-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adding-pirtobrutinib-to-fixed-duration2026-07-10daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-consolidative-thoracic-radiotherapy-with2026-07-10daily0.9 https://clinresonc-new.lhten.com/durvalumab-plus-chemotherapy-for-advanced-biliary-tract-cancer-post2026-07-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-hrs-4642-plus-chemotherapy-for2026-07-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-relatlimab-with-or-without-nivolumab-for2026-07-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-single-early-intravesical-instillation2026-07-11daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-adjuvant-penpulimab-in-very-high-risk2026-07-11daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-everolimus-effectiveness-after2026-07-11daily0.9 https://clinresonc-new.lhten.com/pembrolizumab-with-or-without-chemotherapy-in-hnscc-pd-l1-cps2026-07-12daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-real-world-cancer-associated-arterial2026-07-12daily0.9 https://clinresonc-new.lhten.com/review-of-interstitial-lung-disease-in-patients-treated-with-antibody2026-07-12daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-trends-in-the-use-of-palliative-therapy2026-07-13daily0.9 https://clinresonc-new.lhten.com/case-series-of-outcomes-with-tamilogene-laherparepvec-in-pretreated2026-07-13daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-the-association-of-medically-assisted-reproduction2026-07-13daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-quality-cost-and-timeliness-of-cancer2026-07-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-avatrombopag-versus-placebo-for2026-07-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-low-dose-chidamide-maintenance-following2026-07-14daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-avutometinib-abemaciclib-and-fulvestrant-for-hr-her22026-07-14daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-study-of-lomvastomib-versus2026-07-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-allogeneic-cd70-targeted-car-t-cell2026-07-15daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-bevacizumab-use-and-platinum-choice-in2026-07-15daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-colorectal-cancer-treatment-delay-thresholds-and2026-07-15daily0.9 https://clinresonc-new.lhten.com/rituximab-maintenance-added-to-ibrutinib-containing-therapy-in2026-07-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-fixed-duration-versus-continuous2026-07-16daily0.9 https://clinresonc-new.lhten.com/multinational-cohort-study-of-flot-versus-cross-among-patients-with2026-07-16daily0.9 https://clinresonc-new.lhten.com/population-based-cross-sectional-study-of-area-based-marginalization2026-07-16daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-trial-of-englumasfusp-alfa-plus-glofitamab-in-b2026-07-16daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-durvalumab-with-radiation-therapy-for-inoperable-la2026-07-17daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-pfs-in-metastatic-breast2026-07-17daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-novel-immunotherapy-agents-in-early2026-07-17daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-abiraterone-or-enzalutamide-for2026-07-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-atezolizumab-bevacizumab-and-platinum2026-07-18daily0.9 https://clinresonc-new.lhten.com/comparison-of-obecabtagene-autoleucel-versus-an-external-control-arm2026-07-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-prognostic-significance-of-hyperglycemia-in2026-07-18daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-overall-survival-impact-of-timing-of-ici2026-07-19daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-nivolumab-ipilimumab-versus2026-07-19daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-comparative-efficacy-of-taletrectrinib-versus2026-07-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-real-world-outcomes-with-neoadjuvant2026-07-20daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-incidence-risk-factors-and-tumor-spectrum-of2026-07-20daily0.9 https://clinresonc-new.lhten.com/retrospective-study-comparing-imaging-modalities-for-axillary2026-07-20daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-local-treatment-for-oligo-recurrence-of2026-07-20daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-mismatched-unrelated-versus-matched2026-07-21daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-digital-mental-health-treatment-for-symptoms-of2026-07-21daily0.9 https://clinresonc-new.lhten.com/phase-2-feasibility-study-of-pembrolizumab-plus-metformin-in-patients2026-07-21daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-incidence-and-characteristics-of2026-07-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-dalpiciclib-plus-endocrine-therapy-in2026-07-22daily0.9 https://clinresonc-new.lhten.com/retrospective-population-based-study-of-racial-differences-in2026-07-22daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-long-term-outcomes-of-frameless-stereotactic2026-07-22daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-domvanalimab-plus-zimberelimab-in-unresectable-and2026-07-22daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-enfortumab-vedotin-plus2026-07-23daily0.9 https://clinresonc-new.lhten.com/propensity-matched-cohort-study-of-comparative-risk-of-cardiovascular2026-07-23daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-neoadjuvant-chemotherapy-plus2026-07-23daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-the-association-of-drinking-water-contaminant2026-07-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-hypo-versus-standard-fractionated2026-07-24daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-ultralow-dose-il-10-expressing-car-t-cells-in2026-07-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-the-multikinase-inhibitor2026-07-24daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-gender-diverse-patients-with-breast-cancer2026-07-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-izalontamab-brengitecan-in-extensive2026-07-25daily0.9 https://clinresonc-new.lhten.com/cross-sectional-ecological-study-of-global-burden-of-pediatric2026-07-25daily0.9 https://clinresonc-new.lhten.com/ovarian-reserve-as-a-measure-of-adjuvant-chemotherapy-benefit-in-hr2026-07-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-intraoperative-molecular-imaging-with2026-07-26daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-efficacy-and-safety-of2026-07-26daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-romiplostim-for-chemotherapy-induced2026-07-26daily0.9 https://clinresonc-new.lhten.com/single-center-prospective-trial-of-effects-of-hippocampal-avoidance2026-07-27daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-cohort-study-of-neoadjuvant-treatment-for2026-07-27daily0.9 https://clinresonc-new.lhten.com/active-surveillance-versus-standard-surgery-and-cost-effectiveness2026-07-27daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-active-surveillance-outcomes-after-template2026-07-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-scrt-based-total-neoadjuvant-therapy2026-07-28daily0.9 https://clinresonc-new.lhten.com/predictive-relevance-of-ai-quantified-tumor-cell-density-in-larc2026-07-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-intravesical-cretostimogene2026-07-28daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-metabolic-optimization-and-risk-of2026-07-28daily0.9 https://clinresonc-new.lhten.com/target-trial-emulation-of-impact-of-sglt2-inhibitors-of-distant2026-07-29daily0.9 https://clinresonc-new.lhten.com/five-year-quality-of-life-results-from-a-phase-3-trial-of2026-07-29daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-divergent-tumor-microenvironment-and-response-of2026-07-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-triapine-plus-177lu-lutetium-dotatate2026-07-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-atezolizumab-with-or-without2026-07-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-dynamic-ctdna-methylation-monitoring2026-07-30daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-maximal-ablative-irradiation-for2026-07-30daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-cervical-cancer-screening-with-hpv-self2026-07-30daily0.9 https://clinresonc-new.lhten.com/two-center-phase-3-trial-of-transarterial-chemoembolization-plus2026-07-31daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-cemiplimab-and-fianlimab-with-neoadjuvant2026-07-31daily0.9 https://clinresonc-new.lhten.com/prostate-cancer-radiation-response-signature-predicts-radiation2026-07-31daily0.9 https://clinresonc-new.lhten.com/multinational-real-world-retrospective-study-of-neoadjuvant2026-07-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-study-of-first-line-acalabrutinib-plus-r-chop2026-08-01daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-rcts-of-the-impact-of-icis-on2026-08-01daily0.9 https://clinresonc-new.lhten.com/characteristics-and-long-term-outcomes-of-ewing-sarcoma-patients-in2026-08-01daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-hematopoietic-cell-transplantation-for2026-08-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-low-dose-ruxolitinib-for-graft-versus2026-08-02daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-age-associated-morbidity-after-major2026-08-03daily0.9 https://clinresonc-new.lhten.com/retrospective-case-control-study-of-iron-deficiency-among-daratumumab2026-08-03daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-surveillance-testing-and-pancreatic2026-08-03daily0.9 https://clinresonc-new.lhten.com/review-on-classic-hodgkin-lymphoma-published-in-jama2026-08-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-darolutamide-with-or-without-goserelin2026-08-04daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-multi-antigen-stimulated-cell-therapy-i-with-or2026-08-04daily0.9 https://clinresonc-new.lhten.com/single-center-retrospective-review-of-clinical-characteristics-and2026-08-04daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-stereotactic-radiosurgery-for2026-08-04daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-racial-differences-in-sonographic-evaluation-in2026-08-05daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-ontorpacept-plus-doxorubicin-for2026-08-05daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-clinical-significance-of-egfr-amplification-in2026-08-05daily0.9 https://clinresonc-new.lhten.com/association-of-patient-reported-stress-and-pain-with-survival-in2026-08-05daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-clinical-responses-to-tarlatamab-among2026-08-06daily0.9 https://clinresonc-new.lhten.com/retrospective-population-based-cohort-study-of-colorectal-cancer2026-08-06daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-locoregional-recurrence-and-mortality-after2026-08-06daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-the-association-of-nitrate-and2026-08-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-intracranial-delivery-of-b7-h3-targeting2026-08-07daily0.9 https://clinresonc-new.lhten.com/modeling-study-of-mathematical-biomarkers-of-adaptive-therapy2026-08-07daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-electronic-patient-reported-outcome2026-08-07daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-177lu-psma-617-for-psma-positive2026-08-07daily0.9 https://clinresonc-new.lhten.com/identification-of-predictive-biomarkers-for-chemoradiation-response2026-08-08daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-tumor-infiltrating-lymphocytes-as-predictor-of2026-08-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-rucaparib-and-nivolumab-maintenance2026-08-08daily0.9 https://clinresonc-new.lhten.com/pan-tumor-propensity-matched-analysis-of-association-of-sglt22026-08-09daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-real-world-prognostic-relevance-of2026-08-09daily0.9 https://clinresonc-new.lhten.com/appendiceal-adenocarcinoma-diagnosed-before-age-50-years-temporal2026-08-09daily0.9 https://clinresonc-new.lhten.com/tolerability-of-adjuvant-nivolumab-in-esophageal-or-gastroesophageal2026-08-10daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-osimertinib-with-or-without-chemotherapy2026-08-10daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-the-impact-of-disability-status-on-prostate2026-08-10daily0.9 https://clinresonc-new.lhten.com/retrospective-observational-cohort-study-of-residential-context-and2026-08-10daily0.9 https://clinresonc-new.lhten.com/first-line-nivolumab-plus-chemotherapy-or-ipilimumab-versus2026-08-11daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-association-between-various-psa-response2026-08-11daily0.9 https://clinresonc-new.lhten.com/multinational-diagnostic-accuracy-study-of-a-blood-based-test-for2026-08-11daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-fruit-and-vegetable-intake-in-relation-to2026-08-11daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-trastuzumab-rezetecan-in-advanced-salivary-gland2026-08-12daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-neoadjuvant-intralesional-daromun-in2026-08-12daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-consolidative-hypofractionated2026-08-12daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-impact-of-neoadjuvant-pd-1-inhibitors-on2026-08-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-ivonescimab-plus-chemotherapy2026-08-13daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-belzutifan-plus-lenvatinib-versus2026-08-13daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-national-trends-and-predictors-of2026-08-13daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-durvalumab-plus-tremelimumab-and-sbrt2026-08-13daily0.9 https://clinresonc-new.lhten.com/prognostic-analysis-of-tissue-free-versus-tumor-informed-ctdna-assays2026-08-14daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-pathologic-response-after-neoadjuvant2026-08-14daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-metabolic-dysfunction-after-initiation2026-08-14daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-hematopoietic-stem-cell-transplant-in2026-08-14daily0.9 https://clinresonc-new.lhten.com/mosunetuzumab-with-response-adapted-polatuzumab-vedotin-and2026-08-15daily0.9 https://clinresonc-new.lhten.com/temporal-trends-in-cancer-mortality-among-people-younger-than-502026-08-15daily0.9 https://clinresonc-new.lhten.com/population-based-case-control-study-of-body-mass-index-at-diagnosis2026-08-15daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-multimodal-treatment-for-nsclc2026-08-16daily0.9 https://clinresonc-new.lhten.com/outcomes-of-perioperative-chemotherapy-compared-to-preoperative2026-08-16daily0.9 https://clinresonc-new.lhten.com/development-and-validation-of-a-urine-based-dna-methylation-assay-for2026-08-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-induction-tpf-followed-by-ccrt-versus2026-08-17daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-studies-of-preoperative-sbrt2026-08-17daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-cancer-related-mortality-among-us-pilots-and2026-08-17daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-cancer-mortality-before-age-50-years-in2026-08-17daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-study-of-laser-interstitial-thermal-therapy2026-08-18daily0.9 https://clinresonc-new.lhten.com/eight-year-outcomes-of-testosterone-suppression-plus-enzalutamide-or2026-08-18daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-1-trial-of-adjuvant-viral-based2026-08-18daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-cohort-study-of-long-term-fatigue-after2026-08-18daily0.9 https://clinresonc-new.lhten.com/multicenter-first-in-human-phase-1-study-of-medi1191-plus-durvalumab2026-08-19daily0.9 https://clinresonc-new.lhten.com/circadian-genotypes-in-per3-and-time-of-prostate-cancer-radiotherapy2026-08-19daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-with-enfortumab-vedotin-with-or-without2026-08-19daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-darolutamide-with-concomitant2026-08-19daily0.9 https://clinresonc-new.lhten.com/nationwide-population-based-study-of-risk-of-urologic-cancers-in2026-08-20daily0.9 https://clinresonc-new.lhten.com/large-scale-ai-guided-liver-maligancy-diagnosis-multicenter-study-and2026-08-20daily0.9 https://clinresonc-new.lhten.com/nationwide-study-of-trends-in-meningioma-incidence-treatment-and2026-08-20daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-tert-promoter-variants2026-08-20daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-fecal-occult-blood-screening-outcomes2026-08-21daily0.9 https://clinresonc-new.lhten.com/comparative-study-of-federally-sponsored-and-industry-sponsored2026-08-21daily0.9 https://clinresonc-new.lhten.com/pathologic-complete-response-rate-and-predictors-of-response-to2026-08-21daily0.9 https://clinresonc-new.lhten.com/real-world-treatment-patterns-and-outcomes-with-induction2026-08-21daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-pembrolizumab-for-early-22026-08-22daily0.9 https://clinresonc-new.lhten.com/quality-improvement-study-of-a-telemedicine-supported-home-injection2026-08-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-motixafortide-cemiplimab-gemcitabine-and2026-08-22daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-liver-resection-versus-maintenance-therapy-after2026-08-23daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-zanidatamab-in-patients-with-early-stage-her22026-08-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-first-line-pyrotinib-plus-apatinib-in2026-08-23daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-3-trial-of-chemoradiotherapy-versus2026-08-24daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-sclc-transformation-in-egfr-mutant2026-08-24daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-olaparib-for-germline-brca1-22026-08-25daily0.9 https://clinresonc-new.lhten.com/daratumamab-lenalidomide-and-dexamethasone-in-transplant-ineligible2026-08-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2b-trial-of-sutetinib-for-non-small-cell-lung2026-08-25daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-omitting-bone-marrow-sampling-in-fdg-avid2026-08-25daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-becotatug-vedotin-plus-pucotenlimab2026-08-26daily0.9 https://clinresonc-new.lhten.com/multicohort-analysis-of-impact-of-thymic-radiation-on-outcomes-of2026-08-26daily0.9 https://clinresonc-new.lhten.com/randomized-trial-of-induction-paclitaxel-cisplatin-capecitabine2026-08-26daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-salvage-hypofractionated-versus-standard2026-08-26daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-pembrolizumab-for-clear-cell2026-08-27daily0.9 https://clinresonc-new.lhten.com/population-based-cohort-study-of-treatment-patterns-and-outcomes2026-08-27daily0.9 https://clinresonc-new.lhten.com/two-center-retrospective-cohort-study-of-neoadjuvant-chemotherapy2026-08-27daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-cohort-study-of-surgical-management-of2026-08-27daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-trial-of-disitamab-vedotin-for-her2-positive2026-08-28daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-cancer-biologics-utilization-after2026-08-28daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-pemetrexed-and-pembrolizumab-for-recurrent-and-or2026-08-28daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-dose-escalation-and-cohort-expansion-study-of2026-08-28daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-durvalumab-for-22026-08-29daily0.9 https://clinresonc-new.lhten.com/matched-cohort-study-of-risks-of-adverse-respiratory-outcomes-in2026-08-29daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-weight-loss-responses-to-pharmacotherapy-in-breast2026-08-29daily0.9 https://clinresonc-new.lhten.com/burden-of-male-breast-cancer-in-europe-from-1990-to-2023-results-from2026-08-29daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-ivonescimab-plus-chemotherapy-for2026-08-30daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-clinical-trial-of-specialist-referral-for2026-08-30daily0.9 https://clinresonc-new.lhten.com/prospective-validation-of-a-urine-based-proteomics-test-for2026-08-30daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-of-cd19-car-t-cell-therapy-glpg5101-for2026-08-31daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-high-dose-radiotherapy-in-patients-with2026-08-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2b-trial-of-first-line-epcoritamab-with2026-08-31daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-adjuvant-alectinib-versus-chemotherapy2026-09-01daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-liposomal-irinotecan-plus-nimotuzumab-for-ici2026-09-01daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-anti-her2-antibody-drug-conjugate-shr2026-09-01daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-family-history-of-cancer-and-risks-of-concordant-and2026-09-01daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-everolimus-plus-letrozole-with-or-without2026-09-02daily0.9 https://clinresonc-new.lhten.com/nationwide-cohort-study-of-association-of-tibolone-use-with2026-09-02daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-neoadjuvant-immunochemotherapy-versus2026-09-02daily0.9 https://clinresonc-new.lhten.com/danish-nationwide-cohort-study-of-cancer-rarity-and-mortality2026-09-02daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-azacitidine-venetoclax-or2026-09-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-daraxonrasib-for-previously-treated2026-09-03daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-laterality-of-breast-radiotherapy-and2026-09-03daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-association-between-dietary-fat-intake-and2026-09-03daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-bicistronic-cd19-cd22-car-t-cell-therapy2026-09-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-neoadjuvant-anbenitamab-and-hb1801-in2026-09-04daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-regional-variation-in-bladder-cancer2026-09-04daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-first-line-tislelizumab-plus-22026-09-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-cadonilimab-plus-lenvatinib-for-advanced2026-09-05daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-candidate-surrogate-endpoints-for-overall-survival2026-09-05daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-genetic-testing-uptake-among-patients-with2026-09-05daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-molecularly-guided-therapy-versus2026-09-05daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-an-integrated-lifestyle-intervention2026-09-06daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-the-association-of-estimated-glucose2026-09-06daily0.9 https://clinresonc-new.lhten.com/dutch-population-based-study-of-treatment-free-interval-as2026-09-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-atezolizumab-induction-and-consolidation2026-09-07daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-real-world-outcomes-with-22026-09-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-triplet-chemotherapy-to2026-09-07daily0.9 https://clinresonc-new.lhten.com/multinational-cohort-study-of-artificial-intelligence-based2026-09-07daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-induction-and-extended-consolidation-with2026-09-08daily0.9 https://clinresonc-new.lhten.com/phase-1-2-trial-of-canakinumab-with-chemoradiation-and-durvalumab2026-09-08daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-cardiometabolic-health-and-risk-of-breast-cancer2026-09-08daily0.9 https://clinresonc-new.lhten.com/case-report-of-rapid-lorlatinib-response-in-lung-adenocarcinoma-with2026-09-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-camrelizumab-plus-nimotuzumab-as-second2026-09-09daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-of-nivolumab-plus-ipilimumab-for-unresectable2026-09-09daily0.9 https://clinresonc-new.lhten.com/survey-study-of-blinatumomab-care-delivery-for-pediatric-b-cell-acute2026-09-09daily0.9 https://clinresonc-new.lhten.com/real-world-outcomes-of-anthracycline-containing-versus-anthracycline2026-09-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-perioperative-durvalumab-plus-flot-for2026-09-10daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-evaluation-of-circulating-tumor-dna-testing2026-09-10daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-risk-of-relapse-and-efficacy-of2026-09-10daily0.9 https://clinresonc-new.lhten.com/personalized-ctdna-analysis-for-predicting-outcomes-and-tracking2026-09-10daily0.9 https://clinresonc-new.lhten.com/five-year-follow-up-of-pembrolizumab-plus-chemotherapy-for-cervical2026-09-11daily0.9 https://clinresonc-new.lhten.com/seer-medicare-data-analysis-of-patterns-of-health-care-spending-in2026-09-11daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-neutropenic-diet-versus2026-09-11daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-dual-inhibition-of-lag-3-and-pd-1-with-ibi110-and2026-09-11daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-teclistamab-versus-lenalidomide2026-09-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-study-of-iza-bren-in-patients-with-pretreated2026-09-12daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-seasonal-patterns-and-implications-of-cancer2026-09-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-trastuzumab-botidotin-versus-trastuzumab2026-09-12daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-tambotatug-pelitecan-in-small-cell-lung2026-09-13daily0.9 https://clinresonc-new.lhten.com/single-center-phase-2-trial-of-neoadjuvant-chemoimmunotherapy-with2026-09-13daily0.9 https://clinresonc-new.lhten.com/the-association-of-opioid-limiting-laws-with-opioid-prescriptions2026-09-13daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-trends-in-early-onset-cancer-incidence2026-09-14daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-trends-in-early-onset-cancer-incidence-22026-09-14daily0.9 https://clinresonc-new.lhten.com/patient-clinician-symptom-agreement-before-and-after-radiotherapy-for2026-09-14daily0.9 https://clinresonc-new.lhten.com/prospective-evaluation-of-three-fraction-sbrt-with-4d-transperineal2026-09-14daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-perceived-importance-of-good-death-inventory2026-09-14daily0.9 https://clinresonc-new.lhten.com/adjuvant-osimertinib-for-egfr-mutated-stage-ib-iiia-non-small-cell2026-09-15daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-research-trial-attrition-and-participant-informed2026-09-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-xmab-18968-for-relapsed-or-refractory2026-09-15daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-optimizing-timing-of-immune2026-09-15daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-gfh375-for-previously-treated-advanced2026-09-16daily0.9 https://clinresonc-new.lhten.com/nationwide-cohort-study-of-statin-initiation-and-mortality-after2026-09-16daily0.9 https://clinresonc-new.lhten.com/impact-of-covalent-btk-inhibitor-dose-modifications-on-outcomes-in2026-09-16daily0.9 https://clinresonc-new.lhten.com/phase-2-basket-trial-of-ado-trastuzumab-emtansine-for-patients-with2026-09-16daily0.9 https://clinresonc-new.lhten.com/randomized-noninferiority-trial-of-association-of-colononoscopy2026-09-17daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-trial-of-blinatumomab-versus-chemotherapy2026-09-17daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-topical-ruxolitinib-for-chronic-cutaneous2026-09-17daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-study-of-liquid-biopsy-for-early-detection2026-09-17daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-pds0101-with-pembrolizumab-for-hpv162026-09-18daily0.9 https://clinresonc-new.lhten.com/bayesian-meta-analysis-of-immunotherapy-for-head-and-neck-squamous2026-09-18daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-study-of-emb-01-for-heavily-pretreated2026-09-18daily0.9 https://clinresonc-new.lhten.com/long-term-survival-outcomes-with-perioperative-avelumab-and2026-09-18daily0.9 https://clinresonc-new.lhten.com/multinational-retrospective-study-of-addition-of-bcr-abl1-tki-to2026-09-19daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-outcomes-of-adult-patients-with-l-fraumeni2026-09-19daily0.9 https://clinresonc-new.lhten.com/uk-biobank-analysis-of-association-of-allostatic-load-and-symptom2026-09-19daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2a-study-of-avelumab-in-relapsed-or-refractory2026-09-19daily0.9 https://clinresonc-new.lhten.com/case-cohort-analysis-of-inflammatory-biomarkers-and-risk-of2026-09-20daily0.9 https://clinresonc-new.lhten.com/genomic-and-transcriptomic-landscape-of-spread-through-air-spaces-in2026-09-20daily0.9 https://clinresonc-new.lhten.com/multicenter-real-world-study-of-efficacy-and-safety-of-omitting-the2026-09-20daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-stereotactic-ablative2026-09-21daily0.9 https://clinresonc-new.lhten.com/translational-science-review-of-vaccines-of-cancer-published-in-jama2026-09-21daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-prospective-cohort-studies-of-associations-of2026-09-21daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-patient-level-evaluation-of-optimal-margin2026-09-22daily0.9 https://clinresonc-new.lhten.com/phase-1b-trial-of-botensilimab-plus-balstilimab-for-microsatellite2026-09-22daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-long-term-benefit-with-first-line2026-09-22daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-concomitant-use-of-proton-pump-inhibitors-among2026-09-22daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1b-2-trial-of-first-line-trastuzumab-plus-nivolumab2026-09-23daily0.9 https://clinresonc-new.lhten.com/multicenter-diagnostic-accuracy-study-of-urine-and-vaginal-cytology2026-09-23daily0.9 https://clinresonc-new.lhten.com/annual-report-to-the-nation-on-the-status-of-cancer-featuring-21st2026-09-23daily0.9 https://clinresonc-new.lhten.com/projected-cancer-burden-among-sexual-and-gender-minorities-by2026-09-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-study-of-anitocabtagene-autoleucel-for-refractory2026-09-24daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-projected-benefit-of-bilateral-salpingo2026-09-24daily0.9 https://clinresonc-new.lhten.com/multicenter-prospective-trial-of-feasibility-of-delaying-sentinel2026-09-24daily0.9 https://clinresonc-new.lhten.com/impact-of-lifestyle-and-chemotherapy-on-functional-aging-trajectories2026-09-24daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-first-line-retlirafusp-alfa-plus2026-09-25daily0.9 https://clinresonc-new.lhten.com/multicohort-study-of-disparities-in-cancer-incidence-by-sex-and2026-09-25daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-impact-of-breast-cancer-index-on2026-09-25daily0.9 https://clinresonc-new.lhten.com/multinational-randomized-phase-2-trial-of-evorpacept-plus-trastuzumab2026-09-25daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-dvrd-versus-vrd-for-ndmm-transplant2026-09-26daily0.9 https://clinresonc-new.lhten.com/randomized-phase-2-trial-of-microwave-ablation-versus-stereotactic2026-09-26daily0.9 https://clinresonc-new.lhten.com/randomized-placebo-controlled-trial-of-memantine-for-prevention-of2026-09-26daily0.9 https://clinresonc-new.lhten.com/longitudinal-quality-of-life-after-total-neoadjuvant-therapy-for2026-09-26daily0.9 https://clinresonc-new.lhten.com/retrospective-analysis-of-association-of-sleep-related-symptoms-with2026-09-27daily0.9 https://clinresonc-new.lhten.com/association-of-high-tumor-mutational-burden-with-brain-metastases2026-09-27daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-associations-of-concomitant-medications2026-09-27daily0.9 https://clinresonc-new.lhten.com/propensity-score-matched-pooled-analysis-of-four-phase-3-trials-of2026-09-28daily0.9 https://clinresonc-new.lhten.com/survival-impact-of-adjuvant-chemotherapy-in-pdac-patients-with2026-09-28daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-study-of-efficacy-and-safety-of-22026-09-28daily0.9 https://clinresonc-new.lhten.com/qualitative-study-of-perception-of-chemoprevention-among-women-at2026-09-28daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-response-adapted-postoperative-therapy-after2026-09-29daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-first-line-pembrolizumab-for-advanced2026-09-29daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-tile-based-radiotherapy-versus2026-09-29daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-cd19-car-t-versus-blinatumomab-for-relapsed-or2026-09-29daily0.9 https://clinresonc-new.lhten.com/population-based-matched-cohort-study-of-the-effect-of-pre-existing2026-09-30daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-pembrolizumab-versus-nivolumab-as-initial2026-09-30daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-association-of-sex-with-mortality-among-patients-with2026-09-30daily0.9 https://clinresonc-new.lhten.com/prospective-phase-2-study-of-neoadjuvant-mfolfoxiri-for-potentially2026-09-30daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-trial-of-giredestrant-plus-everolimus-in2026-10-01daily0.9 https://clinresonc-new.lhten.com/real-world-evidence-on-second-line-therapy-in-extensive-stage-small2026-10-01daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-hypofractionated-versus-conventional-fractionated2026-10-01daily0.9 https://clinresonc-new.lhten.com/population-based-study-of-effect-ot-statins-on-mortality-among-long2026-10-01daily0.9 https://clinresonc-new.lhten.com/updated-pooled-analysis-of-five-year-survival-with-neoadjuvant2026-10-02daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-matched-cohort-study-of-immune-checkpoint2026-10-02daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-study-of-nivolumab-plus-ipilimumab-with2026-10-02daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-association-between-medical-debt-and2026-10-02daily0.9 https://clinresonc-new.lhten.com/prognostic-value-of-hormone-receptor-expression-in-hr-her2-advanced2026-10-03daily0.9 https://clinresonc-new.lhten.com/multinational-phase-3-study-of-first-line-ibrutinib-venetoclax-in2026-10-03daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-toripalimab-consolidation2026-10-03daily0.9 https://clinresonc-new.lhten.com/real-world-study-of-lung-cytology-in-the-diagnostic-workflow-of-lung2026-10-04daily0.9 https://clinresonc-new.lhten.com/pooled-analysis-of-studies-of-pulmonary-nodules-in-breast-cancer2026-10-04daily0.9 https://clinresonc-new.lhten.com/prospective-cohort-study-of-circulating-27-hydroxycholesterol-sex2026-10-04daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-trial-of-sl-172154-in-patients-with-higher-risk2026-10-05daily0.9 https://clinresonc-new.lhten.com/phase-1-trial-of-a-ccl21-gene-modified-dendritic-cell-vaccine-plus2026-10-05daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-association-of-college-attendance-and2026-10-05daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-amivantamab-lazertinib-bevacizumab-for-egfr-mutant2026-10-06daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-association-of-specific-cutaneous-iraes2026-10-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-frontline-rvd-lite-in-transplant2026-10-06daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-surgical-characteristics-and-postoperative2026-10-06daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-sitagliptin-for-acute-graft-versus-host2026-10-07daily0.9 https://clinresonc-new.lhten.com/extended-follow-up-of-in-vivo-bcma-car-t-therapy-in-relapsed2026-10-07daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-physician-and-practice-level-variation-in-clinical2026-10-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-chemotherapy-free-neoadjuvant-22026-10-07daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-niraparib-monotherapy-for2026-10-08daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-3-trial-of-metastasis-directed-ablation-with2026-10-08daily0.9 https://clinresonc-new.lhten.com/cross-sectional-analysis-of-outcomes-of-american-indian-and-alaska2026-10-08daily0.9 https://clinresonc-new.lhten.com/multinational-prospective-cohort-study-of-prognostic-value-of-clipi2026-10-08daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-disitamab-vedotin-plus-tislelizumab-in2026-10-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-study-of-olaparib-plus-tremelimumab-in-women2026-10-09daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-study-of-sofetabart-mipitecan-for-high-grade2026-10-09daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-association-of-body-composition-metrics2026-10-09daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-1-2-trial-of-bavdegalutamide-for-metastatic2026-10-10daily0.9 https://clinresonc-new.lhten.com/ncdb-analysis-of-endocrine-therapy-omission-in-estrogen-receptor-low2026-10-10daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-bone-health-in-myelodysplastic-neoplasms2026-10-10daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-pubertal-testicular-function-in2026-10-10daily0.9 https://clinresonc-new.lhten.com/invasive-cervical-cancers-after-an-hpv-negative-test-insights-from2026-10-11daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-two-bevacizumab-doses-for2026-10-11daily0.9 https://clinresonc-new.lhten.com/multicenter-study-of-lipid-biomarkers-associated-with-the-diagnosis2026-10-12daily0.9 https://clinresonc-new.lhten.com/systematic-review-and-meta-analysis-of-the-association-between-coffee2026-10-12daily0.9 https://clinresonc-new.lhten.com/two-randomized-trials-of-effect-of-communicating-uncertainties-about2026-10-12daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-trial-of-hypofractionated-postmastectomy2026-10-13daily0.9 https://clinresonc-new.lhten.com/uk-biobank-analysis-of-integrating-polygenic-risk-score-sex-and2026-10-13daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-immunochemistry-versus-molecular-breast2026-10-13daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-participation-of-patients-with2026-10-13daily0.9 https://clinresonc-new.lhten.com/prospective-phase-4-trial-of-effectiveness-and-safety-of2026-10-14daily0.9 https://clinresonc-new.lhten.com/trends-in-bone-health-agents-use-and-skeletal-events-in-metastatic2026-10-14daily0.9 https://clinresonc-new.lhten.com/joint-associations-of-abdominal-and-general-obesity-and-smoking-with2026-10-14daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-cancer-risk-in-patients-with-overall2026-10-14daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-frontline-ponatinib-blinatumomab-or2026-10-15daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-talazoparib-plus-enzalutamide2026-10-15daily0.9 https://clinresonc-new.lhten.com/multinational-phase-1-2-study-of-selpercatinib-for-ret-altered-solid2026-10-15daily0.9 https://clinresonc-new.lhten.com/phase-1-2-trial-of-dose-escalated-focal-salvage-hdr-brachytherapy-and2026-10-15daily0.9 https://clinresonc-new.lhten.com/first-in-human-study-of-astatine-211-cd45-radioimmunotherapy-before2026-10-16daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-neoadjuvant-stereotactic-ablative-radiotherapy2026-10-16daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-organ-preservation-and-quality-of-life-after-total2026-10-16daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-survival-outcomes-with-lu-177-psma-by-treatment-line2026-10-16daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-addition-of-camrelizumab-to-neoadjuvant2026-10-17daily0.9 https://clinresonc-new.lhten.com/integrative-analysis-of-genomic-driver-alterations-in-prostate-cancer2026-10-17daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-trends-in-cervical-cancer-screening-rates-by2026-10-17daily0.9 https://clinresonc-new.lhten.com/tumor-proximal-deep-serum-analysis-to-identify-protein-biomarkers2026-10-18daily0.9 https://clinresonc-new.lhten.com/outcomes-following-pancreatoduodenectomy-with-arterial-venous-or-no2026-10-18daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-z-100-plus-radiotherapy-while-continuing-ici-for2026-10-19daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-pericardial-fluid-cytology-to-detect-occult2026-10-19daily0.9 https://clinresonc-new.lhten.com/cross-sectional-study-of-nativity-and-us-residence-duration-and2026-10-19daily0.9 https://clinresonc-new.lhten.com/cohort-study-of-allocation-policy-implementation-during-a-severe2026-10-19daily0.9 https://clinresonc-new.lhten.com/phase-3-trial-of-hypofractionated-versus-conventionally-fractionated2026-10-20daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-first-line-cadonilimab-plus-chemotherapy-for2026-10-20daily0.9 https://clinresonc-new.lhten.com/prospective-study-of-the-association-of-body-roundness-index-with2026-10-20daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-activity-of-low-dose-nivolumab-in-patients2026-10-20daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-skin-toxic-effects-and-survival-with2026-10-21daily0.9 https://clinresonc-new.lhten.com/modeling-study-of-cost-effectiveness-of-perioperative-enfortumab2026-10-21daily0.9 https://clinresonc-new.lhten.com/phase-2-trial-of-anhydrous-enol-oxaloacetate-for-improving-cognitive2026-10-21daily0.9 https://clinresonc-new.lhten.com/multicenter-cohort-study-of-observation-versus-maintenance2026-10-21daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-2-trial-of-neoadjuvant-immunotherapy-for-mismatch2026-10-22daily0.9 https://clinresonc-new.lhten.com/retrospective-cohort-study-of-denosumab-therapy-duration-and2026-10-22daily0.9 https://clinresonc-new.lhten.com/multicenter-retrospective-cohort-study-of-initial-enfortumab-vedotin2026-10-22daily0.9 https://clinresonc-new.lhten.com/nationwide-cohort-study-of-childhood-cancer-risk-after-assisted2026-10-22daily0.9 https://clinresonc-new.lhten.com/clinical-heterogeneity-across-oropharyngeal-datasets-and-implications2026-10-23daily0.9 https://clinresonc-new.lhten.com/retrospective-study-of-impact-of-parity-and-breastfeeding-on-breast2026-10-23daily0.9 https://clinresonc-new.lhten.com/multicenter-randomized-phase-2-trial-of-rilvegostomig-plus2026-10-23daily0.9 https://clinresonc-new.lhten.com/multinational-phase-2-trial-of-adding-relatlimab-to-nivolumab-plus2026-10-23daily0.9 https://clinresonc-new.lhten.com/multicenter-phase-3-trial-of-trastuzumab-rezetecan-in-erbb2-low2026-10-24daily0.9 https://clinresonc-new.lhten.com/overall-survival-with-adjuvant-ribociclib-plus-nsai-in-patients-with2026-10-24daily0.9 https://clinresonc-new.lhten.com/five-year-results-of-a-cluster-randomized-trial-of-active2026-10-24daily0.9 https://clinresonc-new.lhten.com/trends-in-direct-oral-anticoagulant-use-for-cancer-associated-venous2026-10-24daily0.9